| Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response |
Suspended |
Breast Neoplasm Female |
NCT03096418 |
| Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors |
Recruiting |
Cancer |
NCT03507491 |
| Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors |
Active, not recruiting |
Solid Tumors |
NCT02762981 |
| Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer |
Not yet recruiting |
Breast Cancer Stage |
NCT03959397 |
| Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer |
Recruiting |
Bladder Cancer |
NCT04060459 |
| Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer |
Not yet recruiting |
Advanced Gastric Cancer |
NCT04286711 |
| Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT |
Not yet recruiting |
Breast Cancer |
NCT04137653 |
| Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer |
Recruiting |
Metastatic Pancreatic Cancer |
NCT03929094 |
| Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer |
Recruiting |
Ovarian Cancer |
NCT03246074 |
| A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel. |
Completed |
Advanced Cancer |
NCT02193633 |
| A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC |
Recruiting |
Non-Small Cell Lung Cancer |
NCT04167774 |
| Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer |
Completed |
Recurrent Ovarian Cancer |
NCT02195973 |
| FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel |
Recruiting |
Squamous Cell Carcinoma of the Head and Neck |
NCT03723967 |
| Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer |
Active, not recruiting |
Pancreatic Cancer |
NCT03316599 |
| Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer |
Recruiting |
Triple Negative Breast Cancer|Nab-paclitaxel |
NCT04159142 |
| Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response |
Active, not recruiting |
Breast Cancer |
NCT02280252 |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer |
Active, not recruiting |
Fallopian Tube Carcinoma|Recurrent Ovarian Cancer|Primary Peritoneal Carcinoma|Recurrent Endometrial Cancer |
NCT02788708 |
| A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT01973309 |
| Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer |
Completed |
Small Cell Lung Cancer |
NCT02551432 |
| Endoscopic Abraxane Injection Into Pancreatic Cysts |
Terminated |
Pancreatic Cysts |
NCT01698710 |
| AMG 386 Drug-Drug Interaction Study With Paclitaxel |
Completed |
Advanced Solid Tumors |
NCT01992341 |
| A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer |
Completed |
Gastric Cancer |
NCT02415023 |
| Single Arm on the Tolerability of Weekly Nab-paclitaxel |
Active, not recruiting |
Non Small Cell Lung Cancer (NSCLC) |
NCT01702844 |
| Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT01442974 |
| Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments |
Unknown status |
Solid Tumors |
NCT01994031 |
| Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer |
Unknown status |
Squamous Cell Carcinoma of Lung |
NCT01969955 |
| Safety, Tolerability and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced GC or GEJ Cancer. |
Recruiting |
Gastric Cancer|Gastroesophageal Junction Adenocarcinoma |
NCT03707028 |
| Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer |
Recruiting |
Breast Cancer|Triple-negative Breast Cancer|Nab-paclitaxel |
NCT04138719 |
| A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen |
Completed |
Cancer |
NCT01497470 |
| A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
Terminated |
Ovarian Cancer |
NCT02389985 |
| Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT02358161 |
| Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer |
Active, not recruiting |
Lung Cancer |
NCT02733250 |
| Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus |
Withdrawn |
Squamous Cell Carcinoma of Esophagus |
NCT02033538 |
| A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer |
Terminated |
Ovarian Cancer |
NCT00585052 |
| Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) |
Unknown status |
Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Breast Cancer Female NOS|Invasive Ductal Breast Cancer|Tubular Breast Cancer Stage III|HER-2 Positive Breast Cancer|Inflammatory Breast Cancer Stage IV|Inflammatory Breast Cancer |
NCT01583426 |
| Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer |
Recruiting |
Gastric Cancer |
NCT03263741 |
| Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients |
Unknown status |
Metastatic Pancreatic Cancer |
NCT02707159 |
| The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer |
Unknown status |
Small Cell Lung Cancer |
NCT02262897 |
| A Study on Predictive Value of ERCC1 in Esophageal Cancer Patients Treated With Paclitaxel and Cisplatin |
Unknown status |
Esophageal Cancer |
NCT01444547 |
| A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer |
Unknown status |
Pancreatic Cancer|Metastatic Pancreatic Cancer |
NCT03435289 |
| Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer |
Unknown status |
Advanced Pancreatic Cancer |
NCT03415802 |
| Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer |
Recruiting |
Small Cell Lung Cancer (SCLC) |
NCT02769832 |
| Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection |
Completed |
Stage IA Pancreatic Adenocarcinoma|Stage IB Pancreatic Adenocarcinoma|Stage IIA Pancreatic Adenocarcinoma|Stage IIB Pancreatic Adenocarcinoma |
NCT02023021 |
| A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel |
Not yet recruiting |
Metastatic Breast Cancer |
NCT04252768 |
| Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors |
Recruiting |
Solid Tumors |
NCT02379416 |
| Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer |
Recruiting |
Cholangiocarcinoma |
NCT03943043 |
| Paclitaxel-Avelumab for Angiosarcoma |
Recruiting |
Angiosarcoma Metastatic |
NCT03512834 |
| Treatment With Nab-paclitaxel in Cutaneous SCC |
Terminated |
Cutaneous Squamous Cell Carcinoma |
NCT02076243 |
| Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer |
Recruiting |
Breast Neoplasms |
NCT02776917 |
| Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer |
Unknown status |
Ovarian Cancer |
NCT02545010 |
| The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma |
Recruiting |
Biliary Tract Cancer |
NCT03830606 |
| A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer |
Not yet recruiting |
Castration-resistant Prostate Cancer |
NCT04148885 |
| A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) |
Recruiting |
Advanced Gastric Cancer |
NCT03223376 |
| F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma |
Terminated |
Merkel Cell Carcinoma |
NCT02054884 |
| NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma |
Recruiting |
Soft Tissue Sarcoma |
NCT03524898 |
| A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors |
Unknown status |
Unspecified Adult Solid Tumor, Protocol Specific|Gastric Cancer|Breast Cancer |
NCT01764087 |
| A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers |
Completed |
Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,|Primary Peritoneal Cancer or Endometrial Cancer|Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer |
NCT01209195 |
| Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma |
Not yet recruiting |
Gastric Adenocarcinoma |
NCT04047953 |
| Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer |
Recruiting |
Pancreatic Cancer|Neoadjuvant Chemotherapy |
NCT03585062 |
| Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT01822314 |
| Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer |
Not yet recruiting |
Locally Advanced Cancer|Cervical Cancer |
NCT04016142 |
| LDE225 and Paclitaxel in Solid Tumors |
Completed |
Solid Tumor|Ovarian Cancer |
NCT01954355 |
| Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer |
Not yet recruiting |
Breast Cancer |
NCT03841747 |
| Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer |
Recruiting |
Recurrent or Metastatic Breast Cancer |
NCT03326102 |
| Abraxane in Treatment of Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT02555696 |
| Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression |
Not yet recruiting |
Metastatic Breast Cancer |
NCT04251169 |
| Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer |
Withdrawn |
Breast Neoplasms |
NCT01953445 |
| Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma |
Active, not recruiting |
Urothelial Carcinoma|Bladder Cancer|Transitional Cell Carcinoma |
NCT02887248 |
| Paclitaxel Detection in NSCLC Treated With TC Regimen |
Terminated |
Non-small Cell Lung Cancer |
NCT02737709 |
| PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer |
Active, not recruiting |
Metastatic Breast Cancer |
NCT03166085 |
| Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer |
Completed |
Stomach and Gastro-Esophageal Junction (GEJ) Cancer |
NCT02251951 |
| Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer |
Unknown status |
Bladder Cancer |
NCT00583349 |
| Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG) |
Terminated |
Penile Squamous Cell Carcinoma Stage IV |
NCT02279576 |
| Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC. |
Withdrawn |
Non-small Cell Lung Cancer |
NCT02405910 |
| The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION) |
Completed |
Esophageal Cancer|Toxicity |
NCT02273713 |
| Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer |
Completed |
Pancreatic Cancer|Metastatic Pancreatic Cancer |
NCT04133155 |
| Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma |
Recruiting |
Tumor, Desmoplastic Small Round Cell, Adult|Tumor, Desmoplastic Small Round Cell, Childhood|Sarcoma, Ewing|Sarcoma|Desmoid |
NCT03275818 |
| Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma |
Completed |
Pancreatic Carcinoma Metastatic |
NCT02391662 |
| A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer |
Completed |
Neoplasms, Breast Neoplasms, Head and Neck Neoplasms |
NCT02051751 |
| Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly |
Completed |
Non-Small Cell Lung Cancer|Carcinoma|Squamous Cell Carcinoma|Adenocarcinoma|Carcinoma, Large Cell|Lung Neoplasm |
NCT02151149 |
| Regional Cryotherapy in Preventing Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients |
Recruiting |
Breast Cancer |
NCT03429972 |
| Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma |
Terminated |
Relapsed or Refractory Multiple Myeloma |
NCT02075021 |
| Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer |
Unknown status |
Non Small Cell Lung Cancer |
NCT02016209 |
| Prevention of Paclitaxel Neuropathy With Cryotherapy |
Unknown status |
Breast Cancer |
NCT02230319 |
| Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer |
Recruiting |
Extensive Stage Small Cell Lung Cancer |
NCT04213937 |
| Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients |
Not yet recruiting |
Advanced Pancreatic Cancer |
NCT04217096 |
| Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) |
Active, not recruiting |
Pancreatic Neoplasms|Digestive System Neoplasms|Neoplasms by Site|Neoplasms|Endocrine Gland Neoplasms|Pancreatic Diseases|Digestive System Diseases|Endocrine System Diseases|Gemcitabine|Antimetabolites, Antineoplastic |
NCT01964430 |
| Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma |
Not yet recruiting |
Cholangiocarcinoma, Intrahepatic |
NCT04077983 |
| Reirradiation With Concurrent Paclitaxel for Breast Cancer |
Withdrawn |
Breast Cancer |
NCT02058667 |
| Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer |
Unknown status |
Breast Cancer |
NCT01565499 |
| Paclitaxel and TAK-228 in Urothelial Carcinoma |
Recruiting |
Metastatic Urothelial Cancer |
NCT03745911 |
| A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma |
Active, not recruiting |
Carcinoma, Pancreatic Ductal |
NCT02993731 |
| Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors |
Completed |
Neuroblastoma|Rhabdomyosarcoma|Ewing's Sarcoma|Ewing's Tumor|Sarcoma, Ewing's|Sarcomas, Epitheliod|Sarcoma, Soft Tissue|Sarcoma, Spindle Cell|Melanoma|Malignant Melanoma|Clinical Oncology|Oncology, Medical|Pediatrics, Osteosarcoma|Osteogenic Sarcoma|Osteosarcoma Tumor|Sarcoma, Osteogenic|Tumors|Cancer|Neoplasia|Neoplasm|Histiocytoma|Fibrosarcoma|Dermatofibrosarcoma |
NCT01962103 |
| Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma |
Completed |
Stage III Melanoma|Stage IV Melanoma|Unresectable Melanoma |
NCT01107665 |
| Treatment of Patients With Atherosclerotic Disease With Paclitaxel-associated to LDL Like Nanoparticles |
Recruiting |
Coronary Artery Disease|Atherosclerosis|Inflammation |
NCT04148833 |
| Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm |
Terminated |
Mucinous Cystic Tumor With Moderate Dysplasia|Mucinous Cystadenoma of Pancreas|Mucinous Cystadenocarcinoma of Pancreas|Benign Neoplasm of Pancreas |
NCT01525706 |
| ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors |
Recruiting |
Advanced Malignant Solid Neoplasm|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Metastatic Malignant Solid Neoplasm|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Recurrent Breast Carcinoma|TP53 wt Allele|Unresectable Malignant Solid Neoplasm |
NCT03725436 |
| Study of Weekly LOC-paclitaxel Injection for Melanoma |
Terminated |
Melanoma |
NCT01039844 |
| Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2 |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT02289456 |
| Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w/ BSA > 2.0 |
Active, not recruiting |
Gynecologic Malignancies |
NCT02756013 |
| Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver |
Completed |
Melanoma|Liver Metastasis |
NCT00833807 |
| Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 |
Recruiting |
Gastric Cancer Stage IV|Peritoneal Carcinomatosis|Intraperitoneal Paclitaxel|mFOLFOX6 |
NCT03618758 |
| Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer |
Terminated |
Borderline Resectable Pancreatic Cancer |
NCT02241551 |
| Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement |
Completed |
Advanced Cancer |
NCT00508326 |
| Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT) |
Completed |
Breast Cancer |
NCT01133912 |
| Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer |
Completed |
Pancreatic Neoplasms |
NCT02017015 |
| Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations |
Recruiting |
Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Refractory Breast Carcinoma|Triple-Negative Breast Carcinoma |
NCT04216472 |
| Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients |
Unknown status |
Solid Tumour,|Breast Cancer,|Metastatic Melanoma,|Non-small Cell Lung Cancer (NSCLC), |
NCT01134250 |
| Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer |
Unknown status |
Advanced Pancreatic Cancer |
NCT02124317 |
| Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer |
Not yet recruiting |
Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8 |
NCT04205903 |
| DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC |
Active, not recruiting |
Breast Cancer |
NCT03716180 |
| A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian |
Terminated |
Primary Peritoneal Carcinoma |
NCT01952249 |
| NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma |
Recruiting |
Cancer of Stomach |
NCT02486601 |
| Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage â…ˇ B and IIIA Squamous Cell Carcinoma of the Lung |
Unknown status |
Non-small Cell Lung Cancer |
NCT01872403 |
| A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients |
Recruiting |
Solid Tumor |
NCT04180384 |
| PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis |
Not yet recruiting |
Peritoneal Carcinomatosis |
NCT04000906 |
| Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors |
Terminated |
Solid Tumors |
NCT01548924 |
| A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer |
Completed |
Pancreatic Cancer|Stage IV Pancreatic Cancer |
NCT02005315 |
| Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT02092363 |
| Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194 |
Completed |
Breast Cancer |
NCT00820170 |
| Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab |
Completed |
Breast Cancer|HER-2 Positive Breast Cancer|Effects of Chemotherapy |
NCT01432223 |
| Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology |
Recruiting |
Pancreatic Adenocarcinoma |
NCT03703089 |
| Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC |
Completed |
Metastatic Pancreatic Ductal Adenocarcinoma |
NCT02501902 |
| Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) |
Unknown status |
Ovarian Carcinoma |
NCT02244502 |
| Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric Cancer |
Unknown status |
Gastric Caner |
NCT02229045 |
| VQI DELTA Paclitaxel Device Safety Analysis |
Completed |
Peripheral Vascular Disease |
NCT04110288 |
| Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer |
Terminated |
Breast Cancer |
NCT01980277 |
| A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers |
Completed |
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer |
NCT01447706 |
| IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT01830244 |
| Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer |
Recruiting |
Pancreatic Cancer |
NCT03636308 |
| Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer |
Active, not recruiting |
Gastroesophageal Cancer |
NCT02317991 |
| Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) |
Completed |
Neoplasms|Breast Neoplasms|Breast Cancer |
NCT00900627 |
| Cisplatin vs Paclitaxel for Triple Neg |
Active, not recruiting |
Triple Negative Breast Cancer |
NCT01982448 |
| TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer |
Recruiting |
Triple Negative Breast Cancer |
NCT03193853 |
| A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer |
Completed |
Stage IV Pancreatic Cancer |
NCT01647828 |
| Schedules of Nab-Paclitaxel in Metastatic Breast Cancer |
Active, not recruiting |
Metastatic Breastcancer |
NCT01746225 |
| Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma |
Recruiting |
Cutaneous Angiosarcoma |
NCT03921008 |
| Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT01264328 |
| Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer |
Unknown status |
Advanced Pancreatic Cancer |
NCT02135822 |
| Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer |
Unknown status |
Uterine Cervical Cancer |
NCT01667211 |
| Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma |
Terminated |
Bladder Cancer |
NCT00933374 |
| Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer |
Recruiting |
Carcinomatosis|Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Metastatic Gastric Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 |
NCT04220827 |
| Locally Advanced Pancreatic Cancer (LAPC) (GCC 1886) |
Recruiting |
Locally Advanced Pancreatic Cancer |
NCT03652428 |
| Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula Stenosis |
Terminated |
Fistula Stenosis |
NCT01868984 |
| The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer |
Unknown status |
Pancreatic Adenocarcinoma|Chemotherapy Effect |
NCT03401827 |
| Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer |
Recruiting |
Anaplastic Thyroid Cancer |
NCT03085056 |
| Lenalidomide and Paclitaxel in Prostate Cancer |
Terminated |
Prostate Cancer |
NCT00933426 |
| Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer |
Recruiting |
Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma |
NCT02672475 |
| Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC |
Active, not recruiting |
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER |
NCT01757288 |
| Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer |
Withdrawn |
Anaplastic Thyroid Cancer |
NCT01701349 |
| Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer |
Completed |
Metastatic Breast Cancer|Locally Recurrent Breast Cancer |
NCT02064829 |
| Study of Vemurafenib, Carboplatin, and Paclitaxel |
Active, not recruiting |
Advanced Cancers |
NCT01636622 |
| Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas |
Completed |
Angiosarcoma |
NCT01303497 |
| A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer |
Completed |
Breast Cancer |
NCT01617668 |
| Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer |
Unknown status |
Breast Cancer |
NCT02059876 |
| Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma |
Completed |
Cholangiocarcinoma |
NCT02181634 |
| Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer |
Recruiting |
Borderline Resectable Pancreatic Cancer |
NCT03850769 |
| Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer |
Active, not recruiting |
Pancreatic Cancer |
NCT03520790 |
| Paclitaxel Eluting Covered Metallic Stent for Unresectable Malignant Bile Duct Obstruction |
Completed |
Bile Duct Obstruction |
NCT00453076 |
| A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT02826161 |
| Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer |
Recruiting |
Locally Advanced Pancreatic Cancer |
NCT03885219 |
| Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage â…˘ Gastric Cancer |
Not yet recruiting |
Gastric Cancer |
NCT03977220 |
| Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer |
Active, not recruiting |
Early Stage Breast Cancer |
NCT02698891 |
| Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer |
Active, not recruiting |
Ovarian Cancer |
NCT02383251 |
| Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer |
Active, not recruiting |
Metastatic Breast Cancer |
NCT02594371 |
| Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. |
Recruiting |
Gastrointestinal Stromal Tumors |
NCT03944304 |
| Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors |
Completed |
Solid Tumors |
NCT00891605 |
| Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT01778803 |
| Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer |
Terminated |
Lung Cancer |
NCT00465907 |
| Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer |
Withdrawn |
Urothelial Cancer|Bladder Cancer |
NCT01700010 |
| Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors |
Terminated |
Advanced Solid Tumors |
NCT02134067 |
| Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage â…ˇ-â…˘ Esophageal Cancer Patients |
Completed |
Esophageal Squamous Cell Carcinoma |
NCT01258192 |
| Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer |
Terminated |
Ovarian Cancer |
NCT00102622 |
| First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine |
Recruiting |
Metastatic Pancreatic Cancer|Adenocarcinoma of the Pancreas |
NCT02564146 |
| Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC |
Active, not recruiting |
Efficacy and Safety |
NCT04284215 |
| MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC |
Completed |
Stage IV Non-small Cell Lung Cancer |
NCT01310244 |
| Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer |
Completed |
Carcinoma|Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cancer |
NCT01253681 |
| Effects of Paclitaxel on Intimal Hyperplasia |
Completed |
Peripheral Vascular Disease |
NCT01454778 |
| Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients |
Unknown status |
NSCLC|HER2-expression|EGFR-mutation |
NCT02226757 |
| Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy |
Recruiting |
Recurrent or Metastatic Breast Cancer |
NCT03315364 |
| Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer |
Active, not recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT02250326 |
| Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer |
Completed |
Metastatic Pancreatic Adenocarcinoma|Metastatic Pancreatic Cancer |
NCT02077881 |
| A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT02272738 |
| PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer |
Completed |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer |
NCT00672295 |
| Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer |
Completed |
HER2-Positive Early Stage Breast Cancer |
NCT01827163 |
| Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer |
Terminated |
Breast Cancer |
NCT00532285 |
| A Study of Atezolizumab (Tecentriq) Plus Nab-Paclitaxel or Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer |
Recruiting |
Triple-Negative Breast Cancer |
NCT04148911 |
| Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies |
Active, not recruiting |
Advanced Cancer |
NCT01015222 |
| Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab |
Completed |
Nonsquamous Nonsmall Cell Neoplasm of Lung |
NCT01814163 |
| A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT00970580 |
| Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer |
Terminated |
Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer|Mixed Tumor, Mesodermal |
NCT00322881 |
| Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer |
Not yet recruiting |
Metastatic Pancreatic Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8 |
NCT04115163 |
| A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas |
Active, not recruiting |
Gastrointestinal Neuroendocrine Carcinomas |
NCT02215447 |
| Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients |
Completed |
Breast Cancer |
NCT02338115 |
| Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment |
Withdrawn |
HER-2 Positive Gastric Cancer|Gastrooesophageal Cancer|Esophageal Cancer |
NCT02274012 |
| Paclitaxel for the Treatment of Distal Radial Artery Arteriovenous Access Fistula Stenosis (PaciFIST-2) |
Withdrawn |
Arteriovenous Access Fistula Stenosis |
NCT02040454 |
| Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer |
Completed |
Breast Cancer |
NCT01203267 |
| Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) |
Completed |
HEAD & NECK Cancer |
NCT00736619 |
| Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors |
Completed |
Neoplasm Metastasis|Carcinoma |
NCT00731861 |
| Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT01326767 |
| Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer |
Recruiting |
Locally Advanced Pancreatic Cancer|Borderline Pancreatic Inoperable Cancer|Pancreatic Cancer |
NCT03600623 |
| Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer |
Completed |
Gastric Cancer |
NCT02229058 |
| Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) |
Completed |
Squamous Cell Cancer|Head and Neck Cancer |
NCT01016769 |
| Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC) |
Completed |
Advanced Non-small Cell Lung Cancer |
NCT00487669 |
| Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome |
Completed |
Breast Carcinoma |
NCT02640053 |
| Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel |
Completed |
Cancer |
NCT01374620 |
| Prospective, Multicenter, Non-randomized, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of e-PTFE Grafts Inner Surface-treated With Paclitaxel as an Access for Hemodialysis in Patients With End-stage Renal Disease. |
Recruiting |
Hemodialysis Access Failure |
NCT04285073 |
| Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma |
Completed |
Esophageal Neoplasms|Stomach Neoplasms|Neoplasm Metastasis |
NCT02406170 |
| Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers |
Recruiting |
Advanced Biliary Tract Cancers |
NCT04111380 |
| Treatment of Pancreatic Cancer With Abraxane |
Active, not recruiting |
Metastatic Pancreatic Cancer |
NCT02555813 |
| A Non Interventional Study With Paclitaxel Onkovis (Paclitaxel) Utilized for the Treatment of Cancer |
Completed |
Carcinoma |
NCT01668108 |
| Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients |
Unknown status |
Gastric Adenocarcinoma |
NCT01641783 |
| Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer |
Completed |
Small Cell Lung Cancer |
NCT01079481 |
| Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer |
Recruiting |
Advanced Gastric Cancer |
NCT04182724 |
| Evaluation of the Efficacy and Safety of a Paclitaxel Eluting PTCA Balloon Catheter in Coronary In-stent Restenosis |
Recruiting |
Coronary In-stent Restenosis |
NCT04213378 |
| Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR) |
Active, not recruiting |
Ovarian Sex-cord Stromal Tumor |
NCT01770301 |
| Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) |
Recruiting |
Ovarian Cancer |
NCT03940196 |
| Belgian-Italian Trial to Evaluate the Efficacy and Safety of Below The Knee (BTK) Treatment With the Luminor 14 Paclitaxel Coated Percutaneous Transluminal Angioplasty Balloon Catheter of iVascular |
Not yet recruiting |
Peripheral Arterial Disease |
NCT03845543 |
| Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma |
Unknown status |
Gastric Cancer|Gastroesophageal Junction Adenocarcinoma |
NCT03083613 |
| Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma |
Completed |
Uterine Cancer |
NCT00506779 |
| BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors |
Completed |
Solid Tumors |
NCT01297452 |
| Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer |
Recruiting |
Advanced Gastric Cancer |
NCT03286244 |
| Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies |
Active, not recruiting |
Advanced Cancer |
NCT01113476 |
| A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors |
Active, not recruiting |
Malignant Solid Tumor |
NCT01515306 |
| Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer |
Terminated |
Breast Cancer |
NCT00622466 |
| Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia |
Terminated |
Pancreatic Neoplasms|Cholestasis |
NCT02267707 |
| A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors |
Completed |
Solid Tumors |
NCT01240655 |
| Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma |
Completed |
Small Cell Carcinoma |
NCT02881125 |
| Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer |
Active, not recruiting |
Metastatic Triple Negative Breast Cancer |
NCT03121352 |
| This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment |
Recruiting |
Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer |
NCT03650738 |
| Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients |
Recruiting |
Stomach Cancer|Stomach Neoplasm|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma |
NCT03760822 |
| Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer |
Recruiting |
Breast Cancer|Breast Adenocarcinoma|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Recurrent Breast Carcinoma|Stage IV Breast Cancer |
NCT02824575 |
| Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors |
Not yet recruiting |
Advanced Hepatobiliary and Malignant Tumors |
NCT04060472 |
| Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer |
Active, not recruiting |
Breast Cancer|Breast Carcinoma|Breast Tumors|Malignant Neoplasm of Breast |
NCT02187991 |
| Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer |
Active, not recruiting |
Ovarian Cancer |
NCT02440425 |
| Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study |
Not yet recruiting |
HER2-positive Breast Cancer |
NCT03919253 |
| Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer |
Recruiting |
Gastric Cancer|Gastroesophageal Junction Cancer |
NCT02501603 |
| A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC |
Suspended |
Triple Negative Breast Cancer |
NCT03777579 |
| A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer |
Recruiting |
Unresectable Biliary Tract Cancer |
NCT02632305 |
| Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel |
Terminated |
Medical Oncology |
NCT02138812 |
| Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer |
Terminated |
Pancreatic Carcinoma Non-resectable|Stage IV Pancreatic Cancer |
NCT01851174 |
| Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure |
Recruiting |
Head and Neck Squamous Cell Carcinoma |
NCT04278092 |
| Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma |
Completed |
Esophageal Carcinoma |
NCT02861690 |
| Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors |
Completed |
Unspecified Adult Solid Tumor - Protocol Specific|Breast Cancer - Female |
NCT01407562 |
| Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer |
Unknown status |
Metastatic Breast Cancer |
NCT02207361 |
| A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer |
Completed |
ER Positive, Her2 Negative Breast Cancer Patients|Triple Negative Breast Cancer Patients |
NCT01421472 |
| Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib |
Completed |
Breast Cancer |
NCT01070706 |
| Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis |
Completed |
In-stent Coronary Artery Restenosis |
NCT00961181 |
| A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer |
Unknown status |
Ovarian Cancer |
NCT00772798 |
| Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer |
Not yet recruiting |
Gastric Cancer|GastroEsophageal Cancer |
NCT04294784 |
| Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients |
Unknown status |
Cancer of Pancreas |
NCT03278015 |
| Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer |
Terminated |
Head and Neck Neoplasms|Squamous Cell Carcinoma |
NCT01333852 |
| Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer |
Withdrawn |
Non-small Cell Lung Cancer |
NCT01179269 |
| Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab |
Recruiting |
Breast Carcinoma |
NCT02436993 |
| Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy |
Recruiting |
Cervical Cancer |
NCT02432365 |
| Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment |
Completed |
Lung Cancer |
NCT00807573 |
| Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma |
Unknown status |
Recurrent, Persistent or Metastasized Cervical Cancer |
NCT01405235 |
| Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC) |
Completed |
Pancreatic Neoplasms |
NCT02301143 |
| Study of Gemcitabine and Abraxane for Pancreas Cancer |
Terminated |
Pancreatic Cancer |
NCT02242409 |
| Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies |
Recruiting |
Advanced Nonhaematologic Malignancies |
NCT03328494 |
| Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer |
Recruiting |
Advanced Biliary Tract Cancer |
NCT04027764 |
| A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel |
Completed |
Breast Cancer |
NCT01722968 |
| Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer |
Recruiting |
Metastatic Pancreatic Cancer |
NCT02340117 |
| Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma |
Not yet recruiting |
Metastatic Urothelial Carcinoma |
NCT03464734 |
| Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin |
Active, not recruiting |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer |
NCT00652119 |
| Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma |
Completed |
Esophageal Cancer |
NCT02133612 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery |
Completed |
Intraocular Melanoma |
NCT00738361 |
| SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer |
Recruiting |
Pancreatic Cancer Stage IV |
NCT04181645 |
| Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN |
Active, not recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma of the Head and Neck |
NCT02124707 |
| Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel |
Completed |
Medical Oncology |
NCT02366949 |
| Feasibility Study of Intraperitoneal Paclitaxel |
Unknown status |
Gastric Cancer |
NCT01739894 |
| Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1Âş Chemotherapy |
Terminated |
Head and Neck Cancer |
NCT03887442 |
| Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients |
Active, not recruiting |
Breast Cancer |
NCT02628132 |
| Study of Afuresertib Combined With Paclitaxel in Gastric Cancer |
Completed |
Cancer |
NCT02240212 |
| [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer |
Completed |
Ovarian Neoplasm |
NCT01608009 |
| Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer |
Recruiting |
Breast Cancer |
NCT02788981 |
| Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer |
Completed |
Pancreatic Cancer|Stage IV Pancreatic Cancer |
NCT02050178 |
| Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer |
Not yet recruiting |
Locally Advanced Cervical Cancer |
NCT04238988 |
| BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT02379247 |
| Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer |
Unknown status |
Pancreatic Adenocarcinoma Resectable|Pancreatic Adenocarcinoma Locally Advanced|Pancreatic Adenocarcinoma Metastatic |
NCT01715142 |
| S 81694 Plus Paclitaxel in Metastatic Breast Cancer |
Active, not recruiting |
Metastatic Breast Cancer|Metastatic Triple Negative Breast Cancer |
NCT03411161 |
| Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer |
Not yet recruiting |
Breast Cancer |
NCT04194684 |
| Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer |
Not yet recruiting |
Gastric Cancer |
NCT04258657 |
| Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors |
Completed |
Solid Tumors |
NCT01525602 |
| Study of Trametinib and Nab-paclitaxel in Patients With Melanoma |
Withdrawn |
Melanoma |
NCT02300935 |
| Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects |
Terminated |
Pancreatic Cancer |
NCT02651727 |
| Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer |
Completed |
HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer |
NCT02060253 |
| Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer |
Recruiting |
Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8 |
NCT04001829 |
| Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer |
Unknown status |
Non Small Cell Lung Cancer |
NCT01171170 |
| Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage â…˘ Gastric Cancer |
Recruiting |
Stomach Cancer |
NCT04135781 |
| Dexamethasone Regimens for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction |
Unknown status |
Hypersensitivity Reaction |
NCT02349763 |
| Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer |
Terminated |
Urothelial Cancer|Bladder Cancer |
NCT00995488 |
| Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer |
Active, not recruiting |
Esophageal Cancer|Gastric Cancer |
NCT01522768 |
| Local Paclitaxel Delivery for SFA Disease |
Completed |
Atherosclerosis|Angioplasty|Peripheral Arterial Disease |
NCT00821028 |
| Pembro/Carbo/Taxol in Endometrial Cancer |
Recruiting |
Endometrial Cancer|Endometrial Adenocarcinoma |
NCT02549209 |
| A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation |
Completed |
Breast Cancer |
NCT01572727 |
| QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer |
Terminated |
Pancreatic Cancer, Adult |
NCT01834235 |
| Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Gemcitabine and Nab-paclitaxel) in Locally Advanced Pancreatic Cancer |
Recruiting |
Pancreatic Cancer Non-resectable |
NCT03941093 |
| Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). |
Recruiting |
Fallopian Tube Carcinoma|Peritoneal Carcinoma|Epithelial Ovarian Cancer |
NCT02834975 |
| Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin |
Terminated |
Ovarian Cancer |
NCT00840450 |
| A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT01268059 |
| A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00717340 |
| Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma |
Recruiting |
Squamous Cell Carcinoma |
NCT03719924 |
| Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib |
Unknown status |
Triple Negative Breast Cancer |
NCT02511847 |
| A Phase 3 Study to Compare Efficacy and Safety of DHP107 Versus Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy |
Completed |
Stage IV Gastric Cancer |
NCT01839773 |
| Prevalence of Paclitaxel Induced CIPN-Related Pain and CIPN in Indian Patients With Breast Cancer |
Unknown status |
Breast Cancer Female|Neuropathic Pain |
NCT03022162 |
| Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract |
Not yet recruiting |
Carcinoma, Transitional Cell |
NCT03051373 |
| Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer |
Not yet recruiting |
Ovarian Cancer |
NCT03942068 |
| Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC |
Terminated |
Lung Cancer |
NCT00544648 |
| A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC) |
Completed |
Non-small Cell Lung Cancer |
NCT00666692 |
| Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT01011075 |
| Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer |
Terminated |
Metastatic Breast Cancer |
NCT01207102 |
| Safety Study of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetics in Non-Small Cell Lung Cancer (NSCLC) |
Unknown status |
Non-Small Cell Lung Cancer |
NCT02058433 |
| A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer |
Recruiting |
Breast Cancer |
NCT02999477 |
| Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Terminated |
Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer |
NCT01962948 |
| Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer |
Active, not recruiting |
Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer |
NCT02152137 |
| Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma |
Recruiting |
Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Soft Tissue Sarcoma |
NCT02945800 |
| Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) |
Completed |
Breast Tumor|Breast Cancer|Cancer of the Breast|Estrogen Receptor- Negative Breast Cancer|HER2- Negative Breast Cancer|Progesterone Receptor- Negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer|Triple-negative Metastatic Breast Cancer|Metastatic Breast Cancer |
NCT01881230 |
| Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer |
Completed |
Male Breast Cancer|Recurrent Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer |
NCT01493310 |
| Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer |
Completed |
Pancreatic Adenocarcinoma |
NCT02174887 |
| Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC |
Active, not recruiting |
Malignant Neoplasm of Breast |
NCT03289819 |
| M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer |
Terminated |
Metastatic Pancreatic Cancer |
NCT01621243 |
| Role of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving Paclitaxel |
Terminated |
Arthralgia|Pain|Unspecified Adult Solid Tumor, Protocol Specific |
NCT01096407 |
| Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer |
Completed |
Bladder Cancer|Bladder (Urothelial, Transitional Cell) Cancer|Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)|Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)|Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable |
NCT01108055 |
| Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) |
Completed |
Non-small Cell Lung Cancer |
NCT02730247 |
| A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) |
Active, not recruiting |
Triple Negative Breast Cancer |
NCT02425891 |
| Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates |
Completed |
Breast Cancer |
NCT01484080 |
| A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Non-small Cell Lung Cancer |
NCT00654758 |
| Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer |
Completed |
Inoperable Locally Advanced Breast Cancer|Metastatic Breast Cancer (MBC) |
NCT01495247 |
| A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC |
Completed |
Carcinoma, Non-small-Cell Lung |
NCT02392507 |
| A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00731380 |
| Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer Spread to the Bones |
Recruiting |
Anatomic Stage IV Breast Cancer AJCC v8|Breast Carcinoma Metastatic in the Bone|Metastatic Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8 |
NCT04090398 |
| Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) |
Completed |
Metastatic Breast Cancer |
NCT02001974 |
| Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma |
Not yet recruiting |
Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma |
NCT04140318 |
| A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy |
Completed |
Advanced Gastric Cancer|Esophagogastric Junction Cancer |
NCT01248403 |
| Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer |
Withdrawn |
Breast Cancer |
NCT02569489 |
| Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer |
Completed |
Breast Cancer |
NCT01023204 |
| Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer |
Recruiting |
Esophageal Squamous Cell Carcinoma |
NCT02350517 |
| PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer |
Active, not recruiting |
Metastatic Breast Cancer |
NCT02423603 |
| Pharmacokinetics Study of Liposomal Paclitaxel in Humans |
Completed |
Cancer |
NCT00606515 |
| Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer |
Completed |
Colorectal Neoplasms |
NCT02103062 |
| Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer |
Completed |
Breast Cancer |
NCT01276041 |
| Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin |
Completed |
Neoplasms, Germ Cell and Embryonal |
NCT00611962 |
| Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer |
Completed |
Non Small Cell Lung Cancer |
NCT01196234 |
| Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00851877 |
| A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) |
Recruiting |
Recurrent Platinum Resistant Ovarian Cancer |
NCT03398655 |
| Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer |
Recruiting |
Refractory Cancer |
NCT02630199 |
| EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly With advanCed breasT Cancer |
Completed |
Breast Cancer |
NCT02783222 |
| Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer |
Terminated |
Metastatic Pancreatic Cancer |
NCT02570711 |
| Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer |
Unknown status |
Surgically-Created Resection Cavity|Drug Safety |
NCT01756183 |
| Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy |
Unknown status |
Gastric Cancer |
NCT01224652 |
| Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Non-Small Cell Lung Cancer |
NCT01024062 |
| Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer |
Completed |
Advanced Pancreatic Cancer |
NCT02382263 |
| A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC |
Not yet recruiting |
Lung Cancer Stage II|PD-1 Antibody|Non-small Cell Lung Cancer |
NCT04108013 |
| Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer |
Completed |
Pancreatic Neoplasm |
NCT03807999 |
| Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00971945 |
| Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00971867 |
| Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel |
Withdrawn |
Cancer|Non Small Cell Lung Cancer|Epithelial Ovarian Cancer |
NCT01000896 |
| Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT01024101 |
| Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer |
Not yet recruiting |
Ovarian Cancer |
NCT03818282 |
| Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer |
Completed |
Neoplasms, Gastrointestinal Tract |
NCT00486954 |
| Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer |
Recruiting |
Metastatic Pancreatic Cancer |
NCT03502343 |
| Clinical Study of Liposomal Paclitaxel in Chinese Patients |
Unknown status |
Solid Tumor |
NCT00881101 |
| Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer |
Unknown status |
Breast Cancer |
NCT02396108 |
| PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma |
Active, not recruiting |
Advanced Gastric Adenocarcinoma |
NCT02615730 |
| Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer |
Active, not recruiting |
Advanced Breast Carcinoma|Metastatic Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Triple-Negative Breast Carcinoma |
NCT02474173 |
| Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer |
Not yet recruiting |
Locally Advanced Pancreatic Cancer |
NCT03815461 |
| Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naĂŻve Metastatic Melanoma |
Withdrawn |
Metastatic Melanoma |
NCT01933061 |
| Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer |
Terminated |
Testicular Cancer |
NCT00531687 |
| Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma |
Recruiting |
Gastric Cancer |
NCT03801668 |
| A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer |
Completed |
HER-2 Positive Advanced Gastric Cancer |
NCT01746771 |
| The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions |
Completed |
Coronary Artery Disease|Chronic Total Occlusion|Native Coronary Artery |
NCT00670436 |
| Paclitaxel Eluting Balloon Catheter in Coronary De-novo Lesions Treatment in China |
Recruiting |
Coronary Disease |
NCT03466749 |
| Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer |
Unknown status |
Metastatic Pancreatic Cancer |
NCT01934634 |
| Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention |
Unknown status |
Restenosis|Peripheral Arterial Disease |
NCT01599078 |
| Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer |
Completed |
Esophageal Cancer |
NCT00971841 |
| Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer |
Completed |
Epithelial Ovarian Cancer |
NCT02312661 |
| Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00855764 |
| Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma |
Completed |
Metastatic Melanoma |
NCT01014351 |
| Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer |
Recruiting |
Transitional Cell Carcinoma |
NCT02581982 |
| Treatment of Moderate Vein Graft Lesions With Paclitaxel Drug Eluting Stents: The VELETI Trial |
Completed |
Coronary Artery Bypass Grafting |
NCT00289835 |
| AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer |
Recruiting |
Lung Cancer |
NCT02513563 |
| The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol |
Recruiting |
Solid Tumor, Adult |
NCT03892018 |
| AZD8186 and Paclitaxel in Advanced Gastric Cancer |
Recruiting |
Solid Tumor|Stomach Cancer |
NCT04001569 |
| Dose-finding Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and Bulky IIA Cervical Cancer |
Unknown status |
Cervical Cancer |
NCT00823186 |
| Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma |
Not yet recruiting |
Advanced Gastric Adenocarcinoma |
NCT04209686 |
| Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors |
Completed |
Neoplasms |
NCT00511849 |
| Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer |
Recruiting |
Esophageal Cancer|Induction Chemotherapy |
NCT02924909 |
| Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab |
Terminated |
Head and Neck Cancer |
NCT00319839 |
| Paclitaxel-coated Balloon Angioplasty Versus Standard Angioplasty for the Treatment of Stenosis of Arteriovenous Fistula |
Recruiting |
Angioplasty|Stenosis of Arteriovenous Fistula |
NCT02753998 |
| Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus |
Completed |
Mixed Tumor, Mullerian |
NCT00502203 |
| Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize) |
Not yet recruiting |
Locally Advanced, Squamous Cell Carcinoma of the Vulva |
NCT04192253 |
| Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT00254891 |
| Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy |
Not yet recruiting |
Metastatic Squamous Cell Carcinoma of the Vulva |
NCT04161664 |
| Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression |
Recruiting |
Cord Compression |
NCT03655080 |
| Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy |
Recruiting |
Squamous Cell Carcinoma of the Esophagus |
NCT03762564 |
| Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer |
Active, not recruiting |
Metastatic Pancreatic Cancer |
NCT02975141 |
| Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis |
Not yet recruiting |
Gastric Adenocarcinoma|Gastric Cancer|Esophagogastric Junction|Peritoneal Carcinomatosis |
NCT04034251 |
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients |
Suspended |
Solid Tumor, Adult|Metastatic Nonsmall Cell Lung Cancer|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Cervical Carcinoma|Metastatic Ovarian Carcinoma|Malignant Uterine Neoplasm|Vulvar Cancer|Invasive Breast Cancer|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Vulvar Carcinoma|Stage IV Cervical Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Vulvar Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IVA Cervical Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Vulvar Cancer AJCC v8|Stage IVB Cervical Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Vulvar Cancer AJCC v8|Vulva Squamous Cell Carcinoma |
NCT03987555 |
| A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies |
Recruiting |
Cancer |
NCT01325441 |
| Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC |
Completed |
Non Small Cell Lung Cancer |
NCT03780010 |
| Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT00268970 |
| Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer |
Completed |
Urologic Neoplasm |
NCT00350025 |
| Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00983424 |
| A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer |
Not yet recruiting |
Advanced Gastric or Gastroesophageal Junction Cancer |
NCT04053205 |
| Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany) |
Terminated |
Metastatic Breast Cancer |
NCT01416558 |
| A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer |
Terminated |
Pancreatic Neoplasms |
NCT02670746 |
| Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor |
Completed |
Breast Cancer|NSCLC|Ovary Cancer|Endometrial Cancer|Small Cell Lung Cancer (SCLC)|Head and Neck (HNSCC) |
NCT02069158 |
| FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine |
Active, not recruiting |
Metastatic Pancreatic Cancer |
NCT02827201 |
| Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00096668 |
| Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC |
Active, not recruiting |
Non-Small Cell Lung Cancer |
NCT02382406 |
| Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer |
Completed |
Metastatic Pancreatic Cancer |
NCT02109341 |
| LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer |
Completed |
Lung Cancer |
NCT02328105 |
| Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix |
Terminated |
Cervical Cancer|Uterine Cancer |
NCT00626561 |
| Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Recruiting |
Recurrent Ovarian Cancer|Recurrent Fallopian Tube Carcinoma|Recurrent Primary Peritoneal Carcinoma |
NCT03776812 |
| Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy |
Completed |
Pancreatic Cancer |
NCT00691054 |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Without PIK3CA Mutation |
Not yet recruiting |
Triple Negative Breast Neoplasms |
NCT04251533 |
| A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors |
Completed |
Advanced Solid Tumors |
NCT01494688 |
| A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer |
Completed |
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma |
NCT02514551 |
| Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer |
Completed |
Chemotherapeutic Agent Toxicity|Neuropathy|Neurotoxicity Syndrome|Pain|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer |
NCT02311907 |
| Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis |
Completed |
Coronary Restenosis |
NCT00124943 |
| Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer |
Terminated |
Esophageal Cancer |
NCT01704690 |
| Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma |
Recruiting |
Pancreatic Ductal Adenocarcinoma |
NCT03915444 |
| ONC201 and Paclitaxel in Treating Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Not yet recruiting |
Malignant Ovarian Epithelial Tumor|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Refractory Fallopian Tube Carcinoma|Refractory Ovarian Carcinoma|Refractory Primary Peritoneal Carcinoma |
NCT04055649 |
| Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC |
Active, not recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT02716038 |
| Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC |
Not yet recruiting |
Esophageal Cancer Stage IIB|Esophageal Cancer Stage III |
NCT03366883 |
| LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors |
Completed |
Solid Tumors |
NCT00556088 |
| Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer |
Completed |
Carcinoma, Pancreatic Ductal |
NCT00226746 |
| Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions |
Unknown status |
Coronary Artery Disease |
NCT01278186 |
| Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer |
Active, not recruiting |
Gastroesophageal Junction Adenocarcinoma|Stage IB Esophageal Adenocarcinoma AJCC v7|Stage II Esophageal Adenocarcinoma AJCC v7|Stage IIA Esophageal Adenocarcinoma AJCC v7|Stage IIB Esophageal Adenocarcinoma AJCC v7|Stage IIIA Esophageal Adenocarcinoma AJCC v7|Stage IIIB Esophageal Adenocarcinoma AJCC v7 |
NCT02530437 |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study |
Not yet recruiting |
Breast Cancer Metastatic |
NCT04215146 |
| Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC) |
Completed |
Non-small-cell Lung Cancer |
NCT00686322 |
| Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC |
Terminated |
Stage IIIA Non-Small Cell Lung Cancer |
NCT02276560 |
| Lenalidomide and Paclitaxel in Advanced Solid Tumors |
Unknown status |
Advanced Solid Tumors |
NCT01155505 |
| Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity |
Recruiting |
Hypersensitivity Reactions |
NCT03598426 |
| A Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer |
Recruiting |
Endometrial Cancer |
NCT03981796 |
| A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer |
Active, not recruiting |
Metastatic Breast Cancer |
NCT02163694 |
| Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients |
Completed |
Metastatic Breast Cancer |
NCT01306942 |
| A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS) |
Recruiting |
Triple-Negative Breast Cancer |
NCT04129996 |
| Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer |
Not yet recruiting |
Gastric Cancer |
NCT04258644 |
| A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer |
Active, not recruiting |
Cancer Ovaries|Cancer Peritoneal|Cancer, Fallopian Tube |
NCT03030287 |
| An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT03505528 |
| Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter in the Treatment of In-stent Restenosis of Coronary Artery Lesion With Paclitaxel Release Coronary Balloon Catheter |
Unknown status |
In-stent Restenosis |
NCT02891018 |
| Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer |
Recruiting |
Breast Cancer |
NCT04192331 |
| Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC |
Recruiting |
Triple Negative Breast Neoplasms |
NCT03997123 |
| Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma |
Not yet recruiting |
NSCLC, Recurrent|Adenocarcinoma of Lung |
NCT03361319 |
| Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT00313768 |
| RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty |
Active, not recruiting |
Peripheral Artery Disease|Atherosclerosis|Artery Diseases, Peripheral|Plaque, Atherosclerotic|Occlusive Arterial Disease |
NCT03064126 |
| Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers |
Completed |
Lung Cancer|Untreated Stage IV or Recurrent Squamous Cell Lung Cancers |
NCT02525653 |
| Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer. |
Completed |
Pancreatic Cancer Stage II |
NCT02043730 |
| Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery |
Terminated |
Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer |
NCT00662311 |
| Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma |
Terminated |
Melanoma |
NCT01200342 |
| Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC |
Recruiting |
Triple Negative Breast Cancer |
NCT04067102 |
| Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer |
Completed |
Prostate Cancer |
NCT02911350 |
| Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients |
Recruiting |
Unresectable Pancreatic Carcinoma |
NCT02767557 |
| Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab |
Completed |
Breast Cancer |
NCT00532857 |
| Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors |
Completed |
Cancer|Non-Small Cell Lung Cancer|Endometrial Carcinoma|Ovarian Carcinoma |
NCT00756847 |
| TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors |
Completed |
Pancreatic Cancer|Colorectal Cancer|Rectal Cancer|Gastric Cancer|Esophageal Cancer|Gastrointestinal Stromal Tumor (GIST) |
NCT02574663 |
| CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer |
Recruiting |
Breast Cancer |
NCT03568422 |
| Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT01423695 |
| Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC |
Active, not recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT02799862 |
| ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer |
Suspended |
Pancreatic Cancer |
NCT02514031 |
| Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer |
Recruiting |
HER2 Negative Metastatic Breast Cancer |
NCT03048942 |
| Shorter Scalp Cooling Time in Paclitaxel |
Recruiting |
Neoplasm Malignant|Breast Cancer|Ovarian Cancer |
NCT03266185 |
| TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors |
Recruiting |
Advanced Malignant Solid Neoplasm|KRAS Gene Mutation|Ovarian Carcinoma|Refractory Malignant Solid Neoplasm|Refractory Ovarian Carcinoma |
NCT03756818 |
| Paclitaxel in Treating Patients With Ovarian Stromal Cancer |
Completed |
Adult Type Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Steroid Cell Tumor |
NCT00006227 |
| Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma |
Completed |
Cutaneous Malignant Melanoma |
NCT02308553 |
| Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian |
Completed |
Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer |
NCT01219777 |
| A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies |
Terminated |
Pharmacokinetics of ASP9853|Non-hematologic Malignancies |
NCT01705483 |
| Safety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV) |
Recruiting |
Coronary Artery Disease |
NCT04058990 |
| MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies |
Completed |
Advanced Solid Tumors|Tumors|Cancer |
NCT01235897 |
| Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma |
Completed |
Pancreatic Neoplasms|Pancreatic Cancer|Adenocarcinoma |
NCT01161186 |
| Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors |
Completed |
Solid Tumors|Pancreatic Cancer |
NCT01858883 |
| Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas |
Completed |
Metastatic Pancreatic Cancer |
NCT01088815 |
| A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma |
Terminated |
Pancreatic Ductal Carcinoma |
NCT02715804 |
| Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer |
Not yet recruiting |
Breast Cancer |
NCT03647514 |
| GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study |
Recruiting |
Metastatic Gastric Cancer |
NCT03751761 |
| Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC |
Unknown status |
Small Cell Lung Cancer |
NCT03219762 |
| A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma |
Recruiting |
Endometrial Cancer|Uterine Cancer|Ovarian Cancer|Carcinosarcoma |
NCT03395080 |
| Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
Recruiting |
Triple-Negative Breast Cancer |
NCT04085276 |
| Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer |
Completed |
Squamous Cell Carcinoma, Non-Small-Cell Lung |
NCT02027428 |
| Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer |
Completed |
Chemotherapeutic Agent Toxicity|Endometrial Adenocarcinoma|Fallopian Tube Carcinoma|Gastrointestinal Complication|Malignant Ovarian Mixed Epithelial Tumor|Neurotoxicity Syndrome|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Primary Peritoneal Carcinoma|Stage II Ovarian Cancer|Stage III Ovarian Cancer|Stage IV Ovarian Cancer|Undifferentiated Ovarian Carcinoma |
NCT00814086 |
| Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma |
Unknown status |
Advanced Gastric Carcinoma |
NCT00881816 |
| Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT02138383 |
| A Study of Napabucasin in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer |
Recruiting |
Metastatic Pancreatic Cancer |
NCT03721744 |
| Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) |
Not yet recruiting |
Recurrent Head and Neck Squamous Cell Carcinoma|Head and Neck Cancer Stage IV |
NCT04282109 |
| Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2) |
Unknown status |
Small Vessel Lesion |
NCT02891005 |
| Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC |
Recruiting |
Nasopharyngeal Carcinoma |
NCT04015661 |
| Efficacy and Safety of TPFinduction Chemotherapy Boundary Resectable Local Advanced Esophageal Squamous Cell Carcinoma |
Unknown status |
Esophageal Squamous Cell Carcinoma |
NCT02976909 |
| Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer |
Not yet recruiting |
Breast Cancer |
NCT04136782 |
| CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT01199055 |
| Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach |
Completed |
Esophageal Cancer|Gastric Cancer |
NCT00020761 |
| Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer |
Completed |
Neoplasms |
NCT01411410 |
| Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma |
Terminated |
Pancreatic Ductal Adenocarcinoma |
NCT01431794 |
| Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer |
Active, not recruiting |
Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Stage IV Pancreatic Cancer |
NCT02178436 |
| Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary |
Recruiting |
Carcinosarcoma, Ovarian |
NCT03206177 |
| Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT02283372 |
| Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer |
Active, not recruiting |
Breast Cancer|Carcinoma of the Breast |
NCT00542451 |
| Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers |
Completed |
Advanced Cancers |
NCT00473720 |
| Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection |
Terminated |
HIV Infection|Recurrent Anal Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Anal Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Unspecified Adult Solid Tumor, Protocol Specific |
NCT01249443 |
| Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer |
Completed |
Lung Cancer, Non-Small Cell |
NCT00866528 |
| Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies |
Completed |
Adenocarcinoma|Pancreatic Neoplasms |
NCT01677559 |
| Evaluation of Paclitaxel in Patients With CLI and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty |
Recruiting |
Ischemia |
NCT02758847 |
| Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer |
Recruiting |
Low Grade Ovarian Serous Adenocarcinoma|Primary Peritoneal Low Grade Serous Adenocarcinoma|Stage II Ovarian Cancer AJCC v8|Stage IIA Ovarian Cancer AJCC v8|Stage IIB Ovarian Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8 |
NCT04095364 |
| Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women |
Recruiting |
Tubular Breast Cancer|Mucinous Breast Cancer|Invasive Duct Carcinoma of Breast |
NCT03201861 |
| A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors |
Recruiting |
Locally Advanced or Metastatic Solid Tumor |
NCT03601897 |
| Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer |
Terminated |
Triple Negative Breast Cancer |
NCT01745367 |
| The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer |
Not yet recruiting |
Breast Cancer |
NCT03647280 |
| A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer |
Unknown status |
Carcinoma, Squamous Cell |
NCT00660218 |
| IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma |
Active, not recruiting |
Adenocarcinoma Breast Stage IV |
NCT02614833 |
| A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients |
Completed |
Human Epithelial Receptor (HER)-2 Positive Breast Cancer |
NCT01764022 |
| Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer |
Completed |
Breast Cancer |
NCT01537536 |
| Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer |
Recruiting |
Advanced Gastric Cancer |
NCT03579784 |
| Efficacy and Safety Evaluation of IBI308 Versus Paclitaxel/Irinotecan in Patients With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment: a Randomized, Open-label, Multicenter, Phase 2 Study (ORIENT-2) |
Active, not recruiting |
Efficacy and Safety |
NCT03116152 |
| Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors |
Recruiting |
Advanced Solid Tumor |
NCT03154294 |
| A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer |
Active, not recruiting |
Metastatic Breast Cancer |
NCT02370238 |
| SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer |
Not yet recruiting |
Triple-negative Breast Cancer |
NCT04213898 |
| Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00274456 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
Completed |
Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma|Recurrent Ovarian Carcinoma |
NCT00499252 |
| QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel |
Completed |
Advanced Pancreatic Cancer |
NCT02559674 |
| Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) |
Completed |
Small Cell Lung Cancer |
NCT02038647 |
| Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer |
Recruiting |
Breast Cancer |
NCT03735082 |
| Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon |
Unknown status |
Coronary Restenosis |
NCT03242096 |
| Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer |
Withdrawn |
Breast Cancer |
NCT02929576 |
| A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer |
Active, not recruiting |
Non-Small-Cell Lung Cancer Metastatic|Non-Small Cell Carcinoma of Lung, TNM Stage 4|Nonsmall Cell Lung Cancer|Non Small Cell Lung Cancer Recurrent |
NCT02967133 |
| BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer |
Active, not recruiting |
Pancreatic Cancer|Cancer of Pancreas|Cancer of the Pancreas|Pancreas Cancer |
NCT02608229 |
| Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer |
Recruiting |
Resectable Cholangiocarcinoma|Stage IB Intrahepatic Cholangiocarcinoma AJCC v8|Stage II Intrahepatic Cholangiocarcinoma AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 |
NCT03579771 |
| A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT01149798 |
| VMAT Concurrent Cisplatin Plus Nab-paclitaxel for Local Advanced Cervical Cancer |
Not yet recruiting |
Cervical Cancer |
NCT04017377 |
| Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer |
Unknown status |
Advanced Gastric Cancer |
NCT02072317 |
| Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma |
Recruiting |
Carcinoma, Squamous Cell|Oral Cancer|Oropharynx Cancer|Larynx Cancer|Lip Cancer|Esophageal Cancer |
NCT03174275 |
| A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel |
Completed |
Solid Tumor |
NCT04035473 |
| CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy |
Terminated |
Ovarian Neoplasms |
NCT00653952 |
| Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma |
Recruiting |
Esophagogastric Adenocarcinoma |
NCT03193918 |
| Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer |
Unknown status |
Esophageal Squamous Cell Cancer|Elderly Patients |
NCT02016287 |
| Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer |
Completed |
Ovarian Carcinoma|Fallopian Tube Cancer|Peritoneal Cancer|Breast Carcinoma |
NCT01091428 |
| Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC |
Completed |
Neoplasms, Breast |
NCT01138046 |
| Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer |
Unknown status |
Breast Cancer |
NCT01647672 |
| Effectiveness of Paclitaxel-coated Luminor® Balloon Catheter Versus Uncoated Balloon Catheter in the Arteria Femoralis Superficialis |
Unknown status |
Peripheral Arterial Disease |
NCT02540018 |
| A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) |
Recruiting |
Triple-Negative Breast Cancer |
NCT03125902 |
| Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus |
Unknown status |
Esophageal Squamous Cell Carcinoma |
NCT02586753 |
| Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer |
Active, not recruiting |
Resectable Pancreatic Cancer|Ductal Adenocarcinoma of the Pancreas |
NCT02047513 |
| A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) |
Terminated |
Carcinoma, Non-Small Cell Lung |
NCT00300885 |
| Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy |
Terminated |
Head and Neck Squamous Cell Carcinoma |
NCT01852292 |
| Treatment of Coronary In-Stent Restenosis by a Sirolimus (Rapamycin) Coated Balloon or a Paclitaxel Coated Balloon |
Recruiting |
DES In-stent Stenosis |
NCT02996318 |
| Evaluation of Paclitaxel Eluting Stent vs Paclitaxel Eluting Balloon Treating Peripheral Artery Disease of the Femoral Artery |
Completed |
Peripheral Artery Disease |
NCT01728441 |
| A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy |
Not yet recruiting |
Cervical Cancer |
NCT04150575 |
| MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer |
Completed |
Adult Solid Neoplasm|Recurrent Breast Carcinoma|Stage IV Breast Cancer |
NCT01263145 |
| CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naĂŻve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC) |
Completed |
Non-small Cell Lung Cancer |
NCT00991796 |
| Trial of PTK787/ZK 222584 Plus Paclitaxel |
Unknown status |
Metastatic Non-hematologic Malignancies |
NCT00358163 |
| A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer |
Completed |
Gastric Cancer|Gastroesophageal Junction Cancer |
NCT02178956 |
| Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer |
Recruiting |
Breast Cancer |
NCT02752685 |
| Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer |
Terminated |
Breast Cancer |
NCT00088829 |
| Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Carcinoma |
NCT00540514 |
| Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer |
Completed |
Neoplasms, Breast |
NCT00356811 |
| Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT01433614 |
| Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas |
Completed |
Colorectal Cancer|Cancer of Gastrointestinal Tract |
NCT01730586 |
| Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors |
Terminated |
Advanced Solid Tumors|Ovarian Cancer|Small Cell Lung Cancer |
NCT02367352 |
| Paclitaxel Eluting Balloon in St Elevation Myocardial Infarction |
Completed |
Acute Myocardial Infarction |
NCT01839890 |
| Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00453167 |
| Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer |
Active, not recruiting |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer|No Prior Chemotherapy |
NCT01220154 |
| Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients |
Terminated |
Metastatic Pancreatic Ductal Adenocarcinoma |
NCT02732938 |
| Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer |
Completed |
Cervical Cancer |
NCT02467907 |
| Angioplasty With Paclitaxel-coated Balloon Only Strategy for Coronary de Novo Lesions |
Recruiting |
Coronary Disease |
NCT04022200 |
| Combination Paclitaxel, Carboplatin and Temozolomide |
Completed |
Lung Diseases|Cancer |
NCT00249964 |
| Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer |
Completed |
Breast Cancer |
NCT00887575 |
| Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00034541 |
| Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC) |
Completed |
Head and Neck Cancer|Squamous Cell Cancer |
NCT01721525 |
| Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. |
Active, not recruiting |
Gastric Cancer |
NCT01924533 |
| A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00937560 |
| Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
Completed |
Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Tumor|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma |
NCT00888615 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer |
Withdrawn |
Recurrent Bladder Urothelial Carcinoma|Stage IV Bladder Urothelial Carcinoma |
NCT02718742 |
| A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer |
Completed |
Breast Cancer |
NCT02301988 |
| Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) |
Completed |
Brenner Tumor|Fallopian Tube Cancer|Ovarian Carcinosarcoma|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mixed Epithelial Carcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Primary Peritoneal Cavity Cancer|Stage II Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer |
NCT00085358 |
| Sutent + Taxol for Advanced Esophageal Cancer |
Completed |
Esophageal Cancer |
NCT00730353 |
| Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE) |
Completed |
Breast Cancer |
NCT00544232 |
| ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00394082 |
| Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma |
Recruiting |
Gastroesophageal Junction Adenocarcinoma|Adenocarcinoma of the Stomach |
NCT03966118 |
| A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) |
Completed |
Ovarian Cancer |
NCT01357161 |
| Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma |
Recruiting |
Metastatic Pancreatic Adenocarcinoma |
NCT03943667 |
| Dose-finding Study in Platinum-Resistant Ovarian Cancer |
Completed |
Recurrent Platinum-resistant Ovarian Cancer |
NCT01653912 |
| Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma |
Recruiting |
Epithelial Ovarian Carcinoma |
NCT02437812 |
| Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT01236716 |
| Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents |
Terminated |
Coronary Artery Bypass Grafting |
NCT01223443 |
| A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer |
Completed |
Advanced Breast Cancer|Advanced Malignant Solid Tumors|Breast Neoplasms |
NCT00445458 |
| Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00096343 |
| Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery |
Completed |
Sarcoma |
NCT00217607 |
| Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel |
Completed |
Breast Cancer |
NCT02073487 |
| Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary |
Completed |
Carcinoma of Unknown Primary |
NCT00873119 |
| Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer |
Completed |
Non-Squamous Non-Small Cell Lung Cancer |
NCT01160601 |
| Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer |
Completed |
Neoplasm |
NCT00100139 |
| Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer |
Terminated |
Metastatic, Gastric or Gastro-oesophageal Junction, Cancer |
NCT01579578 |
| Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer |
Unknown status |
Esophageal Squamous Cell Cancer |
NCT02016274 |
| Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer |
Recruiting |
Breast - Female|Male Breast Cancer |
NCT03018080 |
| Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer |
Terminated |
Breast Cancer |
NCT01120158 |
| Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer |
Completed |
Non Small Cell Lung Cancer |
NCT00753909 |
| Paclitaxel and Irinotecan in Advanced Gastric Cancer |
Completed |
Advanced Gastric Cancer |
NCT01136031 |
| Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors |
Recruiting |
Recurrent Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm |
NCT03430882 |
| A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors |
Completed |
Breast Neoplasms |
NCT02162719 |
| Drug-Eluting Balloon Catheters and the Treatment of Peripheral Arterial Occlusive Disease |
Completed |
Peripheral Arterial Disease|Stenotic Femoro-popliteal Arteries|Occluded Femoro-popliteal Arteries|Atherosclerosis |
NCT01007578 |
| Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer |
Completed |
Breast Neoplasms|Pancreatic Neoplasms |
NCT02309177 |
| Clinical Study of Decitabine and Paclitaxel Combination Therapy |
Unknown status |
Advanced Breast Cancer |
NCT03282825 |
| A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer |
Completed |
Solid Tumor|Stage IV Gastric Cancer |
NCT02890511 |
| Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity |
Completed |
Ovarian Cancer|Peritoneal Cavity Cancer|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00825201 |
| Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy |
Recruiting |
Extensive-Stage Small Cell Lung Cancer |
NCT04056949 |
| Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer |
Recruiting |
Oropharynx Squamous Cell Carcinoma |
NCT03829722 |
| Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer |
Active, not recruiting |
Locally Advanced Breast Carcinoma|Metastatic Breast Carcinoma|Recurrent Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7 |
NCT01463072 |
| Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer |
Active, not recruiting |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT01402271 |
| Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer |
Terminated |
Anaplastic Thyroid Cancer |
NCT00507429 |
| Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery |
Completed |
Adult Solid Neoplasm|Estrogen Receptor Negative|HER2/Neu Negative|Male Breast Carcinoma|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma |
NCT01276496 |
| Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas |
Recruiting |
Pancreatic Cancer|Nab-paclitaxel|Gemcitabine|S1 |
NCT03779464 |
| A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARÎł Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy |
Completed |
Anaplastic Thyroid Cancer |
NCT00603941 |
| Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer |
Unknown status |
Breast Cancer |
NCT01625429 |
| EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer |
Completed |
Ovarian Cancer Recurrent |
NCT01485848 |
| A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT00558636 |
| Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00030368 |
| Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel for Non-small Cell Lung Cancer (NSCLC) |
Recruiting |
Metastatic Lung Non-Small Cell Squamous Carcinoma|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Unresectable Lung Non-Small Cell Carcinoma|Unresectable Lung Non-Squamous Non-Small Cell Carcinoma |
NCT03965689 |
| A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer |
Terminated |
Advanced Breast Cancer |
NCT02054338 |
| Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) |
Unknown status |
Pancreatic Adenocarcinoma |
NCT01971281 |
| Hepatic Arterial Infusion (HAI) of Abraxane |
Completed |
Liver Cancer|Advanced Cancers|Solid Tumors |
NCT00732836 |
| A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer |
Active, not recruiting |
Pancreatic Cancer |
NCT02481635 |
| Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients |
Completed |
Gastric Adenocarcinoma |
NCT01336062 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma |
Terminated |
Refractory Plasma Cell Myeloma |
NCT01646762 |
| Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
Completed |
Brenner Tumor|Fallopian Tube Cancer|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mixed Epithelial Carcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Primary Peritoneal Cavity Cancer|Stage II Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer |
NCT00079430 |
| Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer |
Recruiting |
Breast Cancer|HER2 Positive|Combination Chemotherapy |
NCT04152057 |
| A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology |
Terminated |
Squamous Non-Small Cell Lung Cancer |
NCT02204345 |
| Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer |
Completed |
Breast Cancer|Triple Negative Breast Cancer|Stage IV Breast Cancer|Metastatic Breast Cancer |
NCT01307891 |
| Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer |
Active, not recruiting |
Endometrial Cancer |
NCT01367002 |
| Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin |
Completed |
Invasive Breast Cancer |
NCT00635050 |
| Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer |
Terminated |
Lung Cancer |
NCT00728845 |
| Paclitaxel in Treating Older Patients With Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00003092 |
| Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter (RESTENOZA) |
Unknown status |
In-Stent Restenosis |
NCT01255956 |
| Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer |
Active, not recruiting |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Stage IB Cervical Cancer AJCC v6 and v7|Stage IIA Cervical Cancer AJCC v7|Stage IIB Cervical Cancer AJCC v6 and v7|Stage IIIA Cervical Cancer AJCC v6 and v7|Stage IIIB Cervical Cancer AJCC v6 and v7|Stage IVA Cervical Cancer AJCC v6 and v7 |
NCT01295502 |
| Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer |
Unknown status |
Esophageal Cancer |
NCT01034189 |
| Paclitaxel in Treating Women With Recurrent Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00003130 |
| Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer |
Unknown status |
Metastatic Pancreatic Cancer |
NCT01964534 |
| A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer |
Active, not recruiting |
Stage III Esophageal Squamous Cell Carcinoma |
NCT02459457 |
| Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer |
Active, not recruiting |
Inflammatory Breast Cancer|Stage IIA Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-negative Breast Cancer|Stage IIB Breast Cancer|Estrogen Receptor Negative|Progesterone Receptor Negative|HER2/Neu Negative |
NCT01525966 |
| Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer |
Completed |
Breast Cancer |
NCT00629499 |
| Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly |
N/A |
N/A |
NCT00702299 |
| A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab |
Active, not recruiting |
Esophageal Neoplasms|Adenocarcinoma of the Gastroesophageal Junction|Gastroesophageal Cancer|Squamous Cell Carcinoma|Gastric Adenocarcinoma |
NCT02013154 |
| Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer |
Completed |
Neoplasms, Breast |
NCT00075270 |
| Neoadjuvant Therapy for Ovarian Cancer |
Terminated |
Epithelial Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer |
NCT01146795 |
| Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery |
Recruiting |
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma|Stage II Oropharyngeal Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IV Hypopharyngeal Squamous Cell Carcinoma|Stage IV Laryngeal Squamous Cell Carcinoma|Stage IV Oral Cavity Squamous Cell Carcinoma|Stage IV Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma|Stage IVB Hypopharyngeal Squamous Cell Carcinoma|Stage IVB Laryngeal Squamous Cell Carcinoma|Stage IVB Oral Cavity Squamous Cell Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma|Stage IVC Hypopharyngeal Squamous Cell Carcinoma|Stage IVC Laryngeal Squamous Cell Carcinoma|Stage IVC Oral Cavity Squamous Cell Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma |
NCT03342911 |
| Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma |
Terminated |
Angiosarcomas|Soft Tissue Sarcoma |
NCT01055028 |
| Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel |
Completed |
Breast Cancer|Ovarian Neoplasm|Pain |
NCT01821833 |
| Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma |
Unknown status |
Breast Neoplasms |
NCT00353717 |
| A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies |
Completed |
Non-hematologic Malignancy |
NCT02412722 |
| Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer |
Completed |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer |
NCT00057863 |
| A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT02399137 |
| Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00002939 |
| The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee |
Completed |
Peripheral Arterial Disease|Cardiovascular Disease|Peripheral Vascular Disease |
NCT02464501 |
| A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00337532 |
| S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer |
NCT00003120 |
| Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer |
Completed |
Advanced Breast Cancer |
NCT00561119 |
| Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00005646 |
| Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer |
Completed |
Recurrent Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast Cancer |
NCT00054028 |
| Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00472693 |
| Single Arm Study With a Nitinol Self-Expanding Paclitaxel-Eluting Stent to Treat BTK Arteries |
Completed |
Peripheral Arterial Disease |
NCT01630070 |
| Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates |
Recruiting |
Pancreatic Cancer|Pancreatic Adenocarcinoma|Pancreas Ductal Adenocarcinoma |
NCT02723331 |
| First Line Therapy for Patients With Metastatic Breast Cancer |
Terminated |
Metastatic Breast Cancer |
NCT00456846 |
| Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma |
Active, not recruiting |
Melanoma |
NCT01827111 |
| STREAMER : STent Restenosis And MEdicaments Release |
Completed |
Critical Ischemia |
NCT02835586 |
| Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer |
Not yet recruiting |
Non-small Cell Lung Cancer |
NCT03262948 |
| Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer |
Unknown status |
Triple Negative Breast Cancer |
NCT01276769 |
| EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer |
Active, not recruiting |
Ovarian Cancer |
NCT02001272 |
| Paclitaxel Eluting Balloon for SFA In-stent Restenosis |
Unknown status |
In-stent Arterial Restenosis |
NCT01616888 |
| Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma |
NCT01199263 |
| Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors |
Completed |
Breast Cancer|Ovarian Cancer|Gynecological Cancer|Head and Neck Carcinoma|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Non-squamous Cell Lung Cancer |
NCT01831089 |
| Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma |
Withdrawn |
Relapse/Refractory Multiple Myeloma |
NCT02985333 |
| Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery |
Completed |
Head and Neck Cancer |
NCT01333085 |
| Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE) |
Completed |
Primary Breast Cancer |
NCT01779479 |
| Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors |
Completed |
SOLID TUMORS |
NCT00572078 |
| A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer |
Completed |
Carcinoma|Non-Squamous Non-Small-Cell Lung Cancer |
NCT00152477 |
| Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT01057342 |
| Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer |
Terminated |
Prostate Cancer |
NCT01558492 |
| Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
Completed |
Ovarian Cancer|Primary PERITONEUM|Fallopian Tube Cancer |
NCT00588237 |
| Scheduling Nab-paclitaxel With Gemcitabine |
Completed |
Pancreatic Adenocarcinoma Metastatic |
NCT03529175 |
| Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction |
Active, not recruiting |
Breast Carcinoma|Carcinoma of Unknown Primary|Endometrial Carcinoma|Esophageal Carcinoma|Liver Failure|Lung Carcinoma|Malignant Head and Neck Neoplasm|Malignant Testicular Neoplasm|Melanoma|Metastatic Malignant Neoplasm|Ovarian Carcinoma|Renal Failure|Unresectable Malignant Neoplasm|Urothelial Carcinoma |
NCT01366144 |
| Paclitaxel Eluting Balloon After Bare Metal Stent Implantation vs. Drug-Eluting Stent in St Elevation Myocardial Infarction |
Recruiting |
Acute Myocardial Infarction |
NCT03610347 |
| Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery |
Recruiting |
Locally Advanced Thymic Carcinoma|Metastatic Thymic Carcinoma|Recurrent Thymic Carcinoma|Unresectable Thymic Carcinoma |
NCT03694002 |
| OCT- Versus Angiography-guided Paclitaxel Drug-Coated Balloon Angioplasty in De Novo Coronary Artery |
Recruiting |
Coronary Artery Disease |
NCT04276389 |
| A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours |
Completed |
Solid Tumor |
NCT00737555 |
| Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer |
Unknown status |
Gastric Cancer |
NCT02529878 |
| A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma |
Completed |
Uterine Cancer |
NCT00231868 |
| RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer |
Completed |
Metastatic Pancreatic Cancer |
NCT03189914 |
| Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma |
Active, not recruiting |
Nasopharyngeal Carcinoma |
NCT03047265 |
| Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) |
Completed |
Ovarian Cancer |
NCT00129727 |
| Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility |
Completed |
Breast Cancer|Adenocarcinoma of the Breast |
NCT00617370 |
| Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer |
Active, not recruiting |
Metastatic|Breast Cancer |
NCT01745757 |
| Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma |
Completed |
Brenner Tumor|Fallopian Tube Cancer|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer |
NCT00059787 |
| Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) |
Terminated |
Non-Small Cell Lung Cancer |
NCT02920450 |
| Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib |
Completed |
Gastrointestinal Stromal Tumors |
NCT02607332 |
| Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma |
Completed |
Thymoma|Thymic Carcinoma |
NCT00010257 |
| Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer |
Recruiting |
Breast Cancer |
NCT04182568 |
| Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours |
Completed |
Advanced Solid Tumours |
NCT02341456 |
| Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer |
Completed |
Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer |
NCT00031694 |
| A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma |
Completed |
Gastric Cancer |
NCT01170663 |
| Investigating the Preventative Ability of Massage Therapy on Paclitaxel Induced Peripheral Neuropathy |
Terminated |
Breast Cancer|Neuropathy|Neuropathy |
NCT03557554 |
| Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer |
Recruiting |
Breast Adenocarcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Invasive Breast Carcinoma|Progesterone Receptor Negative|Triple-Negative Breast Carcinoma |
NCT02530489 |
| Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis |
Terminated |
Hemodialysis Graft Dysfunction |
NCT00249002 |
| A Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer |
Active, not recruiting |
Pancreatic Cancer (Unresectable) |
NCT02210559 |
| Local Paclitaxel or Balloon Angioplasty Below the Knee |
Recruiting |
Stenosis|Occlusion|Restenosis |
NCT03149913 |
| Paclitaxel-bevacizumab in Advanced Lung Cancer |
Completed |
Non-squamous Non-small Cell Lung Cancer |
NCT01763671 |
| EGFR/FGFR-targeted Therapy for Gastric Cancer |
Not yet recruiting |
Adenocarcinoma of the Stomach |
NCT04077255 |
| Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer |
Not yet recruiting |
Stage IA Pancreatic Adenocarcinoma|Stage IB Pancreatic Adenocarcinoma|Stage IIA Pancreatic Adenocarcinoma|Stage IIB Pancreatic Adenocarcinoma |
NCT04216758 |
| Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer |
Active, not recruiting |
Thyroid Gland Anaplastic Carcinoma |
NCT01236547 |
| Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors |
Completed |
Bladder Cancer|Brain and Central Nervous System Tumors|Breast Cancer|Esophageal Cancer|Extragonadal Germ Cell Tumor|Gastric Cancer|Lung Cancer|Ovarian Cancer|Prostate Cancer |
NCT00313599 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer |
Terminated |
Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma |
NCT01238133 |
| S-1 in Combination With Abraxane in Treating Cholangiocarcinoma |
Completed |
Cholangiocarcinoma |
NCT01963325 |
| Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT00687817 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer |
Active, not recruiting |
Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer |
NCT01620190 |
| Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma |
Terminated |
Lymphoma, Non-Hodgkin|Hodgkin Disease |
NCT01555853 |
| Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) |
Recruiting |
Pancreas Adenocarcinoma |
NCT03377491 |
| Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer |
Unknown status |
Stage III Ovarian Cancer|Stage IV Ovarian Cancer|Uterine Cancer |
NCT01650376 |
| Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer |
Completed |
Resectable Pancreatic Cancer |
NCT01298011 |
| Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer |
Active, not recruiting |
Resectable Pancreatic Cancers |
NCT02318095 |
| Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer |
Completed |
Male Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer |
NCT00368875 |
| Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen |
Completed |
Breast Cancer|Breast Neoplasms |
NCT01042925 |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063) |
Active, not recruiting |
Gastric Neoplasms|Gastroesophageal Junction Adenocarcinoma |
NCT03019588 |
| A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer |
Completed |
Small Cell Lung Cancer |
NCT00317200 |
| Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) |
Not yet recruiting |
Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma |
NCT04046887 |
| Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer |
Not yet recruiting |
Breast Cancer |
NCT04261218 |
| Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC) |
Completed |
Breast Cancer |
NCT01287624 |
| Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel |
Unknown status |
Nausea|Vomiting |
NCT02290470 |
| Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer |
Terminated |
Pancreatic Cancer |
NCT02047500 |
| Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors |
Completed |
Neoplasms |
NCT00606125 |
| Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? |
Recruiting |
Carcinosarcoma|Endometrial Neoplasms |
NCT03570437 |
| Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line |
Unknown status |
Squamous Cell Carcinoma |
NCT03292822 |
| Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer |
Unknown status |
Advanced Gastric Carcinoma |
NCT02163291 |
| ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors |
Completed |
Advanced Solid Tumors |
NCT02551185 |
| A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer |
Unknown status |
Epithelial Ovarian Carcinoma|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma |
NCT02344095 |
| Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer |
Unknown status |
ErbB2-Positive Stage I-III Breast Cancer |
NCT01309607 |
| Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer |
Completed |
Breast Cancer |
NCT00096291 |
| Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery |
Terminated |
Lung Cancer |
NCT00459121 |
| A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT02182232 |
| Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer |
Completed |
Locally Recurrent or Metastatic Breast Cancer |
NCT01256762 |
| A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer |
Terminated |
Human Mammary Carcinoma |
NCT00558545 |
| Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer |
Recruiting |
Ovarian Cancer |
NCT04000295 |
| Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell CarcinomaďĽESCC）. |
Not yet recruiting |
Esophageal Squamous Cell Carcinoma |
NCT04063683 |
| VISION and VQI Paclitaxel Safety Analysis |
Active, not recruiting |
PAD |
NCT04204564 |
| Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery |
Active, not recruiting |
HER2 Positive Breast Carcinoma|Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7 |
NCT02654119 |
| Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin |
Completed |
Lung Cancer (NSCLC) |
NCT02279732 |
| Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis |
Recruiting |
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma |
NCT02628951 |
| Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer |
Completed |
Breast Cancer |
NCT00308178 |
| Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial |
Active, not recruiting |
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma |
NCT01506856 |
| Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00006018 |
| AZD2014 and Weekly Paclitaxel in Squamous NSCLC |
Terminated |
Squamous Non Small Cell Lung Cancer |
NCT02403895 |
| Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma |
Completed |
Endometrial Cancer |
NCT00513786 |
| Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma |
Recruiting |
Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma|Cancer of the Head and Neck |
NCT02270814 |
| Paclitaxel-HDFL for Locally Advanced and Recurrent/Metastatic Gastric Cancers |
Completed |
Locally Advanced and Recurrent/Metastatic Gastric Cancer |
NCT00154726 |
| Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery |
Active, not recruiting |
Lung Adenocarcinoma|Lung Adenocarcinoma, Mixed Subtype|Lung Large Cell Carcinoma|Lung Squamous Cell Carcinoma|Minimally Invasive Lung Adenocarcinoma|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7 |
NCT01386385 |
| A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
Carcinoma, Non-Squamous Non-Small Cell Lung |
NCT02367781 |
| Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer |
Terminated |
Non-small Cell Lung Cancer |
NCT00702572 |
| Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer |
Recruiting |
Endometrial Cancer |
NCT03935256 |
| Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer |
Active, not recruiting |
Stage IIIB Non-Small Cell Lung Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7 |
NCT02503358 |
| Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in In-Stent Restenosis Lesions (DEBREST) |
Completed |
In-stent Coronary Artery Restenosis |
NCT01485068 |
| Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis |
Completed |
Peritoneal Cancer |
NCT00491855 |
| Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer |
Recruiting |
Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8 |
NCT04249167 |
| LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors |
Unknown status |
Advanced Solid Tumors |
NCT01159418 |
| Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer |
Completed |
Breast Cancer|Triple Negative Breast Cancer|Metastatic Breast Cancer |
NCT00707707 |
| N-acetyl Cysteine Effect in Peripheral Neuropathy in Cancer Patients |
Completed |
Peripheral Neuropathy Due to Chemotherapy |
NCT03492047 |
| Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation |
Not yet recruiting |
Uterine Carcinoma |
NCT04030000 |
| ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer |
Active, not recruiting |
Metastatic Breast Cancer|Breast Carcinoma |
NCT02632071 |
| Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00178256 |
| Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer |
Completed |
Advanced Solid Tumors |
NCT01491204 |
| Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients |
Withdrawn |
Breast Cancer |
NCT01169870 |
| Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients |
Recruiting |
Breast Cancer|Chemotherapy Induced Peripheral Neuropathy|Paclitaxel Induced Neuropathy |
NCT03872141 |
| A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma |
Not yet recruiting |
Urothelial Carcinoma |
NCT04211012 |
| Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice |
Terminated |
Breast Neoplasms |
NCT02655159 |
| Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT00003591 |
| First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r) |
Completed |
Peripheral Artery Disease|Femoropopliteal Artery Disease |
NCT02145065 |
| Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
Completed |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma |
NCT01716715 |
| Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer |
Active, not recruiting |
Esophageal Adenocarcinoma|Esophageal Squamous Cell Carcinoma|Gastroesophageal Junction Adenocarcinoma|Recurrent Esophageal Carcinoma|Stage IV Esophageal Cancer AJCC v7 |
NCT01142388 |
| RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation |
Completed |
Carcinoma, Large Cell|Neuroendocrine Tumors |
NCT01317615 |
| Single Agent Abraxane as Second Line Therapy in Bladder Cancer |
Completed |
Transitional Cell Carcinoma |
NCT00683059 |
| Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients |
Active, not recruiting |
Adenocarcinoma Pancreas |
NCT02812992 |
| A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP) |
Unknown status |
Unknown Primary Tumors |
NCT02607202 |
| Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations |
Completed |
Breast Cancer |
NCT02628613 |
| Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC |
Active, not recruiting |
Non-Small Cell Lung Cancer(NSCLC) |
NCT02667743 |
| Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients |
Active, not recruiting |
Gastric Cancer |
NCT01063517 |
| Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma |
Not yet recruiting |
Nasopharyngeal Carcinoma|Nasopharyngeal Cancer|Nasopharynx Cancer |
NCT04004871 |
| Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel |
Completed |
Pancreatic Cancer |
NCT02106884 |
| A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant MĂĽllerian Cancer |
Completed |
Platinum Resistant Ovarian Cancer |
NCT01711970 |
| Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma |
Recruiting |
Esophageal Squamous Cell Carcinoma |
NCT03964753 |
| Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4 |
Completed |
Restenosis|Stable Angina Pectoris|Acute Coronary Syndrome |
NCT01632371 |
| Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer |
Active, not recruiting |
Metastatic Pancreatic Adenocarcinoma |
NCT02562898 |
| Abraxane and Alimta in Advanced Solid Tumors |
Terminated |
Breast Cancer|Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00470548 |
| A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131] |
Active, not recruiting |
Squamous Non-Small Cell Lung Cancer |
NCT02367794 |
| Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery |
Terminated |
Esophageal Cancer |
NCT00493025 |
| Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer |
Completed |
Metastatic Pancreatic Cancer |
NCT00398086 |
| Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer |
Completed |
Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mixed Epithelial Carcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer |
NCT00002913 |
| A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) |
Active, not recruiting |
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma |
NCT02370498 |
| Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca |
Terminated |
Breast Cancer |
NCT00934895 |
| Paclitaxel/Carboplatin With or Without Cetuximab in CUP |
Unknown status |
Neoplasms, Unknown Primary|Carcinoma |
NCT00894569 |
| Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency |
Completed |
Breast Cancer|Triple Negative Breast Neoplasms|HRpos Breast Neoplasms|BRCA 1 /2 and / or HRD |
NCT02789332 |
| Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer |
Unknown status |
Esophageal Cancer |
NCT02762474 |
| Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer |
Completed |
Metastatic Pancreas Adenocarcinoma |
NCT02620800 |
| A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells |
Not yet recruiting |
Gastric Cancer With Positive Exfoliative Cancer Cells |
NCT03718624 |
| Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer |
Terminated |
Breast Neoplasm |
NCT00251095 |
| Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00390611 |
| Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00654836 |
| A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma |
Terminated |
Melanoma |
NCT01006252 |
| EST) |
London |
United Kingdom|For additional information regarding investigative sites for this trial |
1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours |
| A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent |
Completed |
Coronary Instent Restenosis |
NCT01622075 |
| Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers |
Recruiting |
Stage III Distal Bile Duct Cancer AJCC v8|Stage III Gallbladder Cancer AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIA Distal Bile Duct Cancer AJCC v8|Stage IIIA Gallbladder Cancer AJCC v8|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIB Distal Bile Duct Cancer AJCC v8|Stage IIIB Gallbladder Cancer AJCC v8|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8|Stage IV Distal Bile Duct Cancer AJCC v8|Stage IV Gallbladder Cancer AJCC v8|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8|Stage IVA Gallbladder Cancer AJCC v8|Stage IVB Gallbladder Cancer AJCC v8|Unresectable Extrahepatic Bile Duct Carcinoma|Unresectable Gallbladder Carcinoma|Unresectable Intrahepatic Cholangiocarcinoma |
NCT03768414 |
| United States|Grady Memorial Hospital |
Ohio |
Dublin |
Ohio |
| Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer |
Completed |
Tubular Breast Cancer|Mucinous Breast Cancer|Invasive Ductal Breast Cancer|Inflammatory Breast Cancer |
NCT02199418 |
| Paclitaxel and Cisplatin for Thymic Neoplasm |
Terminated |
Thymoma|Thymic Carcinoma |
NCT00818090 |
| Treatment of Drug-eluting Stent (DES) In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter |
Unknown status |
In-Stent Restenosis |
NCT00998439 |
| A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT01740336 |
| A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer |
Active, not recruiting |
High Grade Serous Ovarian|Fallopian Tube|Primary Peritoneal Cancer |
NCT03245892 |
| Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma |
Unknown status |
Esophageal Squamous Cell Carcinoma |
NCT02677597 |
| T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT02073916 |
| Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer |
Recruiting |
Breast Cancer |
NCT03994107 |
| Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer |
Terminated |
Gastro-oesophageal Junction Cancer|Gastric Cancer |
NCT01457846 |
| Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in Side Branches of de Novo Bifurcation Lesions (DEBSIDE) |
Completed |
Coronary Disease |
NCT01485081 |
| Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma |
Active, not recruiting |
Metastatic Malignant Melanoma |
NCT02617849 |
| Comparison of Two Regimens of Dexamethasone in the Prevention of Hypersensitivity Reactions to Paclitaxel, a Pilot Study |
Completed |
Prevention of Hypersensitivity Reactions to Paclitaxel |
NCT01797991 |
| Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients With Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen. |
Active, not recruiting |
Urothelial Cancer |
NCT02033993 |
| Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer |
Not yet recruiting |
Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Unresectable Pancreatic Carcinoma |
NCT04158635 |
| Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer |
Completed |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma |
NCT01468909 |
| S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract |
Terminated |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer |
NCT00022633 |
| Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) |
Terminated |
Adenocarcinoma of the Esophagus|Adenocarcinoma of the Gastroesophageal Junction |
NCT01395537 |
| Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma ) |
Not yet recruiting |
Head and Neck Squamous Cell Cancer |
NCT03975270 |
| Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00876395 |
| Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer |
Completed |
Breast Neoplasms |
NCT00174434 |
| Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer |
Unknown status |
Stage III-IV or Recurrent Endometrial Cancer |
NCT01770171 |
| A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma |
Completed |
Malignant Melanoma |
NCT00864253 |
| Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions |
Completed |
Neoplasms|Bone Diseases |
NCT02442063 |
| Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Withdrawn |
Ovarian Papillary Serous Carcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Primary Peritoneal Cavity Cancer |
NCT02050009 |
| Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00062010 |
| Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer |
Terminated |
Urinary Bladder Neoplasms |
NCT02560038 |
| A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer |
Withdrawn |
Breast Cancer|Triple Negative Breast Neoplasms|Triple-Negative Breast Neoplasm|Triple-Negative Breast Cancer|Triple Negative Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Neoplasms|ER-Negative PR-Negative HER2-Negative Breast Cancer |
NCT02685306 |
| ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00110084 |
| Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer |
Withdrawn |
Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific |
NCT02048943 |
| A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers |
Terminated |
Advanced Solid Cancers |
NCT00337376 |
| A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer Stage III |
NCT02412371 |
| S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00100789 |
| Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma |
Unknown status |
Gastric Carcinoma |
NCT00639522 |
| NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer |
Completed |
HER2-positive Newly Diagnosed, Primary Breast Cancer |
NCT01816594 |
| Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00479674 |
| BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) |
Recruiting |
Pancreatic Ductal Adenocarcinoma |
NCT03496662 |
| Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin |
Completed |
Lung Cancer - Non Small Cell Squamous |
NCT01285609 |
| Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel |
Active, not recruiting |
Triple Negative Metastatic Breast Cancer|Advanced Ovarian Cancer|Carboplatin|Paclitaxel |
NCT00516724 |
| Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer |
Completed |
Fallopian Tube Carcinoma|Infectious Disorder|Neutropenia|Ovarian Carcinosarcoma|Primary Peritoneal Carcinoma|Stage III Ovarian Cancer|Stage IV Ovarian Cancer |
NCT00352300 |
| Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer |
Recruiting |
Breast Carcinoma|Breast Lump|Edema|Erythema|Estrogen Receptor Negative|HER2/Neu Negative|Inflammatory Breast Carcinoma|Invasive Breast Carcinoma|Peau d'Orange|Progesterone Receptor Negative|Triple-Negative Breast Carcinoma |
NCT02876107 |
| Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer |
Completed |
Advanced Pancreatic Cancer |
NCT01010945 |
| Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer |
Terminated |
Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer |
NCT01413750 |
| Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR) |
Completed |
Coronary Artery Disease|Coronary Restenosis|Coronary Atherosclerosis|Coronary Arteriosclerosis |
NCT02151812 |
| A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Non-Small Cell Lung Cancer |
NCT00918203 |
| A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer |
Completed |
Uterine Cancer |
NCT00584857 |
| Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer |
Active, not recruiting |
Endometrial Neoplasms |
NCT02725268 |
| A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer |
Completed |
Non Small Cell Lung Cancer |
NCT00735696 |
| Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00915018 |
| Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer |
Unknown status |
Breast Cancer |
NCT01321775 |
| Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00062179 |
| A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of NaĂŻve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer |
Recruiting |
Non Small Cell Lung Cancer|Non Small Cell Lung Cancer Metastatic|Non Small Cell Lung Cancer Recurrent |
NCT03533127 |
| Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Recruiting |
Fallopian Tube Endometrioid Adenocarcinoma|High Grade Fallopian Tube Serous Adenocarcinoma|High Grade Ovarian Serous Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Platinum-Resistant Ovarian Carcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Refractory Fallopian Tube Carcinoma|Refractory Ovarian Carcinoma|Refractory Primary Peritoneal Carcinoma |
NCT03587311 |
| Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT02629848 |
| A COMparison Between PAClitaxel-coated Balloon and pacliTaxel-eluting Stent in the Treatment of In-Stent Restenosis (COMPACT-ISR) |
Terminated |
Stable Angina|Unstable Angina |
NCT01204320 |
| Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site |
Completed |
Neoplasm, Unknown Primary |
NCT00360360 |
| A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer. |
Completed |
Women With Primary Breast Cancer |
NCT02225652 |
| Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery |
Active, not recruiting |
Pancreatic Adenocarcinoma|Unresectable Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7 |
NCT02336087 |
| A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer |
Recruiting |
Breast Cancer |
NCT03337724 |
| Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma |
Completed |
Ciliary Body and Choroid Melanoma, Medium/Large Size|Extraocular Extension Melanoma|Iris Melanoma|Recurrent Intraocular Melanoma|Recurrent Melanoma|Stage IV Melanoma |
NCT00288041 |
| FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer |
Recruiting |
HER2 Positive Breast Carcinoma|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer |
NCT03179904 |
| Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients |
Unknown status |
Adrenocortical Carcinoma |
NCT00786110 |
| Pivotal Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon |
Active, not recruiting |
Peripheral Arterial Disease |
NCT01858428 |
| Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT01644825 |
| Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) |
Recruiting |
Squamous Cell Carcinoma of the Head and Neck|Carcinoma, Squamous Cell of the Head and Neck|Cancer of Head and Neck|Cancer of the Head and Neck|Head and Neck Cancer|Neoplasms, Head and Neck |
NCT02573493 |
| Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer |
Completed |
Endometrial Adenosquamous Carcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Mixed Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Squamous Cell Carcinoma|Endometrial Undifferentiated Carcinoma|Recurrent Uterine Corpus Carcinoma|Stage IIIA Uterine Corpus Cancer|Stage IIIC Uterine Corpus Cancer|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer |
NCT00575952 |
| The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer |
Active, not recruiting |
Metastatic Breast Cancer |
NCT01506609 |
| Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors |
Completed |
Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Melanoma (Skin)|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00667641 |
| A Multicenter, Double-blind, Randomized Controlled Phase II Clinical Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity |
Not yet recruiting |
Early Breast Cancer |
NCT04222790 |
| Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00028990 |
| Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer |
Completed |
Prostate Cancer |
NCT00284752 |
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer |
Terminated |
HER2-negative Breast Cancer|Inflammatory Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer |
NCT01938833 |
| Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma |
Terminated |
Melanoma |
NCT00522834 |
| PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients |
Completed |
Carcinoma, Non-Small Cell Lung |
NCT00174356 |
| Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer |
Completed |
Sarcoma |
NCT00112489 |
| Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer |
Recruiting |
Recurrent Endometrial Endometrioid Adenocarcinoma|Recurrent Uterine Corpus Carcinoma|Stage III Uterine Corpus Cancer AJCC v7|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7 |
NCT02684227 |
| Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis |
Withdrawn |
In-stent Stenosis of Infrapopliteal Arteries |
NCT01398033 |
| Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer |
Active, not recruiting |
HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Breast Adenocarcinoma|Inflammatory Breast Carcinoma |
NCT01730833 |
| Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902) |
Unknown status |
Non-small Cell Lung Cancer |
NCT01158144 |
| Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer |
Completed |
Breast Cancer |
NCT01186991 |
| Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer |
Completed |
Pancreatic Acinar Cell Carcinoma|Pancreatic Ductal Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage IV Pancreatic Cancer |
NCT01280058 |
| Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer |
Withdrawn |
Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III |
NCT03058939 |
| Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer |
Recruiting |
Bladder Cancer Cell Transitional|Non-Muscle Invasive Bladder Cancer|Bladder Cancer|Urinary Bladder|Transitional Cell Carcinoma of the Bladder|Urinary Bladder Neoplasms|Urologic Neoplasms|Urogenital Neoplasms|Urinary Bladder Diseases|Urologic Diseases |
NCT03081858 |
| Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer |
Recruiting |
Breast Cancer |
NCT04066790 |
| Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel |
Completed |
Melanoma |
NCT01666418 |
| A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer |
Terminated |
Breast Cancer |
NCT00607438 |
| Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer |
Completed |
Squamous Non-Small Cell Lung Cancer |
NCT02106546 |
| Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer |
Suspended |
Breast Adenocarcinoma|HER2/Neu Negative|Invasive Breast Carcinoma|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7 |
NCT02037529 |
| Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer |
Terminated |
Non-Small-Cell Lung Carcinoma |
NCT01090830 |
| Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC. |
Withdrawn |
Gastric Cancer |
NCT00209612 |
| Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00003644 |
| An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors |
Completed |
Malignant Solid Tumour|Ovarian Cancer|Triple Negative Breast Cancer|Advanced Melanoma|B-cell Malignancy, Low-grade |
NCT01618136 |
| First Line Chemotherapy for Advanced Cancer |
Terminated |
Gastric Cancer |
NCT01980810 |
| Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer |
Terminated |
Endometrial Serous Adenocarcinoma|Stage IIIA Uterine Corpus Cancer|Stage IIIB Uterine Corpus Cancer|Stage IIIC1 Uterine Corpus Cancer|Stage IIIC2 Uterine Corpus Cancer|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer |
NCT02112552 |
| Role of Tirofiban and the Paclitaxel Eluting Stent in Postfibrinolysis Angioplasty |
Completed |
Myocardial Infarction |
NCT00306228 |
| Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer |
Completed |
Breast Cancer |
NCT00691379 |
| Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
Completed |
Adult Solid Neoplasm|Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Male Breast Carcinoma|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma |
NCT01281150 |
| Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin |
Terminated |
Metastatic Breast Cancer |
NCT00691912 |
| Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy |
Completed |
Advanced Gastric Cancer |
NCT02451956 |
| Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection |
Unknown status |
Stage â… A Pancreatic Cancer|Stage â… B Pancreatic Cancer|Stage â…ˇA Pancreatic Cancer|Stage â…ˇB Pancreatic Cancer |
NCT02506842 |
| Study of Paclitaxel in Patients With Ovarian Cancer |
Completed |
Epithelial Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer |
NCT00989131 |
| Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin |
Completed |
Non-small Cell Lung Cancer |
NCT00966914 |
| Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer |
Unknown status |
HER-2 Positive Breast Cancer |
NCT01428414 |
| Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients |
Completed |
Coronary Stenosis|Diabetes Mellitus |
NCT00462631 |
| Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients |
Completed |
Breast Cancer Female |
NCT01204125 |
| Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT02263495 |
| Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer. |
Recruiting |
Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer |
NCT03462212 |
| Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer |
Terminated |
Endometrial Adenocarcinoma|Stage IA Uterine Corpus Cancer|Stage IB Uterine Corpus Cancer|Stage II Uterine Corpus Cancer|Stage IIIA Uterine Corpus Cancer|Stage IIIB Uterine Corpus Cancer|Stage IIIC Uterine Corpus Cancer|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer |
NCT01041027 |
| BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT02155088 |
| Prevention of Restenosis After Genous Stent Implantation Using a Paclitaxel Eluting Balloon in Coronary Arteries |
Completed |
Coronary Artery Disease |
NCT00732953 |
| Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00945191 |
| Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin |
Completed |
Ovarian Carcinoma |
NCT00181701 |
| Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC |
Completed |
Neoplasms, Breast |
NCT00709761 |
| Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00093145 |
| Oxford Ovarian Cancer Predict Chemotherapy Response 01 |
Unknown status |
Ovarian Cancer |
NCT01770535 |
| Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer |
Completed |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Recurrent Cervical Carcinoma|Stage IVB Cervical Cancer AJCC v6 and v7 |
NCT01281852 |
| Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer |
Completed |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer |
NCT01196741 |
| Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer |
Completed |
Endometrial Adenocarcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Mucinous Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Squamous Cell Carcinoma|Endometrial Transitional Cell Carcinoma|Endometrial Undifferentiated Carcinoma|Endometrioid Adenocarcinoma|Recurrent Uterine Corpus Carcinoma|Stage III Uterine Corpus Cancer AJCC v7|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7 |
NCT01440998 |
| PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer |
Recruiting |
Peritoneal Carcinomatosis|Ovarian Cancer Stage IIIB|Ovarian Cancer Stage IIIC|Ovarian Cancer Stage IV|Breast Cancer Stage IIIB|Breast Cancer Stage IIIc|Breast Cancer Stage IV|Stomach Cancer Stage III|Stomach Cancer Stage IV With Metastases|Pancreas Cancer, Stage III|Pancreas Cancer, Stage IV |
NCT03304210 |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
Fallopian Tube Adenocarcinoma|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Malignant Ovarian Brenner Tumor|Ovarian Adenocarcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma |
NCT02923739 |
| Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC) |
Terminated |
Metastatic Breast Cancer |
NCT01512199 |
| First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
Active, not recruiting |
Fallopian Tube Carcinoma|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|FIGO Stage III Ovarian Cancer|FIGO Stage IIIA Ovarian Cancer|FIGO Stage IIIA1 Ovarian Cancer|FIGO Stage IIIA1(i) Ovarian Cancer|FIGO Stage IIIA1(ii) Ovarian Cancer|FIGO Stage IIIA2 Ovarian Cancer|FIGO Stage IIIB Ovarian Cancer|FIGO Stage IIIC Ovarian Cancer|FIGO Stage IVA Ovarian Cancer|FIGO Stage IVB Ovarian Cancer|Malignant Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Carcinoma|Primary Peritoneal Serous Adenocarcinoma |
NCT01097746 |
| SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck |
Completed |
Head and Neck Cancer |
NCT00005647 |
| Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer |
Terminated |
Non-Small Cell Lunch Cancer |
NCT01820325 |
| Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
Active, not recruiting |
Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Squamous Cell Carcinoma of the Hypopharynx|Metastatic Squamous Cell Carcinoma of the Larynx|Metastatic Squamous Cell Carcinoma of the Oral Cavity|Metastatic Squamous Cell Carcinoma of the Oropharynx|Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Oral Cavity Squamous Cell Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma |
NCT00494182 |
| 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00087217 |
| Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer |
NCT00602797 |
| Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma |
Withdrawn |
Stage IV Esophageal Squamous Cell Carcinoma |
NCT02034968 |
| Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy |
Recruiting |
Advanced Gastric or EGJ Cancer |
NCT03081143 |
| Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients. |
Completed |
Neoplasms|Metastatic Cancer|Breast Cancer |
NCT01003158 |
| Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer |
Completed |
Breast Cancer |
NCT00919880 |
| BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors |
Completed |
Neoplasms |
NCT01938846 |
| Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer |
Completed |
Esophageal Cancer |
NCT00344552 |
| Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
Terminated |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer |
NCT00331422 |
| A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease |
Withdrawn |
Non-Squamous Non-Small Cell Lung Cancer |
NCT01702714 |
| Improve Checkpoint-blockade Response in Advanced Urothelial Cancer |
Not yet recruiting |
Urothelial Carcinoma |
NCT03871036 |
| Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC |
Terminated |
Non-Small Cell Lung Cancer |
NCT00291850 |
| Nab-Paclitaxel and Durvalumab With or Without Neoantigen Vaccine in Treating Patients With Metastatic Triple Negative Breast Cancer |
Not yet recruiting |
Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Negative|HER2/Neu Negative|Metastatic Triple-Negative Breast Carcinoma|Progesterone Receptor Negative|Prognostic Stage IV Breast Cancer AJCC v8 |
NCT03606967 |
| A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT01239732 |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT02483104 |
| TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cancer |
NCT01204749 |
| Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) |
Recruiting |
Thymic Carcinoma|Thymoma |
NCT03921671 |
| S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00661193 |
| A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer |
Completed |
Non-Small -Cell Lung Cancer |
NCT01560104 |
| Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary |
Terminated |
Tumors|Unknown Primary Tumors|Adenocarcinoma |
NCT00201734 |
| First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI |
Recruiting |
Metastatic Pancreatic Cancer |
NCT03693677 |
| Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer |
Active, not recruiting |
Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm |
NCT02317874 |
| Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00005059 |
| Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer |
Terminated |
Triple Negative Metastatic Breast Cancer |
NCT01069796 |
| Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma |
Unknown status |
Esophageal Squamous Cell Carcinomas |
NCT02611700 |
| Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer |
Recruiting |
Breast Cancer|Triple Negative Breast Cancer|HER2-positive Breast Cancer |
NCT03907800 |
| Concurrent Chemoradiotherapy With Weekly Cisplatin Versus Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel in Locally Advanced Carcinoma Cervix |
Unknown status |
Carcinoma Cervix |
NCT01593306 |
| Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients |
Active, not recruiting |
Tubular Breast Cancer|Mucinous Breast Cancer|Invasive Ductal Breast Cancer|Inflammatory Breast Cancer |
NCT02221999 |
| Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
Completed |
Malignant Pleural Effusion|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00408460 |
| Study of NAC of GA Therapy for Patients With BRPC |
Recruiting |
Pancreatic Ductal Adenocarcinoma |
NCT02926183 |
| E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC) |
Completed |
Non-small-cell Lung Cancer |
NCT00832819 |
| A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer |
Completed |
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer |
NCT01649336 |
| A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy |
Completed |
Non-Small Cell Lung Cancer |
NCT01364012 |
| Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer |
Recruiting |
Androgen Receptor Positive|Estrogen Receptor Negative|HER2/Neu Negative|Invasive Breast Carcinoma|Progesterone Receptor Negative|Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma |
NCT02689427 |
| Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer |
Not yet recruiting |
Endometrial Cancer |
NCT03503786 |
| Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy |
Recruiting |
Advanced Gastric Adenocarcinoma |
NCT02448329 |
| Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer |
Terminated |
Cervical Cancer |
NCT00138151 |
| Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma |
Terminated |
Melanoma |
NCT01009515 |
| ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer |
Completed |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Small Cell Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma |
NCT00309959 |
| Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer |
Terminated |
Lung Cancer |
NCT00004859 |
| Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck |
Unknown status |
Squamous Cell Carcinoma of the Head and Neck |
NCT01830556 |
| A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors |
Completed |
Solid Tumors |
NCT01617928 |
| A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer |
Completed |
HER-2 Positive Breast Cancer|Metastatic Breast Cancer |
NCT00788931 |
| Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) |
Completed |
CNS Germ Cell Tumor |
NCT01270724 |
| Triple-B Study |
N/A |
N/A |
NCT01898117 |
| Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer |
Terminated |
Breast Cancer |
NCT01194869 |
| Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer |
Active, not recruiting |
Bladder Urothelial Carcinoma|Stage I Bladder Cancer AJCC v6 and v7|Stage II Bladder Cancer AJCC v6 and v7|Stage III Bladder Cancer AJCC v6 and v7 |
NCT00238420 |
| Photoablative Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis in Instent Femoro-popliteal Obstructions |
Unknown status |
Restenosis |
NCT01298947 |
| Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer |
Active, not recruiting |
Invasive Breast Carcinoma|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma |
NCT02883062 |
| Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer |
Recruiting |
Breast Adenocarcinoma|Metastatic Breast Carcinoma|Recurrent Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7 |
NCT03199885 |
| https://ClinicalTrials.gov/show/NCT03199885 |
N/A |
N/A |
N/A |
| Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies |
Completed |
Advanced Solid Malignancies|Hematologic Malignancies |
NCT01351350 |
| A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma |
Recruiting |
Pancreatic Cancer|Metastatic Pancreatic Cancer|Metastatic Pancreatic Adenocarcinoma |
NCT03816163 |
| Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT01763710 |
| Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma |
Active, not recruiting |
Metastatic Pancreatic Adenocarcinoma |
NCT03214250 |
| Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients |
Enrolling by invitation |
Anus Neoplasms|Carcinoma, Squamous Cell|Anus Diseases|Neoplasms|Neoplasms, Squamous Cell|Carcinoma |
NCT02526953 |
| A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus |
Active, not recruiting |
Endometrial Cancer |
NCT02744898 |
| Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00986674 |
| Phase IIb Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer |
Not yet recruiting |
Pancreatic Cancer |
NCT04241276 |
| A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma |
Completed |
Melanoma |
NCT01174238 |
| Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer |
Unknown status |
Thyroid Cancer |
NCT00786552 |
| Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC |
Recruiting |
Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma |
NCT02593175 |
| A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT02366143 |
| Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer |
Active, not recruiting |
Ovarian Cancer |
NCT01081951 |
| Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma |
Unknown status |
Melanoma |
NCT02023710 |
| Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye |
Completed |
Ciliary Body and Choroid Melanoma, Medium/Large Size|Extraocular Extension Melanoma|Iris Melanoma|Metastatic Intraocular Melanoma|Recurrent Intraocular Melanoma |
NCT00329641 |
| Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer |
Active, not recruiting |
Mixed Mesodermal (Mullerian) Tumor|Ovarian Carcinosarcoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage I Ovarian Cancer AJCC v6 and v7|Stage IA Fallopian Tube Cancer AJCC v6 and v7|Stage IA Ovarian Cancer AJCC v6 and v7|Stage IA Uterine Sarcoma AJCC v7|Stage IB Fallopian Tube Cancer AJCC v6 and v7|Stage IB Ovarian Cancer AJCC v6 and v7|Stage IB Uterine Sarcoma AJCC v7|Stage IC Fallopian Tube Cancer AJCC v6 and v7|Stage IC Ovarian Cancer AJCC v6 and v7|Stage IC Uterine Sarcoma AJCC v7|Stage II Ovarian Cancer AJCC v6 and v7|Stage IIA Fallopian Tube Cancer AJCC v6 and v7|Stage IIA Ovarian Cancer AJCC V6 and v7|Stage IIA Uterine Sarcoma AJCC v7|Stage IIB Fallopian Tube Cancer AJCC v6 and v7|Stage IIB Ovarian Cancer AJCC v6 and v7|Stage IIB Uterine Sarcoma AJCC v7|Stage IIC Fallopian Tube Cancer AJCC v6 and v7|Stage IIC Ovarian Cancer AJCC v6 and v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIA Uterine Sarcoma AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIB Uterine Sarcoma AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IIIC Uterine Sarcoma AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7|Stage IVA Uterine Sarcoma AJCC v7|Stage IVB Uterine Sarcoma AJCC v7|Uterine Carcinosarcoma |
NCT00954174 |
| Pennsylvania |
Bryn Mawr |
United States|Geisinger Medical Center |
Bethlehem |
| Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer |
Recruiting |
Solid Tumor, Adult |
NCT03600090 |
| A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT01189929 |
| A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer |
Withdrawn |
Breast Cancer |
NCT01163929 |
| Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00088556 |
| Restenosis Following Paclitaxel Eluting Balloon Angioplasty of Hemodialysis Access Stenosis |
Completed |
Renal Failure |
NCT01001676 |
| Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer |
Terminated |
Triple Negative Metastatic Breast Cancer|BRCA-mutated Solid Tumor |
NCT02358200 |
| A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach |
Terminated |
HER-2 Gene Amplification|Esophagus Cancer|Gastroesophageal Junction Cancer|Stomach Cancer |
NCT01774851 |
| Ipatasertib and Carboplatin With or Without Paclitaxel in Treating Patients With Metastatic Triple Negative Breast Cancer |
Recruiting |
Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Negative|HER2/Neu Negative|Metastatic Triple-Negative Breast Carcinoma|Progesterone Receptor Negative|Prognostic Stage IV Breast Cancer AJCC v8 |
NCT03853707 |
| Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker |
Unknown status |
Non Small Cell Lung Cancer |
NCT01041833 |
| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer |
Recruiting |
Endometrial Clear Cell Adenocarcinoma|Endometrial Dedifferentiated Carcinoma|Endometrial Endometrioid Adenocarcinoma|Endometrial Mixed Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Undifferentiated Carcinoma|Recurrent Endometrial Adenocarcinoma|Recurrent Endometrial Carcinoma|Recurrent Endometrial Clear Cell Adenocarcinoma|Recurrent Endometrial Dedifferentiated Carcinoma|Recurrent Endometrial Endometrioid Adenocarcinoma|Recurrent Endometrial Mixed Cell Adenocarcinoma|Recurrent Endometrial Serous Adenocarcinoma|Recurrent Endometrial Undifferentiated Carcinoma|Stage III Uterine Corpus Cancer AJCC v8|Stage IIIA Uterine Corpus Cancer AJCC v8|Stage IIIB Uterine Corpus Cancer AJCC v8|Stage IIIC Uterine Corpus Cancer AJCC v8|Stage IIIC1 Uterine Corpus Cancer AJCC v8|Stage IIIC2 Uterine Corpus Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8 |
NCT03914612 |
| Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB) |
Completed |
Neoplasms, Breast |
NCT00388076 |
| GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer |
Terminated |
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer |
NCT02012192 |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer |
Withdrawn |
Metastatic Pancreatic Cancer |
NCT03797443 |
| Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU) |
Active, not recruiting |
Squamous Non-small-cell Lung Cancer |
NCT02996214 |
| A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma |
Active, not recruiting |
Pancreatic Adenocarcinoma |
NCT02879318 |
| Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome |
Completed |
Pain |
NCT02063698 |
| Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer |
Completed |
Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer |
NCT00733408 |
| PD0332991/Paclitaxel in Advanced Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT01320592 |
| Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies |
Terminated |
Metastatic Cancer Pancreas |
NCT02109445 |
| Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer |
Withdrawn |
Esophageal Cancer |
NCT01998347 |
| Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00915603 |
| Paclitaxel-coated Balloons in Femoral Indication to Defeat Restenosis |
Completed |
Peripheral Artery Disease |
NCT01083030 |
| Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer |
Unknown status |
Breast Cancer |
NCT01170143 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00307255 |
| Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary |
Completed |
Carcinoma of Unknown Primary Origin |
NCT00936702 |
| Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC |
Recruiting |
Non-small Cell Lung Cancer |
NCT03573947 |
| Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer |
Completed |
Breast Cancer |
NCT00129922 |
| Chemotherapy With Nab-paclitaxel/Germcitabine/Cisplatin +/- BGB324 With Pancreatic Cancer |
Recruiting |
Cancer of Pancreas |
NCT03649321 |
| A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms |
NCT03038100 |
| Trial of NanoPac Intratumoral Injection in Lung Cancer |
Not yet recruiting |
Lung Cancer, Nonsmall Cell|Lung Cancer|Lung Cancer, Small Cell|Neoplasm of Lung |
NCT04314895 |
| A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer |
Completed |
Advanced/Metastatic Non-Small Cell Lung Cancer |
NCT00723957 |
| Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function |
Completed |
Distal Urethral Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Proximal Urethral Cancer|Recurrent Bladder Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Regional Transitional Cell Cancer of the Renal Pelvis and Ureter|Stage III Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder|Urethral Cancer Associated With Invasive Bladder Cancer |
NCT00478361 |
| Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors |
Active, not recruiting |
Neoplasms|Pancreatic Neoplasms |
NCT02810418 |
| Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia |
Completed |
Peritoneal Carcinomatosis |
NCT02739698 |
| A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients |
Unknown status |
Endometrial Cancer |
NCT00373620 |
| RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent) |
Unknown status |
In-Stent Restenosis |
NCT01239953 |
| Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer |
Recruiting |
Primary Malignant Neoplasm of Ovary|FIGO Stages II to IV |
NCT02159820 |
| S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00368992 |
| RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent) |
Unknown status |
In-stent Restenosis |
NCT01239940 |
| HAI Abraxane With Gemcitabine and Bevacizumab |
Completed |
Advanced Cancers |
NCT01057264 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00662129 |
| Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer |
Active, not recruiting |
Endometrial Adenocarcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Undifferentiated Carcinoma|Recurrent Uterine Corpus Carcinoma|Stage III Uterine Corpus Cancer AJCC v7|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7 |
NCT02065687 |
| Wisconsin |
Wausau |
United States|Marshfield Clinic-Wausau Center |
Waukesha |
| Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer |
Terminated |
Stage IA Uterine Sarcoma|Stage IB Uterine Sarcoma|Stage IC Uterine Sarcoma|Stage IIA Uterine Sarcoma|Stage IIB Uterine Sarcoma|Stage IIIA Uterine Sarcoma|Stage IIIB Uterine Sarcoma|Stage IIIC Uterine Sarcoma|Stage IVA Uterine Sarcoma|Stage IVB Uterine Sarcoma|Uterine Carcinosarcoma |
NCT01367301 |
| Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma |
Not yet recruiting |
Lung Adenocarcinoma Stage IV |
NCT04310943 |
| A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT01656538 |
| Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors |
Completed |
Ovarian Sarcoma|Ovarian Stromal Cancer|Recurrent Endometrial Carcinoma|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Stage III Endometrial Carcinoma|Stage III Ovarian Epithelial Cancer|Stage III Ovarian Germ Cell Tumor|Stage IV Endometrial Carcinoma|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00408655 |
| A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients |
Unknown status |
Recurrent and Metastatic Gastric Cancer |
NCT03026881 |
| FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma |
Recruiting |
Gastro-Esophageal Junction Adenocarcinoma|Gastric Cancer |
NCT03283761 |
| Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas |
Completed |
Ovarian Cancer |
NCT00750386 |
| Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer |
Terminated |
Small Cell Lung Cancer |
NCT00454324 |
| A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab |
Completed |
Metastatic or Locally Advanced Solid Tumors |
NCT01285466 |
| Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery |
Completed |
Recurrent Melanoma|Stage IV Melanoma |
NCT00255762 |
| Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy |
Not yet recruiting |
Epithelial Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer |
NCT03607955 |
| Balloon Elution and Late Loss Optimization (BELLO) Study |
Unknown status |
Coronary Artery Disease |
NCT01086579 |
| Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer |
Recruiting |
Non Small Cell Lung Cancer |
NCT03699033 |
| Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer |
Unknown status |
Breast Cancer |
NCT02142790 |
| CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation |
Completed |
Coronary Disease |
NCT00422435 |
| Prospective Study of VEGFR-2 /IL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy |
Unknown status |
Metastatic Breast Cancer |
NCT02329639 |
| Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers |
Recruiting |
Ovarian Cancer|Endometrial Cancer |
NCT02269293 |
| Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer |
Completed |
Advanced Non-small Cell Lung Cancer |
NCT00708812 |
| Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer |
Active, not recruiting |
Advanced Cancer |
NCT01187199 |
| RCT of Paclitaxel DEB Compared to Standard PTA in Dialysis Fistula |
Unknown status |
Complication of Hemodialysis|Vascular Access Complication |
NCT02558153 |
| Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers |
Active, not recruiting |
Stage III Intrahepatic Cholangiocarcinoma AJCC v7|Stage IIIA Gallbladder Cancer AJCC v7|Stage IIIB Gallbladder Cancer AJCC v7|Stage IVA Gallbladder Cancer AJCC v7|Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7|Stage IVB Gallbladder Cancer AJCC v7|Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7|Unresectable Extrahepatic Bile Duct Carcinoma|Unresectable Gallbladder Carcinoma |
NCT02392637 |
| A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer |
Terminated |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma |
NCT02661815 |
| Trial of NanoPac Focal Therapy for Prostate Cancer |
Not yet recruiting |
Prostate Cancer|Prostate Adenocarcinoma|Prostate Cancer Adenocarcinoma|Prostatic Neoplasm|Urogenital Neoplasms|Genital Neoplasms, Male|Localized Cancer |
NCT04221828 |
| Comparison of the Ranger™ Paclitaxel-Coated PTA Balloon Catheter and Uncoated PTA Balloons in Femoropopliteal Arteries |
Completed |
Peripheral Artery Disease|Claudication|Atherosclerosis|Arteriosclerosis |
NCT02013193 |
| Phase I Study in Patients With Solid Tumours |
Completed |
Neoplasms |
NCT00496028 |
| S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites |
Recruiting |
Metastatic Gastric Adenocarcinoma |
NCT03990103 |
| Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004) |
Withdrawn |
Breast Neoplasms |
NCT01953536 |
| Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment |
Completed |
Metastatic Breast Cancer |
NCT01320111 |
| Phase I Trial of Paclitaxel With Perifosine |
Completed |
Neoplasms |
NCT00399126 |
| Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT00006256 |
| Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer |
Completed |
HER2-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer |
NCT01688609 |
| Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction |
Completed |
Esophageal Cancer |
NCT00107341 |
| Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma |
Active, not recruiting |
Metastatic Pancreatic Adenocarcinoma |
NCT02504333 |
| A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread |
Active, not recruiting |
Breast Cancer |
NCT02322814 |
| Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma |
Active, not recruiting |
Untreated Stage III Melanoma or Stage IV Melanoma |
NCT01676649 |
| Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT03092986 |
| A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma |
Completed |
Esophageal Squamous Cell Carcinoma |
NCT01591135 |
| Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer |
Recruiting |
HER2-positive Breast Cancer|Operable Breast Cancer |
NCT03571633 |
| Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer |
Completed |
Esophageal Cancer|Gastric Cancer |
NCT00439608 |
| Paclitaxel Balloon Versus Standard Balloon in In-stent Restenoses of the Superficial Femoral Artery (PACUBA I Trial) |
Unknown status |
Peripheral Arterial Disease |
NCT01247402 |
| Phase II Trial of Standard Chemotherapy (Carboplatin & Paclitaxel) +Various Proton Beam Therapy (PBT) Doses |
Recruiting |
Non Small Cell Lung Cancer |
NCT03132532 |
| A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel |
Completed |
Breast Cancer |
NCT00131963 |
| Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer |
Completed |
Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00481078 |
| Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine |
Completed |
Advanced Melanoma |
NCT00796991 |
| Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer |
Active, not recruiting |
HER-2 Positive Breast Cancer |
NCT01340430 |
| Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast |
Completed |
Breast Cancer |
NCT01204437 |
| Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery |
Completed |
Metastatic Melanoma|Mucosal Melanoma|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Uveal Melanoma AJCC v7|Unresectable Melanoma |
NCT02158520 |
| High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer |
Withdrawn |
Metastatic Pancreatic Cancer|Pancreatic Cancer|Pancreas Cancer|Pancreatic Adenocarcinoma Resectable|Pancreatic Ductal Adenocarcinoma|Pancreatic Metastasis |
NCT03908333 |
| Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer |
Recruiting |
Carcinoma, Non-Small-Cell Lung|Squamous Cell Carcinoma |
NCT03802058 |
| First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma |
Terminated |
Transitional Cell Carcinoma|Bladder Carcinoma|Urothelial Carcinoma |
NCT01215136 |
| A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT01763645 |
| Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer |
Completed |
Breast Neoplasms |
NCT00110695 |
| Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442) |
Completed |
Cancer of Head and Neck |
NCT00343083 |
| Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00301028 |
| Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT01165216 |
| Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions |
Terminated |
Coronary Atherosclerosis |
NCT00606333 |
| Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy |
Recruiting |
Advanced Biliary Tract Carcinoma |
NCT03704480 |
| Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses |
Active, not recruiting |
Peripheral Arterial Disease (PAD) |
NCT02936622 |
| Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma |
Recruiting |
Esophageal Cancer, Squamous Cell|Cetuximab Effect|Chemotherapy Effect |
NCT03126708 |
| A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment |
Recruiting |
Metastatic Adenocarcinoma of the Pancreas |
NCT04083235 |
| Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers |
Completed |
Carcinoma, Squamous Cell of the Head and Neck |
NCT01166542 |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer |
Withdrawn |
Metastatic Pancreatic Cancer|Pancreatic Cancer|Pancreas Cancer|Pancreatic Adenocarcinoma Resectable|Pancreatic Ductal Adenocarcinoma|Pancreatic Metastasis |
NCT03697239 |
| Paclitaxel Eluting Balloon and Conventional Balloon for In-Stent Restenosis of the Superficial Femoral Artery |
Unknown status |
Peripheral Vascular Disease |
NCT01083394 |
| Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder |
Completed |
Bladder Cancer |
NCT00136175 |
| Efficacy and Safety of the Paclitaxel Eluting Covered Biliary Stent to the Common Covered Metallic Biliary Stent |
Terminated |
Biliary Stricture|Malignant Neoplasms |
NCT01413386 |
| Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT00243867 |
| Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus |
Withdrawn |
Squamous Cell Carcinoma of Esophagus |
NCT02041819 |
| Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction |
Terminated |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer|Bowel Obstruction |
NCT01083537 |
| Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer |
Completed |
Breast Cancer |
NCT01423123 |
| Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma |
Recruiting |
Pancreatic Ductal Adenocarcinoma |
NCT02426281 |
| Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women |
Not yet recruiting |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|FIGO Stage IIB Cervix Carcinoma|FIGO Stage III Cervix Carcinoma|FIGO Stage IVA Cervix Carcinoma|HIV Infection |
NCT03834571 |
| Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals |
Completed |
Sarcoma, Kaposi|HIV Infections |
NCT00002189 |
| Evaluation of Votrient in Angiosarcoma |
Unknown status |
Angiosarcoma |
NCT02212015 |
| A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment |
Completed |
Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Bladder Cancer |
NCT00421889 |
| NUVOLA TRIAL Open-label Multicentre Study |
Recruiting |
High Grade Serous Ovarian Cancer |
NCT04261465 |
| MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer |
Withdrawn |
Breast Cancer|Cancer of Breast |
NCT03285607 |
| Split-course Thoracic Radiotherapy Combined With Nab-paclitaxel Plus Nedaplatin for Local Advanced NSCLC With Impaired Baseline Pulmonary Function |
Recruiting |
Non-small Cell Lung Cancer |
NCT04212052 |
| Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00287937 |
| A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus |
Terminated |
Uterine Cancer |
NCT00584909 |
| Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas |
Completed |
Metastatic Pancreatic Cancer |
NCT00844649 |
| Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast Cancer |
Unknown status |
Breast Cancer |
NCT02142010 |
| Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO) |
Completed |
Breast Cancer |
NCT00795899 |
| Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
Terminated |
Ovarian Cancer|Peritoneal Cavity Cancer |
NCT00897806 |
| Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00680758 |
| Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer |
Terminated |
Resectable Pancreatic Cancer|Pancreatic Ductal Carcinoma |
NCT02243007 |
| Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma |
Completed |
Metastatic Melanoma |
NCT00984464 |
| Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT00752115 |
| Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00003281 |
| Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer |
Terminated |
Pancreatic Cancer |
NCT01693276 |
| Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas |
Completed |
Adenocarcinoma |
NCT01253525 |
| Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel |
Completed |
Tumors |
NCT01448759 |
| ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer |
Active, not recruiting |
Uterine Cervical Neoplasms |
NCT02009579 |
| Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients |
Active, not recruiting |
Advanced or Metastatic Breast Cancer|ER+ve Advanced or Metastatic Breast Cancer |
NCT01625286 |
| CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL |
Unknown status |
NSCLC |
NCT00576225 |
| A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study |
Active, not recruiting |
Non-small Cell Lung Cancer |
NCT03875092 |
| Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR II) |
Completed |
Coronary Restenosis |
NCT00409981 |
| A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer |
Recruiting |
Triple-negative Breast Cancer |
NCT03872791 |
| Pharmacokinetic Study of Drug-coated Angioplasty Balloons in the Superficial Femoral or Popliteal Arteries: |
Completed |
Peripheral Artery Disease |
NCT01912937 |
| Real-world Evidence Prospective Study on the Effect of Nab-paclitaxel Treatment on the Clinical Outcomes and HRQoL in Patients With MBC in Greece |
Completed |
Metastatic Breast Cancer |
NCT02626013 |
| Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer |
Completed |
Ovarian Clear Cell Cystadenocarcinoma|Stage III Ovarian Cancer|Stage IV Ovarian Cancer |
NCT01196429 |
| Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer. |
Completed |
Neoplasms, Breast |
NCT00367471 |
| A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung |
Completed |
Metastatic or Recurrent Squamous Cell Carcinoma of the Lung |
NCT00998192 |
| A Phase III Study of NK105 in Patients With Breast Cancer |
Completed |
Breast Cancer Nos Metastatic Recurrent |
NCT01644890 |
| Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00603538 |
| A Safety and Efficacy of CCRT With Paclitaxel/Carboplatin as Adjuvant Therapy to Post-operative Cervical Cancer Patients |
Completed |
Cervical Cancer |
NCT00340184 |
| Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer |
Active, not recruiting |
Recurrent Non-Small Cell Lung Carcinoma|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer |
NCT02581943 |
| Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Non-small Cell Lung Cancer |
NCT00097227 |
| Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma |
Completed |
AIDS-related Kaposi Sarcoma |
NCT00003350 |
| Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer |
Completed |
Breast Cancer |
NCT00331630 |
| Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer |
Terminated |
Adenocarcinoma of the Lung|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Stage II Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer |
NCT00369551 |
| Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer |
Terminated |
Pain|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00217724 |
| Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access |
Terminated |
Kidney Diseases|ESRD |
NCT00448708 |
| Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy |
Completed |
Solid Tumor|Breast Cancer |
NCT00803556 |
| Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers |
Completed |
Non-squamous Non-small Cell Lung Cancer |
NCT02264990 |
| Paclitaxel Coated PTA Balloons for Treatment of Dysfunctional AV Fistulae and Grafts |
Withdrawn |
Dysfunctional AV Graft|Dysfunctional AV Fistula |
NCT02183194 |
| Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma |
Completed |
Melanoma (Skin) |
NCT00976573 |
| A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00320541 |
| A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein |
Completed |
Breast Cancer |
NCT01918254 |
| Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) |
Recruiting |
Pancreatic Cancer|Pancreas Cancer|Pancreatic Adenocarcinoma Resectable|Pancreatic Ductal Adenocarcinoma|Pancreas Metastases |
NCT03410030 |
| Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate |
Completed |
Prostate Cancer |
NCT00151060 |
| RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma |
Recruiting |
Pancreatic Adenocarcinoma |
NCT03745430 |
| A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer |
Unknown status |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cancer |
NCT01570582 |
| Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
Completed |
Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia |
NCT00891072 |
| Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer |
Completed |
Squamous Cell Carcinoma |
NCT00176254 |
| A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors |
Completed |
Advanced Solid Tumors |
NCT01293630 |
| Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel |
Completed |
Pain|Peripheral Neuropathy |
NCT01637077 |
| Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers |
Completed |
Peritoneal Neoplasms |
NCT00666991 |
| Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer |
Completed |
Breast Cancer |
NCT00930930 |
| Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer |
Recruiting |
Metastatic Breast Cancer |
NCT02687490 |
| Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions |
Completed |
Coronary Artery Disease |
NCT00418067 |
| A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) |
Completed |
Head and Neck Cancer |
NCT01911598 |
| Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR I) |
Completed |
Coronary Restenosis |
NCT00106587 |
| Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy |
Terminated |
Advanced Gastric Adenocarcinoma |
NCT02449655 |
| Study Evaluating Safety And Tolerability, Solid Tumor |
Completed |
Advanced Malignant Solid Tumors |
NCT00768469 |
| Study of CB-839 in Combination w/ Paclitaxel in Patients of African Ancestry and Non-African Ancestry With Advanced TNBC |
Completed |
Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer |
NCT03057600 |
| A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT01550848 |
| Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer |
Recruiting |
Pancreatic Cancer Metastatic|Pancreatic Cancer Stage IV|Stage IV Pancreatic Cancer |
NCT03412799 |
| Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00147537 |
| PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer |
Completed |
Metastatic Pancreatic Cancer |
NCT01839487 |
| A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer |
Completed |
Non Small Cell Lung Cancer |
NCT00680940 |
| Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001) |
Completed |
Esophageal Cancer |
NCT00522795 |
| Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00004055 |
| Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy |
Completed |
Neoplasms |
NCT00001387 |
| Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer |
Completed |
Breast Cancer |
NCT00041119 |
| United States|Providence Cancer Center at Providence Portland Medical Center |
Oregon |
Portland |
Oregon |
| Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer |
Completed |
Breast Cancer|HER2-negative Breast Cancer |
NCT01705691 |
| Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer |
Completed |
Breast Cancer |
NCT00675259 |
| Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer |
Completed |
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Male Breast Cancer|Recurrent Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer |
NCT01288261 |
| P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses |
Completed |
In-Stent Restenosis |
NCT00393315 |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers |
Not yet recruiting |
Metastatic Small Intestinal Adenocarcinoma|Stage III Small Intestinal Adenocarcinoma AJCC v8|Stage IIIA Small Intestinal Adenocarcinoma AJCC v8|Stage IIIB Small Intestinal Adenocarcinoma AJCC v8|Stage IV Small Intestinal Adenocarcinoma AJCC v8 |
NCT04205968 |
| Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma |
Terminated |
Gastroesophageal Adenocarcinoma|Adenocarcinoma of the Distal Esophagus|Adenocarcinomas of the Gastroesophageal Junction|Adenocarcinoma of the Proximal Stomach |
NCT01182610 |
| Stromal TARgeting for PAncreatic Cancer (STAR_PAC) |
Completed |
Pancreatic Adenocarcinoma |
NCT03307148 |
| Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC |
Recruiting |
Triple Negative Breast Cancer |
NCT03616886 |
| Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck |
Recruiting |
Squamous Cell Carcinoma Of The Head And Neck |
NCT03830385 |
| A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer |
Completed |
Breast Cancer |
NCT00846027 |
| Acute Pain Caused by Paclitaxel in Patients With Cancer |
Completed |
Chemotherapeutic Agent Toxicity|Neurotoxicity|Pain|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00860041 |
| Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 |
Active, not recruiting |
Breast Cancer |
NCT01593020 |
| Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer |
Active, not recruiting |
Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7 |
NCT00108745 |
| Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors |
Completed |
Cervical|Ovarian|Lung|Breast|Renal |
NCT00972205 |
| Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) |
Completed |
Metastatic Pancreatic Adenocarcinoma |
NCT02436668 |
| Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy |
Completed |
Paclitaxel-induced Neuropathy |
NCT01682499 |
| ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib |
Completed |
Neoplasms, Breast |
NCT00272987 |
| A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) |
Active, not recruiting |
Non-small Cell Lung Cancer |
NCT02775435 |
| Abraxane/Bevacizumab |
Terminated |
Ovarian Cancer|Peritoneal Cancer |
NCT01821859 |
| Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer |
Active, not recruiting |
Stage II Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer |
NCT02621398 |
| A Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial |
Completed |
Stable Angina|Unstable Angina|Acute Coronary Syndrome |
NCT01016041 |
| Papillary Serous Carcinoma of the Endometrium |
Completed |
Endometrial Cancer |
NCT00515073 |
| A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel |
Withdrawn |
Lung Neoplasms|Carcinoma, Non-Small-Cell Lung |
NCT00768131 |
| Efficacy Study of Paclitaxel-eluting Balloon, -Stent vs. Plain Angioplasty for Drug-eluting Stent Restenosis |
Completed |
Heart Disease|Ischemia|Restenosis |
NCT00987324 |
| Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers |
Completed |
Ovarian Cancer|Endometrial Cancer|Uterine Cervical Cancer |
NCT01523678 |
| Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer |
Active, not recruiting |
Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Stage IA Uterine Corpus Cancer AJCC v7|Stage IB Uterine Corpus Cancer AJCC v7|Stage II Uterine Corpus Cancer AJCC v7|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7 |
NCT00942357 |
| Stony Brook |
United States|State University of New York Upstate Medical University |
New York |
United States|Stony Brook University Medical Center |
| A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer |
Completed |
Advanced or Metastatic Solid Tumors|Advanced or Metastatic Breast Cancer |
NCT00748553 |
| Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer |
Completed |
Recurrent Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer |
NCT00093756 |
| Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy |
Withdrawn |
Prostate Cancer |
NCT00003622 |
| A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer |
Recruiting |
Adenocarcinoma|Pancreatic Neoplasms|Neoplasm, Glandular|Neoplasms|Neoplasms Pancreatic|Digestive System Neoplasm|Endocrine Gland Neoplasms|Digestive System Disease|Pancreatic Diseases|Endocrine System Diseases |
NCT03535727 |
| Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer |
Not yet recruiting |
Breast Cancer|Paclitaxel|Epirubicin|Cyclophosphamide |
NCT01848197 |
| Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer |
Unknown status |
Breast Cancer |
NCT00499603 |
| A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer |
Recruiting |
Gastroesophageal Junction Adenocarcinoma|Gastric Adenocarcinoma |
NCT02898077 |
| Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer |
Recruiting |
HER2-positive Breast Cancer |
NCT03125928 |
| [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer |
Recruiting |
Breast Neoplasm|Metastatic Breast Cancer|Rb+ Breast Cancer |
NCT02608216 |
| Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer |
Terminated |
Breast Neoplasms|Neoplasm Metastasis |
NCT00281528 |
| Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer |
Active, not recruiting |
Pancreatic Adenocarcinoma |
NCT02550327 |
| Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer |
Completed |
Locally Recurrent and Metastatic Breast Cancer |
NCT00322400 |
| A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) |
Completed |
Ovarian Cancer|Solid Tumors |
NCT00889382 |
| Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00002587 |
| Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00520000 |
| Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis |
Unknown status |
Gastric Cancer|Metastases to Perineum |
NCT01471132 |
| Nab-PCE vs PC for MM After Failure of Anti-PD-1 |
Recruiting |
Advanced Melanoma |
NCT03917069 |
| Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer |
Completed |
Non-small-cell Lung Cancer |
NCT01836679 |
| POF Versus FOLFOX Plus IP Paclitaxel in AGC |
Not yet recruiting |
Gastric Cancer |
NCT04155671 |
| Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer |
Recruiting |
Advanced Esophageal Cancer |
NCT03691090 |
| Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00551733 |
| Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids |
Completed |
Endometrial Cancer|Ovarian Cancer |
NCT01256268 |
| Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer |
Recruiting |
Advanced Pancreatic Cancer |
NCT04239001 |
| Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization |
Completed |
Coronary Heart Disease |
NCT00297661 |
| Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma |
Completed |
Epithelial Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer |
NCT00226915 |
| Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT02172846 |
| A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin |
Completed |
Cancer (Solid Tumors) |
NCT00420186 |
| Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer |
Terminated |
Breast Cancer |
NCT00537173 |
| Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer |
Completed |
Breast Cancer |
NCT04224922 |
| Per-cutaneous Intervention Based Paclitaxel and Sirolimus-Eluting Versus Bare Stents for the Treatment of de Novo Coronary Lesions (PAINT) |
Completed |
Coronary Restenosis |
NCT00752362 |
| Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma |
Completed |
Testicular Cancer|Germ Cell Neoplasm |
NCT00183820 |
| Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT00616967 |
| Small Coronary Artery Treated by TAXUS Liberté Registry in Japan |
Unknown status |
Stable Angina Pectoris|Unstable Angina Pectoris |
NCT00955214 |
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery |
Completed |
Mucosal Melanoma|Recurrent Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma |
NCT00110019 |
| The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA |
N/A |
N/A |
NCT04045730 |
| Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer |
Recruiting |
Carcinoma, Non-Small Cell Lung |
NCT02743923 |
| The Safety and Efficacy of DIOR Balloon in Coronary Bifurcation Lesions |
Not yet recruiting |
Percutaneous Coronary Intervention |
NCT03820622 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer |
Recruiting |
Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Tongue Cancer |
NCT01847326 |
| The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. |
Completed |
Advanced Solid Tumours |
NCT02430311 |
| PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer |
Recruiting |
Esophageal Neoplasms |
NCT02359968 |
| Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer |
Completed |
Ovarian Carcinoma |
NCT03562533 |
| T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) |
Active, not recruiting |
Breast Cancer |
NCT01853748 |
| Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer |
Completed |
Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00006929 |
| Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT00642759 |
| Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT01663727 |
| A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer |
Recruiting |
Metastatic Pancreatic Cancer |
NCT03086369 |
| Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients |
Completed |
Breast Cancer |
NCT00128856 |
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
Active, not recruiting |
Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinofibroma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Stage IIA Fallopian Tube Cancer AJCC v6 and v7|Stage IIA Ovarian Cancer AJCC V6 and v7|Stage IIB Fallopian Tube Cancer AJCC v6 and v7|Stage IIB Ovarian Cancer AJCC v6 and v7|Stage IIC Fallopian Tube Cancer AJCC v6 and v7|Stage IIC Ovarian Cancer AJCC v6 and v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7 |
NCT01167712 |
| Oregon |
Portland |
United States|Abington Memorial Hospital |
Portland |
| Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00095914 |
| ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems |
Withdrawn |
Neoplasms |
NCT01419548 |
| Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer |
Completed |
Breast Cancer |
NCT00394251 |
| Comparison of Paclitaxel-Eluting Coroflex Please Stent Versus Paclitaxel-Eluting Stent |
Completed |
Coronary Artery Disease |
NCT00995423 |
| A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC |
Completed |
Non-Small Cell Lung Cancer |
NCT00343291 |
| A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC |
Completed |
Non-Small Cell Lung Cancer |
NCT02364999 |
| Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer |
Recruiting |
HER-2 Negative Breast Cancer |
NCT03799692 |
| Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa |
Active, not recruiting |
Breast Cancer |
NCT01796197 |
| Therapy Management With Nab-Paclitaxel in Daily Routine |
Active, not recruiting |
Metastatic Breast Cancer |
NCT02642406 |
| Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer |
Completed |
Fallopian Tube Cancer|Ovarian Cancer |
NCT00052468 |
| Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer |
Completed |
Lung Adenocarcinoma|Lung Adenosquamous Carcinoma|Malignant Pericardial Effusion|Malignant Pleural Effusion|Minimally Invasive Lung Adenocarcinoma|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7 |
NCT00126581 |
| TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen |
Withdrawn |
Breast Cancer |
NCT02053597 |
| Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery |
Completed |
HER2/Neu Positive|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer |
NCT00513292 |
| Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT01263613 |
| Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies |
Terminated |
Solid Tumors |
NCT01930292 |
| Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy |
Completed |
Prostate Cancer |
NCT00049257 |
| Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer |
Completed |
Neoplasm |
NCT00080418 |
| Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00062062 |
| Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours |
Completed |
Neoplasms |
NCT00809133 |
| Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer |
Completed |
Prostate Cancer |
NCT00005028 |
| A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer |
Active, not recruiting |
Triple Negative Breast Cancer |
NCT03168880 |
| A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer |
Unknown status |
Invasive Breast Cancer |
NCT00486668 |
| PacLitaxel Eluting Balloon Application In Sfa In Stent Restenosis |
Completed |
Peripheral Arterial Disease |
NCT01587482 |
| A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer |
Completed |
Tumors |
NCT00653939 |
| Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00004126 |
| Paclitaxel Coated Balloon Catheter for Prevention of Restenosis in Femoropopliteal Arteries |
Completed |
Peripheral Arterial Disease |
NCT00472472 |
| LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT01085136 |
| Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma |
Unknown status |
First Line Chemotherapy|Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel|Advanced or Recurrent Esophageal Squamous Cell Carcinoma |
NCT00816634 |
| Efficacy and Safety of Paclitaxel-eluting Balloon for Treatment of Lesions in Native Small Coronary Arteries |
Unknown status |
Coronary Artery Disease |
NCT01903902 |
| Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer |
Unknown status |
Her2-Positive Breast Cancer |
NCT01855828 |
| Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis |
Completed |
Bladder Cancer|Cervical Cancer|Endometrial Cancer|Vaginal Cancer |
NCT00002949 |
| TReAtmeNt of Small Coronary Vessels: MagicTouch Sirolimus Coated Balloon |
Not yet recruiting |
Coronary Artery Disease |
NCT03913832 |
| Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer |
Recruiting |
Triple Negative Breast Cancer |
NCT04083963 |
| Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00005849 |
| Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel |
Active, not recruiting |
Non Small Cell Lung Cancer |
NCT02684461 |
| Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread |
Not yet recruiting |
Metastatic Pancreatic Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8 |
NCT04233866 |
| STA-4783 and Paclitaxel for Treatment of Solid Tumors |
Completed |
Neoplasms |
NCT00088114 |
| Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer |
Completed |
Cervical Cancer|Vaginal Cancer |
NCT00002562 |
| Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer |
Completed |
Neoplasms, Breast |
NCT00111787 |
| A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) |
Completed |
NSCLC|Solid Tumors |
NCT01100931 |
| Paclitaxel in Treating Patients With Advanced Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00002922 |
| Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter Malaysia |
Recruiting |
Coronary Artery Disease |
NCT04017364 |
| Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma |
Recruiting |
Esophageal Cancer |
NCT02461043 |
| Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE) |
Terminated |
Pancreatic Adenocarcinoma |
NCT02124369 |
| Intra-Individual Comparison of Sirolimus and Paclitaxel Coated Stent (FRE-RACE Study) |
Completed |
Coronary Artery Disease |
NCT00130546 |
| Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix |
Completed |
Cervical Cancer |
NCT00003377 |
| Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma |
Completed |
Pancreatic Cancer |
NCT02588443 |
| Paclitaxel in Treating Patients With Early-Stage Bladder Cancer |
Completed |
Bladder Cancer |
NCT00002917 |
| Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer |
Terminated |
Large Cell Lung Carcinoma|Lung Adenocarcinoma|Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer|Bronchioloalveolar Lung Carcinoma |
NCT00955305 |
| Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00004265 |
| First Line TIP in Poor Prognosis TGCTs. |
Recruiting |
Germ Cell Tumor |
NCT02414685 |
| A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer |
Completed |
Non Small Cell Lung Cancer |
NCT00583830 |
| Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00645177 |
| A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer |
Unknown status |
Advanced Breast Cancer |
NCT00915369 |
| Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer |
Completed |
Breast Cancer |
NCT00647218 |
| Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00002928 |
| Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus |
Terminated |
Sarcoma |
NCT00003054 |
| Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer |
Completed |
Bladder Cancer |
NCT00585689 |
| Efficacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease |
Unknown status |
Peripheral Vascular Diseases |
NCT00986752 |
| Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer |
Terminated |
Prostate Cancer |
NCT00459810 |
| Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer |
Suspended |
Pancreatic Cancer Resectable |
NCT03344172 |
| A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma |
Completed |
Non-Small Cell Lung Cancer|Adenocarcinoma |
NCT01051934 |
| A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC |
Recruiting |
Squamous Non Small Cell Lung Cancer |
NCT04033354 |
| A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer |
Terminated |
Breast Neoplasms|Breast Tumors|Breast Cancer|Locally Recurrent and Metastatic Breast Cancer |
NCT00356681 |
| Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors |
Active, not recruiting |
Germ Cell Tumors |
NCT01873326 |
| A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer |
Completed |
Non-Squamous Non-Small Cell Lung Cancer |
NCT01519804 |
| Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer |
Completed |
Non-squamous Non-small Cell Lung Cancer |
NCT03169335 |
| A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC |
Not yet recruiting |
Advanced Non-squamous NSCLC |
NCT04325698 |
| International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel |
Unknown status |
Squamous Cell Carcinoma of the Anus |
NCT02051868 |
| Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor |
Recruiting |
Gestational Trophoblastic Neoplasms |
NCT02639650 |
| Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer |
Unknown status |
Head and Neck Cancer |
NCT00003327 |
| Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus |
Unknown status |
Esophageal Cancer |
NCT00003326 |
| Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer |
Completed |
Endometrial Cancer |
NCT00022620 |
| Talimogene Laherparepvec With Paclitaxel or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer |
Recruiting |
Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Invasive Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma |
NCT03554044 |
| Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors |
Completed |
Solid Tumors |
NCT01862328 |
| A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer |
Recruiting |
Advanced Breast Cancer |
NCT02599363 |
| Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer |
Completed |
Endometrial Adenocarcinoma|Endometrial Adenosquamous Carcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Stage IA Uterine Corpus Cancer AJCC v7|Stage IB Uterine Corpus Cancer AJCC v7|Stage II Uterine Corpus Cancer AJCC v7|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7 |
NCT01005329 |
| Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer |
Active, not recruiting |
Anal Basaloid Carcinoma|Anal Canal Cloacogenic Carcinoma|Anal Squamous Cell Carcinoma|Metastatic Anal Canal Carcinoma|Recurrent Anal Canal Carcinoma|Stage IIIB Anal Canal Cancer|Stage IV Anal Canal Cancer |
NCT02560298 |
| A Randomized, Double-blind Study to Assess Paclitaxel-eluting Stents in Treatment of Longer Lesions |
Completed |
Coronary Artery Disease |
NCT00297804 |
| Observational Study on Quality of Life of Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy, Including a Translational Program |
Active, not recruiting |
Metastatic Pancreatic Cancer |
NCT02691052 |
| Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery |
Completed |
Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer |
NCT01106898 |
| A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00661739 |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer |
Terminated |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer |
NCT01493505 |
| Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer |
Terminated |
Breast Cancer |
NCT02360059 |
| A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer |
Unknown status |
Recurrent Breast Cancer |
NCT00912639 |
| Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas |
Terminated |
Neoplasm|Lymphomas|Neoplasm Metastasis |
NCT00023166 |
| Local Paclitaxel Delivery to Prevent Restenosis in Peripheral Arterial Disease |
Withdrawn |
Peripheral Arterial Disease|Restenosis |
NCT03858764 |
| Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00005032 |
| Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer |
Active, not recruiting |
Breast Adenocarcinoma|Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer |
NCT01697293 |
| Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol |
Recruiting |
Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Stage IIIA Uterine Corpus Cancer|Stage IIIB Uterine Corpus Cancer|Stage IIIC Uterine Corpus Cancer|Stage IVA Uterine Corpus Cancer |
NCT02501954 |
| A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC |
Not yet recruiting |
Lung Cancer Squamous Cell|Lung Cancer Stage IV|PD-1 Antibody|Chemotherapy Effect |
NCT03668496 |
| Micellar Paclitaxel to Treat Severe Psoriasis |
Completed |
Psoriasis |
NCT00006276 |
| Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer |
Recruiting |
Triple Negative Breast Cancer |
NCT03799679 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers |
Recruiting |
Cervical Adenosarcoma|Cervical Adenosquamous Carcinoma|Cervical Carcinosarcoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Endometrial Clear Cell Adenocarcinoma|Endometrial Endometrioid Adenocarcinoma|Endometrial Mixed Adenocarcinoma|Endometrial Mucinous Adenocarcinoma|Endometrial Squamous Cell Carcinoma|Endometrial Transitional Cell Carcinoma|Endometrial Undifferentiated Carcinoma|Fallopian Tube Adenocarcinoma|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Malignant Ovarian Epithelial Tumor|Malignant Peritoneal Neoplasm|Ovarian Carcinosarcoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IV Skin Melanoma|Undifferentiated Fallopian Tube Carcinoma|Undifferentiated Ovarian Carcinoma|Uterine Corpus Carcinosarcoma |
NCT02020707 |
| Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors |
Completed |
Cancer|Tumor |
NCT00113438 |
| An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin |
Completed |
Non-Small Cell Lung Cancer (NSCLC) |
NCT00274443 |
| Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix |
Recruiting |
Carcinoma of the Cervix, Stage IVB |
NCT03556839 |
| Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer |
Completed |
Urologic Neoplasms |
NCT00151034 |
| Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors |
Completed |
Advanced Solid Tumors|Metastatic Solid Tumors |
NCT00793897 |
| Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis |
Unknown status |
Peripheral Arterial Disease |
NCT02033135 |
| A Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in ELM Gastric Cancer |
Enrolling by invitation |
Gastric Cancer |
NCT03258034 |
| Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
Terminated |
Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00023907 |
| Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC |
Recruiting |
Locally Advanced Pancreatic Cancer |
NCT03257033 |
| Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma |
Completed |
Prostate Cancer |
NCT00038168 |
| A Study to Assess the Efficacy and Safety of ABTL0812 |
Recruiting |
Endometrial Cancer|Squamous Non-Small Cell Lung Cancer |
NCT03366480 |
| Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic |
Completed |
HER2-negative Breast Cancer|HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer |
NCT00003440 |
| Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors |
Completed |
Male Breast Cancer|Recurrent Breast Cancer|Recurrent Endometrial Carcinoma|Recurrent Gastric Cancer|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Small Cell Lung Cancer |
NCT00028535 |
| Sirolimus- and Paclitaxel-Eluting Stents for Small Vessels (ISAR-SMART-3) |
Completed |
Coronary Disease |
NCT00146575 |
| Ultrasound to Enhance Paclitaxel Uptake in Critical Limb Ischemia: the PACUS Trial |
Completed |
Peripheral Arterial Disease, Angioplasty |
NCT02625740 |
| Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA |
Completed |
Stage IV Pancreatic Cancer |
NCT01893801 |
| A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors |
Terminated |
Cancer |
NCT02317419 |
| Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer |
Completed |
Esophageal Cancer|Gastric Cancer |
NCT00006081 |
| Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer |
Completed |
Metastatic Non-small Cell Lung Cancer |
NCT00806286 |
| Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions |
Completed |
Coronary Stenosis |
NCT00301522 |
| A Real-world Study of Albumin-bound Paclitaxel in the Treatment of Pancreatic Cancer |
Not yet recruiting |
Pancreatic Cancer |
NCT03768687 |
| Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology |
Terminated |
Carcinoma, Squamous Cell|Carcinoma, Adenosquamous|Carcinoma, Large Cell|Carcinoma, Non-Small-Cell Lung |
NCT00596830 |
| A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. |
Recruiting |
Triple-Negative Breast Cancer |
NCT04177108 |
| Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer |
Completed |
NSCLC |
NCT00874848 |
| ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer |
Completed |
Breast Neoplasms|Metastases, Neoplasm |
NCT00046514 |
| Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00442260 |
| A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer |
Completed |
Head and Neck Neoplasm|Squamous Cell Carcinoma |
NCT00001442 |
| Concomitant Limb Cryocompression and Scalp Cooling to Reduce Paclitaxel-induced Neuropathy and Alopecia |
Recruiting |
Chemotherapy-induced Peripheral Neuropathy (CIPN) |
NCT03248193 |
| Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery |
Completed |
Melanoma (Skin) |
NCT00404235 |
| A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT00352690 |
| Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum |
Unknown status |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00003160 |
| Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel |
Completed |
Acute Pain|Breast Carcinoma|Peripheral Neuropathy |
NCT02297412 |
| Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis |
Unknown status |
Gastric Cancer |
NCT01167049 |
| Taxol Carboplatin and Erythropoetin |
Completed |
Ovarian Cancer |
NCT00158379 |
| Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer |
Terminated |
Stages II-III Breast Cancer |
NCT01090128 |
| Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma |
Active, not recruiting |
Esophageal Neoplasm |
NCT02395705 |
| A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors |
Completed |
Urinary Bladder Neoplasms|Carcinoma, Transitional Cell|Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms|Carcinoma, Non-Small-Cell Lung|Carcinoma, Pancreatic Ductal|Tumor Virus Infections |
NCT01478685 |
| Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer |
Withdrawn |
Gastric Cancer |
NCT03766607 |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
Active, not recruiting |
Clear Cell Adenocarcinoma|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Undifferentiated Carcinoma|Mucinous Adenocarcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinofibroma|Ovarian Endometrioid Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Carcinoma |
NCT00565851 |
| New York |
Rochester |
United States|Stony Brook University Medical Center |
New York |
| First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia |
Completed |
Non-Small Cell Lung Cancer |
NCT00322452 |
| Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC |
Recruiting |
Esophageal Squamous Cell Carcinoma|Chemoradiation |
NCT03623737 |
| Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer |
Completed |
Head and Neck Cancer|Oral Complications |
NCT00003193 |
| TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium |
Completed |
Bladder Neoplasms|Ureteral Neoplasms|Urethral Neoplasms|Carcinoma, Transitional Cell |
NCT00077688 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer |
Withdrawn |
Lung Cancer |
NCT00748163 |
| Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer |
Completed |
Endometrial Carcinoma |
NCT00879359 |
| A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00960960 |
| Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Lung Cancer|Non-Small Cell Lung Cancer |
NCT00094835 |
| S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00002969 |
| DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer |
Unknown status |
Pancreatic Cancer |
NCT00024375 |
| Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy |
Completed |
Brenner Tumor|Fallopian Tube Cancer|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mixed Epithelial Carcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer |
NCT00466960 |
| S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery |
Active, not recruiting |
Pancreatic Adenocarcinoma|Resectable Pancreatic Carcinoma |
NCT02562716 |
| Missouri |
Kansas City |
United States|The University of Kansas Cancer Center-Lee's Summit |
Kansas City |
| Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
Active, not recruiting |
Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer |
NCT02121990 |
| DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer |
Unknown status |
Prostate Cancer |
NCT00024414 |
| Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer |
Active, not recruiting |
Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|HER2/Neu Positive|Progesterone Receptor Negative|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IIIC Breast Cancer AJCC v6|Stage IV Breast Cancer AJCC v6 and v7 |
NCT00785291 |
| North Carolina |
Chapel Hill |
United States|Novant Health Presbyterian Medical Center |
Burlington |
| Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors |
Active, not recruiting |
Neoplasms |
NCT01362374 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00729612 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT00609791 |
| Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer |
Terminated |
Breast Cancer|Estrogen Receptor Negative Neoplasm|HER-2 Positive Breast Cancer |
NCT02598310 |
| Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer |
Active, not recruiting |
Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Fatigue|Neurotoxicity Syndrome|Obesity|Stage I Uterine Corpus Cancer AJCC v7|Stage II Uterine Corpus Cancer AJCC v7 |
NCT00807768 |
| United States|Greenville Health System Cancer Institute-Eastside |
South Carolina |
Greer |
South Carolina |
| Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction |
Completed |
Esophageal Cancer|Gastric Cancer |
NCT00022139 |
| Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00089297 |
| A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 |
Completed |
Breast Cancer|Cancer|Carcinoma, Renal Cell|Lymphoma|Ovarian Cancer |
NCT00001383 |
| A Trial Comparing a Paclitaxel Eluting Stent With Biodegradable Polymer Versus a Bare Metal Stent |
Completed |
Coronary Artery Disease |
NCT00825279 |
| Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma |
Recruiting |
Aggressive Non-Hodgkin Lymphoma|CD20 Positive|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma |
NCT03003546 |
| A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems (GENESIS) |
Completed |
Coronary Disease |
NCT00322569 |
| Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation |
Completed |
Carcinoma, Non-small Cell Lung |
NCT00861627 |
| A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer |
Completed |
Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast Cancer|Breast Cancer|Locally Advanced |
NCT00378313 |
| Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer |
Unknown status |
Esophageal Cancer |
NCT00453323 |
| A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China |
Recruiting |
Non Small Cell Lung Cancer |
NCT04015778 |
| Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer |
Completed |
Adult Solid Neoplasm|BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Hereditary Breast and Ovarian Cancer Syndrome |
NCT00535119 |
| Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00334802 |
| ABI-007 in Treating Patients With Chemotherapy-NaĂŻve Stage IV Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00077246 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
Fallopian Tube Carcinosarcoma|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Neoplasm|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Brenner Tumor|Ovarian Carcinosarcoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Tumor|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Stage IIA Fallopian Tube Cancer AJCC v6 and v7|Stage IIA Ovarian Cancer AJCC V6 and v7|Stage IIB Fallopian Tube Cancer AJCC v6 and v7|Stage IIB Ovarian Cancer AJCC v6 and v7|Stage IIC Fallopian Tube Cancer AJCC v6 and v7|Stage IIC Ovarian Cancer AJCC v6 and v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7 |
NCT00989651 |
| Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT01036087 |
| Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00054548 |
| Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer |
Completed |
Human Papilloma Virus Infection|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Verrucous Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Verrucous Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Verrucous Carcinoma of the Larynx |
NCT02048020 |
| Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer |
Terminated |
Locally Advanced HER2-negative Breast Cancer |
NCT01329627 |
| Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma |
Unknown status |
Nasopharyngeal Neoplasms |
NCT02250599 |
| The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC |
Unknown status |
Breast Cancer |
NCT01378533 |
| Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer |
Unknown status |
Ovarian Cancer |
NCT00964626 |
| Treatment of Advanced Gastrointestinal Tumors With Albumin Taxol |
Not yet recruiting |
Advanced Gastrointestinal Tumors |
NCT03977077 |
| Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer |
Unknown status |
Triple Negative Breast Cancer |
NCT03348098 |
| Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients |
Terminated |
Myocardial Infarction |
NCT00422565 |
| CCRT With Twice Weekly Paclitaxel and Cisplatin Followed by Surgery for Locally Advanced Esophageal Cancer |
Completed |
Esophageal Cancer |
NCT00154804 |
| Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer |
Terminated |
Prostatic Neoplasms |
NCT00521781 |
| Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer |
Recruiting |
ERBB2 Gene Amplification|Estrogen Receptor Positive|Inflammatory Breast Carcinoma|Metastatic Breast Carcinoma|Progesterone Receptor Positive|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7 |
NCT03101748 |
| Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter |
Active, not recruiting |
Stenosis|Restenosis |
NCT01970579 |
| Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck |
Terminated |
Squamous Cell Carcinoma of the Head and Neck|Basaloid Squamous Cell Carcinoma|Undifferentiated Carcinoma|Adenosquamous Cell Carcinoma |
NCT00570674 |
| Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer |
Suspended |
Urothelial Carcinoma |
NCT03240016 |
| Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3) |
Completed |
Uterine Cervical Neoplasms |
NCT00295789 |
| Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
Unknown status |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00838656 |
| Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer |
Active, not recruiting |
Recurrent Uterine Corpus Carcinoma|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7 |
NCT00063999 |
| Ohio |
Cleveland |
United States|MetroHealth Medical Center |
Cincinnati |
| A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) |
Active, not recruiting |
Metastatic Breast Cancer |
NCT01989676 |
| Singapore INfra-Genicular Angioplasty With PAclitaxel-eluting Balloon for Critical Limb Ischaemia (SINGA-PACLI) Trial |
Completed |
Peripheral Arterial Disease |
NCT02129634 |
| LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer |
Completed |
Ovarian Neoplasms|Peritoneal Neoplasms |
NCT01015118 |
| Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction |
Unknown status |
Advanced Gastric Cancer |
NCT01015339 |
| A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer |
Completed |
Breast Neoplasms |
NCT00373256 |
| High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery |
Terminated |
Pancreatic Adenocarcinoma|Stage III Pancreatic Cancer |
NCT01921751 |
| Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer |
Terminated |
Advanced Pancreatic Cancer |
NCT02101580 |
| Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC) |
Withdrawn |
Non-small Cell Lung Cancer, Stage III |
NCT00903942 |
| Primary Patency in Post-angioplasty Dysfunctional Arteriovenous Fistula in Renal Dialysis: Paclitaxel-releasing PTA Balloon Catheter vs PTA Balloon |
Completed |
Arteriovenous Fistula Renal Dialysis Devices Obstruction |
NCT02565953 |
| Phase II Study of ABI-007 for Gastric Cancer |
Completed |
Gastric Cancer |
NCT00661167 |
| Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer |
Terminated |
Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer |
NCT01009983 |
| Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients |
Completed |
Ovarian Epithelial Cancer Stage III|Stage IV Ovarian Cancer|Stage IV Breast Cancer |
NCT00316407 |
| Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer |
Active, not recruiting |
Endometrial Adenocarcinoma|Endometrial Adenosquamous Carcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Recurrent Uterine Corpus Carcinoma|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7 |
NCT00977574 |
| BP1001-A in Patients With Advanced or Recurrent Solid Tumors |
Not yet recruiting |
Solid Tumor, Adult|Carcinoma, Ovarian Epithelial|Fallopian Tube Neoplasms|Endometrial Cancer|Peritoneal Cancer|Solid Tumor |
NCT04196257 |
| Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer |
Suspended |
Breast Cancer|Triple Negative Breast Cancer |
NCT03301350 |
| Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT01031446 |
| Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer |
Enrolling by invitation |
Borderline Resectable Pancreatic Cancer |
NCT02717091 |
| Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial |
Terminated |
Breast Cancer |
NCT00041470 |
| Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients |
Unknown status |
Non-small Cell Lung Cancer (NSCLC) |
NCT01980472 |
| Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma |
Unknown status |
Malignant Melanoma of Skin Stage III|Metastatic Melanoma |
NCT02142335 |
| Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00265733 |
| Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery |
Suspended |
Melanoma (Skin) |
NCT00278122 |
| Optical Coherence Tomography Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease |
Completed |
Coronary Artery Disease |
NCT00704145 |
| Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma |
Active, not recruiting |
Mesothelioma |
NCT02798536 |
| A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer |
Terminated |
Stage IV (Metastatic) Breast Cancer |
NCT00140140 |
| Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy |
Completed |
Ovarian Cancer |
NCT02948075 |
| CCRT for Esophageal Cancer. |
Completed |
Esophageal Cancer|Concurrent Chemoradiotherapy|Oxaliplatin|Paclitaxel |
NCT02607982 |
| Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00087802 |
| STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma |
Completed |
Melanoma |
NCT00084214 |
| Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors |
Recruiting |
Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor |
NCT01042522 |
| Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC) |
Completed |
Carcinoma, Non-Small-Cell Lung|Lung Cancer |
NCT01069328 |
| A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX) |
Withdrawn |
Breast Cancer |
NCT01156961 |
| Prospective, Multi-Center, Random. Study of CoStar Paclitaxel-Eluting Coronary Stent(Direct Stenting vs. Pre-Dilatation) |
Terminated |
Coronary Artery Disease |
NCT00440674 |
| Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma |
Completed |
Prostate Cancer |
NCT00038246 |
| Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling |
Completed |
Neoplasms |
NCT01868022 |
| RESOLUTE China RCT |
Completed |
Ischemic Heart Disease|Stenotic Coronary Lesion|Cardiovascular Diseases|Arteriosclerosis|Coronary Artery Disease |
NCT01334268 |
| European Study of POBA Versus Cotavance(R) Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia (EURO CANAL) |
Terminated |
PAD |
NCT01260870 |
| A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies |
Completed |
Advanced Nonhematologic Malignancies |
NCT02327169 |
| Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer |
Completed |
Breast Neoplasms|Metastases, Neoplasm |
NCT00046527 |
| Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel |
Completed |
Ovarian Cancer Recurrent |
NCT01332656 |
| 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab |
Completed |
Metastatic Breast Cancer |
NCT00600340 |
| Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
Completed |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma |
NCT00096200 |
| Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer |
Active, not recruiting |
Esophageal Cancer |
NCT00655876 |
| An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer |
Terminated |
Ovarian Cancer |
NCT00738699 |
| Paclitaxel in Treating Patients With Lung Cancer |
Completed |
Lung Cancer |
NCT00002972 |
| Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00042809 |
| Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer |
Completed |
Triple-negative Breast Cancer |
NCT02413320 |
| A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma |
Completed |
Melanoma |
NCT00434252 |
| Paclitaxel Eluting Stent in Long SFA Obstruction: A Prospective, Randomized Comparison With Bypass Surgery |
Recruiting |
Chronic Lower Limb Ischemia|Peripheral Athero Obstructive Disease|Critical Ischemia|Claudication |
NCT01450722 |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy |
Recruiting |
Recurrent Cervical Carcinoma|Persistent Advanced Cervical Carcinoma|Chemotherapy|Anti-PD-1 Antibody|Immunotherapy |
NCT04188860 |
| Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00795340 |
| Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer |
Completed |
Head and Neck Cancer |
NCT00002632 |
| Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim |
Completed |
Non Small Cell Lung Cancer |
NCT00280787 |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
Completed |
Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer|Undifferentiated Fallopian Tube Carcinoma|Undifferentiated Ovarian Carcinoma |
NCT00262847 |
| Winston-Salem |
United States|Southeast Cancer Consortium-Upstate NCORP |
North Carolina |
United States|Novant Health Oncology Specialists |
| Treatment of In-Stent Restenosis 2 Study |
Recruiting |
Coronary Restenosis |
NCT03667313 |
| A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood |
Completed |
Breast Cancer|Lung Cancer|Ovarian Cancer |
NCT00117442 |
| Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT00073723 |
| Abraxane and Temodar Plus Genasense in Advanced Melanoma |
Unknown status |
Melanoma |
NCT00409383 |
| Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer |
Completed |
Breast Cancer |
NCT01669239 |
| Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
Terminated |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer|Stage 3 Cancer|Stage 4 Cancer |
NCT00408070 |
| Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer |
Recruiting |
Breast Adenocarcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma |
NCT02488967 |
| Louisiana |
Shreveport |
United States|Harold Alfond Center for Cancer Care |
Shreveport |
| Ohio |
Maumee |
United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center |
Marion |
| Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00091377 |
| Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery |
Active, not recruiting |
Male Breast Carcinoma|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7 |
NCT00770809 |
| Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo) |
Not yet recruiting |
Esophageal Squamous Cell Carcinoma |
NCT03833466 |
| A Study of ABTL0812 in Pancreatic Cancer |
Not yet recruiting |
Pancreatic Cancer |
NCT03417921 |
| Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00003117 |
| Treatment of Coronary In-Stent Restenosis |
Unknown status |
Restenosis |
NCT01735825 |
| Retrospective Study of Ramucirumab and Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma |
Not yet recruiting |
Gastric or Gastroesophageal Junction Adenocarcinoma |
NCT04192734 |
| Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer |
Unknown status |
Epithelial Ovarian Cancer |
NCT01680575 |
| Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer |
Completed |
Non Small Cell Lung Cancer |
NCT00347412 |
| Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC |
Not yet recruiting |
Non-small Cell Lung Cancer |
NCT03991403 |
| Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer |
Recruiting |
Breast Neoplasms |
NCT02489448 |
| Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer |
Unknown status |
Carcinoma, Non-Small-Cell Lung|Carcinoma, Squamous Cell |
NCT01494415 |
| Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer |
Completed |
Kidney Cancer |
NCT00077129 |
| Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT00003230 |
| TEW-7197 With Paclitaxel for the Treatment of Metastatic Gastric Cancer |
Recruiting |
Metastatic Gastric Cancer |
NCT03698825 |
| PERVIDEO I Registry, The Lutonix Paclitaxel-Coated Balloon Catheter for the Treatment of Coronary In-Stent Restenosis |
Completed |
In-Stent Restenosis |
NCT00916279 |
| Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer |
Completed |
Breast Cancer |
NCT00617942 |
| Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00002662 |
| Phase â…ˇ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00467012 |
| Global Study of a Drug-coated Balloon to Treat Obstructive SFA and/or Popliteal Lesions |
Active, not recruiting |
Peripheral Arterial Disease |
NCT01927068 |
| BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Lung Cancer |
NCT00533585 |
| Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00316199 |
| Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer |
Terminated |
Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00084448 |
| Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00003299 |
| A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00951665 |
| Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus |
Completed |
Esophageal Cancer |
NCT00066716 |
| Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access |
Terminated |
End Stage Renal Failure on Dialysis|Hyperplasia |
NCT01033357 |
| Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00503906 |
| Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00006459 |
| Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN) |
Completed |
Breast Cancer |
NCT04031703 |
| Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00724386 |
| Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors |
Completed |
Neoplasms |
NCT01968915 |
| A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) |
Active, not recruiting |
Urothelial Cancer |
NCT02256436 |
| Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab |
Completed |
Adenosquamous Cell Lung Cancer|Drug/Agent Toxicity by Tissue/Organ|Hemoptysis|Squamous Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00387374 |
| Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00002937 |
| Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00009802 |
| A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT00558922 |
| Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer|Dysgeusia|Taste Disorders|Lung Neoplasms|Small Cell Lung Carcinoma |
NCT01540045 |
| An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors |
Terminated |
Solid Tumors|Pancreatic Cancer |
NCT01822756 |
| Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery |
Active, not recruiting |
Estrogen Receptor Negative|HER2/Neu Negative|Male Breast Carcinoma|Progesterone Receptor Negative|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma |
NCT00861705 |
| Wisconsin |
Racine |
United States|HSHS Saint Nicholas Hospital |
Oconto Falls |
| Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer |
Completed |
Ovarian Cancer|Peritoneal Neoplasms|Fallopian Tube Neoplasms |
NCT00063401 |
| Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00016315 |
| Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse |
Completed |
Ovarian Cancer|Fallopian Tube Cancer |
NCT00189553 |
| Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer |
Completed |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer |
NCT00479817 |
| Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma |
Terminated |
Metastatic Pancreatic Ductal Adenocarcinoma |
NCT02101021 |
| Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer. |
Completed |
Breast Cancer|Neoplasm Metastasis |
NCT00270491 |
| ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK |
Recruiting |
Ovarian Cancer |
NCT03287271 |
| Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer |
Completed |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma|Stage IVB Cervical Cancer |
NCT00803062 |
| South Dakota |
Sioux Falls |
United States|Medical X-Ray Center |
Sioux Falls |
| Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer |
Active, not recruiting |
Borderline Resectable Pancreatic Adenocarcinoma|Locally Advanced Pancreatic Adenocarcinoma|Pancreatic Adenocarcinoma|Stage II Pancreatic Cancer AJCC v6 and v7|Stage IIA Pancreatic Cancer AJCC v6 and v7|Stage IIB Pancreatic Cancer AJCC v6 and v7|Stage III Pancreatic Cancer AJCC v6 and v7 |
NCT02394535 |
| Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer |
Completed |
Breast Cancer |
NCT00193206 |
| Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ |
Terminated |
Solid Tumor |
NCT02593708 |
| Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients |
Completed |
Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer |
NCT02066103 |
| A Randomized, Double-Blind, Controlled Study of the Safety and Performance of the NIRx™ Paclitaxel-Coated Conformer Coronary Stent |
Completed |
Coronary Artery Disease |
NCT00299026 |
| Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer |
Unknown status |
Breast Cancer |
NCT00025688 |
| Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Advanced or Metastatic Non-Small Cell Lung Cancer |
NCT00716534 |
| Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma |
Completed |
Pancreatic Cancer |
NCT01470417 |
| FREERIDE STUDY, Freeway Paclitaxel Coated Balloon Catheter to Treat Peripheral Artery Disease |
Unknown status |
Peripheral Artery Disease |
NCT01960647 |
| Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva |
Completed |
Vulvar Cancer |
NCT00014599 |
| Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer |
Completed |
Epithelial Ovarian Cancer|Primary Peritoneal Carcinoma |
NCT00407563 |
| Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00003592 |
| Prevention of Restenosis Following Revascularization |
Terminated |
Vascular Disease, Peripheral |
NCT00518284 |
| A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer |
Recruiting |
Triple-Negative Breast Cancer |
NCT03002103 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) |
Recruiting |
Ovarian Cancer|Ovarian Neoplasms|Ovarian Carcinosarcoma|Ovarian Serous Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Clear Cell Adenocarcinoma|Fallopian Tube Cancer|Fallopian Tube Neoplasms|Primary Peritoneal Carcinoma|Primary Peritoneal Serous Adenocarcinoma |
NCT03648489 |
| Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
Completed |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary |
NCT01316757 |
| A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Non-Squamous Non-Small Cell Lung Cancer |
NCT00974584 |
| MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer |
Unknown status |
Ovarian Cancer |
NCT00326456 |
| Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas |
Completed |
Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00004057 |
| To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer |
Not yet recruiting |
Non-squamous Cell Non-small Cell Lung Cancer |
NCT03792074 |
| Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer |
Completed |
Breast Cancer |
NCT00004013 |
| An "All-Comers" Study of the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter Used in Real-World Clinical Practice in Chinese Patients |
Recruiting |
Chinese Patients Treated With Agent DCB |
NCT04085445 |
| Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts |
Recruiting |
Pancreatic Cyst|Pancreatic Intraductal Papillary-Mucinous Neoplasm|Cystadenoma, Mucinous|Papillary Mucinous Cystadenoma, Borderline Malignancy |
NCT01643460 |
| Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. |
Terminated |
Carcinoma, Non-Small-Cell Lung|Lung Adenocarcinoma |
NCT01578551 |
| Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer |
Completed |
Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00005046 |
| Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC |
Completed |
Carcinoma, Non-Small-Cell Lung|Lung Neoplasms |
NCT00001450 |
| Taxol(Paclitaxel),UFT and Leucovorin in Patients With Advanced Gastric Cancer |
Completed |
Gastric Cancer |
NCT00154778 |
| Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 |
Active, not recruiting |
Neoplasms, Breast |
NCT00281658 |
| A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer |
Completed |
Breast Cancer |
NCT00789581 |
| TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer |
Completed |
Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Ovarian Carcinoma |
NCT01294293 |
| Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer |
Completed |
Squamous Cell Carcinoma |
NCT00176267 |
| High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors |
Active, not recruiting |
Adult Solid Neoplasm |
NCT01281176 |
| The SOS (Stenting Of Saphenous Vein Grafts) Trial |
Completed |
Coronary Artery Bypass|Arteriosclerosis |
NCT00247208 |
| Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer |
Completed |
Breast Cancer|Metastatic Breast Cancer |
NCT00403130 |
| A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites |
Recruiting |
Gastric Cancer|Stomach Neoplasms |
NCT03475615 |
| Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer |
Withdrawn |
Ovarian Cancer |
NCT00842582 |
| Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC |
Active, not recruiting |
NSCLC |
NCT02954172 |
| A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00370552 |
| Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00245154 |
| A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies |
Withdrawn |
Solid Tumor |
NCT00820768 |
| A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer |
Recruiting |
Breast Cancer |
NCT03726879 |
| Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors |
Completed |
Ovarian Cancer|Testicular Germ Cell Tumor |
NCT00003518 |
| Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Non-Small Cell Lung Cancer |
NCT00874107 |
| Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer |
Unknown status |
Metastatic Breast Cancer |
NCT01989780 |
| A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L) |
Terminated |
Non-Small Cell Lung Cancer |
NCT00434226 |
| A Phase I/II Study of Chemoradiotherapy in Unresectable Esophageal Cancer |
Recruiting |
Esophageal Cancer|Chemoradiotherapy|Albumin-bound Paxlitaxel|Unresectable Malignant Neoplasm |
NCT04278287 |
| Metronomic Therapy in Metastatic Breast Cancer. |
Completed |
Breast Cancer |
NCT01131195 |
| Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma |
Recruiting |
Pancreatic Cancer|Advanced Pancreatic Ductal Adenocarcinoma |
NCT02921022 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery |
Active, not recruiting |
Metastatic Pancreatic Adenocarcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Unresectable Pancreatic Carcinoma |
NCT02194829 |
| A Study of The Femoral Popliteal Artery Treated With LEGFLOW OTW |
Recruiting |
Peripheral Arterial Disease |
NCT02965677 |
| CVI Drug Coated Balloon European Randomized Clinical Trial |
Active, not recruiting |
Peripheral Arterial Disease|Claudication |
NCT01858363 |
| Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors |
Completed |
Neoplasms |
NCT00607048 |
| Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer |
Active, not recruiting |
Human Papilloma Virus Infection|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Oropharynx |
NCT02258659 |
| Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer |
Completed |
Gastroesophageal Junction Adenocarcinoma|Malignant Neoplasm of the Cervical Esophagus|Malignant Neoplasm of the Thoracic Esophagus|Stage IIA Esophageal Cancer AJCC v7|Stage IIB Esophageal Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7|Stage IIIC Esophageal Cancer AJCC v7 |
NCT02389751 |
| A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00251472 |
| Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases |
Withdrawn |
Metastatic Melanoma|Brain Metastases |
NCT02065466 |
| Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer |
Completed |
Prostate Cancer |
NCT00003614 |
| Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer |
Unknown status |
Prostate Cancer |
NCT00003717 |
| Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer |
Completed |
Breast Cancer|Breast Neoplasms|Breast Tumors|Cancer|Locally Recurrent and Metastatic Breast Cancer|Metastases|Metastatic Cancer|Oncology|Solid Tumors|Tumors |
NCT00807859 |
| Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer |
Not yet recruiting |
Efficacy and Safety |
NCT03794778 |
| Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
Completed |
Lymphoma |
NCT00021372 |
| A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients |
Unknown status |
Breastcancer |
NCT03165955 |
| Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00005649 |
| MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00401674 |
| Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT00499525 |
| Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting |
Active, not recruiting |
Breast Cancer|HER2-negative Breast Cancer|HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer |
NCT00618657 |
| Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC |
Completed |
Lung Cancer |
NCT00226590 |
| Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma |
Completed |
Uterine Carcinosarcoma |
NCT00687687 |
| Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00003555 |
| A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-NaĂŻve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) |
Not yet recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT04194203 |
| SU5416 and Paclitaxel in Treating Patients With Advanced Cancer |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00006257 |
| PCB for Long De Novo Lesions of Main Coronary Arteries (D-Lesion Long Trial) |
Unknown status |
Stable Angina Pectoris|Unstable Angina Pectoris |
NCT03155971 |
| Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma |
Completed |
Carcinoma, Squamous Cell of the Head and Neck |
NCT00753038 |
| Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01) |
Completed |
Colorectal Cancer |
NCT00625573 |
| Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00004924 |
| Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00616031 |
| Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00426556 |
| Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer |
Recruiting |
Inflammatory Breast Cancer |
NCT03515798 |
| A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer |
Completed |
Non Small Cell Lung Cancer |
NCT01023347 |
| A Study Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer. |
Active, not recruiting |
Non-Small Cell Lung Cancer |
NCT03594747 |
| Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer |
Unknown status |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00004173 |
| Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer |
Terminated |
Stomach Neoplasms|Oesophageal Junction Cancer|Lower Oesophagus Cancer |
NCT01830270 |
| Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor |
Terminated |
Lung Cancer |
NCT00004159 |
| POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC |
Enrolling by invitation |
Malignant Neoplasm of Stomach Stage IV |
NCT02845908 |
| Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER) |
Completed |
Primary Breast Cancer |
NCT04127019 |
| Evaluating the Effectiveness of Paclitaxel-eluting Balloons for Below-the-knee Angioplasty in Patients With Critical Limb Ischemia |
Unknown status |
Critical Limb Ischemia |
NCT01938872 |
| Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer |
Completed |
Head and Neck Cancer |
NCT00003206 |
| Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00031876 |
| Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery |
Terminated |
Breast Cancer |
NCT00589238 |
| Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC |
Terminated |
Non-Small Cell Lung Cancer |
NCT00960297 |
| Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer |
Terminated |
Head and Neck Cancer |
NCT00176241 |
| Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer |
Completed |
Breast Cancer |
NCT00392392 |
| Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer |
Withdrawn |
Lung Cancer |
NCT00547443 |
| A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer |
Recruiting |
Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy|Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy |
NCT02207465 |
| Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors |
Completed |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer|Papillary Serous Mullerian Tumor|Clear Cell Mullerian Tumor |
NCT00520013 |
| Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00004979 |
| Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer |
Completed |
Breast Cancer |
NCT00136539 |
| S9912 Combination Chemo in Stage III Ovarian Cancer, |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer |
NCT00003896 |
| Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery |
Terminated |
Lung Cancer |
NCT00526890 |
| A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer. |
Completed |
Non-Small-Cell Lung Carcinoma|Adenocarcinoma |
NCT00600821 |
| A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Non-Small Cell Lung Cancer |
NCT01225302 |
| Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer |
Completed |
Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00002717 |
| Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma |
Recruiting |
Pancreatic Cancer |
NCT04054362 |
| Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer |
Unknown status |
Breast Cancer |
NCT00006120 |
| Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel |
Terminated |
Chemotherapeutic Agent Toxicity|Pain|Peripheral Neuropathy|Recurrent Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Therapy-related Toxicity |
NCT01243541 |
| Assessment of Paclitaxel-Induced Neuropathy |
Active, not recruiting |
Cancer|Breast Cancer|Ovarian Cancer |
NCT01953159 |
| BATTLE Trial: Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions |
Unknown status |
Peripheral Arterial Disease|Femoropopliteal Lesions |
NCT02004951 |
| Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas |
Completed |
Brain and Central Nervous System Tumors|Breast Cancer|Kidney Cancer|Lung Cancer|Lymphoma|Melanoma (Skin)|Ovarian Cancer|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00019019 |
| TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent |
Completed |
Coronary Artery Disease |
NCT00292474 |
| Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer |
Terminated |
Ovarian Neoplasms |
NCT00919984 |
| Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer |
Withdrawn |
Breast Cancer |
NCT01227408 |
| A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00618826 |
| Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer |
Completed |
Esophageal Cancer|Gastric Cancer |
NCT00005599 |
| Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 |
Completed |
Breast Cancer |
NCT00005635 |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery |
Completed |
Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer |
NCT00407888 |
| Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel |
Completed |
Esophageal Cancer |
NCT00006245 |
| Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis |
Completed |
Carcinoma|Peritoneal Neoplasm |
NCT00001569 |
| Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours |
Completed |
Neoplasms |
NCT00716417 |
| Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer |
Active, not recruiting |
Endometrial Cancer|Papillary Serous|Clear Cell Endometrial Cancer |
NCT03189446 |
| MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma |
Terminated |
Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma |
NCT02551055 |
| The COPPER-B Trial |
Completed |
Cardiovascular Diseases|Peripheral Vascular Disease|Arterial Occlusive Diseases|Peripheral Arterial Disease|Critical Limb Ischemia |
NCT02395744 |
| A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer |
Recruiting |
Breast Cancer |
NCT03800836 |
| Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors |
Completed |
Breast Neoplasms |
NCT02307227 |
| Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma |
Unknown status |
Esophageal Squamous Carcinoma |
NCT01752205 |
| Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
Recruiting |
Stage III Fallopian Tube Cancer AJCC v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Primary Peritoneal Cancer AJCC v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7 |
NCT02520154 |
| Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver |
Recruiting |
Metastatic Cholangiocarcinoma|Metastatic Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Cholangiocarcinoma|Unresectable Hepatocellular Carcinoma|Unresectable Intrahepatic Cholangiocarcinoma |
NCT04175912 |
| Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer |
Recruiting |
Epithelial Ovarian Cancer |
NCT02681432 |
| Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer |
Recruiting |
Pancreatic Adenocarcinoma Resectable|Neoadjuvant Chemotherapy |
NCT03750669 |
| A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer |
Active, not recruiting |
Pancreatic Cancer |
NCT02873598 |
| Paclitaxel Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma |
Terminated |
Brain and Central Nervous System Tumors |
NCT00031577 |
| ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors |
Withdrawn |
Tumors |
NCT01031212 |
| Uterine Papillary Serous Cancer (UPSC) Trial |
Completed |
Uterine Cancer |
NCT00147680 |
| An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Non-small Cell Lung Cancer |
NCT00674102 |
| Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery |
Completed |
Lung Cancer|Metastatic Cancer |
NCT00020007 |
| A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer |
Completed |
Pancreatic Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma |
NCT02045589 |
| Luminor Registry: Registry of the Results of Angioplasty With Drug-eluting Balloon (Paclitaxel) in the Treatment of Infrainguinal Occlusive Lesions and Restenosis From Prior Endovascular Procedures in This Sector. |
Completed |
Peripheral Vascular Disease |
NCT02458911 |
| Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer |
Active, not recruiting |
Borderline Ovarian Mucinous Tumor|Ovarian Mucinous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Stage IA Fallopian Tube Cancer AJCC v6 and v7|Stage IA Ovarian Cancer AJCC v6 and v7|Stage IB Fallopian Tube Cancer AJCC v6 and v7|Stage IB Ovarian Cancer AJCC v6 and v7|Stage IC Fallopian Tube Cancer AJCC v6 and v7|Stage IC Ovarian Cancer AJCC v6 and v7|Stage IIA Fallopian Tube Cancer AJCC v6 and v7|Stage IIA Ovarian Cancer AJCC V6 and v7|Stage IIB Fallopian Tube Cancer AJCC v6 and v7|Stage IIB Ovarian Cancer AJCC v6 and v7|Stage IIC Fallopian Tube Cancer AJCC v6 and v7|Stage IIC Ovarian Cancer AJCC v6 and v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7 |
NCT01081262 |
| A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer |
Completed |
Squamous Non Small Cell Lung Cancer |
NCT01769391 |
| Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread |
Not yet recruiting |
Cervical Cancer TNM Staging Regional Lymph Nodes (N) |
NCT03534713 |
| Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00003539 |
| Immunopheresis Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Advanced Triple Negative Breast Cancer (TNBC) |
Recruiting |
Advanced Triple Negative Breast Cancer |
NCT04004910 |
| Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer |
Completed |
Fallopian Tube Carcinoma|Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Primary Peritoneal Carcinoma|Stage III Ovarian Cancer|Stage IV Ovarian Cancer|Undifferentiated Ovarian Carcinoma |
NCT00060359 |
| Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 |
Unknown status |
Breast Cancer |
NCT00004067 |
| MEtronomic TrEatment Option in Advanced bReast cAncer |
Recruiting |
Breast Cancer |
NCT02954055 |
| Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) |
Recruiting |
Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma|Pancreatic Adenocarcinoma|Pancreas Metastases|Adenocarcinoma |
NCT03415854 |
| A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer |
Active, not recruiting |
Metastatic Breast Cancer |
NCT01526369 |
| S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer |
Active, not recruiting |
Recurrent Large Cell Lung Carcinoma|Recurrent Lung Adenocarcinoma|Recurrent Squamous Cell Lung Carcinoma|Stage IV Large Cell Lung Carcinoma|Stage IV Lung Adenocarcinoma|Stage IV Squamous Cell Lung Carcinoma |
NCT00946712 |
| Missouri |
Billings |
United States|Northern Rockies Radiation Oncology Center |
Springfield |
| A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) |
Active, not recruiting |
Unresectable or Metastatic Melanoma |
NCT01721746 |
| Infinnium-Core™ Registry for the Treatment of Patients With De Novo Coronary Lesions |
Terminated |
Coronary Artery Disease |
NCT00936780 |
| Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer |
Unknown status |
Non-squamous Nonsmall Cell Neoplasm of Lung |
NCT01303926 |
| Phase II Study in Patients With Operable Breast Cancer |
Unknown status |
Breast Cancer |
NCT00518583 |
| A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors |
Completed |
Solid Cancers |
NCT01075464 |
| Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT00539331 |
| QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer |
Terminated |
Advanced Squamous Non-Small Cell Lung Cancer |
NCT00807612 |
| Titanium Nitride Oxide Coated Stents and Paclitaxel Eluting Stents for Acute Myocardial Infarction |
Completed |
Acute Myocardial Infarction |
NCT00495664 |
| Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT00578149 |
| Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy |
Recruiting |
Non Small Cell Lung Cancer Metastatic |
NCT03977194 |
| IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma |
Completed |
Metastatic Breast Cancer |
NCT00349934 |
| Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer |
Completed |
Breast Cancer |
NCT01172223 |
| A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer |
Recruiting |
Lung Cancer Non-small Cell Stage IV|Squamous Cell Lung Cancer |
NCT03866993 |
| Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca |
Active, not recruiting |
Recurrent Breast Cancer|Metastatic Breast Cancer |
NCT02041429 |
| Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients |
Completed |
Locally Recurrent and Metastatic Breast Cancer |
NCT00511459 |
| A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer |
NCT03635489 |
| Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer |
Completed |
Inflammatory Breast Cancer|Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer |
NCT00513695 |
| Pharmacogenomics of Paclitaxel in Ovarian Cancer |
Completed |
Ovarian Neoplasms|Fallopian Tube Neoplasms |
NCT00415181 |
| Alisertib in Chemotherapy-pretreated Urothelial Cancer |
Completed |
Bladder Cancer|Transitional Cell Carcinoma |
NCT02109328 |
| Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study |
Completed |
Metastatic Malignant Melanoma |
NCT00462423 |
| Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00278148 |
| Pharmacogenomics of Paclitaxel in Ovarian Cancer |
Completed |
Ovarian Neoplasms|Fallopian Tube Neoplasms |
NCT00415207 |
| Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site |
Completed |
Neoplasms, Unknown Primary |
NCT00193596 |
| ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma |
Completed |
Melanoma (Skin) |
NCT00081042 |
| Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT01493843 |
| Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT01792050 |
| An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy |
Completed |
Genital Neoplasms, Female|Fallopian Tube Neoplasms|Ovarian Neoplasms|Pelvic Neoplasms|Peritoneal Neoplasms |
NCT00191646 |
| Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer |
Completed |
Cervical Cancer |
NCT00276796 |
| Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT01024712 |
| FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients |
Completed |
Breast Cancer |
NCT00129389 |
| Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery |
Active, not recruiting |
Pancreatic Adenocarcinoma|Resectable Pancreatic Carcinoma |
NCT02427841 |
| A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT00534027 |
| Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00054210 |
| A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer |
Recruiting |
Breast Neoplasms |
NCT03705429 |
| Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin |
Completed |
Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Ovarian Cancer|Teratoma|Testicular Germ Cell Tumor |
NCT00423852 |
| Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck |
Completed |
Head and Neck Cancer |
NCT00083057 |
| Paclitaxel and Carboplatin With or Without BMS-275291 in Treating Patients With Advanced or Metastatic Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00006229 |
| Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00004863 |
| Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma (SEQUEL) |
Not yet recruiting |
Gastric Cancer|GastroEsophageal Cancer|Adenocarcinoma |
NCT04069273 |
| A Safety Study of ABI-007 for In-Stent Restenosis |
Completed |
Angina Pectoris|Coronary Artery Disease |
NCT00093223 |
| Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients |
Completed |
Non Small Cell Lung Cancer |
NCT00457119 |
| TAXUS PERSEUS Small Vessel |
Completed |
Coronary Artery Disease |
NCT00489541 |
| Non-interventional Study With Nab-Paclitaxel (Abraxane®) |
Completed |
Metastatic Breast Cancer |
NCT01689610 |
| Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer |
Completed |
Epithelial Ovarian Cancer|Primary Peritoneal Cancer |
NCT00314678 |
| Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer |
Completed |
Breast Cancer |
NCT00546156 |
| Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter |
Recruiting |
Coronary Artery Disease |
NCT03908450 |
| A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. |
Terminated |
Squamous Cell Carcinoma of the Head and Neck |
NCT01732640 |
| Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer |
Completed |
Epithelial Ovarian Cancer |
NCT00490711 |
| N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer |
Withdrawn |
Ovarian Carcinoma, Stage 3 or 4|Epithelial Ovarian Carcinoma|Primary Peritoneal Carcinoma |
NCT01138137 |
| Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC |
Active, not recruiting |
Head and Neck Cancer |
NCT00997906 |
| Gastric Cancer RAD001 Study |
Completed |
Gastric Cancer |
NCT01514110 |
| Optical Coherence Tomography to Evaluate Paclitaxel-Eluting Balloons and Everolimus-Eluting Coronary Stents |
Completed |
Stents|Neointimal Proliferation |
NCT01056744 |
| Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas |
Terminated |
Adenocarcinoma Pancreas |
NCT01783054 |
| Treatment of Coronary Artery Disease (CAD) With Bare Metal Stent (BMS) Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent |
Completed |
Coronary Artery Disease |
NCT01166711 |
| Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients |
Active, not recruiting |
Breast Cancer|Peripheral Neuropathy |
NCT02364726 |
| Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma |
Recruiting |
Esophageal Squamous Cell Carcinoma |
NCT03278626 |
| Phase I Study of TENPA in Advanced Solid Cancer |
Terminated |
Advanced Solid Tumor |
NCT02979392 |
| A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
Non-small Cell Lung Cancer |
NCT03296163 |
| A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT02015676 |
| Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™) |
Completed |
Breast Cancer |
NCT00503750 |
| Comparison of the Efficacy of Paclitaxel-releasing Balloon Catheter System Versus the Everolimus-Eluting Stent System for Treatment of In-Stent Restenosis Lesions - Harmonizing Optimal Strategy for Treatment of In-Stent Restenosis Lesions (The HOST-ISR Trial) - |
Unknown status |
In-stent Restenosis Lesion |
NCT01093300 |
| Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer |
Completed |
Epithelial Ovarian Cancer |
NCT00281515 |
| Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers: the ARMANI Phase III Trial |
Unknown status |
Stomach Neoplasms |
NCT02934464 |
| Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00017407 |
| Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer |
Completed |
Advanced Ovarian Carcinoma|Primary Peritoneal Carcinoma|Ovarian Carcinosarcoma |
NCT00511992 |
| Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure. |
Completed |
Pancreatic Adenocarcinoma Advanced or Metastatic |
NCT01971034 |
| Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00035152 |
| Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer |
Completed |
Breast Cancer |
NCT00544167 |
| Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer |
Unknown status |
Breast Cancer |
NCT00397761 |
| Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors |
Withdrawn |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00009828 |
| Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma |
Terminated |
Melanoma (Skin) |
NCT00568451 |
| A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer |
Completed |
Ovarian Neoplasm |
NCT00001426 |
| Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer |
Withdrawn |
Prostate Cancer |
NCT00084565 |
| Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy |
Completed |
Peripheral Neuropathy |
NCT01313117 |
| Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib |
Completed |
Solid Tumors |
NCT00667147 |
| Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer |
Completed |
Fallopian Tube Cancer|Ovarian Cancer |
NCT00006454 |
| Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer |
Completed |
Breast Cancer |
NCT00431080 |
| Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane |
Completed |
Metastatic Pancreatic Cancer |
NCT01461915 |
| S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00016406 |
| Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT01844817 |
| Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO) |
Completed |
Epithelial Ovarian Cancer |
NCT00538603 |
| A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma |
Completed |
Melanoma |
NCT00111007 |
| Safety Study to Assess the Feasibility of Use in Humans of the TAXUS Petal Bifurcation Coronary Stent System |
Completed |
Cardiovascular Diseases |
NCT00497367 |
| Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma |
Completed |
Neuroendocrine Carcinoma |
NCT00193531 |
| Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00170664 |
| Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma |
Completed |
Esophageal Neoplasms |
NCT02446574 |
| Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00005087 |
| ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00071188 |
| Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00276588 |
| Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel |
Recruiting |
Breast Cancer|Lung Cancer|Ovarian Cancer|Oesophageal Cancer|Head Cancer Neck|Cervical Cancer|Endometrial Cancer |
NCT04237090 |
| Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer |
Recruiting |
Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-negative Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-negative Breast Cancer |
NCT02315196 |
| Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer |
Terminated |
Epithelial Ovarian Cancer |
NCT00889733 |
| A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B) |
Terminated |
Metastatic Breast Cancer |
NCT00434356 |
| Randomized Phase II Study of Intraperitoneal Versus Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer |
Completed |
Fallopian Tube Cancer|Metastatic Cancer|Ovarian Cancer|Peritoneal Cavity Cancer |
NCT00993655 |
| Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) |
Active, not recruiting |
Stage III Fallopian Tube Cancer AJCC v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Primary Peritoneal Cancer AJCC v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7 |
NCT02726997 |
| Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer |
Unknown status |
Non Small Cell Lung Cancer |
NCT01527864 |
| Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer |
Completed |
Breast Cancer|Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer |
NCT00470301 |
| A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE) |
Completed |
Non-small Cell Lung Cancer |
NCT00318136 |
| Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma |
Active, not recruiting |
Ovarian Neoplasms|Ovarian Epithelial Cancer |
NCT02107937 |
| Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma |
Completed |
Ovary Cancer |
NCT00193297 |
| Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00025389 |
| Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer |
Completed |
Breast Cancer |
NCT00482391 |
| A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer |
Terminated |
Carcinoma, Non-small-cell Lung |
NCT00153842 |
| PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00028587 |
| Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel |
Completed |
Breast Neoplasms|Breast Diseases|Metastases, Neoplasm |
NCT00039780 |
| Neoadjuvant Treatment of Breast Cancer |
Completed |
Breast Cancer |
NCT00254592 |
| A Pilot Study of PPX in Women With Metastatic Colorectal Cancer |
Completed |
Advanced Colorectal Cancer |
NCT00598247 |
| Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer |
Unknown status |
Breast Cancer |
NCT00154882 |
| Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung|Lung Neoplasms |
NCT00001499 |
| S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer |
Withdrawn |
Cervical Cancer |
NCT00057928 |
| Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer |
Recruiting |
Ovarian Cancer Stage IV|Peritoneal Cancer|Fallopian Tube Cancer |
NCT03126812 |
| STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) |
Completed |
Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer |
NCT00088088 |
| Second-line Therapy With Nal-IRI After Failure Gemcitabine/Nab-paclitaxel in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy |
Recruiting |
Locally Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer |
NCT03468335 |
| Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus |
Completed |
Sarcoma |
NCT00003128 |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer |
Active, not recruiting |
Breast Adenocarcinoma |
NCT00433511 |
| Cape Girardeau |
United States|Saint Francis Medical Center |
Missouri |
United States|Southeast Missouri Hospital |
| Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis |
Completed |
Coronary Restenosis |
NCT00287573 |
| 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00016874 |
| Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer. |
Unknown status |
Pancreatic Cancer |
NCT02506803 |
| Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer |
Completed |
Breast Cancer |
NCT00536939 |
| Safety and Feasibility of SurModics SurVeil (TM) Drug Coated Balloon |
Active, not recruiting |
Peripheral Arterial Disease|Peripheral Vascular Diseases |
NCT02648620 |
| ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer |
Terminated |
Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy |
NCT00929162 |
| Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer |
Completed |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer |
NCT00466986 |
| The European Cobalt STent With Antiproliferative for Restenosis Trial (EuroSTAR Trial) |
Completed |
Treatment of Symptomatic Ischemic Heart Disease |
NCT00974181 |
| Chemoradiotherapy for Advanced Esophageal Cancer |
Not yet recruiting |
Esophageal Cancer |
NCT02297217 |
| Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab |
Unknown status |
Ovarian Cancer |
NCT01706120 |
| ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) |
Completed |
Non-Small Cell Lung Cancer|Neoplasm Metastasis|Lung Cancer |
NCT00034346 |
| Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer |
Completed |
Non-Small-Cell Lung Carcinoma |
NCT01048645 |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer |
Active, not recruiting |
Breast Adenocarcinoma|HER2 Positive Breast Carcinoma|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7 |
NCT00005970 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors |
Withdrawn |
Cancer |
NCT00499291 |
| S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00856492 |
| ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma |
Terminated |
Fallopian Tube Neoplasms|Peritoneal Neoplasms|Ovarian Neoplasms |
NCT00407407 |
| Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy to Treat Non-Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT01494558 |
| A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer |
Completed |
Ovarian Neoplasms |
NCT01616303 |
| Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00003242 |
| Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy |
Completed |
Prostate Cancer |
NCT00005048 |
| Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients |
Withdrawn |
Resectable Pancreatic Cancer |
NCT03392571 |
| Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma |
Completed |
Melanoma |
NCT00970996 |
| A New Diagnostic Method to Assess Paclitaxel-Induced Peripheral Neuropathy |
Recruiting |
Chemotherapy-induced Peripheral Neuropathy |
NCT04237194 |
| Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma |
N/A |
N/A |
NCT02307812 |
| Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma |
Terminated |
Ovarian Neoplasms |
NCT00976183 |
| Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00002953 |
| Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer |
Completed |
Testicular Germ Cell Tumor |
NCT00004077 |
| Phase II Neoadjuvant in Inflammatory Breast Cancer |
Terminated |
Breast Cancer |
NCT00756470 |
| Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II) |
Completed |
Coronary Disease |
NCT00165035 |
| Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00005078 |
| The Efficacy and Safety of SeQuent® Please in the Treatment of Small Vessel Disease (SVD) Patient |
Recruiting |
Small Vessel Disease |
NCT03625830 |
| Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium |
Completed |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter |
NCT00310011 |
| An Effective and Compliance Regimen of Paclitaxel Plus Cisplatin to Treat Metastatic Breast Cancer |
Unknown status |
Breast Neoplasms |
NCT00270569 |
| Maintenance Chemotherapy in Metastatic Breast Cancer |
Unknown status |
Breast Cancer |
NCT00289263 |
| TAXUS PERSEUS Workhorse |
Completed |
Coronary Artery Disease |
NCT00484315 |
| A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response |
Active, not recruiting |
Early Primary Breast Cancer |
NCT02214381 |
| Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer |
Completed |
Endometrial Cancer |
NCT00052312 |
| Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer |
Completed |
Carcinoma Breast Stage IV |
NCT00669565 |
| PEPCAD I. The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel |
Completed |
Coronary Stenosis |
NCT00404144 |
| Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00077220 |
| Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer |
Unknown status |
Bladder Cancer |
NCT00006118 |
| Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery |
Completed |
Lung Cancer |
NCT00553462 |
| S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium |
Completed |
Bladder Cancer|Urethral Cancer |
NCT00055835 |
| Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel |
Completed |
Non-small Cell Lung Cancer |
NCT01234038 |
| Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer |
Completed |
Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00002894 |
| Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer |
Recruiting |
Breast Carcinoma |
NCT03941743 |
| Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer |
Completed |
Cervical Cancer |
NCT00003379 |
| Gene Expression in Predicting Response to Paclitaxel in Patients With Breast Cancer |
Unknown status |
Breast Cancer |
NCT00898690 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer |
Completed |
Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer |
NCT00005840 |
| Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor |
Withdrawn |
Unknown Primary Tumors |
NCT00458315 |
| Paclitaxel-coated or Uncoated AngioSculpt Scoring Balloon Catheter |
Unknown status |
In-stent Arterial Restenosis |
NCT01495533 |
| Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma |
Completed |
Pancreatic Cancer |
NCT02289898 |
| Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty |
Completed |
Stable Angina|Coronary Stenosis |
NCT02120859 |
| Patency and Safety of the Drug Eluting Covered Biliary Stent Comparing to the Common Covered Biliary Stent |
Completed |
Biliary Stricture|Malignant Neoplasms |
NCT01512563 |
| A Study of Oraxol® in Gastric Cancer Patients |
Unknown status |
Advanced Metastatic Gastric Cancer|Recurrent Gastric Cancer |
NCT01491217 |
| Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer |
Terminated |
Lung Cancer |
NCT00063258 |
| A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer |
Terminated |
Endometrial Cancer |
NCT00883116 |
| Nonpolymer- and Polymer-Based Drug-Eluting Stents for Restenosis (ISAR-TEST-1) |
Completed |
Coronary Disease |
NCT00140530 |
| Efficacy and Safety of Paclitaxel-eluting Balloons for Below the Knee Peripheral Arterial Disease |
Unknown status |
Peripheral Arterial Disease |
NCT02772224 |
| A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer |
Withdrawn |
Breast Cancer |
NCT02637375 |
| A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) |
Recruiting |
Pancreatic Neoplasms|Cancer of Pancreas|Cancer of the Pancreas|Neoplasms, Pancreatic|Pancreas Cancer|Pancreas Neoplasms|Adenocarcinoma |
NCT02905578 |
| Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer |
Completed |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer |
NCT00022191 |
| Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer |
Recruiting |
Pancreatic Adenocarcinoma |
NCT03703063 |
| Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer |
Completed |
Endometrial Cancer |
NCT00006377 |
| Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer |
Withdrawn |
Esophageal Cancer|Biliary Tract Cancer|GastroEsophageal Cancer|Hepatobiliary Neoplasm |
NCT03818997 |
| Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01) |
Terminated |
Locally Advanced HER2-positive Breast Cancer |
NCT01329640 |
| Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients |
Unknown status |
Non-small Cell Lung Cancer |
NCT01393080 |
| A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) |
Terminated |
Stage IIIB or IV Non-Small Cell Lung Cancer |
NCT00473889 |
| Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
Active, not recruiting |
Head and Neck Cancer |
NCT01412229 |
| Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
Unknown status |
Drug/Agent Toxicity by Tissue/Organ|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00024310 |
| Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV |
Completed |
Ovarian Cancer |
NCT00231075 |
| Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer |
Completed |
Breast Cancer |
NCT00068757 |
| Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer |
Not yet recruiting |
Small-cell Lung Cancer |
NCT04210037 |
| Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer |
Terminated |
Non-small Cell Lung Cancer (NSCLC) |
NCT00850577 |
| Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia |
Unknown status |
Taxane|Drug-related Side Effects and Adverse Reactions|Pain|Breast Cancer |
NCT02024568 |
| Drug Coated Balloons for Prevention of Restenosis |
Unknown status |
Atherosclerosis|Restenosis|Limb Ishemia |
NCT00696956 |
| Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00002519 |
| Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery |
Completed |
Melanoma (Skin) |
NCT00626405 |
| Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00004934 |
| PAclitaxel-eluting Balloon in Primary PCI in Amsterdam |
N/A |
N/A |
NCT01274728 |
| Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis |
Unknown status |
Breast Cancer |
NCT00574587 |
| Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer |
Not yet recruiting |
Ovarian Cancer |
NCT03410784 |
| Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00193362 |
| Metronomic Chemotherapy in Advanced Gastric Cancer |
Unknown status |
Metastatic Gastric Cancer|Locally Advanced Gastric Cancer |
NCT02855788 |
| Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer |
Completed |
Breast Cancer |
NCT00050167 |
| Efficiency of a New Therapy to Treat Stenosis of Coronary Vessels in Comparison With Two Already Admitted Therapies |
Unknown status |
Stable or Unstable Angina Pectoris|Myocardial Ischemia |
NCT00396929 |
| Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors |
Unknown status |
Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor |
NCT00551122 |
| Real-world Study for the Safety of Albumin-Bound Paclitaxel in Recurrent or Metastatic Breast Cancer |
Not yet recruiting |
Breast Cancer |
NCT04060290 |
| EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202) |
Completed |
Head and Neck Cancer |
NCT00270790 |
| Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLC |
Terminated |
Non Small Cell Lung Cancer |
NCT00449657 |
| First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma. |
Active, not recruiting |
Metastatic Pancreatic Adenocarcinoma |
NCT01964287 |
| A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab |
Recruiting |
Breast Cancer |
NCT03264547 |
| Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer |
Completed |
Breast Cancer |
NCT00656669 |
| NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation |
Terminated |
Nasopharyngeal Carcinoma |
NCT01694576 |
| Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00510445 |
| A Prospective Evaluation in a Randomized Trial of TAXUS in the Treatment of De Novo Coronary Artey Lesions |
Unknown status |
Coronary Heart Disease |
NCT00693979 |
| A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer |
Completed |
Breast Cancer, Non-small Lung Cancer |
NCT01862081 |
| Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting |
Recruiting |
Breast Cancer |
NCT02546232 |
| Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00003612 |
| Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT00050960 |
| Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum |
Terminated |
Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum|Platinum Sensitve Relapse|Anemia |
NCT00189371 |
| Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT01254526 |
| An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404 |
Terminated |
Metastatic Cancer With Impaired Renal Function|Metastatic Cancer With Normal Renal Function |
NCT01240642 |
| Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer |
Terminated |
Ovarian Cancer |
NCT00189579 |
| A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. |
Terminated |
NSCLC |
NCT00269828 |
| Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma |
Completed |
Melanoma|Metastases |
NCT00093119 |
| Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer |
Unknown status |
Head and Neck Cancer |
NCT00022217 |
| A Study of Below The Knee Arteries' Stenosis or Occlusion Treated With LEGFLOW OTW |
Recruiting |
Peripheral Artery Disease |
NCT02962232 |
| Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer |
Completed |
Breast Cancer |
NCT01008150 |
| Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
Ovarian Cancer|Ovarian Neoplasm |
NCT02470585 |
| Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II |
Completed |
Non-small Cell Lung Cancer|Advanced Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer |
NCT01649947 |
| S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium |
Completed |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer |
NCT00045630 |
| Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery |
Completed |
Lung Cancer |
NCT00003387 |
| A Study of Hemodialysis Arteriovenous Fistulae Stenosis Treated With APERTO |
Completed |
Peripheral Arterial Disease|Fistula |
NCT02962141 |
| Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|FIGO Stage III Ovarian Cancer|FIGO Stage IIIA Ovarian Cancer|FIGO Stage IIIA1 Ovarian Cancer|FIGO Stage IIIA2 Ovarian Cancer|FIGO Stage IIIB Ovarian Cancer|FIGO Stage IIIC Ovarian Cancer|FIGO Stage IVA Ovarian Cancer|FIGO Stage IVB Ovarian Cancer|High Grade Fallopian Tube Serous Adenocarcinoma|High Grade Ovarian Serous Adenocarcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Stage III Fallopian Tube Cancer AJCC v7|Stage III Primary Peritoneal Cancer AJCC v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7 |
NCT02713386 |
| A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery |
Unknown status |
Cancer of the Esophagus, Gastroesophageal Junction or Stomach |
NCT01183559 |
| Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy |
Completed |
Abdominal Neoplasm|Colonic Neoplasm|Mesothelioma|Peritoneal Neoplasm |
NCT00004547 |
| Treatment With Pazopanib for Neoadjuvant Breast Cancer |
Completed |
Neoplasms, Breast |
NCT00849472 |
| Cotavance™ Paclitaxel-Coated Balloon Versus Uncoated Balloon Angioplasty for Treatment of In-stent Restenosis in SFA and Popliteal Arteries |
Unknown status |
Catherization |
NCT01594684 |
| A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma |
Completed |
Oral Cancer |
NCT00933387 |
| Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer |
Completed |
Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00003998 |
| Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors |
Terminated |
Extragonadal Germ Cell Tumor|Testicular Germ Cell Tumor |
NCT00072215 |
| Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes |
Completed |
Breast Cancer |
NCT00007904 |
| Efficacy Study of Two Different Strategies for Restenosis in Sirolimus-Eluting Stents |
Completed |
Coronary Artery Disease |
NCT00598715 |
| Do Cobalt Chrome Stent and Paclitaxel-Eluting Stent Have Equivalent Clinical Result in Non-Complex Lesion? |
Unknown status |
Coronary Artery Disease |
NCT00852215 |
| Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. |
Completed |
Neoplasms, Breast |
NCT00524303 |
| Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer |
Recruiting |
Ovarian Cancer |
NCT02766582 |
| Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel |
Completed |
Cancer |
NCT01192165 |
| Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer. |
Not yet recruiting |
Pancreas Cancer|Pancreatic Adenocarcinoma|Pancreatic Ductal Adenocarcinoma |
NCT04257448 |
| Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse |
Completed |
Ovarian Cancer|Fallopian Tube Cancer|Malignant Tumor of Peritoneum |
NCT00189566 |
| Trial of a Novel Paclitaxel-coated Balloon With Citrate Excipient for Restenosis in -Limus Analogue DES |
Completed |
Coronary Restenosis |
NCT02367495 |
| Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT00111904 |
| Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer |
Completed |
Head and Neck Cancer|Lung Cancer |
NCT00021333 |
| Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy |
Terminated |
Stage IB Esophageal Adenocarcinoma|Stage IIA Esophageal Adenocarcinoma|Stage IIB Esophageal Adenocarcinoma|Stage IIIA Esophageal Adenocarcinoma|Stage IIIB Esophageal Adenocarcinoma|Stage IIIC Esophageal Adenocarcinoma |
NCT02392377 |
| Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer |
Withdrawn |
Ovarian Cancer|Endometrial Cancer|Recurrent Ovarian Cancer|Recurrent Endometrial Cancer |
NCT02117817 |
| Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix |
Completed |
Cervical Cancer |
NCT00003065 |
| Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors |
Completed |
Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Ovarian Cancer|Teratoma|Testicular Germ Cell Tumor |
NCT00470366 |
| Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian and Breast Cancer |
Recruiting |
Cognition Disorders|Polyneuropathies |
NCT02753036 |
| Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer |
Completed |
Male Breast Cancer|Recurrent Breast Cancer|Skin Metastases|Stage IV Breast Cancer |
NCT00821964 |
| Clinical Study of Passeo-18 Lux Balloon Catheter for the Treatment of Atherosclerotic Lesions(BIOLUX-P IV CHINA) |
Unknown status |
Peripheral Arterial Disease |
NCT02912715 |
| Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery |
Completed |
Cervical Cancer |
NCT01229930 |
| Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine |
Recruiting |
Metastatic Pancreatic Cancer |
NCT03714555 |
| Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE) |
Completed |
Non-Squamous Non-Small Cell Lung Cancer |
NCT01366131 |
| Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC |
Completed |
Breast Neoplasm |
NCT00201435 |
| Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients |
Unknown status |
Neurotoxicity |
NCT02500810 |
| Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer |
Active, not recruiting |
Ovarian Epithelial Cancer |
NCT03078400 |
| A Comparison Between Paclitaxel-eluting Balloon in Combination With BMS Implantation vs Conventional Balloon and DES Implantation |
Terminated |
Myocardial Ischemia |
NCT01637896 |
| Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer |
Recruiting |
Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma |
NCT02779855 |
| Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas |
Unknown status |
Cystic Tumors of the Pancreas |
NCT00689715 |
| Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 |
Active, not recruiting |
Invasive Ductal Breast Carcinoma |
NCT02620280 |
| Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer |
Unknown status |
Head and Neck Cancer |
NCT01185171 |
| Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions |
Completed |
Ischemia|Stenosis |
NCT00540813 |
| The Real Word Study of Albumin-binding Taxol for Lung Cancer Treatment |
Not yet recruiting |
Lung Cancer |
NCT03802409 |
| Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer |
Recruiting |
Ovarian Cancer |
NCT03639246 |
| Assess the Efficacy and Safety of RESTORE Paclitaxel Eluting Balloon Versus RESOLUTE Zotarolimus Eluting Stent for the Treatment of Small Coronary Vessel Disease |
Completed |
Coronary Stenosis |
NCT02946307 |
| Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility |
Completed |
Breast Cancer |
NCT00591851 |
| Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer |
Active, not recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT02810457 |
| A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients |
Completed |
Breast Cancer|Breast Neoplasms |
NCT00001384 |
| Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer |
Recruiting |
Breast Cancer|Breast Cancer, Male|Breast Cancer Female|HER2-positive Breast Cancer |
NCT03112590 |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00483782 |
| DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer |
Unknown status |
Colorectal Cancer |
NCT00024401 |
| Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study |
Completed |
Breast Cancer|HER2 Positive |
NCT00768859 |
| Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer |
Completed |
Breast Cancer |
NCT00107094 |
| Concurrent Chemoradiotherapy for Cervical Cancer in Elderly Women |
Unknown status |
Cervical Cancer |
NCT01594099 |
| A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT01998906 |
| An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA) |
Completed |
Peritoneal Neoplasms |
NCT01697488 |
| Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00006108 |
| Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00039039 |
| A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC |
Terminated |
Advanced Non-squamous NSCLC |
NCT00369070 |
| Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy |
Recruiting |
Invasive Ductal Breast Cancer|Tubular Breast Cancer|Mucinous Breast Cancer|Inflammatory Breast Cancer |
NCT02879513 |
| Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma |
Unknown status |
Pulmonary Large Cell Neuroendocrine Carcinoma |
NCT02943798 |
| An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies |
Terminated |
Solid Tumor|Hodgkin's Lymphoma|NHL (Non-Hodgkin Lymphoma)|Pancreatic Cancer|Breast Cancer|UC (Ureter and Urethera)|Advanced Cancer|Metastatic Cancer |
NCT01929941 |
| The ASPECT Study - Asian Paclitaxel-Eluting Stent Clinical Trial |
Completed |
Coronary Artery Disease |
NCT00196079 |
| PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma |
Terminated |
Adenocarcinoma |
NCT02487277 |
| Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer |
Completed |
Breast Cancer |
NCT00006110 |
| MPDL3280A With Chemoradiation for Lung Cancer |
Active, not recruiting |
Lung Cancer|Non-Small Cell Lung Cancer |
NCT02525757 |
| Study of Participants With Advanced Non-Small Cell Lung Cancer |
Active, not recruiting |
Advanced Non-Small Cell Lung Cancer |
NCT00948675 |
| Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma |
Not yet recruiting |
Esophageal Squamous Cell Carcinoma |
NCT04177797 |
| Phase II Study of ZD6474 in Advanced NSCLC |
Terminated |
Lung Cancer |
NCT00290537 |
| Denosumab as an add-on Neoadjuvant Treatment (GeparX) |
Active, not recruiting |
Breast Cancer Female NOS|Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer|Tubular Breast Cancer Stage III |
NCT02682693 |
| Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel |
Completed |
Head and Neck Cancer|Lung Cancer|Neurotoxicity|Ovarian Cancer |
NCT00003569 |
| S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT00070564 |
| Ohio |
Zanesville |
United States|Cleo Craig Cancer Research Clinic |
Xenia |
| Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer |
Completed |
Breast Cancer |
NCT00072319 |
| Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer |
Recruiting |
Breast Cancer |
NCT03982485 |
| A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers |
Terminated |
Breast Cancer|Lung Cancer|Renal Cancer|Adrenal Cancer |
NCT01086696 |
| Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors |
Completed |
Cancer |
NCT01892046 |
| Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis |
Terminated |
Coronary Restenosis |
NCT01967199 |
| Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer |
Recruiting |
Inflammatory Breast Cancer (IBC) |
NCT02876302 |
| Treatment of Bifurcation Lesions by SINGLE STENT and KISSing Balloon Trial |
Completed |
Ischemic Heart Disease|Restenosis |
NCT00798954 |
| Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma |
Completed |
Sarcoma |
NCT00003008 |
| Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery. |
Unknown status |
Breast Cancer |
NCT00777673 |
| Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix |
Unknown status |
Metastatic Carcinoma to the Uterine Cervix|Recurrent Carcinoma Cervix|Cervix Carcinoma Recurrent |
NCT02492503 |
| Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00079287 |
| NR in Chemo-induced Peripheral Neuropathy |
Recruiting |
Chemotherapy-induced Peripheral Neuropathy|Breast Cancer Metastatic|Platinum-resistant Recurrent Ovarian Cancer |
NCT03642990 |
| Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer |
Completed |
Adenocarcinoma of the Pancreas|Stage II Pancreatic Cancer|Stage III Pancreatic Cancer |
NCT00026104 |
| Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma |
Unknown status |
Lymphoma |
NCT00009776 |
| Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) |
Active, not recruiting |
Non-small Cell Lung Cancer |
NCT01454102 |
| ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer |
Unknown status |
Breast Cancer |
NCT00404404 |
| To Reduce the Use of Chemotherapy in Elderly Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) |
Recruiting |
Breast Cancer|Estrogen Receptor Positive Tumor|HER2-positive Breast Cancer |
NCT03644186 |
| Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer |
Unknown status |
Esophageal Squamous Cell Cancer |
NCT01336049 |
| A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors |
Completed |
Solid Cancers |
NCT01301716 |
| Single-arm, Open-label, Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma |
Not yet recruiting |
Locally Advanced Esophageal Squamous Cell Carcinoma |
NCT03917966 |
| Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study |
Completed |
Neoplasms, Breast |
NCT00553358 |
| Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens |
N/A |
N/A |
NCT01653470 |
| S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer |
Completed |
Endometrial Cancer |
NCT00003127 |
| Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer |
Recruiting |
Pancreas Adenocarcinoma|Resectable Pancreatic Cancer |
NCT03492671 |
| Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate |
Completed |
Melanoma (Skin) |
NCT01209299 |
| Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00280150 |
| PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer |
Recruiting |
Neoplasms Pancreatic |
NCT04151277 |
| "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer |
Completed |
Advanced Breast Cancer|Metastatic Breast Cancer |
NCT03072992 |
| FID-007 in Treating Participants With Advanced Solid Tumors |
Recruiting |
Advanced Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm |
NCT03537690 |
| A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer |
Recruiting |
Pancreatic Ductal Adenocarcinoma|Pancreatic Cancer |
NCT01676259 |
| A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer |
Completed |
Non-Squamous Non-Small Cell Lung Cancer |
NCT01496742 |
| An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT01661153 |
| Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741 |
Completed |
Breast Cancer |
NCT00991263 |
| A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With Gemcitabine +/- Nab-paclitaxel. |
Active, not recruiting |
Unresectable Locally Advanced Pancreatic Carcinoma |
NCT03076216 |
| Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN) |
Completed |
Coronary Disease |
NCT00133237 |
| Combination Chemotherapy in Treating Patients With Advanced Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00005819 |
| Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma |
Recruiting |
Pancreatic Adenocarcinoma Metastatic|Chemotherapy Effect |
NCT03633734 |
| Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer |
Completed |
Breast Cancer |
NCT00003050 |
| The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency |
Recruiting |
Triple Negative Breast Cancer |
NCT03876886 |
| A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00732056 |
| High-dose Intensity Modulated Radiotherapy and Concurrent Chemotherapy in Esophageal Cancer |
Recruiting |
Esophageal Cancer |
NCT03535207 |
| BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study |
Completed |
Metastatic Pancreatic Cancer |
NCT01744353 |
| 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer |
Completed |
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Metastatic Breast Cancer |
NCT01935492 |
| Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00003035 |
| High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer |
Completed |
Breast Cancer |
NCT00002837 |
| A Randomized Trial Comparing Epirubicin/Cyclophosphamide Followed by Weekly Paclitaxel Versus Epirubicin/Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old |
Completed |
Breast Neoplasms |
NCT01026116 |
| Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery |
Unknown status |
Lung Cancer |
NCT00004887 |
| Pre-operative Treatment for Patients With Untreated Pancreatic Cancer |
Recruiting |
Resectable Pancreatic Cancer|Unresectable Pancreatic Cancer|Pancreatic Adenocarcinoma|Neoadjuvant Pancreatic Cancer |
NCT03138720 |
| Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy |
Active, not recruiting |
Patients With Stage IV or Recurrent Adenocarcinoma of the Lung |
NCT02303977 |
| SEDUCE OCT Study in Coronary Artery rEstenosis:an Optical Coherence Tomography (OCT) Study |
Unknown status |
Restenosis |
NCT01065532 |
| Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma |
Active, not recruiting |
Head and Neck Squamous Cell Carcinoma |
NCT01154920 |
| The Valentines Trial |
Completed |
Instent Restenosis |
NCT01066832 |
| Economic Outcomes in Patients With Stage III Ovarian Cancer Receiving Paclitaxel and Cisplatin on Clinical Trial GOG-172 |
Withdrawn |
Ovarian Cancer |
NCT00477867 |
| Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors |
Active, not recruiting |
Locally Advanced Solid Tumors|Metastatic Solid Tumors|Pancreatic Adenocarcinoma |
NCT02045602 |
| NSABP Biospecimen Discovery Project |
Unknown status |
Breast Cancer |
NCT01850628 |
| Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006) |
Completed |
Carcinoma |
NCT00941863 |
| Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC) |
Completed |
NSCLC |
NCT00298415 |
| TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors |
Recruiting |
Ovarian Germ Cell Cancer|Ovarian Neoplasms|Ovarian Cancer |
NCT02429687 |
| A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046. |
Completed |
Pancreatic Cancer |
NCT02021500 |
| TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors |
Recruiting |
Ovarian Sex Cord Stromal Tumor|Ovarian Neoplasms|Ovarian Cancer |
NCT02429700 |
| MONET1-MOtesanib NSCLC Efficacy and Tolerability Study |
Terminated |
Non-Small Cell Lung Cancer |
NCT00460317 |
| A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma |
Not yet recruiting |
Esophageal Squamous Cell Carcinoma |
NCT03857763 |
| Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries |
Completed |
Coronary Disease|Coronary Artery Disease|Coronary Restenosis |
NCT00140101 |
| ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer |
Recruiting |
Solid Tumor|Breast Cancer Metastatic |
NCT03950570 |
| Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries |
Completed |
Coronary Disease|Coronary Artery Disease|Coronary Restenosis |
NCT00148356 |
| Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients |
Unknown status |
Cervical Cancer |
NCT01755845 |
| INDICOR The Paclitaxel-Eluting PTCA-Balloon Catheter in Combination With a Cobalt-Chromium Stent |
Completed |
Coronary Heart Diseases |
NCT00747357 |
| Chemotherapy in Treating Patients With Metastatic Kidney Cancer |
Unknown status |
Kidney Cancer |
NCT00024388 |
| Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00102375 |
| The Efficacies of The New Paclitaxel-Eluting CoroflexTM Please Stent in Percutaneous Coronary Intervention |
Unknown status |
Coronary Artery Disease |
NCT00699543 |
| Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer |
Completed |
Stage IV Pancreatic Cancer |
NCT01488552 |
| Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer |
Unknown status |
Esophageal Cancer |
NCT00686114 |
| Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer |
Not yet recruiting |
Gastric Cancer |
NCT04149015 |
| Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer |
Unknown status |
Breast Cancer |
NCT00009763 |
| Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients |
Completed |
Ovarian Neoplasms |
NCT00127920 |
| Standard Balloon Angioplasty Versus Angioplasty With a Paclitaxel-eluting Balloon for Femoral Artery In-stent Restenosis |
Completed |
Peripheral Vascular Disease |
NCT01305070 |
| Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study |
Active, not recruiting |
Esophageal Carcinoma|Esophagogastric Junction Carcinoma |
NCT03933449 |
| Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer |
Terminated |
Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00976677 |
| The 001-DIOR Multicenter Registry |
Unknown status |
Coronary Artery Disease |
NCT01375465 |
| Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes |
Completed |
Breast Cancer |
NCT00668616 |
| An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation |
Recruiting |
Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation |
NCT03810872 |
| A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066) |
Terminated |
Neoplasms |
NCT00424775 |
| A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma |
Completed |
Malignant Melanoma |
NCT00483301 |
| Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer |
Unknown status |
Breast Cancer |
NCT00436709 |
| Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies |
Completed |
Genital Neoplasms, Female |
NCT02182245 |
| TOF Versus SOX in Metastatic Gastric Cancer |
Completed |
Gastric Cancer |
NCT02442362 |
| Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology |
Active, not recruiting |
Diseases of Oesophagus Stomach and Duodenum |
NCT03330028 |
| Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase |
Completed |
Solid Malignancies |
NCT02640755 |
| S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00085501 |
| A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer |
Completed |
Breast Neoplasms |
NCT00191672 |
| A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors |
Completed |
Solid Cancers |
NCT00954642 |
| Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer. |
Not yet recruiting |
Locally Advanced Pancreatic Cancer (LAPC) |
NCT04247165 |
| Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel |
Recruiting |
Metastatic Pancreatic Cancer |
NCT03666832 |
| Paclitaxel-Loaded Polymeric Micelle and Carboplatin as First-Line Therapy in Treating Patients With Advanced Ovarian Cancer |
Unknown status |
Ovarian Cancer |
NCT00886717 |
| Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00023673 |
| Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) |
Active, not recruiting |
Esophageal Carcinoma|Esophagogastric Junction Carcinoma |
NCT02564263 |
| Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma |
Completed |
Lymphoma |
NCT00004916 |
| Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma |
Completed |
Colorectal Adenocarcinoma |
NCT00034190 |
| Phase I Study of the Combination of Apatinib and POF |
Unknown status |
Gastric Adenocarcinoma |
NCT03244774 |
| CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer |
Active, not recruiting |
Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma |
NCT03517176 |
| MIL60 Versus Bevacizumab in Patients With Treatment-naĂŻve Non-squamous Non-small Cell Lung Cancer |
Recruiting |
Non-small Cell Lung Cancer |
NCT03196986 |
| Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00034151 |
| Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma |
Completed |
Prostate Cancer |
NCT00193193 |
| Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00034164 |
| Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients With Unresectable Pancreatic Cancer. |
Active, not recruiting |
Pancreatic Cancer Stage III|Pancreatic Cancer Stage IV |
NCT03252808 |
| First-line Chemotherapy for Recurrent Cervical Cancer |
Recruiting |
Recurrent Cervical Carcinoma|Persistent Advanced Cervical Carcinoma|Chemotherapy|Vascular Endothelial Growth Factor 2 Inhibitor|Apatinib|Targeted Therapy |
NCT04188847 |
| Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium |
Completed |
Urologic Neoplasms |
NCT00034177 |
| Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer |
Unknown status |
Breast Cancer |
NCT00070278 |
| Atherectomy and Drug-Coated Balloon Angioplasty in Treatment of Long Infrapopliteal Lesions |
Completed |
Peripheral Artery Disease|Occlusion of Artery |
NCT01763476 |
| Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors |
Completed |
Primary Peritoneal Carcinoma|Tumor|Epithelial Ovarian Cancer|Uterine Disease|Cervix Diseases|Neoplasms, Ovarian|Cancer |
NCT00561795 |
| Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors |
Completed |
Breast Cancer|Lung Cancer|Neurotoxicity|Ovarian Cancer|Prostate Cancer|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00078845 |
| Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC |
Withdrawn |
Adenocarcinoma of the Lung|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIA Non-small Cell Lung Cancer|Stage IIB Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer |
NCT02059967 |
| Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy |
Terminated |
Uterine Neoplasms |
NCT00505492 |
| Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients |
Active, not recruiting |
Non Small Cell Lung Cancer |
NCT03081689 |
| Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line |
Completed |
Breast Cancer |
NCT00191854 |
| A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies |
Suspended |
Cancer |
NCT01604863 |
| A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin |
Recruiting |
HER2-positive Breast Cancer |
NCT03085368 |
| Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer |
Completed |
Esophageal Cancer|Gastric Cancer |
NCT00033657 |
| Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer |
Recruiting |
Locally Advanced Unresectable Pancreatic Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma|Recurrent Pancreatic Adenocarcinoma|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8 |
NCT03910387 |
| A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients |
Completed |
Ovarian Neoplasms |
NCT00001272 |
| Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks |
N/A |
N/A |
NCT00194753 |
| Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib |
Active, not recruiting |
Ovarian Neoplasms |
NCT03314740 |
| Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer |
Recruiting |
Ovarian Cancer|Fallopian Tube Carcinoma|Peritoneal Carcinoma |
NCT02125513 |
| A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer |
Terminated |
Non-Small Cell Lung Cancer |
NCT00437749 |
| Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer |
Recruiting |
Esophageal Cancer, Squamous Cell |
NCT03301454 |
| A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma |
Completed |
Non-Hodgkin's Lymphoma |
NCT00038545 |
| CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
Completed |
Primary Peritoneal Carcinoma|Recurrent Ovarian Carcinoma |
NCT00045682 |
| Adjuvant FEC Versus EP in Breast Cancer (MIG5) |
Completed |
Breast Cancer|Chemotherapy, Adjuvant |
NCT02450058 |
| AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors |
Recruiting |
Advanced Cancer |
NCT03579628 |
| Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00096226 |
| A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC) |
Terminated |
Non-Small Cell Lung Cancer |
NCT00787852 |
| Ph Ib/BGJ398/Cervix and Other Solid Tumors |
Withdrawn |
Cancer of Cervix|Tumors |
NCT02312804 |
| Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT00832494 |
| Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer |
Completed |
Esophageal Cancer |
NCT00154700 |
| Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED) |
Terminated |
Carcinoma, Non-small-cell Lung|Metastases, Neoplasm |
NCT00050336 |
| Drug Eluting Balloon for Prevention of Hemodialysis Access Restenosis |
Active, not recruiting |
Arteriovenous Fistulae|Arteriovenous Graft |
NCT01928498 |
| Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire |
Completed |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms |
NCT00517621 |
| Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00287989 |
| Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma |
Unknown status |
Nasopharyngeal Neoplasms |
NCT01735409 |
| Alternating Cycles of Carboplatin/Gemcitabine and Carboplatin/Taxol for Advanced Stage NSCLC |
Completed |
Non Small Cell Lung Cancer |
NCT00259675 |
| Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00054184 |
| Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer |
Completed |
Adenocarcinoma of the Lung|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00021060 |
| Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer |
Unknown status |
Cervical Cancer |
NCT00997009 |
| Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer |
Unknown status |
Cervical Cancer |
NCT02446652 |
| Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Lung Cancer |
NCT00495170 |
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer |
Completed |
Peripheral Neuropathy |
NCT02549534 |
| A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma |
Completed |
Pancreatic Cancer |
NCT01730222 |
| A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable |
Completed |
Ovarian Cancer |
NCT01739218 |
| A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin |
Completed |
Ovarian Neoplasms |
NCT00001427 |
| Clinical Post Market Clinical Follow-up (PMCF) on Peripheral Arteries Treated With SeQuent® Please Over The Wire (OTW) |
Active, not recruiting |
Peripheral Arterial Occlusive Disease |
NCT02460042 |
| A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Participants With Advanced Cervical Cancer |
Completed |
Cervical Cancer |
NCT03071848 |
| Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT) |
Completed |
Breast Neoplasms|Breast Cancer |
NCT01446016 |
| Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma |
Completed |
Pancreatic Adenocarcinoma |
NCT02514421 |
| A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00475670 |
| Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer |
Recruiting |
Breast Cancer |
NCT03150576 |
| Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer |
Withdrawn |
Pancreatic Cancer |
NCT02581501 |
| Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00002826 |
| A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer |
Completed |
Breast Cancer|Breast Neoplasms |
NCT00001498 |
| Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer |
Recruiting |
Pancreatic Neoplasms |
NCT04289792 |
| A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors |
Recruiting |
Advanced Cancer|Gastric Cancer|Breast Cancer|Pancreatic Cancer|Prostate Cancer Metastatic|Colo-rectal Cancer|Solid Tumor|Solid Carcinoma|Solid Carcinoma of Stomach|Cancer of Stomach |
NCT03129139 |
| ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer |
Completed |
Breast Cancer |
NCT00261313 |
| A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer |
Active, not recruiting |
Lung Cancer |
NCT02429843 |
| Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model |
Recruiting |
Organoid |
NCT03544047 |
| A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer |
Unknown status |
Oesophageal Cancer |
NCT01843829 |
| Optical Coherence Tomography for Drug Eluting Stent Safety |
Unknown status |
Coronary Artery Disease |
NCT00693030 |
| Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer |
Unknown status |
Breast Cancer |
NCT00002628 |
| Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer |
Active, not recruiting |
Ovarian Carcinoma |
NCT03029585 |
| Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) |
Completed |
Lung Cancer|Small Cell Lung Cancer|Carcinoma, Non-Small-Cell Lung |
NCT00527735 |
| Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer |
Unknown status |
Breast Cancer |
NCT00002627 |
| Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT00655850 |
| Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma |
Terminated |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|Uterine Cancer |
NCT00582205 |
| Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Stage IIIA Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00003317 |
| Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer |
Active, not recruiting |
Triple Negative Breast Cancer |
NCT02734290 |
| Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma |
Terminated |
Stage I Non-Small Cell Lung Cancer|Stage II Non-Small Cell Lung Cancer |
NCT02319889 |
| Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy |
Unknown status |
Non Small Cell Lung Cancer |
NCT01902875 |
| Paclitaxel-eluting Balloon Angioplasty With Provisional Use of Nitinol Stent Versus Systematic Implantation of Paclitaxel-eluting Stent for the Treatment of Femoropopliteal de Novo Lesions |
Unknown status |
Peripheral Artery Disease |
NCT01969630 |
| ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer |
Terminated |
Non-Small Cell Lung Cancer |
NCT00662597 |
| Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers |
Recruiting |
Gastric Cancer in Situ|Pancreatic Cancers|Biliary Cancers |
NCT03162510 |
| A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC) |
Terminated |
Stage IIIb Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00042302 |
| Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers |
Completed |
Advanced Cancer |
NCT00798252 |
| Induction Chemotherapy for Advanced Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00959387 |
| Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT01815242 |
| Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer |
Completed |
Cancer |
NCT00581971 |
| Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers |
Not yet recruiting |
Lung Neoplasms |
NCT04230408 |
| Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy |
Completed |
Locally Advanced Non-Small Cell Lung Cancer|NSCLC |
NCT00702975 |
| Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
Terminated |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00373217 |
| Alimta and Gemcitabine in Non-Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer|Stage IIIB or IV |
NCT00434135 |
| CVI Drug Coated Balloon First In Human Trial |
Completed |
Peripheral Arterial Disease |
NCT02110524 |
| Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1 |
Recruiting |
Pancreatic Cancer |
NCT03777462 |
| Quality of Life in Patients Who Are Receiving Either Vinorelbine, Gemcitabine, and Docetaxel or Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00242983 |
| Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer |
Unknown status |
Breast Cancer |
NCT00003253 |
| CHFR Methylation Status Esophageal Cancer Study |
Terminated |
Esophageal Cancer |
NCT01372202 |
| PTA and Drug Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia |
Active, not recruiting |
Peripheral Vascular Disease |
NCT00471289 |
| SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System |
Completed |
Coronary Disease|Coronary Artery Disease|Coronary Restenosis |
NCT00180310 |
| Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer |
Unknown status |
Ovarian Neoplasms |
NCT01628380 |
| A Phase â…˘ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage â…˘ Non-Small-Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00144053 |
| A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer |
Recruiting |
Triple Negative Breast Neoplasms |
NCT03742102 |
| Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics |
Terminated |
Breast Cancer |
NCT02297230 |
| LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis |
Completed |
Atherosclerosis|Vascular Disease|Arteriosclerosis |
NCT00930813 |
| Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer |
Withdrawn |
Breast Cancer|HER-2 Positive Breast Cancer |
NCT02102438 |
| Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) |
Recruiting |
Triple-negative Breast Cancer |
NCT04296175 |
| Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2 |
Completed |
Breast Cancer |
NCT00019812 |
| A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies |
Completed |
Neoplasms|Metastases, Neoplasm |
NCT00046423 |
| Assessment of Surface Coverage of Two Types of DES in Diabetes Mellitus and Non- Diabetes Mellitus |
Unknown status |
Coronary Artery Disease|Diabetes Mellitus |
NCT01023919 |
| A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies |
Recruiting |
Solid Tumor |
NCT02730481 |
| Drug Eluting Balloon Angioplasty for Recurrent Cephalic Arch Stenosis in Dialysis Fistulas |
Terminated |
Dialysis Access Dysfunction |
NCT02368197 |
| Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer |
Completed |
Breast Cancer |
NCT00455533 |
| Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine |
Completed |
Pancreatic Cancer |
NCT01978184 |
| Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Non Small Cell Lung Cancer |
NCT01820754 |
| Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer |
Completed |
Breast Cancer |
NCT00723125 |
| EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients |
Completed |
Breast Neoplasms |
NCT00448305 |
| Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract |
Completed |
Endometrial Cancer|Fallopian Tube Cancer|Ovarian Cancer|Sarcoma |
NCT00003334 |
| Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer |
Recruiting |
HPV-Related Squamous Cell Carcinoma|HNSCC |
NCT03107182 |
| ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma |
Not yet recruiting |
EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC |
NCT04245085 |
| The REALITY Study - Head-to-Head Comparison Between Cypher and Taxus |
Completed |
Coronary Artery Disease |
NCT00235092 |
| Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer |
Recruiting |
Ovarian Cancer|Ovarian Neoplasms |
NCT03394885 |
| Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer |
Active, not recruiting |
Esophageal Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Stage IB Esophageal Cancer AJCC v7|Stage IIA Esophageal Cancer AJCC v7|Stage IIB Esophageal Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7 |
NCT01196390 |
| United States|Knox Community Hospital |
Ohio |
Newark |
Ohio |
| Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients |
Unknown status |
Metastatic Breast Cancer |
NCT01802970 |
| Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer |
Completed |
Breast Neoplasms|Neoplasm Metastasis |
NCT00001493 |
| REFLOW Study, Investigating the Efficacy of the LEGFLOW DCB in TASC C&D Fempop Lesions |
Active, not recruiting |
Peripheral Arterial Disease |
NCT02580955 |
| High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery |
Active, not recruiting |
Lung Cancer|Radiation Toxicity |
NCT00533949 |
| A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane |
Active, not recruiting |
Unresectable Locally Advanced Pancreatic Carcinoma |
NCT03003078 |
| SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) |
Completed |
Stents|Coronary Artery Disease|Total Coronary Occlusion|Coronary Artery Restenosis|Stent Thrombosis|Vascular Disease|Myocardial Ischemia|Coronary Artery Stenosis |
NCT00180479 |
| The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations |
Completed |
Angioplasty |
NCT01180517 |
| Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer |
Recruiting |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Carcinoma |
NCT03056833 |
| Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer |
Unknown status |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Chemotherapeutic Agent Toxicity|Cognitive Side Effects of Cancer Therapy|Psychological Impact of Cancer|Radiation Toxicity|Sexual Dysfunction and Infertility|Stage IB Cervical Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage IIIB Cervical Cancer|Stage IVA Cervical Cancer |
NCT01414608 |
| Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer |
Completed |
Gastric Cancer |
NCT00003298 |
| A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells |
Not yet recruiting |
Gastric Cancer |
NCT03428425 |
| Drug Eluting Balloon for Prevention of Constrictive Remodeling |
Terminated |
Coronary Disease|Diabetes Mellitus |
NCT01690572 |
| Comparison of Paclitaxel-Coated Balloons Against Drug-Eluting Bioresorbable Scaffolds for Elective PCI Using OCT |
Terminated |
Coronary Artery Disease |
NCT02607241 |
| Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer |
Active, not recruiting |
Squamous Cell Carcinoma of the Head and Neck |
NCT00736944 |
| A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors |
Completed |
Breast Cancer|Ovarian Cancer|Colon Cancer|Lung Cancer|Gastric Cancer|Solid Tumors |
NCT02033551 |
| Expanded Access to NanoPac |
Available |
N/A |
NCT03756311 |
| A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1) |
Terminated |
Cancer: Solid Tumors |
NCT01110603 |
| Clinical Trial on Safety and Efficacy of Drug-coated Balloon in Treatment of Coronary Bifurcation Lesions |
Recruiting |
Coronary Disease |
NCT03223974 |
| Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer |
Completed |
Non-Small-Cell Lung Cancer |
NCT00913705 |
| The Treatment of Coronary De-novo Lesions With the Elutax Paclitaxel-eluting Balloon Alone, a Pilot Study |
Terminated |
Stable Angina|Coronary Stenosis |
NCT01899235 |
| Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048) |
Completed |
Breast Neoplasm |
NCT00550771 |
| DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer |
Active, not recruiting |
Ovarian Cancer Recurrent |
NCT03657966 |
| Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab |
Completed |
Lung Cancer |
NCT00898417 |
| Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma |
Recruiting |
Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy |
NCT03829969 |
| Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer |
Terminated |
Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00003880 |
| Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer |
Completed |
Stage IIIA Non-small Cell Lung Cancer |
NCT00005065 |
| Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction |
Completed |
Myocardial Infarction |
NCT00433966 |
| Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC |
Unknown status |
Non-Small Cell Lung Carcinoma |
NCT02879097 |
| JET-RANGER Trial - JETStream Atherectomy With Adjunctive Paclitaxel-Coated Balloon Angioplasty vs Plain Old Balloon Angioplasty Followed by Paclitaxel-Coated Balloon |
Enrolling by invitation |
Peripheral Vascular Disease |
NCT03206762 |
| DCB for Dialysis Access Stent Graft Restenosis |
Unknown status |
Hemodialysis Access Failure (Disorder)|Stent-Graft Restenosis|Arteriovenous Graft|Drug-coated Balloon |
NCT03360279 |
| Combination Chemotherapy in Treating Patients With Breast Cancer |
Completed |
Breast Cancer |
NCT00003088 |
| Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00833261 |
| Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00031954 |
| The Chocolate Touch Study |
Recruiting |
Intermittent Claudication|Ischemia |
NCT02924857 |
| A Feasibility Study Investigating Chemotherapy-induced Neuropathy Using Multi-frequency Tactilometry and Patient-reported Outcomes (PRO) |
Recruiting |
Chemotherapy-induced Peripheral Neuropathy |
NCT04167319 |
| Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00049790 |
| Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors |
Completed |
Childhood Extracranial Germ Cell Tumor|Childhood Extragonadal Malignant Germ Cell Tumor|Childhood Malignant Ovarian Germ Cell Tumor|Childhood Malignant Testicular Germ Cell Tumor|Ovarian Choriocarcinoma|Ovarian Embryonal Carcinoma|Ovarian Yolk Sac Tumor|Recurrent Childhood Malignant Germ Cell Tumor|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Ovarian Germ Cell Tumor|Testicular Choriocarcinoma|Testicular Embryonal Carcinoma|Testicular Mixed Choriocarcinoma and Embryonal Carcinoma|Testicular Mixed Choriocarcinoma and Yolk Sac Tumor|Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor|Testicular Yolk Sac Tumor |
NCT00467051 |
| Infrapopliteal Drug Eluting Angioplasty Versus Stenting |
Completed |
Arterial Occlusive Disease |
NCT01517997 |
| Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer |
Unknown status |
Ovarian Cancer |
NCT00660842 |
| Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC |
Completed |
Metastatic Breast Cancer (MBC) |
NCT00236899 |
| Compare I Pilot Study for the Treatment of Subjects With Symptomatic Femoropopliteal Artery Disease |
Active, not recruiting |
Peripheral Artery Disease |
NCT02701543 |
| PEPCAD III Substudy: Stem Cell Mobilization |
Completed |
Coronary Artery Disease |
NCT00473499 |
| Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer |
Recruiting |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer |
NCT03430700 |
| Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00054197 |
| Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma |
Recruiting |
Nasopharyngeal Carcinoma|Children |
NCT03020329 |
| Drug-Coated Chocolate PTA Balloon in Patients With Peripheral Arterial Disease - The ENDURE Trial |
Completed |
Peripheral Vascular Disease |
NCT02129127 |
| Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) |
Recruiting |
Endometrial Carcinoma|Ovarian Carcinoma|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma|Cervical Carcinoma |
NCT02584478 |
| CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts |
Recruiting |
Pancreatic Cyst|EUS-FNA |
NCT03085004 |
| Clinical Study of the Boston Scientific Paclitaxel-Coated PTAďĽPercutaneous Transluminal Angioplasty） Balloon Catheter (Ranger™ and Ranger™ SL (OTW) DCB) in China |
Unknown status |
Femoropopliteal Artery Lesions |
NCT02944071 |
| Pharmacological Ascorbate for Lung Cancer |
Recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT02420314 |
| A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer |
Active, not recruiting |
Triple-negative Breast Cancer |
NCT03197935 |
| Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer |
Available |
Triple Negative Breast Cancer |
NCT01216111 |
| Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin |
Terminated |
Cancer, Ovarian |
NCT01847677 |
| Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer |
Active, not recruiting |
Genital Diseases, Female|Ovarian Diseases|Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms |
NCT01462890 |
| Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis |
Completed |
Penile Cancer |
NCT00512096 |
| Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel |
Terminated |
Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer |
NCT01050075 |
| Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer |
Completed |
Endometrial Adenocarcinoma|Endometrial Adenosquamous Carcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation|Endometrial Serous Adenocarcinoma|Stage III Uterine Corpus Cancer |
NCT00006011 |
| Treatment of Femoro-popliteal Atherosclerotic Lesions Using the Ranger Paclitaxel Coated Balloon Catheter. All Comers Registry. |
Completed |
Atherosclerotic Disease |
NCT02462005 |
| Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer |
Recruiting |
Breast Cancer |
NCT04193059 |
| Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen |
Active, not recruiting |
Breast Cancer |
NCT02419742 |
| Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors |
Recruiting |
Germ Cell Tumor|Teratoma|Choriocarcinoma|Germinoma|Mixed Germ Cell Tumor|Yolk Sac Tumor|Childhood Teratoma|Malignant Germ Cell Neoplasm|Extragonadal Seminoma|Non-seminomatous Germ Cell Tumor|Seminoma |
NCT02375204 |
| Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors |
Recruiting |
Solid Tumor |
NCT03588039 |
| TAXUS Libertē Post Approval Study |
Completed |
Coronary Artery Disease |
NCT00997503 |
| Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer |
Unknown status |
Head and Neck Cancer |
NCT01126216 |
| Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma |
Recruiting |
Untreated Metastatic Pancreatic Ductal Adenocarcinoma |
NCT02754726 |
| Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer |
Completed |
Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00002734 |
| Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer |
Terminated |
Pancreatic Cancer|Pancreatic Carcinoma Non-resectable|Locally Advanced Malignant Neoplasm |
NCT01836432 |
| Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer |
Active, not recruiting |
Head and Neck Neoplasms |
NCT01566435 |
| Taxoprexin® Treatment for Advanced Primary Cancers of the Liver |
Terminated |
Cancer of the Liver |
NCT00422877 |
| Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma |
Terminated |
Epithelial Ovarian Carcinoma |
NCT02107378 |
| Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer |
Completed |
Breast Cancer |
NCT00256243 |
| PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus |
Completed |
Esophageal Cancer |
NCT00016900 |
| Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line |
Recruiting |
Breast Cancer|Hormone Receptor Positive Tumor|HER 2 Negative Breast Cancer |
NCT03462251 |
| Randomized Trial of Coronary Angioplasty for de Novo Lesions in sMall vesSElS With Drug Eluting Balloon. |
Completed |
Coronary Disease |
NCT01722799 |
| Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer |
Recruiting |
Lung Cancer|Esophageal Cancer |
NCT03094884 |
| SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer |
Recruiting |
Esophageal Squamous Cell Carcinoma |
NCT03603756 |
| Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer |
Completed |
Esophagus Cancer |
NCT00193141 |
| De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo Lesions |
Completed |
Coronary Artery Stenosis |
NCT00934752 |
| Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer |
Terminated |
Carcinoma, Ductal, Breast |
NCT01891357 |
| Neoadjuvant Versus Adjuvant Therapy in Treating Resectable Thoracic Esophageal Cancer |
Unknown status |
Esophageal Cancer |
NCT01463501 |
| Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer |
Active, not recruiting |
Head and Neck Cancer|Carcinoma, Squamous Cell|Neoplasms, Oral|Neoplasms, Pharyngeal |
NCT03067610 |
| Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer |
Terminated |
Locally Advanced Non-Small Cell Lung Cancer |
NCT00614484 |
| IN.PACT BTK Randomized Study to Assess Safety and Efficacy of IN.PACT 014 vs. PTA |
Active, not recruiting |
Critical Limb Ischemia|Peripheral Arterial Disease |
NCT02963649 |
| Evaluate Safety, Efficacy and Pharmacokinetics |
Active, not recruiting |
Metastatic Breast Cancer |
NCT01084863 |
| Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing Strategy |
Unknown status |
Non-small Cell Lung Cancer|Breast Cancer|Nasal Cancer |
NCT01891123 |
| p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
Unknown status |
Ovarian Epithelial Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer |
NCT02435186 |
| Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer |
Completed |
Breast Cancer |
NCT00093795 |
| Multi-Center Clinical Trial: Evaluation of Effectiveness and Safety |
Terminated |
Coronary Disease |
NCT00415961 |
| Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis |
Active, not recruiting |
Germ Cell Tumors |
NCT00864318 |
| Study of Topical SOR007 Ointment for Cutaneous Metastases |
Active, not recruiting |
Cutaneous Metastasis |
NCT03101358 |
| S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00003587 |
| Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach |
Completed |
Esophageal Cancer|Gastric Cancer |
NCT00003237 |
| Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer |
Completed |
Breast Cancer |
NCT00336791 |
| A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis |
Completed |
Rheumatoid Arthritis |
NCT00055133 |
| Combination Chemotherapy in Treating Patients With Solid Tumors |
Unknown status |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00009932 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00006378 |
| Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours |
Recruiting |
Solid Tumor |
NCT03894540 |
| Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation |
NCT02272790 |
| Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer |
Active, not recruiting |
Breast Neoplasms|Malignant Tumor of the Breast |
NCT02229149 |
| Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00003004 |
| Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA |
Completed |
Laryngeal Neoplasms|Hypopharyngeal Neoplasms |
NCT00534729 |
| A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC |
Recruiting |
Carcinoma, Non-Small-Cell Lung|Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer|Non-Small-Cell Lung Carcinoma|NSCLC |
NCT02905591 |
| Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer |
Completed |
Ovarian Cancer |
NCT00002568 |
| Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer |
Unknown status |
Head and Neck Cancer |
NCT00566540 |
| Combination Chemotherapy in Treating Patients With Advanced Cancer |
Completed |
Leukemia|Lymphoma|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00004105 |
| Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer |
Completed |
Advanced Malignant Solid Neoplasm|ALK Positive|Metastatic Pancreatic Adenocarcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer |
NCT02227940 |
| Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00081302 |
| Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2 |
Completed |
Breast Cancer |
NCT00003992 |
| Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab |
Recruiting |
HER2-positive Breast Cancer|Breast Cancer |
NCT03747120 |
| The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT |
Completed |
Nasopharyngeal Neoplasms |
NCT01797900 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed |
Completed |
Lung Cancer |
NCT00003235 |
| Trial of E10A in Head and Neck Cancer |
Unknown status |
Head and Neck Squamous Carcinoma|Nasopharyngeal Carcinoma |
NCT00634595 |
| Chemotherapy and Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Stomach Who Have Undergone Surgery |
Completed |
Esophageal Cancer|Gastric Cancer |
NCT00011960 |
| Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00003449 |
| DEBlue Stent vs Cypher Stent in the Treatment of Advanced Coronary Artery Disease |
Completed |
Coronary Artery Disease |
NCT00473772 |
| Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer |
Completed |
Head and Neck Cancer|Precancerous Condition |
NCT01084083 |
| Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00003881 |
| PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy |
Recruiting |
Ovarian Cancer |
NCT03206645 |
| Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer |
Recruiting |
Esophageal Cancer |
NCT02213497 |
| 64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel, and Bevacizumab |
Withdrawn |
Carcinoma, Non-Small-Cell Lung |
NCT01006226 |
| Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix |
Completed |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma|Stage IVB Cervical Cancer |
NCT00064077 |
| Atezolizumab Trial in Endometrial Cancer - AtTEnd |
Recruiting |
Endometrial Cancer |
NCT03603184 |
| Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer |
Terminated |
Cervical Cancer|Endometrial Cancer|Fallopian Tube Cancer|Neurotoxicity|Ovarian Cancer|Primary Peritoneal Cavity Cancer|Sarcoma |
NCT00003624 |
| Combination Chemotherapy for Patients With Brain Cancer |
Completed |
Brain and Central Nervous System Tumors |
NCT00002814 |
| Randomized Amifostine For SCCHN |
Completed |
Chemotherapeutic Agent Toxicity|Head and Neck Cancer|Mucositis|Radiation Toxicity|Xerostomia |
NCT00095927 |
| Phase III Trial of Stage I Ovarian Cancer After Surgery |
Recruiting |
Epithelial Ovarian Cancer |
NCT04063527 |
| Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00002888 |
| Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel |
Completed |
Breast Cancer |
NCT00003540 |
| Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00730925 |
| Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer |
Completed |
Lung Cancer|Neurotoxicity|Ovarian Cancer |
NCT00003072 |
| LUX-Breast 2 |
N/A |
N/A |
NCT01271725 |
| Short-Term Exposure to Lipophilic Anti-proliferative Drugs Delivered by Angiographic Contrast Media |
Completed |
Coronary Artery Disease |
NCT01140204 |
| Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00006484 |
| A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma |
Recruiting |
Esophageal Cancer |
NCT02570893 |
| A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
Recruiting |
Advanced Solid Tumors Cancer |
NCT04196283 |
| Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer |
Enrolling by invitation |
Breast Cancer |
NCT03580395 |
| Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer |
Terminated |
HER2-negative Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer |
NCT00679029 |
| Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer |
Completed |
Drug/Agent Toxicity by Tissue/Organ|Lung Cancer|Radiation Toxicity |
NCT00006012 |
| ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations |
Recruiting |
Cancer|Solid Tumors |
NCT02761694 |
| Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00003732 |
| Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer |
Completed |
Bladder Cancer|Urethral Cancer |
NCT00002684 |
| Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer |
Withdrawn |
Lung Cancer |
NCT00054392 |
| Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer |
Unknown status |
Gynecologic Cancer |
NCT02739529 |
| Locally Advanced NSCLC Hyperfractionated RT |
Active, not recruiting |
Carcinoma, Non Small Cell Lung (NSCLC) |
NCT03128008 |
| Trial on Safety & Performance of TAXUS Element vs. XIENCE Prime Stent in Treatment of Coronary Lesion in Diabetics |
Completed |
Type 2 Diabetes|Coronary Heart Disease |
NCT03125772 |
| Efficacy of the SeQuent®Please in the Treatment of De-novo Stenoses Versus Taxus™Liberté™ |
Unknown status |
Coronary De-novo Stenoses |
NCT01084408 |
| S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer |
Completed |
Prostate Cancer |
NCT00028769 |
| Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer |
Recruiting |
Non Small Cell Lung Cancer |
NCT04304248 |
| Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma |
Recruiting |
Esophageal Squamous Cell Carcinoma|Immunotherapy |
NCT04225364 |
| Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00003385 |
| Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903) |
Recruiting |
Esophageal Squamous Cell Carcinoma |
NCT04138212 |
| Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction |
Completed |
Esophageal Cancer |
NCT00069953 |
| Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer |
Completed |
Esophageal Cancer |
NCT00281788 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus |
Completed |
Esophageal Cancer |
NCT00002984 |
| Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer |
Completed |
Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-negative Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-negative Breast Cancer |
NCT01818063 |
| A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003) |
Completed |
Locally Advanced, Metastatic Solid Tumors |
NCT00848718 |
| ERCC1 Targeted Trial |
Terminated |
Lung Cancer |
NCT00801736 |
| SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System |
Completed |
Coronary Artery Disease |
NCT00307047 |
| A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma |
Recruiting |
Prosthesis Survival |
NCT02409186 |
| (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma |
Terminated |
Ovarian Carcinoma|Fallopian Tube Carcinoma|Peritoneal Carcinoma |
NCT01936974 |
| TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Non-Small Cell Lung Cancer|Lung Cancer |
NCT00563784 |
| First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer |
Terminated |
Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion|Stage IV Non-small Cell Lung Cancer |
NCT01337154 |
| A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer |
Terminated |
Gastric Cancer |
NCT01641939 |
| Radiation Dose Escalation in Esophageal Cancer |
Completed |
Esophageal Cancer |
NCT03082586 |
| Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer |
Terminated |
Carcinoma, Non-small Cell Lung |
NCT02590003 |
| Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma |
Active, not recruiting |
Pancreatic Cancer |
NCT02551991 |
| S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00004011 |
| A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis |
Completed |
Non-Small Cell Lung Cancer |
NCT00800202 |
| Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer |
Active, not recruiting |
Ovarian Cancer |
NCT03901118 |
| High Dose PET/CT-guided Intensity Modulated Radiotherapy and Concurrent Chemotherapy in Esophageal Cancer |
Recruiting |
Esophageal Cancer |
NCT03936179 |
| A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor |
Completed |
Solid Tumor |
NCT04046016 |
| Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation |
Terminated |
Non-small-cell Lung Cancer |
NCT02095782 |
| A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors |
Recruiting |
Advanced Solid Tumors |
NCT03595059 |
| Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) |
Active, not recruiting |
Endometrial Neoplasms |
NCT03517449 |
| Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer |
Completed |
Bladder Cancer |
NCT00055601 |
| Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Breast Cancer |
Recruiting |
Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|HER2/Neu Positive|Invasive Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive|Stage IA Breast Cancer|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma |
NCT01750073 |
| Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer |
Active, not recruiting |
Malignant Neoplasm of Stomach Stage II |
NCT02697838 |
| Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer |
Unknown status |
Cervical Cancer |
NCT00462397 |
| Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors |
Recruiting |
Solid Tumor, Adult |
NCT03747965 |
| BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. |
Recruiting |
Breast Cancer |
NCT02789657 |
| Weekly TP-HDFL in the Treatment of Advanced TCC |
Completed |
Transitional Cell Carcinoma |
NCT00154687 |
| A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer |
Active, not recruiting |
Advanced Adenocarcinoma|Metastatic Adenocarcinoma |
NCT01506973 |
| Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma |
Completed |
Metastatic Pancreatic Ductal Adenocarcinoma |
NCT02583477 |
| Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") |
Completed |
Ovarian Cancer|Fallopian Tube Neoplasms|Peritoneal Neoplasm |
NCT00391118 |
| Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer |
Completed |
Endometrial Cancer|Papillary Serous|Clear Cell Endometrial Cancer |
NCT00542490 |
| Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer |
Withdrawn |
Neoplasms, Breast |
NCT01205217 |
| Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer |
Completed |
Prostate Cancer |
NCT00003084 |
| PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer |
Active, not recruiting |
Metastatic Malignant Neoplasm in the Brain|Recurrent Non-Small Cell Lung Carcinoma|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer |
NCT02073968 |
| A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer |
Active, not recruiting |
Platinum-Sensitive Ovarian Cancer in First Relapse |
NCT02289950 |
| Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer |
Unknown status |
Non Small Cell Lung Cancer |
NCT00706862 |
| BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy |
Completed |
Early Triple Negative Breast Cancer |
NCT01672671 |
| ION US Post-Approval Study |
Completed |
Atherosclerosis|Coronary Artery Disease |
NCT01422889 |
| A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer |
Completed |
Breast Cancer |
NCT01094184 |
| Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002) |
Terminated |
Pancreas Cancer|Pancreatic Cancer|Adenocarcinoma of the Pancreas|Pancreas Adenocarcinoma|Pancreatic Adenocarcinoma |
NCT02707328 |
| Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer |
NCT00028743 |
| A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) |
Recruiting |
Carcinoma, Squamous Cell, Non-small-cell Lung |
NCT03976362 |
| Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy |
Recruiting |
Cervical Cancer |
NCT00980954 |
| A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma |
Terminated |
Glioblastoma Multiforme|Brain Neoplasms |
NCT00479765 |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed |
Completed |
Lung Cancer |
NCT00004160 |
| Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer |
Completed |
Triple Negative Breast Cancer |
NCT01969032 |
| Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor |
Completed |
Neoplasms |
NCT00454649 |
| Efficacy Study of Adjuvant Chemotherapy for Chinese Primary Breast Cancer Patients |
Unknown status |
Breast Cancer |
NCT01314833 |
| Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma |
Completed |
Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00005021 |
| Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT |
Unknown status |
Coronary Heart Disease|Diabetes Mellitus |
NCT01021930 |
| Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer |
Recruiting |
Non Small Cell Lung Cancer|Stage III Non-small-cell Lung Cancer |
NCT03871153 |
| TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma |
Active, not recruiting |
Nasopharyngeal Carcinoma |
NCT02940925 |
| Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT03887130 |
| Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer |
Active, not recruiting |
Ovarian Cancer |
NCT03117933 |
| Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery |
Completed |
Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer |
NCT00194779 |
| Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer |
Active, not recruiting |
Endometrial Cancer |
NCT02730416 |
| Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer |
Unknown status |
Carcinoma Breast Stage IV |
NCT02183805 |
| Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer |
Recruiting |
Esophageal Squamous Cell Carcinoma |
NCT03946969 |
| Drug-Eluting Balloon in Arteriovenous Graft |
Completed |
Kidney Failure, Chronic|Angioplasty|Dialysis |
NCT03388892 |
| Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery |
Terminated |
Bladder Cancer |
NCT00268450 |
| Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer |
Recruiting |
Ovarian Cancer Recurrent |
NCT04072263 |
| Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer |
Completed |
Cervical Cancer |
NCT02128126 |
| Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer |
Unknown status |
Drug/Agent Toxicity by Tissue/Organ|Head and Neck Cancer|Radiation Toxicity |
NCT00003251 |
| Palpitate-Eluting Balloon Angioplasty in the Treatment of Coronary Bifurcation Lesion Evaluated by OCT |
Unknown status |
Angioplasty|Percutaneous Coronary Intervention |
NCT02276846 |
| Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function |
Completed |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer |
NCT00005644 |
| Atherectomy Followed by a Drug Coated Balloon to Treat Peripheral Arterial Disease |
Completed |
Peripheral Arterial Disease|Claudication |
NCT01366482 |
| S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00003158 |
| Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00011999 |
| Intensive Sequential Chemotherapy With Adriamycin Taxol and Cytoxan in the Treatment of Locally Advanced Breast Cancer |
Unknown status |
Breast Cancer |
NCT00538395 |
| PET/CT-directed Hyperfractionated Radiation Dose Escalation in Stage III Non-small Cell Lung Cancer |
Completed |
Non Small Cell Lung Cancer |
NCT03099577 |
| A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT02613208 |
| Paclitaxel, Cyclophosphamide, and Doxorubicin Followed by Autologous Dendritic Cells and Surgery With or Without Radiation Therapy and/or Hormone Therapy in Treating Women With Stage II or Stage III Breast Cancer |
Completed |
Breast Cancer |
NCT00499083 |
| The Safety and Efficacy of SeQuent® Please in Real World Chinese Coronary Instent Restenosis Patients |
Active, not recruiting |
Coronary In Sentrestenosis |
NCT03624205 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies |
Completed |
Solid Tumor |
NCT01967043 |
| Phase II CT-2103/Carboplatin in Ovarian Cancer |
Completed |
Ovarian Neoplasm |
NCT00069901 |
| IN.PACT™ AV Access Study |
Active, not recruiting |
Arteriovenous Fistula Stenosis|Arteriovenous Fistula Occlusion|Arteriovenous Fistula|Fistula |
NCT03041467 |
| A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer |
Completed |
Prosthesis Survival |
NCT01918124 |
| To Achieve an Early Reendothelialization at the Expense of Low Restenosis: The EREMUS Study |
Unknown status |
Angioplasty, Transluminal, Percutaneous Coronary|Percutaneous Coronary Intervention |
NCT00870038 |
| Demonstrate Efficacy and Safety of Metastatic Breast Cancer |
Unknown status |
Metastatic Breast Cancer |
NCT01084876 |
| Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer |
Completed |
Drug/Agent Toxicity by Tissue/Organ|Lung Cancer |
NCT00003089 |
| Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer |
Recruiting |
Esophageal Neoplasms |
NCT02891083 |
| BIO 300 Non-Small Cell Lung Cancer Study |
Active, not recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT02567799 |
| Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma |
Recruiting |
Esophageal Adenocarcinoma |
NCT02998268 |
| Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery |
Active, not recruiting |
Recurrent Lung Non-Small Cell Carcinoma|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7 |
NCT01912625 |
| Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site |
Completed |
Carcinoma |
NCT00737243 |
| Study of the Apatinib Combine With POF Versus POF in Gastric Cancer |
Not yet recruiting |
Gastric Adenocarcinoma|Advanced Cancer |
NCT04121039 |
| Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer |
Withdrawn |
Ovarian Cancer |
NCT01606358 |
| 'ADVANCE' (A Pilot Trial) |
Recruiting |
Breast Cancer |
NCT03858322 |
| Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer |
Completed |
Leukemia|Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00003294 |
| Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole |
Active, not recruiting |
Solid Tumors|Ovarian Cancer|Endometrial Cancer |
NCT02476955 |
| A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g) |
Completed |
Non-Small Cell Lung Cancer |
NCT00480831 |
| Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer |
Recruiting |
Cancer of Pancreas |
NCT02902484 |
| Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer |
Active, not recruiting |
Head and Neck Cancer |
NCT01716195 |
| Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer |
Completed |
Endometrial Cancer |
NCT00003691 |
| Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment |
Completed |
Critical Limb Ischemia|Peripheral Artery Disease |
NCT02539940 |
| COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer |
Recruiting |
Breast Cancer|Estrogen Receptor-positive Breast Cancer |
NCT04038489 |
| Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling |
Terminated |
Advanced Non-Small Cell Lung Cancer |
NCT00161278 |
| Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression |
Completed |
Breast Cancer |
NCT00944047 |
| Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC |
Recruiting |
Non-small Cell Lung Cancer |
NCT02619448 |
| Indirect Comparison Topotecan Cervical Carcinoma |
Completed |
Cervical Intraepithelial Neoplasia |
NCT01345279 |
| Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer |
Recruiting |
Stage IV Breast Cancer AJCC v6 and v7 |
NCT03535701 |
| Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer |
Active, not recruiting |
Endometrial Cancer |
NCT01244789 |
| Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer |
Completed |
Adenocarcinoma of Unknown Primary|Adult Cholangiocarcinoma|Gallbladder Carcinoma|Gastric Adenocarcinoma|Malignant Gastrointestinal Neoplasm|Metastatic Pancreatic Adenocarcinoma|Pancreatic Adenocarcinoma|Stage III Ampulla of Vater Cancer|Stage III Pancreatic Cancer|Stage IIIA Gallbladder Cancer|Stage IIIA Gastric Cancer|Stage IIIB Gallbladder Cancer|Stage IIIB Gastric Cancer|Stage IV Ampulla of Vater Cancer|Stage IV Gallbladder Cancer|Stage IV Gastric Cancer|Stage IV Pancreatic Cancer |
NCT02333188 |
| 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer |
Terminated |
First Line Metastatic Breast Cancer |
NCT01303679 |
| Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients |
Recruiting |
Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer |
NCT03321188 |
| Efficacy and Safety Study of Xyotax to Treat Prostate Cancer |
Completed |
Prostatic Neoplasms |
NCT00446836 |
| Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC |
Active, not recruiting |
Non-Small Cell Lung Cancer |
NCT02591615 |
| De-Escalation Therapy for Human Papillomavirus Negative Disease |
Recruiting |
Human Papilloma Virus|Squamous Cell Carcinoma|Squamous Cell Carcinoma of the Head and Neck|HPV-Related Squamous Cell Carcinoma|HNSCC |
NCT03944915 |
| Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas |
Recruiting |
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis) |
NCT03136055 |
| Study of NMB (Company's Name) Drug Ejecting Balloon for Arteriovenous Fistulae |
Unknown status |
Obstructive Lesions of Arteriovenous Dialysis Fistulae |
NCT01538108 |
| Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer |
Not yet recruiting |
Endometrial Neoplasms |
NCT04269200 |
| FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer |
Terminated |
Platinum Resistant Ovarian Cancer |
NCT02641639 |
| A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis |
Recruiting |
Germ Cell Tumour |
NCT01782339 |
| Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer |
Unknown status |
Adenocarincoma of Pancreas|Stage III Pancreatic Cancer|Stage IVA Pancreatic Cancer|Stage IVB Pancreatic Cancer |
NCT00323583 |
| ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer |
Completed |
Non Small Cell Lung Carcinoma |
NCT00252798 |
| Study of the Combination of Apatinib and POF |
Not yet recruiting |
Gastric Adenocarcinoma |
NCT03707639 |
| APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers |
Recruiting |
Esophageal Cancer|GastroEsophageal Cancer |
NCT03165994 |
| Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer |
Completed |
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Bladder Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Squamous Cell Carcinoma of the Bladder|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder |
NCT00005831 |
| SGI-110 in Combination With Carboplatin in Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT01696032 |
| Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel |
Completed |
Lung Cancer |
NCT00900172 |
| Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma |
Recruiting |
Locally Advanced Pancreatic Adenocarcinoma |
NCT03077685 |
| Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project |
Completed |
Atherosclerosis of Native Arteries of the Extremities |
NCT01820637 |
| A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors |
Active, not recruiting |
Solid Tumors |
NCT02597036 |
| SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries |
Unknown status |
Coronary Artery Disease |
NCT00114972 |
| Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer |
Terminated |
Lung Cancer |
NCT00334763 |
| Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT01057069 |
| Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC |
Recruiting |
Pancreatic Adenocarcinoma |
NCT03665441 |
| Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma |
Recruiting |
Gastric Adenocarcinoma |
NCT03788174 |
| Zilver PTX Delivery System |
Completed |
Peripheral Vascular Disease |
NCT02271529 |
| MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma |
Withdrawn |
Pancreatic Ductal Adenocarcinoma |
NCT04134468 |
| Chemoradiation and Panitumumab for Esophageal Cancer |
Completed |
Squamous Cell Carcinoma|Adenocarcinoma|Esophageal Cancer|Gastro-esophageal Junction Cancer |
NCT01077999 |
| Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) |
Withdrawn |
Lung Cancer |
NCT02044601 |
| Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery |
Completed |
Breast Cancer|Cardiac Toxicity |
NCT00436566 |
| Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer |
Recruiting |
Locally Advanced Breast Cancer |
NCT03329378 |
| Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy |
Active, not recruiting |
Primary Breast Cancer |
NCT01019616 |
| Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer |
Active, not recruiting |
Stage IV Non-small Cell Lung Cancer |
NCT02470468 |
| An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
Stage IIA Non-small Cell Lung Cancer|Stage IIB Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer |
NCT01711697 |
| Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer |
Completed |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer |
NCT00040794 |
| Drug Eluting Stent (DES) in Primary Angioplasty |
Completed |
Acute Myocardial Infarction |
NCT00759850 |
| Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer |
Recruiting |
Gastric Cancer |
NCT03575637 |
| A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes |
Completed |
Supportive|Ill-defined Sites |
NCT00277043 |
| Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus |
Unknown status |
Esophageal Cancer |
NCT00008047 |
| A Trial Comparing Adjuvant Chemotherapy With Observation After Concurrent Chemoradiotherapy of Cervical Cancer (With Pelvic or Para-aortic Node Involvement) |
Recruiting |
Cervical Cancer|Adjuvant Chemotherapy|Radiation|Lymph Node Metastases |
NCT03468010 |
| Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer |
Active, not recruiting |
Endometrial Cancer |
NCT00411138 |
| Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) |
Recruiting |
Breast Cancer|Renal Cell Carcinoma |
NCT03961698 |
| A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer |
Recruiting |
Gastric Cancer Stage III |
NCT03788226 |
| Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 |
Active, not recruiting |
Metastatic Cancer|Advanced Cancer|Solid Tumor|Non Small Cell Lung Cancer Metastatic|Non Small Cell Lung Cancer Stage IIIB|Non Small Cell Lung Cancer |
NCT03307785 |
| Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer |
Active, not recruiting |
Lung Cancer |
NCT00979212 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00032032 |
| TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program |
Completed |
Cardiovascular Disease|de Novo Coronary Lesions |
NCT00569751 |
| LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer |
Recruiting |
Pancreatic Cancer |
NCT02705196 |
| Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer |
Recruiting |
Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer |
NCT01897441 |
| Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma |
Completed |
Esophageal Cancer |
NCT00815308 |
| AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer |
Completed |
Ovarian Neoplasms|Ovarian Cancer |
NCT00610714 |
| Drug Eluting Balloon in peripherAl inTErvention SFA |
Completed |
Peripheral Arterial Disease |
NCT01556542 |
| Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer |
Recruiting |
Cervical Cancer |
NCT01566240 |
| Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma |
Suspended |
Esophageal Squamous Cell Carcinoma |
NCT02272699 |
| First-line Therapy in Metastatic PDAC |
Recruiting |
Metastatic Pancreatic Cancer |
NCT03487016 |
| Lutonix® DCB for Treatment of Long Lesions in Femoropopliteal Arteries |
Completed |
Femoral Artery Occlusion|Femoral Arterial Stenosis |
NCT02013271 |
| Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery |
Completed |
Lung Cancer |
NCT01486602 |
| A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma |
Active, not recruiting |
Esophageal Squamous Cell Carcinoma (ESCC) |
NCT03430843 |
| Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients |
Unknown status |
Cervical Cancer |
NCT01756170 |
| Study Comparing Legflow Versus Bare Balloon Angioplasty for Treatment of Atherosclerotic Disease |
Completed |
Atherosclerosis |
NCT02710656 |
| Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery |
Unknown status |
Breast Cancer |
NCT00039546 |
| Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients |
Completed |
Endometrial Cancer |
NCT00334321 |
| Clinical Performance of the Pantera Lux Balloon Versus the Orsiro Stent in Patients With In-stent Restenosis. |
Completed |
Coronary Artery Disease|Coronary Restenosis |
NCT01651390 |
| Study of NMB Drug Ejecting Balloon for Arteriovenous Fistulae |
Unknown status |
Obstructive Lesions of Arteriovenous Dialysis Fistulae |
NCT01646788 |
| A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) |
Withdrawn |
Squamous Cell Carcinoma of the Head and Neck |
NCT01820312 |
| A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma |
Active, not recruiting |
Metastatic Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma |
NCT02539225 |
| Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Non-Small Cell Lung Cancer |
NCT02944396 |
| ATRi Transition Rollover Study |
Active, not recruiting |
Advanced Stage Solid Tumors |
NCT03309150 |
| Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma |
Not yet recruiting |
Esophageal Cancer|Surgery|Neoadjuvant Treatment|Survival |
NCT04280822 |
| Percutaneous Intervention Versus Surgery in the Treatment of Common Femoral Artery Lesions |
Recruiting |
Peripheral Artery Disease|Artery Stenosis |
NCT02517827 |
| Phase II Study for Solid Metastatic Tumors |
Completed |
Breast Cancer|Metastatic Breast Cancer|Solid Tumor |
NCT02474186 |
| The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors. |
Recruiting |
Advanced Solid Tumors |
NCT03577704 |
| Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
Withdrawn |
Lung Cancer |
NCT00006374 |
| A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer |
Recruiting |
Triple Negative Breast Cancer |
NCT03498716 |
| Paclitaxel/Cisplatin/Fluorouracil Followed by Paclitaxel/Cisplatin/Radiotherapy and Esophagectomy for Esophageal Cancer |
Unknown status |
Esophageal Cancer |
NCT01034332 |
| Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases |
Recruiting |
Early-Stage Breast Carcinoma|Estrogen Receptor Positive Tumor |
NCT02603679 |
| Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer |
Completed |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter |
NCT00003342 |
| Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography |
Unknown status |
Non Small Cell Lung Cancer|Nasopharyngeal Cancer|Liver Metastasis |
NCT01347424 |
| WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer |
Terminated |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Carcinoma |
NCT01144442 |
| ICON8: Weekly Chemotherapy in Ovarian Cancer |
Unknown status |
Ovarian Cancer |
NCT01654146 |
| Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer |
Recruiting |
Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma |
NCT04081389 |
| Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery |
Active, not recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma of the Head and Neck |
NCT01612351 |
| Biolimus A9™ (BA9™) Drug Coated Balloon (DCB) Study |
Not yet recruiting |
Coronary Artery Disease|In-Stent Restenosis |
NCT04079192 |
| 6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer |
Unknown status |
Breast Cancer |
NCT00189644 |
| Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study |
Active, not recruiting |
Non-small Cell Lung Cancer |
NCT03850444 |
| A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer |
Completed |
Breast Cancer |
NCT01940497 |
| Study of Neo-Adjuvant Chemotherapy and Surgery to Preserve Fertility in Patients With Cervical Cancer |
Not yet recruiting |
Cervical Cancer |
NCT04016389 |
| Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00009997 |
| Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT00433420 |
| Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma |
Terminated |
Pancreatic Ductal Adenocarcinoma |
NCT02468557 |
| A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer |
Completed |
HER-2 Gene Amplification |
NCT01304784 |
| Chemoradiotherapy in Elderly Patients With Oesophagus Cancer |
Recruiting |
Oesophagus Cancer|Elderly Patients |
NCT02735057 |
| A Study of ABT-165 in Subjects With Solid Tumors |
Active, not recruiting |
Advanced Solid Tumors |
NCT01946074 |
| An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer |
Recruiting |
Ovarian Cancer |
NCT03989336 |
| Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval |
Unknown status |
Ovarian Cancer |
NCT00657878 |
| Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer |
Completed |
Breast Cancer |
NCT00038402 |
| A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenecity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients |
Recruiting |
Lung Cancer|Non-small Cell Lung Cancer |
NCT03390686 |
| Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine, Abraxane, Gemcitabine) |
Recruiting |
Pancreatic Cancer |
NCT01845805 |
| Regimens Comparison for Breast Cancers of Positive Lymph Nodes |
Recruiting |
Breast Cancer |
NCT01134523 |
| mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA |
Unknown status |
Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction |
NCT03045770 |
| Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer |
Unknown status |
Esophageal Cancer |
NCT02569242 |
| A Pilot Study of Oraxol in Subjects With Cutaneous Angiosarcoma |
Recruiting |
Angiosarcoma of Skin |
NCT03544567 |
| Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) |
Active, not recruiting |
Non-small Cell Lung Cancer |
NCT02220894 |
| A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer |
Completed |
Lung Cancer|Non-small Cell Lung Cancer |
NCT02754882 |
| Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer |
Completed |
Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00003322 |
| BEnefit of Arterial Preparation by LONGitudinal Scoring |
Recruiting |
Peripheral Arterial Disease |
NCT03721939 |
| Hyperthermic Intraperitoneal Chemotherapy or Intraperitoneal Chemotherapy in Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Recruiting |
Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer |
NCT03188432 |
| Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss |
Recruiting |
Advanced Solid Tumors|Lymphoma |
NCT03435250 |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors |
Completed |
Extragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor |
NCT00002558 |
| Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer |
Completed |
Prostate Cancer |
NCT00003394 |
| A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT00113516 |
| Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer |
Not yet recruiting |
Breast Cancer|Triple Negative Breast Cancer |
NCT03872505 |
| Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery |
Unknown status |
Lung Cancer |
NCT00004253 |
| Neoadjuvant Chemoradiotherapy Combined With PD-1 Antibody in Locally Advanced Esophageal Cancer |
Recruiting |
Esophagus Cancer |
NCT04177875 |
| Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer |
Terminated |
Ovarian Cancer |
NCT00002819 |
| Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery |
Active, not recruiting |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Large Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIA Non-small Cell Lung Cancer|Stage IIB Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer |
NCT01345851 |
| Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery |
Recruiting |
Lung Cancer|Esophageal Cancer |
NCT03095209 |
| Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00003742 |
| Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer |
Active, not recruiting |
Micropapillary Serous Carcinoma|Ovarian Serous Adenocarcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Low Grade Ovarian Serous Adenocarcinoma|Recurrent Primary Peritoneal Serous Adenocarcinoma |
NCT02101788 |
| Washington |
Puyallup |
United States|Virginia Mason Medical Center |
Puyallup |
| Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer |
Active, not recruiting |
Metastatic Breast Cancer|Recurrent Breast Cancer |
NCT02390427 |
| PET/CT-directed Hyperfractionated Radiation Dose Escalation in Esophageal Cancer |
Completed |
Esophageal Cancer |
NCT03113214 |
| Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer |
Unknown status |
Ovarian Cancer |
NCT00003733 |
| A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment |
Completed |
Breast Cancer |
NCT01301729 |
| Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer |
Recruiting |
Ovarian Cancer Stage IIIC|Ovarian Cancer Stage IV|Fallopian Tube Cancer|Peritoneal Cancer |
NCT03693248 |
| Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer |
Active, not recruiting |
Head and Neck Squamous Cell Carcinoma|Stage IVA Oropharyngeal Carcinoma AJCC v7|Stage IVB Oropharyngeal Carcinoma AJCC v7 |
NCT01711541 |
| A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer |
Not yet recruiting |
Endometrial Cancer|Serous Tumor|P53 Mutation |
NCT04159155 |
| Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) |
Completed |
Ovarian Cancer |
NCT01684878 |
| A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas |
Completed |
Soft Tissue Sarcoma |
NCT00087997 |
| Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00005806 |
| Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer |
Recruiting |
Oropharynx Cancer |
NCT03416153 |
| Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
Active, not recruiting |
Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Carcinoma|Stage IIA Fallopian Tube Cancer AJCC v6 and v7|Stage IIA Ovarian Cancer AJCC V6 and v7|Stage IIB Fallopian Tube Cancer AJCC v6 and v7|Stage IIB Ovarian Cancer AJCC v6 and v7|Stage IIC Fallopian Tube Cancer AJCC v6 and v7|Stage IIC Ovarian Cancer AJCC v6 and v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7 |
NCT00951496 |
| Utah |
Salt Lake City |
United States|Huntsman Cancer Institute/University of Utah |
Saint George |
| TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove) |
Completed |
Coronary Heart Disease |
NCT01242696 |
| The IN.PACT SFA Clinical Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery Using the IN.PACT Admiral™ Drug-Eluting Balloon in a Chinese Patient Population |
Completed |
Atherosclerosis |
NCT02118532 |
| Study for Patients With Non Small Cell Lung Cancer (NSCLC) |
Unknown status |
Carcinoma, Non-Small-Cell Lung |
NCT00168883 |
| Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer |
Terminated |
Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00003378 |
| Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer |
Completed |
Prostate Cancer |
NCT00016913 |
| Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer |
Completed |
Carcinoma, Non Small Cell Lung |
NCT00191256 |
| Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer |
Completed |
Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00005026 |
| Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer |
Terminated |
Relapsed Breast Cancer|Neoplasms, Breast |
NCT00479856 |
| Study of ORIC-101 in Combination With Anticancer Therapy |
Recruiting |
Solid Tumor |
NCT03928314 |
| Study of Nab-Paclitaxel in High Risk Early Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT01690702 |
| S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00006248 |
| S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer |
NCT00008138 |
| Study of SOR007 Ointment for Actinic Keratosis |
Completed |
Actinic Keratosis |
NCT03083470 |
| Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane |
Completed |
Ovarian Cancer|Peritoneal Cancer|Cancer of the Fallopian Tube |
NCT02728622 |
| Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer |
NCT00550784 |
| A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC |
Recruiting |
Biliary Tract Cancer (BTC) |
NCT04004234 |
| An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer |
Recruiting |
Pancreatic Cancer |
NCT03989310 |
| Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma |
Unknown status |
Lymphoma |
NCT00008021 |
| ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00006049 |
| Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility |
Terminated |
Cervical Cancer |
NCT03852979 |
| A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer |
Completed |
Breast Neoplasms |
NCT01572038 |
| Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) |
Completed |
Esophageal Squamous Cell Carcinoma |
NCT01822613 |
| PDL-1 Targeting in Resectable Oesophageal Cancer |
Recruiting |
Esophageal Cancer, Stage II|Esophageal Cancer Stage III |
NCT03087864 |
| Excellence in Peripheral Arterial Disease Treatment of Superficial Femoral Artery Disease With Drug-eluting Stents |
Terminated |
Peripheral Vascular Diseases|Chronic Total Occlusion of Artery of the Extremities |
NCT03671655 |
| Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer |
Recruiting |
Breast Cancer |
NCT03433313 |
| PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer |
Recruiting |
Neoplasms Pancreatic |
NCT04176952 |
| A Phase I Study of Intraperitoneal Hyperthermic Docetaxel |
Completed |
Ovarian Carcinoma |
NCT00474669 |
| ILLUMENATE Pivotal Post-Approval Study (PAS) |
Active, not recruiting |
Peripheral Artery Disease |
NCT03421561 |
| Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer |
Recruiting |
Pancreatic Neoplasm |
NCT03310632 |
| Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00876486 |
| BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older |
Completed |
Ovarian Cancer |
NCT02393898 |
| Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO) |
Recruiting |
Breast Cancer Female |
NCT04170465 |
| Comparison of Drug Eluting Stent and Covered Metal Stent in Malignant Biliary Obstruction (MIRA III) |
Completed |
Biliary Neoplasms|Biliary Obstruction|Pancreatic Neoplasms |
NCT02460432 |
| Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB and IIIA Non-small Cell Lung Cancer |
Recruiting |
Stage IIB Non-Small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer |
NCT03916419 |
| Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter |
Active, not recruiting |
Benign Prostatic Hyperplasia|Benign Prostatic Hypertrophy |
NCT03423979 |
| To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid |
Completed |
Small Cell Lung Cancer |
NCT00617409 |
| Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer|Venous Thromboembolism |
NCT00476216 |
| Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00033696 |
| A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer. |
Recruiting |
Ovarian Cancer |
NCT03763123 |
| A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT00762034 |
| Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 |
Completed |
Non-Small Cell Lung Cancer |
NCT00085839 |
| NADIM II: Neo-Adjuvant Immunotherapy |
Recruiting |
Non Small Cell Lung Cancer |
NCT03838159 |
| Evaluation of a New Nanotechnology Based Drug-Eluting Stent for Opening of Narrowed Arteries of the Heart |
Unknown status |
Coronary Stenosis |
NCT00428662 |
| Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer |
Recruiting |
Breast Carcinoma|Neuropathy |
NCT02610439 |
| A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer |
Terminated |
Breast Cancer |
NCT01200212 |
| Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy |
Recruiting |
Locally Advanced Gastric Cancer |
NCT03322969 |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00003812 |
| Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy |
Completed |
Non-small Cell Lung Cancer|Epithelial Ovarian Cancer |
NCT02728492 |
| Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
Completed |
Primary Peritoneal Carcinoma|Stage III Ovarian Cancer|Stage IV Ovarian Cancer |
NCT00011986 |
| A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT02132949 |
| Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma |
Recruiting |
Esophageal Neoplasms |
NCT02858206 |
| Perioperative Vs. Preoperative Chemotherapy With Surgery in the Squamous Carcinoma of Esophagus |
Completed |
Squamous Carcinoma of Esophagus|Esophagus Disorders |
NCT01225523 |
| Comparison of Optical Coherence Tomographic Findings After Balloon Angioplasty With Two Different Paclitaxel-Coated Balloons for the Treatment of In-Stent Restenosis in Drug-Eluting Stents |
Terminated |
Coronary Artery Disease |
NCT02528474 |
| to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) |
Not yet recruiting |
Triple Negative Breast Cancer |
NCT04301739 |
| A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer |
Active, not recruiting |
Metastatic Pancreatic Adenocarcinoma |
NCT02231723 |
| Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma. |
Not yet recruiting |
Pancreas Cancer |
NCT04258072 |
| Stage I/II NSCLC Perioperative Chemotherapy |
Completed |
Non-small Cell Lung Cancer Stage I and II|Peri-operative Chemotherapy |
NCT00198354 |
| Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52) |
Active, not recruiting |
Non-Small Cell Lung Cancer |
NCT03117049 |
| Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer |
Active, not recruiting |
Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Positive|Progesterone Receptor Negative|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7 |
NCT01275677 |
| Maryland |
Baltimore |
United States|Johns Hopkins University/Sidney Kimmel Cancer Center |
Baltimore |
| Springfield |
United States|Trinity's Tony Teramana Cancer Center |
Ohio |
United States|Springfield Regional Medical Center |
| Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study |
Recruiting |
Gastric Adenocarcinoma |
NCT04190745 |
| Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide™ Stent Versus Taxus™ |
Unknown status |
Coronary Artery Disease|Acute Coronary Syndrome |
NCT00914420 |
| Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) |
Recruiting |
Endometrial Neoplasms |
NCT03884101 |
| Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer |
Terminated |
Cardiac Toxicity|Inflammatory Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast Cancer |
NCT00016276 |
| Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma |
Recruiting |
Esophageal Squamous Cell Carcinoma |
NCT02916511 |
| SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel |
Completed |
Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage IV Prostate Cancer |
NCT00096499 |
| Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen |
Recruiting |
Metastatic Pancreatic Cancer |
NCT04101929 |
| Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III) |
Completed |
Coronary Artery Disease |
NCT01515228 |
| KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma |
Recruiting |
Esophageal Squamous Cell Carcinoma |
NCT03927495 |
| Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus |
Completed |
Esophageal Cancer |
NCT00003087 |
| mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial |
Unknown status |
Advanced Esophageal Carcinoma |
NCT01044420 |
| Drug Eluting Pantera Lux Catheter Registry |
Completed |
Coronary Artery Disease |
NCT01081366 |
| Afatinib in NSCLC With HER2 Mutation |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT02597946 |
| Biweekly Docetaxel in Patients With Metastatic Breast Cancer. |
Completed |
Metastatic Breast Cancer |
NCT02041351 |
| Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum |
Completed |
Bladder Cancer|Ureter Cancer |
NCT01426126 |
| Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer |
Unknown status |
Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00017303 |
| IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery |
Suspended |
Stage III Fallopian Tube Cancer|Stage III Ovarian Cancer|Stage III Primary Peritoneal Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer |
NCT03029611 |
| A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers |
Recruiting |
GastroEsophageal Cancer |
NCT03279237 |
| DEFINITIVE AR Two Year Follow-up Extension Study |
Completed |
Peripheral Arterial Disease |
NCT02363894 |
| Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma |
Unknown status |
Esophageal Squamous Cell Carcinoma Resectable |
NCT01688700 |
| Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin |
Completed |
Ovarian Cancer|Testicular Germ Cell Tumor |
NCT00002559 |
| The ELUTES Clinical Trial |
Completed |
Coronary Artery Disease |
NCT00225654 |
| Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer |
Recruiting |
Unresectable Esophageal Cancer |
NCT04005170 |
| BIOLUX P-III All-Comers Passeo-18 Lux Registry |
Active, not recruiting |
Atherosclerosis|Peripheral Artery Disease |
NCT02276313 |
| Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer |
Recruiting |
Breast Neoplasm |
NCT02455141 |
| Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naĂŻve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYNOTE-01A) |
Recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT04165070 |
| The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer |
Not yet recruiting |
Breast Cancer|Breast Diseases|Breast Neoplasms |
NCT03756090 |
| A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] |
Completed |
Bladder Cancer |
NCT02302807 |
| Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) |
Terminated |
Ovarian Cancer |
NCT02718417 |
| Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer |
Completed |
Adenocarcinoma of the Prostate |
NCT03077659 |
| Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in Cervical Cancer |
Unknown status |
Cervical Cancer |
NCT01487226 |
| A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001) |
Terminated |
Advanced Cancer |
NCT01688791 |
| Gemcitabine and Nabpaclitaxel in Metastatic Pancreatic Carcinoma. |
Completed |
Metastatic Pancreatic Cancer |
NCT03620461 |
| Divestment for Artery-involved Pancreatic Cancer |
Not yet recruiting |
Pancreatic Cancer|Locally Advanced Pancreatic Cancer|Neoadjuvant Therapy|Borderline Resectable Pancreatic Cancer |
NCT03443921 |
| Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer |
Unknown status |
Esophageal Neoplasms|Neoplasms|Digestive System Neoplasms|Esophageal Cancer |
NCT02644863 |
| Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma |
Recruiting |
Esophageal Cancer|Adenocarcinoma, Esophageal|Adenocarcinoma, Gastroesophageal Junction |
NCT01404156 |
| Systemic Consolidation Therapy After Primary Chemoradiation Therapy for Locally Advanced Cervical Cancer |
Unknown status |
Cervical Cancer |
NCT00591656 |
| A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies |
Recruiting |
Advanced Pancreatic Cancer |
NCT04104672 |
| A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00559845 |
| Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion |
Recruiting |
Peritoneal Adhesion |
NCT03095001 |
| Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer |
Completed |
Esophageal Cancer |
NCT00393068 |
| Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy |
Terminated |
Head and Neck Cancer |
NCT00898430 |
| Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT01190982 |
| MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC) |
Suspended |
Esophageal|Toxicity |
NCT00618917 |
| Pressure-wire Guided PTCA: Drug Eluting Stent Versus Drug Eluting Balloon (WinDEB Study) |
Unknown status |
Coronary Artery Disease |
NCT01399463 |
| Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 |
Not yet recruiting |
Non-small Cell Lung Cancer |
NCT04297605 |
| Systemic Consolidation Therapy After Chemoradiation Therapy Following Operation for High Risk Early Stage Cervical Cancer |
Unknown status |
Cervical Cancer |
NCT00592059 |
| Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy |
Completed |
Peripheral Neuropathy|Breast Cancer |
NCT00195013 |
| Safety and Efficacy of the SurVeil™ Drug-Coated Balloon |
Active, not recruiting |
Peripheral Arterial Disease|Peripheral Vascular Disease|Artery Disease, Peripheral|Femoropopliteal Artery Occlusion |
NCT03241459 |
| Trial of Myocet in Metastatic Breast Cancer |
Unknown status |
Breast Cancer |
NCT00294996 |
| Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast |
Recruiting |
Triple Negative Breast Cancer|Early-stage Breast Cancer|HER2-positive Breast Cancer |
NCT03812393 |
| Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients |
Recruiting |
Head and Neck Squamous Cell Carcinoma |
NCT04164238 |
| QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine |
Withdrawn |
Triple Negative Breast Cancer (TNBC) |
NCT03554109 |
| A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer |
Recruiting |
Esophageal Squamous Cell Carcinoma |
NCT03940001 |
| BIOLUX P-I First in Man Study |
Completed |
Atherosclerosis|Arteriosclerosis|Vascular Disease|Peripheral Artery Disease |
NCT01221610 |
| Intimal Hyperplasia Evaluated by Optical Coherence Tomography (OCT) in de Novo Coronary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent |
Unknown status |
Coronary Artery Disease |
NCT01057563 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer |
Unknown status |
Head and Neck Cancer |
NCT00004097 |
| 4 Versus 6 Courses of Adjuvant Chemotherapy in LACC Patients Previously Treated With NACT Plus Radical Surgery |
Completed |
Uterine Cervical Neoplasms |
NCT02365935 |
| AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor |
Completed |
Neoplasms |
NCT00719524 |
| Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation |
Recruiting |
Oesophageal Cancer |
NCT02741856 |
| Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer |
Completed |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IB Non-small Cell Lung Cancer |
NCT00002852 |
| Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00193310 |
| Clopidogrel Use and Long-term Safety After Drug-Eluting Stents Implantation |
Completed |
Coronary Artery Disease |
NCT00590174 |
| Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00033410 |
| The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions |
Completed |
Coronary Artery Disease |
NCT00217269 |
| A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients |
Active, not recruiting |
Uterine Cervical Neoplasms|Cervical Cancer|Uterine Cervical Cancer |
NCT01755897 |
| S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer |
Terminated |
Breast Cancer |
NCT00002772 |
| Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer |
Not yet recruiting |
Lung Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 |
NCT04262869 |
| Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer |
Recruiting |
Clinical Stage I Esophageal Adenocarcinoma AJCC v8|Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8|Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage I Esophageal Adenocarcinoma AJCC v8|Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Thoracic Esophagus Squamous Cell Carcinoma |
NCT03801876 |
| Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer |
Terminated |
Neoplasms|Ovarian Neoplasms|Fallopian Tube Neoplasms|Primary Peritoneal Neoplasm |
NCT01279291 |
| Search for Predictors of Therapeutic Response in Ovarian Carcinoma |
Completed |
Carcinoma of the Ovary|Fallopian Tube Cancer|Peritoneal Serous-type Advanced Stage |
NCT01391351 |
| High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy |
Not yet recruiting |
Chemotherapy-induced Peripheral Neuropathy|Recurrent Ovarian Carcinoma|Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma |
NCT04201561 |
| High Dose Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer |
Recruiting |
Non-small Cell Lung Cancer |
NCT03598517 |
| S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00004137 |
| Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence |
Completed |
Non-Small-Cell Lung Carcinoma |
NCT00915005 |
| Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer Metastatic |
NCT01966003 |
| Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study |
Recruiting |
Breast Cancer |
NCT03820063 |
| Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer |
Completed |
Breast Neoplasm|Neoplasm Metastasis |
NCT00001507 |
| Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer |
Terminated |
Ovarian Carcinoma|Peritoneal Carcinoma |
NCT00047632 |
| Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer |
Unknown status |
Breast Cancer |
NCT00005581 |
| Drug-coated Balloon Versus Drug-eluting Stent in Acute Myocardial Infarction |
Unknown status |
Coronary Artery Disease|Acute Myocardial Infarction |
NCT02219802 |
| LEVANT Japan Clinical Trial |
Completed |
Femoral Arterial Stenosis|Stenosis of Popliteal Arteries|Femoral Artery Occlusion|Occlusion of Popliteal Arteries |
NCT01816412 |
| A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors |
Active, not recruiting |
Cancer |
NCT01633970 |
| Study of KN046 With Chemotherapy in First Line Advanced NSCLC |
Recruiting |
Non-small Cell Lung Cancer |
NCT04054531 |
| CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy |
Recruiting |
Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8 |
NCT04266249 |
| Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2 |
Recruiting |
Gastric Cancer |
NCT02356276 |
| Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43) |
Recruiting |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms |
NCT03740165 |
| Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer |
Recruiting |
Endometrial Cancer |
NCT03932409 |
| Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors |
Active, not recruiting |
Head and Neck Squamous Cell Carcinoma|Metastatic Pancreatic Adenocarcinoma|Non-Resectable Cholangiocarcinoma|Pancreatic Adenocarcinoma|Recurrent Gallbladder Carcinoma|Recurrent Non-Small Cell Lung Carcinoma|Stage III Pancreatic Cancer|Stage IIIA Gallbladder Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Gallbladder Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Gallbladder Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Pancreatic Cancer|Unresectable Gallbladder Carcinoma|Unresectable Pancreatic Cancer |
NCT02495896 |
| Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00006004 |
| Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer |
Completed |
Ovarian Cancer |
NCT00005051 |
| High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer |
Recruiting |
Breast Cancer |
NCT01646034 |
| Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU |
Terminated |
Breast Carcinoma|Recurrent Breast Carcinoma|Stage IV Breast Cancer |
NCT00520975 |
| A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT02019277 |
| Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix |
Active, not recruiting |
Cancer of Cervix |
NCT00193739 |
| Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer |
Completed |
Prostate Cancer |
NCT00004054 |
| Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS |
Active, not recruiting |
HIV-1 Infection |
NCT01435018 |
| Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer |
Completed |
Breast Cancer |
NCT00014222 |
| Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00006469 |
| Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer |
Recruiting |
Breast Cancer Female |
NCT04126525 |
| Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients |
Active, not recruiting |
Breast Neoplasms |
NCT03272477 |
| First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers |
Active, not recruiting |
Neoplasm, Gynecologic |
NCT02978755 |
| A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy |
Completed |
Lung Neoplasms |
NCT00074854 |
| Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach |
Completed |
Esophageal Cancer|Gastric Cancer |
NCT00009880 |
| Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer |
Recruiting |
Invasive Breast Cancer |
NCT03595592 |
| Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus |
Completed |
Esophageal Cancer |
NCT00002711 |
| Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) |
Active, not recruiting |
Cervical Cancer |
NCT03635567 |
| Clinical Significance of Circulating Tumor Cells (CTCs) in Blood of Patients With Advanced/Metastatic Gastric Cancer |
Completed |
Gastric Cancer |
NCT01625702 |
| Feasibility of Biodynamic Imaging for Predicting Therapeutic Effect in Metastatic Adenocarcinoma of the Pancreas |
Withdrawn |
Metastatic Pancreatic Cancer |
NCT02205788 |
| Polymorphism Interaction to Predict Bevacizumab Efficacy |
Completed |
Metastatic Breast Cancer |
NCT01935102 |
| Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer |
Recruiting |
Pancreatic Cancer |
NCT03158779 |
| Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00033553 |
| R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy |
Completed |
Breast Cancer |
NCT00028873 |
| A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors |
Recruiting |
Metastatic Renal Cell Carcinoma|Advanced Urothelial Carcinoma|Advanced Gastric Adenocarcinoma|Metastatic Colorectal Adenocarcinoma |
NCT02599324 |
| A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer |
Terminated |
Non-Small Cell Lung Cancer |
NCT00404703 |
| Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer |
Active, not recruiting |
Lung Cancer |
NCT01107626 |
| Wisconsin |
Manitowoc |
United States|Bay Area Cancer Care Center at Bay Area Medical Center |
La Crosse |
| Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer |
Recruiting |
Esophageal Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma |
NCT02962063 |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy |
Terminated |
Non-small Cell Lung Cancer |
NCT02322281 |
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer |
Active, not recruiting |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma |
NCT03783949 |
| A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung |
Completed |
Adenocarcinoma of the Lung |
NCT01218516 |
| Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) |
Completed |
Nasopharyngeal Carcinoma |
NCT01712919 |
| Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer |
Recruiting |
Breast Cancer |
NCT04109066 |
| Trastuzumab & Pertuzumab Followed by T-DM1 in MBC |
Active, not recruiting |
Metastatic Breast Cancer |
NCT01835236 |
| Adjuvant Chemotherapy for Locally Advanced Cervical Cancer |
Unknown status |
Uterine Cervical Cancer |
NCT02036164 |
| Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor |
Terminated |
Solid Tumors |
NCT01299415 |
| Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer |
Not yet recruiting |
Triple-negative Breast Cancer |
NCT04248998 |
| Plasma-Adapted First-Line Pembro In NSCLC |
Recruiting |
NSCLC Stage IV|Metastatic Non-Small Cell Lung Cancer |
NCT04166487 |
| Systematic Review and Meta-Analysis on DCB vs. POBA in De-novo Femoropopliteal Disease |
Completed |
Peripheral Arterial Disease|Intermittent Claudication |
NCT02927574 |
| A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients With Metastatic Esophageal Cancer |
Unknown status |
Esophageal Neoplasm |
NCT00037089 |
| Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA |
Recruiting |
Epstein-Barr Virus Infection|Stage II Nasopharyngeal Carcinoma|Stage III Nasopharyngeal Carcinoma|Stage IVA Nasopharyngeal Carcinoma|Stage IVB Nasopharyngeal Carcinoma |
NCT02135042 |
| An Efficacy and Safety Study to Evaluate Ranger DEB for BTK Angioplasty in Patients With CLI (RANGER-BTK) |
Active, not recruiting |
Lower Limb Ischemia|Peripheral Vascular Diseases |
NCT02856230 |
| Salvage Ovarian FANG™ Vaccine + Carboplatinum |
Completed |
Stage III Ovarian Cancer|Stage IV Ovarian Cancer |
NCT01867086 |
| Observational STudy to Evaluate the EFfectiveness of OnLife® in Improving CIPN in Patients With Colon or Breast Cancer After End of Adj. Therapy |
Completed |
CIPN in Adjuvant Colon Cancer Patients|CIPN in Adjuvant Breast Cancer Patients |
NCT03065478 |
| Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer |
Recruiting |
Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Anaplastic Carcinoma|Unresectable Thyroid Gland Carcinoma |
NCT03181100 |
| Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
Recruiting |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma |
NCT02312245 |
| Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer |
Unknown status |
Esophageal Cancer |
NCT00006472 |
| Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer |
Unknown status |
Breast Cancer |
NCT02685059 |
| Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) |
Completed |
Malignant Melanoma |
NCT01704287 |
| Combination Chemotherapy in Treating Men With Germ Cell Cancer |
Unknown status |
Extragonadal Germ Cell Tumor|Teratoma|Testicular Germ Cell Tumor |
NCT00003643 |
| Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer |
Active, not recruiting |
Adenosquamous Lung Carcinoma|Bronchioloalveolar Carcinoma|Large Cell Lung Carcinoma|Lung Adenocarcinoma|Non-Small Cell Lung Carcinoma|Recurrent Non-Small Cell Lung Carcinoma|Squamous Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer |
NCT02186847 |
| Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED) |
Recruiting |
Locally Advanced Esophageal and Gastric Cancers (EGC) |
NCT03064490 |
| GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma |
Recruiting |
Pancreatic Adenocarcinoma|Esophageal Adenocarcinoma|Esophageal Squamous Cell Carcinoma|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Triple Negative Breast Cancer|Castration-resistant Prostate Cancer|Microsatellite Stable Colorectal Cancer |
NCT04060342 |
| Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer |
Recruiting |
Ovarian Cancer, Epithelial |
NCT03025477 |
| FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial |
Active, not recruiting |
Locally Advanced Pancreatic Cancer|Pancreatic Cancer |
NCT02578732 |
| Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients |
Unknown status |
Breast Cancer |
NCT02694224 |
| CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00017017 |
| Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00004202 |
| dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact. |
Unknown status |
Non-small Cell Lung Cancer |
NCT02195336 |
| Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer |
Completed |
Bladder Cancer |
NCT00003930 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer |
Terminated |
Lung Cancer |
NCT00004093 |
| A Study of Triprizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. |
Recruiting |
Esophageal Squamous Cell Carcinoma |
NCT04084158 |
| Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation |
Completed |
Critical Limb Ischemia |
NCT01558505 |
| Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer |
Completed |
Breast Cancer |
NCT00548899 |
| Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC |
Not yet recruiting |
NSCLC|Adenocarcinoma|Squamous Cell Carcinoma |
NCT03636685 |
| Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer |
Completed |
Drug/Agent Toxicity by Tissue/Organ|Lung Cancer|Oral Complications|Radiation Toxicity |
NCT00003313 |
| Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer |
Not yet recruiting |
Squamous Non-small Cell Lung Cancer |
NCT04073537 |
| Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer |
Completed |
Breast Cancer |
NCT01901146 |
| Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma |
Completed |
Adenocarcinoma, Bronchiolo-Alveolar |
NCT00384826 |
| An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007 |
Recruiting |
Breastcancer |
NCT04168957 |
| Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer |
Withdrawn |
Metastatic Breast Cancer |
NCT02651610 |
| Satisfaction & Efficacy of Compression Using Surgical Gloves in Chemo-induced Peripheral Neuropathies |
Not yet recruiting |
Breast Cancer|Colorectal Cancer |
NCT03872908 |
| Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus |
Terminated |
Esophageal Diseases |
NCT00208936 |
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00004174 |
| A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies |
Terminated |
Advanced Solid Malignancies |
NCT00351325 |
| Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer |
Recruiting |
PFS|OS|Quality of Life |
NCT02629718 |
| Drug Eluting Balloon Angioplasty for Dialysis Access Treatment |
Completed |
Dialysis|Angioplasty |
NCT01174472 |
| Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer |
Terminated |
Esophageal Cancer|Adenocarcinoma of the Esophagus|Squamous Cell Carcinoma |
NCT00573131 |
| A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC |
Not yet recruiting |
Non-Small-Cell Lung Cancer |
NCT04316364 |
| Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC |
Completed |
Non-Small Cell Lung Cancer |
NCT00828841 |
| Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer |
Completed |
Breast Cancer|Osteoporosis |
NCT00587925 |
| A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC) |
Terminated |
Non Small Cell Lung Cancer |
NCT00461110 |
| A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer |
Recruiting |
Metastatic Pancreatic Cancer|Metastatic Pancreatic Adenocarcinoma |
NCT04229004 |
| Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas |
Recruiting |
Recurrent Adenocarcinoma of the Pancreas|Metastatic Adenocarcinoma of the Pancreas |
NCT02739633 |
| Neoadjuvant Chemotherapy and Radical Surgery in Stage IIB Cervical Cancer |
Recruiting |
Cervical Carcinoma Stage IIB |
NCT02595554 |
| Alpha-Lipoic Acid in Breast Cancer Patients |
Recruiting |
Breast Cancer|Chemotherapeutic Toxicity |
NCT03908528 |
| FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer |
Completed |
Malignant Pleural Effusion|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00564733 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer |
Completed |
Esophageal Cancer |
NCT00021320 |
| A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration |
Completed |
Breast Cancer |
NCT02194166 |
| A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer |
Terminated |
Pancreatic Cancer |
NCT01632306 |
| Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2) |
Recruiting |
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer |
NCT03393884 |
| Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer |
Completed |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter |
NCT00003133 |
| Genetic Predictors of Benefit to Pembrolizumab |
Active, not recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT02710396 |
| Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2 |
Recruiting |
Pancreatic Neoplasms (Locally Advanced Non-metastatic) |
NCT02024009 |
| A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) |
Completed |
Tubular Breast Cancer Stage II|Tubular Breast Cancer Stage III|Mucinous Breast Cancer Stage II|Breast Cancer Female NOS|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer |
NCT02125344 |
| Safety Study of SEA-CD40 in Cancer Patients |
Recruiting |
Cancer|Carcinoma|Carcinoma, Non-Small-Cell Lung|Carcinoma, Squamous Cell|Hematologic Malignancies|Hodgkin Disease|Lymphoma|Lymphoma, B-Cell|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse|Melanoma|Neoplasms|Neoplasm Metastasis|Neoplasms, Head and Neck|Neoplasms, Squamous Cell|Non-Small Cell Lung Cancer|Non-Small Cell Lung Cancer Metastatic|Non-small Cell Carcinoma|Squamous Cell Cancer|Squamous Cell Carcinoma|Squamous Cell Carcinoma of the Head and Neck|Squamous Cell Neoplasm|Lymphoma, Non-Hodgkin|Pancreatic Adenocarcinoma |
NCT02376699 |
| Safety and Efficacy Study of the Nile PAX Drug-Eluting Coronary Bifurcation Stent |
Completed |
Coronary Disease |
NCT01308229 |
| Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. |
Recruiting |
Breast Cancer|Triple Negative Breast Cancer|Luminal B |
NCT03356860 |
| Basel Stent Kosten Effektivitäts Trial Drug Eluting Balloons vs. Drug Eluting Stents in Small Vessel Interventions |
Active, not recruiting |
Coronary Heart Disease |
NCT01574534 |
| A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function |
Completed |
Advanced Solid Tumors|Kidney Disease|Renal Impairment |
NCT01331941 |
| Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN) |
Withdrawn |
Cervical Intraepithelial Neoplasia |
NCT03143491 |
| Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy |
Unknown status |
Ovarian Cancer With Malignant Ascites |
NCT01838538 |
| Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer |
Recruiting |
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage|Resectable Esophageal Cancer |
NCT04006041 |
| GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors |
Recruiting |
Neoplasms |
NCT03693612 |
| To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer |
Unknown status |
Non Small Cell Lung Cancer |
NCT03195569 |
| Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma |
Recruiting |
Esophageal Carcinoma|Neoadjuvant Chemoradiation|Surgery |
NCT03381651 |
| Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer |
Recruiting |
Stage II Non-Small Cell Lung Cancer AJCC v7|Stage IIA Non-Small Cell Lung Carcinoma AJCC v7|Stage IIB Non-Small Cell Lung Carcinoma AJCC v7|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Non-Small Cell Lung Cancer AJCC v7 |
NCT01993810 |
| Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Unresectable Gastric Cancer |
Recruiting |
Gastric Cancer Stage |
NCT04267549 |
| A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC ) |
Not yet recruiting |
Pancreatic Cancer |
NCT03825328 |
| Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer |
Terminated |
Pancreatic Cancer |
NCT02548169 |
| FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma |
Recruiting |
Adenocarcinoma of the Esophagus|Adenocarcinoma of the Gastroesophageal Junction|Adenocarcinoma of the Gastric Cardia|Stage IIIA Esophageal Cancer|Stage IIIB Esophageal Cancer|Stage IIIC Esophageal Cancer |
NCT02037048 |
| Metformin Plus Neoadjuvant Chemotherapy in Breast Cancer |
Unknown status |
Locally Advanced Malignant Neoplasm |
NCT01566799 |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer. |
Completed |
Carcinoma of Unknown Primary|Lung Cancer |
NCT00003943 |
| Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy |
Completed |
Unilateral HER2 Positive Breast Cancer |
NCT01594177 |
| A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2-Breast Cancer That Has Spread |
Not yet recruiting |
Breast Cancer |
NCT04132817 |
| A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) |
Completed |
Breast Cancer |
NCT01120184 |
| Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC) |
Recruiting |
Esophageal Cancer |
NCT03544736 |
| Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery |
Terminated |
Head and Neck Cancer |
NCT00113399 |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer |
Terminated |
Malignant Ovarian Mixed Epithelial Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Primary Peritoneal Carcinoma|Stage III Ovarian Cancer|Undifferentiated Ovarian Carcinoma |
NCT00004221 |
| Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer |
Recruiting |
Resectable Esophageal Cancer|GastroEsophageal Cancer |
NCT03490292 |
| Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer |
Completed |
Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer |
NCT00119262 |
| Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse |
Completed |
Ovarian Cancer |
NCT00437307 |
| Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer |
Recruiting |
Squamous Cell Carcinoma|Esophageal Cancer|Perioperative Period |
NCT03985670 |
| Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin |
Unknown status |
Carcinoma of Unknown Primary |
NCT00003558 |
| Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery |
Recruiting |
Gastric Cardia Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Stage IB Gastric Cancer AJCC v7|Stage II Gastric Cancer AJCC v7|Stage IIA Gastric Cancer AJCC v7|Stage IIB Gastric Cancer AJCC v7|Stage IIIA Gastric Cancer AJCC v7|Stage IIIB Gastric Cancer AJCC v7 |
NCT02730546 |
| Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma |
Recruiting |
Nasopharyngeal Carcinoma |
NCT03668730 |
| Study of PD-1 Inhibition With Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients Undergoing Standard Neoadjuvant Chemotherapy |
Not yet recruiting |
Invasive Breast Cancer |
NCT04243616 |
| Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer |
Completed |
Carcinoma of Unknown Primary|Head and Neck Cancer |
NCT00003582 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx |
Unknown status |
Head and Neck Cancer |
NCT00004094 |
| Prospective Randomized Trial Comparing DEB Versus Conventional PTA for the Treatment of Hemodialysis AVF or AVG Stenoses |
Completed |
Stenosis of Arteriovenous Dialysis Fistula|Arteriovenous Graft Stenosis |
NCT01544907 |
| Taxoprexin Treatment for Advanced Skin Melanoma |
Completed |
Metastatic Melanoma |
NCT00249262 |
| Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial) |
Not yet recruiting |
Mammary Cancer |
NCT04301375 |
| Taxoprexin® Treatment for Advanced Eye Melanoma |
Completed |
Metastatic Melanoma |
NCT00244816 |
| Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC |
Recruiting |
Patients With Non-small Cell Lung Cancer |
NCT04182698 |
| Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer |
Unknown status |
Epithelial Ovarian Cancer |
NCT02022917 |
| Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT00295893 |
| Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer |
Unknown status |
Breast Cancer|Neoadjuvant Chemotherapy |
NCT02041338 |
| Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) |
Completed |
Breast Cancer |
NCT02688803 |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer |
NCT00003944 |
| Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT02125019 |
| EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease |
Completed |
Coronary Disease|Coronary Artery Disease|Coronary Artery Stenosis|Coronary Artery Restenosis |
NCT00531011 |
| A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors |
Completed |
Advanced Solid Tumors|Advanced Recurrent Ovarian Tumors |
NCT01248949 |
| Short-course HIPEC in Advanced Epithelial Ovarian Cancer |
Active, not recruiting |
Ovarian Cancer |
NCT02249013 |
| Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT01583322 |
| Neratinib HER Mutation Basket Study (SUMMIT) |
Recruiting |
Malignant Solid Tumor|Fibrolamellar Carcinoma |
NCT01953926 |
| Comparative Study of Different Neoadjuvant Therapies Before Radical Hysterectomy in Stage Ib2-IIa2 Cervical Cancer |
Completed |
Cervical Cancer |
NCT03243825 |
| Treatment of Head & Neck Cancer With Chemotherapy and Radiation |
Completed |
Head and Neck Cancer |
NCT00392704 |
| Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium |
Completed |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer |
NCT00003376 |
| Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients |
Recruiting |
Esophageal Cancer |
NCT03731442 |
| Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer |
Not yet recruiting |
Ovarian Cancer|Intraperitoneal Chemotherapy |
NCT04282356 |
| Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer |
Recruiting |
Locally Advanced and Metastatic Pancreatic Cancer |
NCT04324307 |
| Thunder Trial - Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries |
Unknown status |
Arterial Occlusive Diseases |
NCT00156624 |
| Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients |
Recruiting |
Breast Cancer |
NCT02910219 |
| Selective Dose Escalation for Esophageal Cancer |
Unknown status |
Esophageal Cancer |
NCT00139633 |
| Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes |
Completed |
Breast Cancer |
NCT00004125 |
| Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT00003927 |
| A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors |
Active, not recruiting |
Solid Tumor |
NCT02715531 |
| Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer |
Completed |
Breast Cancer |
NCT00004092 |
| Combination Chemotherapy in Treating Patients With Bladder Cancer |
Completed |
Bladder Cancer|Urethral Cancer |
NCT00003701 |
| Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) |
Recruiting |
Carcinoma, Non-Small-Cell Lung|Metastatic Lung Cancer|Non Small Cell Lung Cancer|Lung Adenocarcinoma Metastatic|Large Cell Lung Carcinoma Metastatic |
NCT03345810 |
| Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy |
Completed |
Prostate Cancer |
NCT00005847 |
| Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca. |
Completed |
Breast Cancer |
NCT02472964 |
| Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer |
Terminated |
Endometrial Cancer |
NCT00016341 |
| Pancreatic Locally Advanced Irresectable Cancer Ablation |
Recruiting |
Locally Advanced Pancreatic Cancer |
NCT03690323 |
| Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer |
Completed |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter |
NCT00003105 |
| Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer |
Recruiting |
Gastric Cancer|Esophageal Cancer|GastroEsophageal Cancer |
NCT03044613 |
| Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test |
Completed |
Plaque Psoriasis |
NCT03004339 |
| E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck |
Unknown status |
Head and Neck Neoplasms |
NCT02630264 |
| Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT00580333 |
| Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer |
Unknown status |
Breast Cancer |
NCT00820690 |
| BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial |
Active, not recruiting |
Metastatic Pancreatic Cancer |
NCT02080221 |
| Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC |
Recruiting |
Lung Cancer|Non Small Cell Lung Cancer|Advanced Cancer|Metastatic Lung Cancer|Squamous Cell Lung Cancer|Non-Squamous Non-Small Cell Neoplasm of Lung |
NCT03177291 |
| Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) |
Not yet recruiting |
PD-L1 Positive Non-small Cell Lung Cancer |
NCT04203485 |
| A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer |
Not yet recruiting |
Cancer - Ovarian |
NCT03400306 |
| HIPEC in the Treatment of Stage IIc-IV Epithelial Ovarian Cancer After CRS (HIPECOC) |
Not yet recruiting |
Ovarian Cancer|Hyperthermic Intraperitoneal Chemotherapy |
NCT04280185 |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) |
Active, not recruiting |
Triple Negative Breast Cancer (TNBC) |
NCT02819518 |
| High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer |
Unknown status |
Lung Cancer |
NCT00003284 |
| Adjuvant CCRT vs CT in Minimal N2 NSCLC |
Unknown status |
Non-small Cell Lung Cancer |
NCT01066234 |
| GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma |
Completed |
Melanoma |
NCT01245062 |
| Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) |
Active, not recruiting |
Solid Tumor|Non-small Cell Lung Cancer|Small Cell Lung Cancer |
NCT01840579 |
| A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT01491737 |
| Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma |
Active, not recruiting |
Esophageal Cancer |
NCT02850991 |
| Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer |
Suspended |
Endometrial Cancer|Uterine Cancer |
NCT03694834 |
| Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) |
Recruiting |
Locally Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm |
NCT03907475 |
| Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla |
Terminated |
Ductal Adenocarcinoma of Pancreas|Adenocarcinoma of Ampulla |
NCT02626520 |
| Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy |
Unknown status |
Prostate Cancer |
NCT00009750 |
| Meta-analysis of Efficacy of Topotecan |
Completed |
Cervical Intraepithelial Neoplasia |
NCT01160185 |
| Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors |
Unknown status |
Head and Neck Neoplasms |
NCT02283489 |
| Chemotherapy Plus Surgery in Treating Women With Breast Cancer |
Completed |
Breast Cancer |
NCT00003013 |
| A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies |
Recruiting |
TNBC - Triple-Negative Breast Cancer|Ovarian Cancer |
NCT03719326 |
| A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT00773695 |
| Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors |
Completed |
Malignant Disease |
NCT00881166 |
| Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy |
Recruiting |
Breast Cancer|Breast Neoplasms |
NCT03393741 |
| Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC) |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT00061646 |
| Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer |
Completed |
Breast Cancer |
NCT02365805 |
| Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT02083679 |
| Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer |
Active, not recruiting |
Stage I Ovarian Cancer AJCC v6 and v7|Stage IA Fallopian Tube Cancer AJCC v6 and v7|Stage IB Fallopian Tube Cancer AJCC v6 and v7|Stage IC Fallopian Tube Cancer AJCC v6 and v7|Stage II Ovarian Cancer AJCC v6 and v7|Stage IIA Fallopian Tube Cancer AJCC v6 and v7|Stage IIB Fallopian Tube Cancer AJCC v6 and v7|Stage IIC Fallopian Tube Cancer AJCC v6 and v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Primary Peritoneal Cancer AJCC v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7 |
NCT01366183 |
| Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC |
Not yet recruiting |
Staging IV NSCLC |
NCT04094909 |
| Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00637897 |
| Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma |
Completed |
Esophageal Neoplasms |
NCT02429622 |
| MK-3475 Immunotherapy in Endometrial Carcinoma |
Active, not recruiting |
Endometrial Cancer|Endometrial Carcinoma|Neoplasms, Endometrial |
NCT02630823 |
| Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients _MITO-23 |
Recruiting |
Ovarian Neoplasms |
NCT02903004 |
| Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer |
Recruiting |
Esophageal Neoplasms|Squamous Cell Carcinoma|Concurrent Chemoradiotherapy |
NCT03579004 |
| Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer |
Unknown status |
Cervical Cancer |
NCT02039791 |
| A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol |
Recruiting |
Breast Cancer |
NCT01817452 |
| Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer |
Not yet recruiting |
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Recurrent Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Unresectable Lung Non-Squamous Non-Small Cell Carcinoma |
NCT04310007 |
| PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer . |
Not yet recruiting |
Ovarian Cancer Stage IV |
NCT03275506 |
| Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) |
Completed |
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma|Gastric Cancer Third Line |
NCT02625623 |
| Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer |
Terminated |
Adenocarcinoma of the Lung|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer |
NCT00042835 |
| Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer |
Not yet recruiting |
Metastatic Triple Negative Breast Cancer|Safety Issues|Efficacy |
NCT03577743 |
| A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy. |
Completed |
Breast Cancer |
NCT00063102 |
| Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00294762 |
| Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms |
Recruiting |
Pancreatic Mucinous-Cystic Neoplasm |
NCT03188991 |
| Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck |
Unknown status |
Head and Neck Cancer |
NCT01133678 |
| Outcome of Second Generation Drug-eLuting Stents in Patients With Diabetes Mellitus |
Withdrawn |
Coronary Artery Disease|Diabetes Mellitus |
NCT01293773 |
| Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT03367182 |
| Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer |
Unknown status |
Breast Cancer |
NCT02934828 |
| Study of Endostar Combined With TP Regimen for Esophageal Cancer |
Recruiting |
Patients With Esophageal Cancer(â…ˇ-â…˘) |
NCT04164797 |
| Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00315185 |
| A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation |
Recruiting |
Gastric Cancer|Stomach Cancer |
NCT04308837 |
| Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants |
Completed |
Ovarian Cancer |
NCT00228319 |
| HOT: HIPEC in Ovarian Cancer as Initial Treatment |
Recruiting |
Stage III Ovarian Cancer|Stage IV Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|Ovarian Carcinoma|Fallopian Tube Carcinoma |
NCT02124421 |
| TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance Program |
Completed |
Coronary Artery Disease |
NCT00569491 |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors |
Recruiting |
Solid Tumor|Colon Cancer|Cholangiocarcinoma|Bladder Cancer|Ovarian Cancer|Gastric Cancer|Palpable Subcutaneous Malignant Lesions |
NCT03872947 |
| Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer |
Terminated |
Stage III Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Non-Small Cell Lung Cancer AJCC v7 |
NCT01822496 |
| International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) |
Recruiting |
Squamous Cell Carcinoma of the Penis, Usual Type |
NCT02305654 |
| Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer |
Active, not recruiting |
Ductal Adenocarcinoma of the Pancreas |
NCT02125136 |
| Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC |
Completed |
Non Small Cell Lung Cancer |
NCT01783197 |
| Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery |
Recruiting |
Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Esophageal Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 |
NCT03604991 |
| Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast Cancer |
Completed |
Breast Cancer |
NCT03221881 |
| MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease |
Not yet recruiting |
Pancreatic Cancer |
NCT04089150 |
| Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases |
Not yet recruiting |
Malignant Tumor of Pancreas Metastatic to Liver |
NCT04037241 |
| Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer |
Completed |
Breast Cancer|Stage IV Breast Cancer |
NCT00146549 |
| Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer |
Completed |
Endometrial Cancer |
NCT00006027 |
| Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients |
Completed |
Recurrent Platinum Resistant Ovarian Cancer |
NCT02028117 |
| Induction Chemotherapy for Locally Advanced Esophageal Cancer |
Recruiting |
Esophageal Carcinoma |
NCT03110926 |
| Study of Predictive Factors of Chemoresistance in Ovarian Cancer |
Unknown status |
Ovarian Cancer |
NCT02878122 |
| Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer |
Terminated |
Head and Neck Cancer|Carcinoma, Squamous Cell |
NCT00448240 |
| Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer |
Unknown status |
Non Small Cell Lung Cancer |
NCT02568033 |
| Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal DoxorubicinďĽPLD) |
Recruiting |
Early Breast Cancer |
NCT03949634 |
| Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma |
Recruiting |
Esophageal Squamous Cell Carcinoma |
NCT03748134 |
| Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions |
Recruiting |
Stenosis|Occlusion|Restenosis |
NCT03332264 |
| Induction FLOT With CROSS CRT for Esophageal Cancer |
Recruiting |
Adenocarcinoma Esophagus|Adenocarcinoma of the Gastroesophageal Junction |
NCT04028167 |
| Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer |
Completed |
Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer |
NCT01959490 |
| Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC) |
Completed |
Non Small Cell Lung Cancer |
NCT01099124 |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression |
Recruiting |
Epithelial Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer |
NCT04209855 |
| Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery |
Unknown status |
Breast Cancer |
NCT01147016 |
| PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy |
Active, not recruiting |
Adenocarcinoma of the Gastroesophageal Junction|Esophageal Cancer |
NCT01333033 |
| A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer |
Unknown status |
Non-small Cell Lung Cancer |
NCT02734524 |
| POISE I Pilot Study |
Recruiting |
Intestinal Stricture |
NCT03886324 |
| A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D) |
Recruiting |
Ovarian Cancer Stage IIIC|Ovarian Cancer Stage IV |
NCT03899610 |
| An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma |
Terminated |
Gastric Cancer|Cancer of the Stomach|Stomach Cancer|Gastroesophageal Junction |
NCT03704077 |
| Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer |
Recruiting |
Cervical Cancer |
NCT03367871 |
| A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer |
Completed |
Previously Untreated Resectable Adenocarcinoma of the Pancreas |
NCT02030860 |
| QUILT-3.088: NANT Pancreatic Cancer Vaccine |
Withdrawn |
Metastatic Pancreatic Cancer |
NCT03563144 |
| Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research |
Unknown status |
Non-small Cell Lung Cancer |
NCT02513355 |
| Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02 |
Recruiting |
Esophageal Neoplasms |
NCT03308552 |
| Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric Cancer |
Active, not recruiting |
Stage IV Gastric Cancer With Metastasis |
NCT03237507 |
| Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols |
Enrolling by invitation |
Oncology |
NCT04299880 |
| A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) |
Recruiting |
Non-Small-Cell Lung |
NCT03456063 |
| First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer |
Completed |
Bulky Stage IIIC and IV Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma |
NCT01669226 |
| Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer |
Not yet recruiting |
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma |
NCT03180177 |
| CPG 7909 Injection in Non-Small Cell Lung Cancer |
Completed |
Carcinoma, Non-Small Cell Lung |
NCT00070629 |
| Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer |
Terminated |
Ovarian Neoplasms |
NCT00718523 |
| Drug-Eluting Balloon Angioplasty for the Treatment of Hemodialysis Vascular Access Stenosis (DEBAVAS) |
Unknown status |
Dysfunction of Hemodialysis Vascular Access (Fistula and Graft) |
NCT02408822 |
| Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3 |
Terminated |
Non-small Cell Lung Cancer |
NCT00273507 |
| Optimal Stenting Strategy For True Bifurcation Lesions |
Completed |
Coronary Artery Disease |
NCT00693251 |
| Choice Of Optimal Strategy For Bifurcation Lesions With Normal Side Branch |
Completed |
Coronary Artery Disease |
NCT00694005 |
| Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo |
Recruiting |
Triple Negative Breast Cancer |
NCT03281954 |
| A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) |
Active, not recruiting |
Ureteral Cancer|Urothelial Cancer|Bladder Cancer |
NCT03474107 |
| Intra-peritoneal Chemotherapy in Ovarian Cancer |
Unknown status |
Ovarian Neoplasms|Immune Tolerance|Neoplasms|Effects of Chemotherapy |
NCT02861872 |
| A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer |
Recruiting |
Non-squamous Non-small Cell Lung Cancer |
NCT03329911 |
| Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy |
Active, not recruiting |
Locally Advanced Malignant Neoplasm|Breast Cancer |
NCT01847001 |
| Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer |
Active, not recruiting |
Non Small Cell Lung Cancer (Squamous or Non Squamous) |
NCT01850303 |
| EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas |
Completed |
Adenocarcinoma|Metastasis|Pancreas Neoplasms |
NCT00377936 |
| Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer |
Completed |
Recurrent or Metastatic Gastric Cancer |
NCT01283204 |
| A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors |
Active, not recruiting |
Advanced Solid Neoplasm |
NCT03330106 |
| Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis (AFU-GETUG 25) |
Recruiting |
Penile Cancer|Squamous Carcinoma |
NCT02817958 |
| A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625) |
Completed |
Ovarian Neoplasms |
NCT00780039 |
| Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer |
Unknown status |
Lung, Carcinoma |
NCT02139579 |
| Direct Stenting of TAXUS Liberté™-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions |
Completed |
Coronary Artery Disease |
NCT00371423 |
| Chemoradiotherapy of NSCLC Stage IIIB |
Completed |
NSCLC Stage IIIB|Concomitant Radiochemotherapy |
NCT00198432 |
| A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies |
Terminated |
Solid Tumor Malignancies |
NCT01290380 |
| Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis |
Completed |
Gastrointestinal Neoplasm |
NCT00052962 |
| A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer |
Unknown status |
Non-small Cell Lung Cancer (NSCLC) |
NCT02662634 |
| Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Tumor|Ovarian Seromucinous Carcinoma|Ovarian Serous Tumor|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Primary Peritoneal Carcinoma |
NCT02446600 |
| Comparison of Different Subsequent Treatments After Radical Surgery |
Active, not recruiting |
Cervical Cancer |
NCT00806117 |
| Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer |
Not yet recruiting |
Ovarian Cancer |
NCT03539328 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer |
Recruiting |
Fallopian Tube Transitional Cell Carcinoma|Malignant Ovarian Clear Cell Tumor|Malignant Ovarian Endometrioid Tumor|Malignant Ovarian Serous Tumor|Ovarian Seromucinous Carcinoma|Ovarian Transitional Cell Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Fallopian Tube Carcinoma|Undifferentiated Ovarian Carcinoma |
NCT02364713 |
| Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT00667251 |
| Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC |
Unknown status |
Melanoma |
NCT00779714 |
| Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer |
Active, not recruiting |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer|Ovarian Diseases|Fallopian Tube Diseases|Peritoneal Diseases |
NCT02973750 |
| Study of the Glutaminase Inhibitor CB-839 in Solid Tumors |
Completed |
Solid Tumors|Triple-Negative Breast Cancer|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Mesothelioma|Fumarate Hydratase (FH)-Deficient Tumors|Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)|Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors|Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations|Tumors Harboring Amplifications in the cMyc Gene |
NCT02071862 |
| Safety and Efficacy Registry of Yinyi Stent (SERY-II) |
Unknown status |
Coronary Artery Disease |
NCT01373658 |
| Safety and Efficacy Registry of Yinyi Stent |
Completed |
Coronary Artery Disease |
NCT01373645 |
| A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors |
Completed |
Advanced Solid Tumors, Neoplasms, Advanced Solid |
NCT03057366 |
| A Phase II Trial of Genexol-PM and Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT01770795 |
| Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) |
Terminated |
Advanced Cancer|Breast Cancer|Sarcoma|Pancreatic Cancer|Small Cell Lung Cancer|Ovarian |
NCT02331251 |
| The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL |
Recruiting |
CIPN - Chemotherapy-Induced Peripheral Neuropathy |
NCT03873272 |
| Biomarker-Integrated Umbrella, Advanced Gastric Cancer |
Recruiting |
Gastric Cancer |
NCT02951091 |
| Chemotherapeutic Agents in Brain/Breast |
Completed |
Breast Cancer|Metastatic Cancer |
NCT00795678 |
| Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer |
Unknown status |
Esophageal Neoplasms |
NCT03254511 |
| Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients |
Recruiting |
Breast Cancer|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III |
NCT04180579 |
| Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer |
Completed |
Adenocarcinoma |
NCT00140075 |
| Lutonix or Inpact for tHE tReatment Of fEmeropopliteal Stenosis - DCB |
Unknown status |
Peripheral Arterial Disease |
NCT02812966 |
| The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients |
Recruiting |
Ovarian Cancer |
NCT03019315 |
| Zilver PTX Post-Market Study in Japan |
Completed |
Peripheral Arterial Disease (PAD) |
NCT02254837 |
| Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC |
Completed |
Non Small Cell Lung Cancer (NSCLC) |
NCT00492206 |
| A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN) |
Completed |
Breast Cancer |
NCT00196872 |
| Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery |
Recruiting |
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma |
NCT03373058 |
| Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer |
Unknown status |
Breast Cancer |
NCT02842099 |
| Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca |
Recruiting |
Breast Adenocarcinoma|Estrogen Receptor- Negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2/Neu Negative|Invasive Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive Tumor|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Triple-negative Breast Carcinoma |
NCT02957968 |
| Sirolimus Coated Angioplasty Balloon in the Salvage of Thrombosed Arteriovenous Graft |
Completed |
End Stage Renal Failure on Dialysis|Arteriovenous Graft Occlusion |
NCT03666208 |
| ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT01779206 |
| Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE) |
Not yet recruiting |
Stage III NSCLC |
NCT03945227 |
| A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer |
Active, not recruiting |
HER2-positive Locally Advanced or Metastatic Breast Cancer |
NCT02514681 |
| ANG1005 in Leptomeningeal Disease From Breast Cancer |
Not yet recruiting |
Leptomeningeal Carcinomatosis|Leptomeningeal Metastases|Brain Metastases|HER2-negative Breast Cancer |
NCT03613181 |
| Yonsei OCT (Optical Coherence Tomography) Registry for Evaluation of Efficacy and Safety of Coronary Stenting |
Recruiting |
Coronary Artery Disease|Ischemic Heart Disease |
NCT02099162 |
| Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy |
Not yet recruiting |
Nonsmall Cell Lung Cancer|Performance Status |
NCT04253964 |
| Stellarex DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries |
Recruiting |
Critical Limb Ischemia |
NCT03175744 |
| Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) |
Withdrawn |
Squamous Cell Carcinoma of the Penis |
NCT02014831 |
| Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00550537 |
| Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer |
Completed |
Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Breast Cancer Female NOS|Invasive Ductal Breast Cancer|Tubular Breast Cancer Stage III|HER-2 Positive Breast Cancer|Inflammatory Breast Cancer Stage IV|Inflammatory Breast Cancer |
NCT01426880 |
| DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer |
Completed |
Breast Cancer |
NCT02838225 |
| High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II |
Completed |
Testicular Neoplasms |
NCT00231582 |
| Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer |
Not yet recruiting |
Advanced Ovarian Cancer |
NCT03611179 |
| A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer |
Terminated |
Non Small Cell Lung Cancer |
NCT02117024 |
| Androgen Deprivation Therapy in Advanced Salivary Gland Cancer |
Recruiting |
Salivary Gland Cancer |
NCT01969578 |
| A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer |
Recruiting |
Pancreatic Cancer |
NCT03519308 |
| Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC) |
Terminated |
Non Small Cell Lung Cancer |
NCT01108666 |
| Efficacy of Rotational Atherectomy System Associated With Drug Coated Balloon Angioplasty in Limb Ischemia |
Not yet recruiting |
Peripheral Vascular Diseases |
NCT04276311 |
| BIOLUX P-III SPAIN All-Comers Registry |
Unknown status |
Peripheral Arterial Disease |
NCT03052296 |
| BIOLUX P-III BENELUX All-Comers Registry |
Unknown status |
Peripheral Arterial Disease |
NCT03052309 |
| Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Non-small Cell Lung Cancer |
NCT00198367 |
| Advance® 18PTX® Balloon Catheter Study |
Completed |
Peripheral Arterial Disease |
NCT00776906 |
| D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain |
Terminated |
Neurotoxicity|Pain|Breast Cancer |
NCT00301080 |
| Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00003696 |
| Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies |
Active, not recruiting |
Advanced Solid Malignancies |
NCT02398747 |
| BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery |
Active, not recruiting |
Lung Cancer |
NCT00828009 |
| Gene Therapy in Treating Patients With Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00003588 |
| Curative Study of Chinese Traditional Medicine to Treat Lung Cancer |
Unknown status |
Cancer |
NCT02777788 |
| Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer |
Recruiting |
Breast Cancer |
NCT03839823 |
| Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients |
Unknown status |
Metastatic Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast |
NCT02175446 |
| Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System |
Completed |
Peripheral Arterial Disease|Intermittent Claudication|Vascular Diseases|Cardiovascular Diseases |
NCT02097082 |
| OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 |
Completed |
Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms |
NCT00112086 |
| Phase I/IIa Study of Pharmacokinetics and Safety of Epidiferphane™ and Taxanes in Breast Cancer Patients |
Withdrawn |
Breast Cancer |
NCT03611985 |
| AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00976911 |
| Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial |
Completed |
Hypertension|Coronary Artery Disease |
NCT00139386 |
| Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer |
Completed |
Prostate Cancer|Thromboembolism |
NCT00014352 |
| Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer |
Terminated |
Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00004037 |
| Diffuse Type In-Stent Restenosis After Drug-Eluting Stent |
Completed |
In-stent Restenosis |
NCT00485030 |
| Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck |
Completed |
Squamous Cell Carcinoma of the Head and Neck |
NCT00513383 |
| IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA) |
Completed |
Femoral Artery Stenosis|Popliteal Artery Stenosis|Femoral Artery Occlusion|Popliteal Artery Occlusion |
NCT01566461 |
| The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma |
Recruiting |
Endometrial Neoplasms |
NCT01820858 |
| Drug-eluting Balloon in Bifurcations Trial |
Completed |
Coronary Artery Disease|Atherosclerosis|Stable Angina|Unstable Angina |
NCT00857441 |
| A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors |
Active, not recruiting |
Advanced Solid Neoplasm |
NCT03486314 |
| Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma |
Unknown status |
Lung Adenocarcinoma |
NCT02621333 |
| Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy |
Completed |
Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer |
NCT00025155 |
| Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00043108 |
| A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). |
Recruiting |
Metastatic Breast Cancer |
NCT03355157 |
| AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07) |
Completed |
Colorectal Cancer|Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00107250 |
| Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00025480 |
| BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer |
Completed |
Ovarian Neoplasms |
NCT01121406 |
| Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer. |
Withdrawn |
Esophageal Cancer |
NCT02598687 |
| Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Dysphagia|Non-Small Cell Lung Cancer|Lung Cancer |
NCT00094861 |
| A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer |
Completed |
Lung Cancer |
NCT00047736 |
| ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00014690 |
| Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer |
Completed |
Prostate Cancer |
NCT00027859 |
| The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer |
Unknown status |
Advanced Gastric Cancer |
NCT02038621 |
| PREventing CHemotherapy Induced Neuropathy (PreChIN) |
Completed |
Chemotherapy-induced Peripheral Neuropathy (CIPN) |
NCT03299582 |
| Optical Coherence Tomography in Long Lesions |
Unknown status |
Coronary Artery Disease |
NCT01133925 |
| Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer |
Recruiting |
Recurrent Ovarian Cancer |
NCT03632798 |
| HIPEC, Intravenous Chemotherapy and Surgery for the Treatment of Advanced GC With Peritoneal Metastasis |
Unknown status |
Gastric Cancer |
NCT02549911 |
| Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years |
Completed |
Breast Cancer |
NCT00563953 |
| IN.PACT Global Clinical Study |
Active, not recruiting |
Peripheral Arterial Disease |
NCT01609296 |
| Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: |
Recruiting |
Luminal B |
NCT03875573 |
| PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer |
Active, not recruiting |
Epithelial Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer|Ovarian Cancer |
NCT02631876 |
| A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer |
Not yet recruiting |
Stage III Non-small-cell Lung Cancer |
NCT04181372 |
| Multicentric Randomised Trial for Resectable Gastric Cancer |
Recruiting |
Gastric Cancer |
NCT02931890 |
| Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer |
Completed |
Non-Small-Cell Lung Carcinoma |
NCT00112294 |
| 9-ING-41 in Patients With Advanced Cancers |
Recruiting |
Cancer|Lymphoma|Pancreatic Cancer|Glioblastoma Multiforme|Sarcoma|Breast Cancer|Bladder Cancer|Renal Cancer|Ovarian Cancer|Refractory Cancer|Refractory Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Brain Tumor|Pancreatic Adenocarcinoma|Resistant Cancer|Neoplasm Metastasis|Neoplasm of Bone|Neoplasm, Breast|Neoplasm of Lung|Neoplasms,Colorectal|Neoplasms Pancreatic|Malignant Glioma|Malignancies|Malignancies Multiple|Bone Metastases|Bone Neoplasm|Bone Cancer|Pancreas Cancer|Pancreatic Neoplasms|Breast Neoplasms |
NCT03678883 |
| MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy |
Recruiting |
Esophagus Cancer|Esophagogastric Junction Cancer |
NCT02988921 |
| PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer |
Not yet recruiting |
Advanced Gastric Adenocarcinoma |
NCT04174339 |
| Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy |
Recruiting |
Ovarian Cancer |
NCT04163094 |
| Arteriovenous Fistulae: Drug-eluting Balloon Angioplasty |
Recruiting |
Stenosis of Arteriovenous Dialysis Fistula |
NCT02913274 |
| A Phase II Trial of Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma |
Active, not recruiting |
Esophageal Squamous Cell Carcinoma |
NCT02844075 |
| A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer |
Active, not recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT02492867 |
| Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy |
Recruiting |
Head and Neck Cancer |
NCT03769506 |
| An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION) |
Recruiting |
Platinum-resistant Recurrent Ovarian Cancer |
NCT03699449 |
| Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer |
Terminated |
Breast Cancer |
NCT00542191 |
| Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT01547741 |
| Saint Joseph |
United States|Saint Louis Cancer and Breast Institute-South City |
Missouri |
United States|Saint Joseph Oncology Inc |
| Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) |
Recruiting |
Breast Cancer |
NCT03725059 |
| Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer |
Completed |
Breast Cancer |
NCT00002679 |
| Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma |
Active, not recruiting |
Carcinoma, Transitional Cell |
NCT03410693 |
| Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC |
Recruiting |
Potentially Resectable Stage II/IIIa NSCLC |
NCT03694236 |
| The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts |
Completed |
Mucinous Pancreatic Cysts |
NCT01475331 |
| Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells |
Active, not recruiting |
Breast Neoplasms |
NCT01779050 |
| A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis |
Recruiting |
Gastric Cancer With Peritoneal Metastasis (PCI<12) |
NCT02995850 |
| A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib |
Recruiting |
Carcinoma, Hepatocellular |
NCT03008512 |
| Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY) |
Recruiting |
Chemotherapy-induced Peripheral Neuropathy |
NCT03997981 |
| A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols |
Completed |
Solid Tumors |
NCT01369433 |
| Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer |
Recruiting |
Breast Cancer|Breast Neoplasms|HER2-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer |
NCT03556358 |
| Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy |
Completed |
Lung Cancer |
NCT00738452 |
| Hypofractionated Radiation Therapy Combined With Concurrent Chemotherapy for Patients With Non-small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT02720614 |
| Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer |
Not yet recruiting |
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma |
NCT04274426 |
| Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer |
Not yet recruiting |
Locally Advanced Pancreatic Cancer|Irreversible Electroporation |
NCT04276857 |
| A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer |
Withdrawn |
Neoplasms, Breast |
NCT01137994 |
| A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma |
Recruiting |
Esophageal Squamous Cell Carcinoma (ESCC) |
NCT03783442 |
| PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer |
Terminated |
Breast Cancer |
NCT02067416 |
| Study on Early Stage Bulky Cervical Cancers |
Unknown status |
Carcinoma Cervix |
NCT01917695 |
| Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer |
Recruiting |
Recurrent Ovarian Carcinoma|Platinum-resistant Ovarian Cancer |
NCT03949283 |
| Fasting on Newly Diagnosed Breast Cancer |
Terminated |
HER2-positive Breast Cancer |
NCT02379585 |
| Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer |
Not yet recruiting |
Cancer Metastatic |
NCT04158362 |
| A Study of Toripalimab or Placebo Plus Chemotherapy as Treatment in Early Stage NSCLC |
Not yet recruiting |
Stage IIIA Non-small Cell Lung Cancer |
NCT04158440 |
| Neoadjuvant Carboplatin in Triple Negative Breast Cancer |
Recruiting |
BRCA1 Hereditary Breast and Ovarian Cancer Syndrome |
NCT02978495 |
| A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer |
Active, not recruiting |
Low-grade Serous Ovarian Cancer|Low-grade Serous Fallopian Tube Cancer|Low-grade Serous Peritoneal Cancer |
NCT01849874 |
| A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799). |
Recruiting |
Non-small Cell Lung Cancer |
NCT03631784 |
| Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC |
Recruiting |
Non-small Cell Lung Cancer|Stage IV|Oligometastasis |
NCT03965468 |
| Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly Patients With Advanced Non-small Cell Lung Cancer |
Not yet recruiting |
Advanced Non Small Cell Lung Cancer |
NCT03351361 |
| High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer |
Completed |
Cancer |
NCT00002854 |
| Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma |
Completed |
Multiple Myeloma and Plasma Cell Neoplasm |
NCT00003399 |
| Management of Symptomatic Advanced Pancreatic Adenocarcinoma |
Recruiting |
Pancreas|Management Supportive Care Program |
NCT02979483 |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) |
Active, not recruiting |
Triple Negative Breast Neoplasms |
NCT03036488 |
| PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma |
Recruiting |
Neoplasm, Esophageal|Squamous Cell Carcinoma |
NCT03791905 |
| Drug Eluting Balloon in Peripheral Intervention for In-Stent Restenosis |
Suspended |
Peripheral Arterial Disease |
NCT01558531 |
| A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) |
Active, not recruiting |
Non-small Cell Lung Carcinoma |
NCT02039674 |
| A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors |
Completed |
Cancer |
NCT01204996 |
| Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer |
Terminated |
Breast Neoplasms|Metastases, Neoplasm |
NCT00048893 |
| Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma |
Completed |
Multiple Myeloma and Plasma Cell Neoplasm |
NCT00003401 |
| Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies |
Withdrawn |
Cancer |
NCT00666081 |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study |
Not yet recruiting |
Lung Non-Small Cell Carcinoma|Stage IB Lung Cancer AJCC v7|Stage II Lung Cancer AJCC v7|Stage IIA Lung Cancer AJCC v7|Stage IIB Lung Cancer AJCC v7|Stage IIIA Lung Cancer AJCC v7 |
NCT04267848 |
| Vaccine Therapy With Either Neoadjuvant or Adjuvant Chemotherapy and Adjuvant Radiation Therapy in Treating Women With p53-Overexpressing Stage III Breast Cancer |
Completed |
Breast Cancer |
NCT00082641 |
| Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors |
Completed |
Advanced Solid Tumors |
NCT02122770 |
| Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia |
Completed |
Leukemia|Lymphoma |
NCT00003402 |
| Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery |
Completed |
Lung Cancer |
NCT00091039 |
| NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Cervical Cancer FIGO Stage IB2 and IIB |
Not yet recruiting |
Cervical Cancer |
NCT02422563 |
| Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer |
Recruiting |
Recurrent Ovarian Carcinoma |
NCT03353831 |
| M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) |
Recruiting |
Non-small Cell Lung Cancer |
NCT03840902 |
| Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers |
Recruiting |
Colorectal Cancer|Gastroesophageal Cancer|Renal Cell Carcinoma |
NCT03798626 |
| Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer |
Active, not recruiting |
Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7 |
NCT01507428 |
| Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal Carcinoma |
Recruiting |
Esophageal Neoplasms|Esophageal Cancer |
NCT02279134 |
| Optimized Intensity Modulated Irradiation for Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00580983 |
| Drug Eluting Balloons PTA in Infra-popliteal Arteries in Patients With Critical Limb Ischemia |
Unknown status |
Critical Limb Ischemia |
NCT02498080 |
| A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer |
Recruiting |
Non-Small Cell Lung Cancer |
NCT03800134 |
| A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors |
Recruiting |
Biliary Tract Cancer (BTC)|Colorectal Cancer (CRC)|Endometrial Cancer|Gastroesophageal Cancer (GC)|Ovarian Cancer|Solid Tumors |
NCT03314935 |
| The BEACON Study (Breast Cancer Outcomes With NKTR-102) |
Completed |
Locally Recurrent Breast Cancer|Metastatic Breast Cancer |
NCT01492101 |
| An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) |
Recruiting |
Squamous-Cell Lung Cancer |
NCT03823625 |
| A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab |
Completed |
Non-Small Cell Lung Cancer |
NCT00508625 |
| A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies |
Recruiting |
Neoplasm Metastasis |
NCT00781612 |
| Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) |
Recruiting |
Carcinoma，Non-Small-Cell Lung|Lung Carcinomas, Non-Small-Cell|Non-small-cell Lung Carcinoma|Nonsmall Cell Lung Cancer |
NCT03088540 |
| Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer |
Completed |
Non Small Cell Lung Carcinoma |
NCT00199758 |
| Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium |
Recruiting |
Ovarian Clear Cell Carcinoma|Endometrial Clear Cell Carcinoma |
NCT02866370 |
| Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer |
Recruiting |
Quality of Life|Ovarian Cancer|Recurrent Ovarian Carcinoma |
NCT03164980 |
| Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer |
Withdrawn |
Breast Cancer |
NCT00022230 |
| Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention |
Completed |
Coronary Artery Disease |
NCT00611286 |
| A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion |
Unknown status |
Atherosclerosis|Coronary Artery Disease |
NCT01285999 |
| Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx |
Terminated |
Drug/Agent Toxicity by Tissue/Organ|Head and Neck Cancer|Oral Complications|Radiation Toxicity |
NCT00025298 |
| A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain |
Terminated |
Breast Cancer |
NCT00476827 |
| Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery |
Active, not recruiting |
Resectable Pancreatic Carcinoma|Stage I Pancreatic Cancer AJCC v6 and v7|Stage IA Pancreatic Cancer AJCC v6 and v7|Stage IB Pancreatic Cancer AJCC v6 and v7|Stage II Pancreatic Cancer AJCC v6 and v7|Stage IIA Pancreatic Cancer AJCC v6 and v7|Stage IIB Pancreatic Cancer AJCC v6 and v7 |
NCT02930902 |
| Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer |
Unknown status |
Recurrent Ovarian Cancer |
NCT01802749 |
| A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial |
Completed |
Advanced Solid Tumors |
NCT02057380 |
| A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors |
Active, not recruiting |
Melanoma|Prostate Cancer|Ovarian Cancer|Renal Cell Carcinoma|Colorectal Carcinoma|Pancreatic Carcinoma|Non-small Cell Lung Carcinoma|Solid Tumors|Breast Cancer |
NCT02009449 |
| A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT02004093 |
| TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers |
Recruiting |
Solid Tumor|Lymphoma |
NCT03884556 |
| Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib |
Not yet recruiting |
Ovarian Carcinosarcoma|Endometrial Carcinosarcoma |
NCT03651206 |
| A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT01358877 |
| SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations |
Unknown status |
NSCLC|SBRT|GM-CSF |
NCT02940990 |
| Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100) |
Active, not recruiting |
First Line Non-Small Cell Lung Cancer |
NCT02576574 |
| A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer |
Active, not recruiting |
Triple Negative Breast Cancer |
NCT02032277 |
| Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304) |
Not yet recruiting |
Metastatic Squamous Non-Small Cell Lung Cancer|Metastatic Nonsquamous Non-Small Cell Lung Cancer |
NCT04205812 |
| Zilver Flex Post-Market Study in Japan |
Completed |
Peripheral Arterial Disease (PAD) |
NCT02254356 |
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site |
Recruiting |
Cancer of Unknown Primary Site |
NCT03498521 |
| A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer |
Completed |
Breast Cancer |
NCT01964391 |
| Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] |
Recruiting |
Breast Cancer |
NCT03734029 |
| A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary Small Vessel Disease |
Active, not recruiting |
Coronary Small Vessel Disease |
NCT03376646 |
| Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery |
Completed |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer |
NCT00005838 |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients |
Recruiting |
Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer |
NCT02855944 |
| A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT03745222 |
| Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients |
Not yet recruiting |
Early Breast Cancer |
NCT04293393 |
| Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer |
Recruiting |
Ovarian Epithelial Cancer |
NCT02822157 |
| A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer |
Active, not recruiting |
Early Breast Cancer |
NCT03493854 |
| Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC |
Not yet recruiting |
Locally Advanced Non-small Cell Lung Cancer |
NCT04153734 |
| Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer |
Terminated |
Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer |
NCT00194792 |
| Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00876070 |
| GRN1005 for Brain Metastases From Breast or Lung Cancer |
Withdrawn |
Breast Cancer|Lung Neoplasms|Breast Neoplasms|Lung Cancer |
NCT01679743 |
| Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. |
Not yet recruiting |
Recurrent, Platinum-resistant Ovarian Cancer |
NCT03467178 |
| Effect of Rotablator on Balloon Resistant Calcified Coronary Lesion |
Completed |
Coronary Artery Disease |
NCT01887704 |
| Trial of ZW25 in Patients With Advanced HER2-expressing Cancers |
Recruiting |
HER2-expressing Cancers |
NCT02892123 |
| Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT02909751 |
| Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer |
Active, not recruiting |
Non-Small Cell Lung Cancer |
NCT03519971 |
| New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma |
Recruiting |
Hypopharyngeal Cancer |
NCT03558035 |
| Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer |
Active, not recruiting |
Oropharyngeal Squamous Cell Cancer |
NCT02784288 |
| A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer |
Withdrawn |
Cancer of Head and Neck |
NCT02013453 |
| Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer. |
Active, not recruiting |
Breast Cancer |
NCT03248427 |
| A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer |
Active, not recruiting |
Advanced Pancreatic Cancer |
NCT03336216 |
| Dose Escalation Study of SH U04722 in Solid Tumors |
Terminated |
Tumors |
NCT00375453 |
| An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) |
Active, not recruiting |
Stage IV or Recurrent Non-Small Cell Lung Cancer |
NCT02041533 |
| PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer |
Completed |
Breast Cancer |
NCT01973660 |
| A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors |
Recruiting |
Cancer|Advanced Solid Tumors|Triple-Negative Breast Cancer (TNBC)|Non-small-cell-lung-cancer (NSCLC)|Metastatic Solid Tumors |
NCT03893955 |
| Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation |
Withdrawn |
Hepatocellular Carcinoma |
NCT02580253 |
| Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects |
Active, not recruiting |
Non-small Cell Lung Cancer |
NCT03631199 |
| Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer |
Recruiting |
FIGO Stage IVA Ovarian Cancer|FIGO Stage IVB Ovarian Cancer|Platinum-Resistant Ovarian Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Carcinoma|Stage III Fallopian Tube Cancer AJCC v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Primary Peritoneal Cancer AJCC v7|Stage III Uterine Corpus Cancer AJCC v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7 |
NCT01970722 |
| A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours |
Unknown status |
Hepatocellular Carcinoma|Pancreatic Cancer |
NCT02423239 |
| Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 |
Active, not recruiting |
Breast Cancer|HER2 Positive |
NCT01996267 |
| Trial Comparing Niraparib-bevacizumab-TSR042 and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer |
Not yet recruiting |
Ovarian Cancer |
NCT03806049 |
| MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I |
Completed |
Breast Cancer |
NCT01501487 |
| QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL |
Withdrawn |
Non Hodgkin Lymphoma |
NCT03169790 |
| M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) |
Recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT03840915 |
| QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy |
Withdrawn |
Triple Negative Breast Cancer |
NCT03175666 |
| QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy |
Active, not recruiting |
Pancreatic Cancer |
NCT03329248 |
| QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy |
Withdrawn |
Urothelial Carcinoma |
NCT03197571 |
| QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy |
Active, not recruiting |
Pancreatic Cancer |
NCT03387098 |
| QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. |
Active, not recruiting |
Triple Negative Breast Cancer |
NCT03387085 |
| QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy |
Withdrawn |
Head and Neck Squamous Cell Carcinoma |
NCT03169764 |
| QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC |
Withdrawn |
Colorectal Cancer |
NCT03169777 |
| QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors |
Withdrawn |
Non-small Cell Lung Cancer |
NCT03169738 |
| QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed |
Active, not recruiting |
Squamous Cell Carcinoma |
NCT03387111 |
| TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma |
Recruiting |
Nasopharyngeal Carcinoma |
NCT03306121 |
| Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients |
Unknown status |
Malignant Hydrothorax|Non Small Cell Lung Cancer |
NCT02579564 |
| Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer |
Completed |
Breast Cancer |
NCT01180335 |
| QUILT-3.080: NANT Pancreatic Cancer Vaccine |
Active, not recruiting |
Pancreatic Cancer |
NCT03586869 |
| A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC |
Completed |
Solid Tumors |
NCT01957007 |
| Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy |
Completed |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms |
NCT00318370 |
| Preoperative Herceptin and Navelbine for Breast Cancer |
Completed |
Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer |
NCT00148681 |
| QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine |
Withdrawn |
Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent |
NCT03563170 |
| Drug Coated Balloon Compared to Bare Metal Stent for de Novo Coronary Artery Lesions |
Completed |
Stable Angina|Unstable Angina |
NCT02456402 |
| QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine |
Active, not recruiting |
Colorectal Cancer Metastatic|mCRC |
NCT03563157 |
| QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy |
Withdrawn |
Ovarian Cancer |
NCT03197584 |
| A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT01966471 |
| Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer |
Completed |
Breast Cancer |
NCT00965276 |
| Ovarian Clear Cell Adenocarcinoma Review |
Completed |
Ovarian Cysts |
NCT02129036 |
| Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy |
Recruiting |
Antineoplastic Combined Chemotherapy Protocols |
NCT02953184 |
| SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy |
Completed |
Thrombocytopaenia |
NCT00102726 |
| Safety and Tolerability Study in Solid Tumors |
Completed |
Tumors|Pancreatic Cancer|Non-small Cell Lung Cancer|Esophagogastric Cancer|Colorectal Cancer|Breast Cancer |
NCT01803282 |
| Gemcitabine as a Single Agent in the Maintenance Chemotherapy of Patients With Metastatic Breast Cancer |
Unknown status |
Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer|Gemcitabine|Maintenance Chemotherapy |
NCT02188693 |
| Molecular Triaging of Newly Diagnosed Breast Cancer |
Withdrawn |
Breast Cancer |
NCT01159236 |
| QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy |
Active, not recruiting |
Pancreatic Cancer |
NCT03136406 |
| Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma |
Completed |
Nasopharyngeal Carcinoma |
NCT01534585 |
| Adjuvant Palbociclib in Elderly Patients With Breast Cancer |
Recruiting |
Breast Cancer Stage II|Breast Cancer Stage III |
NCT03609047 |
| Study of Program Interest "Bouge" to Improve the Daily Physical Activity in Processings Treatment of Non-metastatic Breast Cancer |
Recruiting |
Physical Activity|Breast Cancer|Mobile Health Apps |
NCT03674515 |
| INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) |
Withdrawn |
Advanced and/or Metastatic Solid Tumors|Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer|Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma |
NCT03920839 |
| A Safety and Efficacy Study of Hemodialysis Arteriovenous Fistulae Stenosis Treated With DissolveAV |
Recruiting |
Fistulas Arteriovenous |
NCT04226599 |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer |
Recruiting |
Advanced Cancer|Metastatic Melanoma|Metastatic Non-small Cell Lung Cancer|Metastatic Pancreatic Ductal Adenocarcinoma|Colorectal Cancer |
NCT02857270 |
| Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
Active, not recruiting |
Metastatic Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer |
NCT02620865 |
| MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study |
Active, not recruiting |
Carcinoma|Metastatic Pancreatic Adenocarcinoma |
NCT03611556 |
| QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy |
Withdrawn |
Merkel Cell Carcinoma |
NCT03167164 |
| QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy |
Withdrawn |
Melanoma |
NCT03167177 |
| Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) |
Active, not recruiting |
Non-Small Cell Lung Carcinoma |
NCT02142738 |
| Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer |
Recruiting |
Pancreatic Neoplasms |
NCT03199144 |
| Spot Drug-Eluting Stenting for Long Coronary Stenoses |
Completed |
Angioplasty |
NCT00738556 |
| Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA) |
Recruiting |
Recurrent Ovarian Carcinoma |
NCT03598270 |
| Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer |
Active, not recruiting |
Locally Advanced Lung Cancer |
NCT03432598 |
| Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer |
Recruiting |
Testicular Cancer |
NCT02478502 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu |
Completed |
Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|Liver Metastases|Localized Unresectable Adult Primary Liver Cancer|Lung Metastases|Male Breast Cancer|Malignant Pericardial Effusion|Malignant Pleural Effusion|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Parathyroid Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Newly Diagnosed Carcinoma of Unknown Primary|Occult Non-small Cell Lung Cancer|Pancreatic Polypeptide Tumor|Primary Peritoneal Cavity Cancer|Proximal Urethral Cancer|Pulmonary Carcinoid Tumor|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adrenocortical Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Carcinoma of Unknown Primary|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Parathyroid Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Thyroid Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Skin Metastases|Small Intestine Adenocarcinoma|Somatostatinoma|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Adrenocortical Carcinoma|Stage III Bladder Cancer|Stage III Cervical Cancer|Stage III Colon Cancer|Stage III Endometrial Carcinoma|Stage III Esophageal Cancer|Stage III Follicular Thyroid Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Pancreatic Cancer|Stage III Papillary Thyroid Cancer|Stage III Prostate Cancer|Stage III Rectal Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Vaginal Cancer|Stage III Vulvar Cancer|Stage IIIA Anal Cancer|Stage IIIA Breast Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Anal Cancer|Stage IIIB Breast Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Adrenocortical Carcinoma|Stage IV Anal Cancer|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Gastric Cancer|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Papillary Thyroid Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IVA Cervical Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IVB Vaginal Cancer|Stage IVB Vulvar Cancer|Thyroid Gland Medullary Carcinoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer|WDHA Syndrome |
NCT00004074 |
| Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer |
Recruiting |
Metastatic Triple Negative Breast Cancer |
NCT03055312 |
| Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434) |
Active, not recruiting |
Neoplasms|Carcinoma, Non-Small-Cell Lung |
NCT02862457 |
| Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom |
Active, not recruiting |
Cervical Cancer |
NCT03413579 |
| Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer |
Completed |
Breast Cancer |
NCT00899509 |
| BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial |
Active, not recruiting |
Pancreatic Cancer |
NCT02022033 |
| A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine |
Active, not recruiting |
Metastasis|Breast Cancer |
NCT02915744 |
| Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction |
Active, not recruiting |
Adenocarcinoma of the Esophagogastric Junction |
NCT02287129 |
| A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors |
Recruiting |
Non Small Cell Lung Cancer|Pancreatic Ductal Adenocarcinoma|Triple Negative Breast Cancer|Colorectal Cancer |
NCT03267316 |
| Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC |
Completed |
Non-small Cell Lung Cancer |
NCT02064491 |
| Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03 |
Recruiting |
IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer |
NCT03328234 |
| Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients |
Not yet recruiting |
Stage IIIA Non-small Cell Lung Cancer |
NCT03053856 |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) |
Recruiting |
Pancreatic Adenocarcinoma |
NCT03193190 |
| Central Catheters Used for Chemotherapy in Women With Breast Cancer |
Recruiting |
Catheter Related Complications |
NCT04324346 |
| Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer |
Completed |
Advanced Ovarian Cancer |
NCT01462149 |
| FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX |
Not yet recruiting |
Pancreatic Adenocarcinoma |
NCT04167007 |
| A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors |
Completed |
Neoplasms |
NCT00030173 |
| A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy |
Recruiting |
Metastatic Pancreatic Ductal Adenocarcinoma |
NCT03331640 |
| AcoArt III / AVF China |
Recruiting |
Arteriovenous Fistula Stenosis |
NCT03366727 |
| Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer |
Completed |
Neoplasms, Breast |
NCT00429299 |
| Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer |
Unknown status |
Endometrial Cancer |
NCT01461746 |
| Study of Safety & Biological Activity of IP GEN-1 With Neoadjuvant Chemo in Ovarian Cancer |
Active, not recruiting |
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer |
NCT02480374 |
| A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) |
Active, not recruiting |
Lung Cancer |
NCT03322566 |
| Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma |
Not yet recruiting |
Biliary Tract Adenocarcinoma |
NCT04156958 |
| Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC |
Unknown status |
Lung Cancer|Sarcopenia|Toxicity |
NCT02734069 |
| Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix |
Unknown status |
Peripheral Artery Disease |
NCT02279784 |
| NAC Followed by RH for the Treatment of LACC |
Recruiting |
Neoadjuvant Chemotherapy|Locally Advanced Cervical Cancer|Radical Hysterectomy|Objective Response|Laparoscopy|Laparotomy|Concurrent Chemoradiotherapy|Adjuvant Therapy|Systematic Chemotherapy |
NCT03963882 |
| Drug Eluting Balloon for Early Fistula Failure Trial |
Unknown status |
Stenosis of Arteriovenous Dialysis Fistula |
NCT02632955 |
| Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial |
Completed |
Solid Tumors |
NCT01593228 |
| A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors |
Completed |
Tumors |
NCT00422682 |
| Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT00391586 |
| DXR Stent for Vascular Healing and Thrombus Formation: OCT Study |
Not yet recruiting |
Coronary Artery Disease|Coronary Stent Occlusion |
NCT02932995 |
| A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary In-stent Restenosis |
Active, not recruiting |
Coronary In-stent Restenosis |
NCT03373695 |
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Recruiting |
Brenner Tumor|Malignant Ascites|Malignant Pleural Effusion|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mixed Epithelial Carcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Primary Peritoneal Cavity Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Epithelial Cancer|Stage IIIA Ovarian Germ Cell Tumor|Stage IIIA Primary Peritoneal Cavity Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Epithelial Cancer|Stage IIIB Ovarian Germ Cell Tumor|Stage IIIB Primary Peritoneal Cavity Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Epithelial Cancer|Stage IIIC Ovarian Germ Cell Tumor|Stage IIIC Primary Peritoneal Cavity Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Primary Peritoneal Cavity Cancer |
NCT02122185 |
| A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer |
Active, not recruiting |
Cancer |
NCT02483247 |
| Comparison of Safety and Efficacy of Coronary Drug-coated Balloon (DCB) Combined With Spot Stenting of Drug-eluting Stent (DES) Versus Second-generation DES for Treating Diffuse Coronary Artery Lesions: a Prospective, Randomized, Controlled Clinical Trial |
Not yet recruiting |
Diffuse Coronary Artery Lesions |
NCT03589157 |
| Proton Therapy for Esophageal Cancer |
Recruiting |
Esophagus Cancer |
NCT01684904 |
| Evaluation of Effectiveness and Safety of NOBORI Stent |
Completed |
Coronary Artery Disease |
NCT01348360 |
| Evaluation of Effectiveness and Safety of BIOMATRIX Stent (IRIS-BIOMATRIX) |
Active, not recruiting |
Coronary Artery Disease |
NCT01350778 |
| Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival |
Completed |
Coronary Artery Disease |
NCT03417050 |
| Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma |
Completed |
Advanced or Recurrent Esophageal Squamous Cell Carcinoma |
NCT01474642 |
| the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment |
Terminated |
Triple Negative Breast Cancer |
NCT03358004 |
| IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer |
Completed |
Ovarian Epithelial Cancer Recurrent |
NCT01588964 |
| Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma |
Completed |
Sarcoma |
NCT00020449 |
| Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent Restenosis |
Completed |
Coronary Restenosis |
NCT02944890 |
| The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions |
Unknown status |
Peripheral Vascular Disease |
NCT01952457 |
| Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer |
Completed |
Peritoneal Carcinomatosis|Gastric Cancer |
NCT01379482 |
| BIOLUX P-II First-in-Man Study to Compare the Passeo-18 Lux DRB Against POBA in Infrapopliteal Arteries |
Completed |
Atherosclerosis|Arteriosclerosis|Vascular Disease|Peripheral Artery Disease |
NCT01867736 |
| Post Market Surveillance of SeQuent Please Neo With Scoring Balloon |
Active, not recruiting |
Coronary Artery Disease (CAD) |
NCT02554292 |
| Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus |
Recruiting |
Esophageal Adenocarcinoma (UICC TNM7)|Adenocarcinoma of the Esophagogastric Junction |
NCT02509286 |
| Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00003589 |
| Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy |
Completed |
Adrenal Suppression |
NCT01209507 |
| Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers |
Unknown status |
Triple Negative Breast Cancer |
NCT02616848 |
| Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer |
Completed |
Breast Cancer|Metastases |
NCT00081796 |
| Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer |
Terminated |
Non-Small-Cell Lung Carcinoma |
NCT01383148 |
| Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC |
Recruiting |
Non-Small Cell Carcinoma of Lung, TNM Stage 4 |
NCT03786692 |
| A Trial to Evaluate the Safety and Efficacy of the Passeo-18 Lux Drug-coated Balloon of Biotronik in the Treatment of the Femoropopliteal Artery Compared to the Medtronic IN.PACT Admiral Drug-coated Balloon. |
Not yet recruiting |
Peripheral Arterial Disease |
NCT03884257 |
| Detect V / CHEVENDO (Chemo vs. Endo) |
Recruiting |
Metastatic Breast Cancer |
NCT02344472 |
| Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer |
Unknown status |
Epithelial Ovarian Cancer |
NCT01164995 |
| Rotational Atherectomy Prior to Taxus Stent |
Completed |
Complex Calcified Coronary Lesions |
NCT00380809 |
| Pilot Study of IV and IP Chemotherapy Plus Abdominal Hyperthermia for Ovarian Ca |
Withdrawn |
Ovarian Cancer |
NCT00787488 |
| Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) |
Completed |
Endometrial Cancer |
NCT00739830 |
| Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer |
Not yet recruiting |
Recurrent Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Unresectable Lung Non-Small Cell Carcinoma |
NCT04092283 |
| Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer |
Completed |
Ovarian Neoplasms |
NCT00130520 |
| Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors |
Unknown status |
Extragonadal Germ Cell Tumor|Teratoma|Testicular Germ Cell Tumor |
NCT00104676 |
| Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy |
Unknown status |
Testicular Cancer |
NCT00772694 |
| A Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH |
Recruiting |
Benign Prostatic Hyperplasia |
NCT04131907 |
| Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Digestive System |
Unknown status |
Gastrointestinal Neoplasms |
NCT02233205 |
| A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) |
Active, not recruiting |
Solid Tumors|Colorectal Cancer (CRC)|Adenocarcinoma (PDAC)|Lung Cancer|UC (Urothelial Cancer)|Head and Neck Cancer |
NCT03085914 |
| Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT01404260 |
| Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors |
Recruiting |
Germ Cell Tumor |
NCT01966913 |
| Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 |
Completed |
Non Small Cell Lung Carcinoma |
NCT01836575 |
| FUSCC Refractory TNBC Umbrella (FUTURE) |
Recruiting |
Triple-negative Breast Cancer |
NCT03805399 |
| Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors |
Withdrawn |
Solid Tumors |
NCT01245543 |
| Chemotherapy Induced Peripheral Neuropathy (CIPN) |
Recruiting |
Chemotherapy-induced Peripheral Neuropathy |
NCT03272919 |
| Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer |
Unknown status |
Advanced Gastric Adenocarcinoma |
NCT02240524 |
| A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer |
Recruiting |
Ovarian Cancer |
NCT03602859 |
| A Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous in Patients With Stage IV Non-Small Cell Lung Cancer (IMscin001) |
Recruiting |
Non-Small Cell Lung Cancer |
NCT03735121 |
| PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients |
Active, not recruiting |
Non-small Cell Lung Cancer |
NCT03064854 |
| Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies |
Completed |
Resistant Solid Malignancies |
NCT00703625 |
| Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab With and Without Chemotherapy in Locally Advanced or Metastatic Tumors |
Recruiting |
Advanced/Metastatic Tumors |
NCT02794571 |
| Effects of Celecoxib After Percutaneous Coronary Intervention |
Completed |
Coronary Arteriosclerosis |
NCT00292721 |
| Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer |
Completed |
Malignant Neoplasm of Stomach |
NCT02528110 |
| AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT01777932 |
| BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer |
Completed |
Ovarian Cancer, Peritoneal Neoplasms |
NCT01788995 |
| Selinexor With Multiple Standard Chemotherapy Regimens in Treating Patients With Advanced Malignancies |
Recruiting |
Advanced Malignant Neoplasm|Recurrent Malignant Neoplasm|Refractory Malignant Neoplasm |
NCT02419495 |
| mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus |
Unknown status |
Advanced Esophageal Carcinoma |
NCT01486992 |
| Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE 173) |
Completed |
Triple Negative Breast Neoplasms |
NCT02622074 |
| DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) |
Recruiting |
Bladder Cancer |
NCT03472274 |
| Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) |
Recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT03663166 |
| Tesetaxel as First-line Therapy for Metastatic Breast Cancer |
Unknown status |
Breast Neoplasm |
NCT01221870 |
| Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer |
Unknown status |
Advanced or Recurrent Endometrial Cancer |
NCT01461759 |
| Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma |
Recruiting |
Gastric Adenocarcinoma|Gastro-esophageal Junction Adenocarcinoma |
NCT03141034 |
| Clinical Outcomes in Hereditary Cancer |
Withdrawn |
Breast Cancer|Pancreatic Cancer |
NCT00580021 |
| Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers |
Recruiting |
Gastric Cancer|Esophageal Cancer|Gastro-esophageal Cancer |
NCT02970539 |
| International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) |
Recruiting |
Peritoneum Cancer|Peritoneum Neoplasm|Pleural Cancer|Pleural Effusion|Pleural Mesothelioma|Ovarian Cancer|Gastric Cancer|Appendix Cancer|Pseudomyxoma Peritonei|Colorectal Cancer|Pancreas Cancer|Gallbladder Cancer|Ascites|CUP|Chemotherapeutic Toxicity |
NCT03210298 |
| Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer |
Completed |
Breast Cancer |
NCT02018458 |
| PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer |
Recruiting |
Pancreatic Adenocarcinoma |
NCT04119362 |
| Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin |
Completed |
Chemotherapy-Induced Nausea and Vomiting|Ovarian Cancer |
NCT01012336 |
| Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer |
Completed |
Esophageal Cancer |
NCT02347904 |
| Tesetaxel for Previously Treated Patients With Bladder Cancer |
Unknown status |
Carcinoma, Transitional Cell |
NCT01215877 |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer) |
Recruiting |
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma |
NCT03281369 |
| Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting |
Completed |
Ovarian Cancer|Uterine Cancer |
NCT01432015 |
| Lutonix Global SFA Registry |
Completed |
Peripheral Artery Disease |
NCT01864278 |
| Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease |
Completed |
Peripheral Arterial Disease (PAD) |
NCT01175850 |
| Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer |
Recruiting |
Ovarian Cancer Stage IV|Ovarian Cancer Stage IIIC|Ovarian Cancer Stage IIIb |
NCT03579394 |
| Cannabinoids for Taxane Induced Peripheral Neuropathy |
Recruiting |
Chemotherapy-induced Peripheral Neuropathy |
NCT03782402 |
| Genetic Variants and Chemotherapy-induced Abnormal Thermal Sensation |
Recruiting |
Chemotherapy-induced Abnormal Thermal Sensation |
NCT03252834 |
| Comparison of Angioplasty/Drug Coated Balloon/Laser + Drug Coated Balloon for Femoropopliteal Artery In-stent Restenosis |
Recruiting |
Angioplasty, Balloon |
NCT02599389 |
| TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions |
Completed |
Coronary Artery Disease |
NCT00371709 |
| ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases |
Completed |
Breast Cancer|Brain Metastases |
NCT02048059 |
| Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) |
Unknown status |
Untreated Advanced Non-Small Cell Lung Cancer |
NCT00254319 |
| The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment |
Terminated |
Pain|Peripheral Neuropathy|Neuropathic Pain |
NCT01655823 |
| A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma |
Recruiting |
Metastatic Cancer|Solid Tumor|Advanced Cancer|NonHodgkin Lymphoma |
NCT03013218 |
| A Study of the TAXUS Liberté Stent for the Treatment of Long De Novo Coronary Artery Lesions |
Completed |
Coronary Artery Disease |
NCT00371475 |
| GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L) |
Terminated |
Non-small Cell Lung Cancer (NSCLC) With Brain Metastases |
NCT01497665 |
| Bard LifeStent and Lutonix DCB for Treatment of Long Lesions in Femoropopliteal Arteries |
Completed |
Peripheral Artery Disease |
NCT02278991 |
| Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix |
Recruiting |
Metastatic Carcinoma of the Cervix |
NCT03644342 |
| Athrectomy and Drug Eluting Balloon Therapy (ADEBT) on the Femoral Popliteal Arteries |
Approved for marketing |
Peripheral Arterial Disease |
NCT02686541 |
| A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer |
Unknown status |
Small Cell Lung Cancer |
NCT01872416 |
| Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients. |
Completed |
Breast Cancer Female |
NCT03381417 |
| A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer. |
Completed |
Non-Small Cell Lung Cancer |
NCT00700180 |
| Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients |
Active, not recruiting |
Solid Tumors|Docetaxel|Drug-Related Side Effects and Adverse Reactions|Pharmacogenetics|Pharmacokinetics |
NCT03258151 |
| Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients |
Unknown status |
Non-small Cell Lung Cancer|Effects of Chemotherapy |
NCT01749072 |
| Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery |
Recruiting |
Breast Cancer |
NCT02627248 |
| Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy |
Terminated |
Lung Cancer |
NCT00424840 |
| Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer |
Completed |
Non Small Cell Lung Cancer |
NCT00686959 |
| contact 1-877-CTLILLY (1-877-285-4559 |
EST) |
Taichung |
Taiwan|For additional information regarding investigative sites for this trial |
| Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer |
Completed |
Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage IV Prostate Cancer |
NCT00058084 |
| A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients |
Completed |
Cancer |
NCT00659269 |
| Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer |
Completed |
Breast Cancer |
NCT00866905 |
| Late Incomplete Stent Apposition Evaluation II: Comparison Between Polimer-based and No-polimer Stent System. IVUS Based Study |
Unknown status |
Coronary Artery Disease |
NCT01375855 |
| The PREVAIL Study |
Completed |
In-stent Restenosis|Ischemic Heart Disease|Coronary Artery Disease |
NCT03260517 |
| Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule |
Recruiting |
Soft Tissue Sarcomas |
NCT04223583 |
| Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine |
Completed |
Ovarian Cancer|Peritoneal Primary Cancer|Fallopian Tube Cancer |
NCT00293293 |
| Evaluation by Oncologists of Strategies for the Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathies |
Completed |
Chemotherapy-induced Peripheral Neuropathy |
NCT03854864 |
| Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma |
Recruiting |
Nasopharyngeal Carcinoma |
NCT03598218 |
| Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction |
Completed |
Myocardial Infarction |
NCT01347554 |
| Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer |
Terminated |
Head and Neck Squamous Cell Cancer |
NCT01326923 |
| Comparison of Safety and Efficacy of Two Different Drug Eluting Stents Implanted Into Saphenous Vein Grafts |
Unknown status |
Stenosis in Saphenous Vein Graft, Drug Eluting Stent |
NCT00766129 |
| Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer |
Recruiting |
Advanced Non Small Cell Lung Cancer |
NCT04144608 |
| Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery |
Recruiting |
Metastatic Esophageal Carcinoma|Metastatic Gastric Carcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Gastroesophageal Junction Adenocarcinoma|Stage III Esophageal Cancer AJCC v7|Stage III Gastric Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIA Gastric Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7|Stage IIIB Gastric Cancer AJCC v7|Stage IIIC Esophageal Cancer AJCC v7|Stage IIIC Gastric Cancer AJCC v7|Stage IV Esophageal Cancer AJCC v7|Stage IV Gastric Cancer AJCC v7|Unresectable Esophageal Carcinoma|Unresectable Gastric Carcinoma|Unresectable Gastroesophageal Junction Adenocarcinoma |
NCT03008278 |
| Ixabepilone + Carboplatin Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT01075100 |
| Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC |
Unknown status |
NSCLC |
NCT01742767 |
| Dose EScalation Induction of EvERolimus |
Recruiting |
Breast Cancer|Hormone Receptor Positive Tumor |
NCT02387099 |
| Optical Coherence Tomography for EVERolimus Eluting STent |
Completed |
Coronary Artery Disease |
NCT01146080 |
| MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery |
Completed |
Femoral Artery Stenosis|Popliteal Artery Stenosis|Femoral Artery Occlusion|Popliteal Artery Occlusion |
NCT01947478 |
| Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy |
Recruiting |
Primary Breast Cancer |
NCT03270007 |
| BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC |
Completed |
Non-Small Cell Lung Cancer |
NCT01243775 |
| FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer |
Completed |
Inoperable Gastric Cancer |
NCT03067792 |
| DES Versus BiOSS LIM - POLBOS II Study |
Completed |
Coronary Artery Disease |
NCT02198300 |
| POLish Bifurcation Optimal Stenting Study |
Completed |
Coronary Artery Disease |
NCT02192840 |
| A Study of LY3200882 in Participants With Solid Tumors |
Active, not recruiting |
Solid Tumor |
NCT02937272 |
| Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE) |
Recruiting |
Organoids|HNSCC|Epithelial Ovarian Cancer|Colorectal Cancer |
NCT04279509 |
| Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT00882973 |
| Safety and Efficacy of the SurVeil™ Drug-Coated Balloon (AVess FIH) |
Active, not recruiting |
Hemodialysis Access Failure |
NCT03734679 |
| Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) |
Completed |
Non-small Cell Lung Cancer (NSCLC) |
NCT00770588 |
| A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma |
Completed |
Pancreatic Adenocarcinoma |
NCT01839799 |
| A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer |
Active, not recruiting |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer |
NCT01610206 |
| LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615) |
Not yet recruiting |
Colorectal Cancer Metastatic |
NCT04031872 |
| Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer |
Terminated |
Neoplasms |
NCT00979641 |
| Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer |
Unknown status |
Small Cell Lung Cancer |
NCT01752517 |
| Non-acute Coronary occlusIon Treated By Everolimus ELuting Stent |
Completed |
Coronary Artery Disease|Coronary Occlusion|Percutaneous Coronary Intervention |
NCT00793221 |
| Study of NMB Drug Ejecting Balloon for Peripheral Arteries |
Unknown status |
Peripheral Arterial Disease |
NCT01646801 |
| Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders. |
Recruiting |
Chemotherapy Induced Peripheral Neuropathy|Multiple Myeloma |
NCT03344328 |
| Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer |
Withdrawn |
Colorectal Cancer Metastatic |
NCT03470350 |
| Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00198393 |
| Evaluation of GEMCITEST in Patients With Pancreatic Cancer and Treated by Chemotherapy |
Recruiting |
Pancreatic Cancer |
NCT03599154 |
| Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer |
Active, not recruiting |
Ovarian Cancer |
NCT03249142 |
| Diagnosis and Prediction of Taxanes Induced Cardiac Dysfunction |
Unknown status |
Breast Cancer |
NCT01641562 |
| Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer |
Active, not recruiting |
Head and Neck Carcinoma |
NCT02718820 |
| Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study) |
Recruiting |
Primary Breast Cancer |
NCT03711877 |
| Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma |
Completed |
Esophageal Carcinoma |
NCT02120911 |
| ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) |
Completed |
Non-small Cell Lung Cancer|Neoplasm Metastasis|Lung Cancer |
NCT00101920 |
| Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor |
Completed |
Platinum Refractory Epithelial Ovarian Cancer|Primary Cancer of the Peritoneum|Cancer of the Fallopian Tube |
NCT00543049 |
| Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma |
Terminated |
Loco-regional Esophageal Cancer |
NCT00570531 |
| FrActional Flow Reserve Guided Drug Coated Balloon Only Strategy in De Novo coronarY Lesions (FADDY) |
Unknown status |
Coronary Stenosis |
NCT03452904 |
| Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy |
Terminated |
Ovarian Carcinoma |
NCT01175772 |
| Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) |
Recruiting |
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma |
NCT02859038 |
| DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma |
Not yet recruiting |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Carcinoma |
NCT03905902 |
| Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer |
Terminated |
Metastatic Cancer |
NCT03009058 |
| Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer |
Completed |
Breast Cancer |
NCT01150513 |
| Safety and Efficacy of DCB Therapy for ISR Under the Guidance of QFR (UNIQUE-DCB-II Study ) |
Not yet recruiting |
Coronary Heart Disease |
NCT04119986 |
| Effect on the Nutritional and Inflammatory Status of Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)- Containing Supplement in Patients With Advanced Lung Cancer |
Unknown status |
Lung Cancer |
NCT01048970 |
| Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO) |
Unknown status |
Angiosarcoma |
NCT02732678 |
| Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients |
Completed |
Breast Neoplasms|Breast Cancer, Metastatic |
NCT00044525 |
| Cortisone or Drug Eluting Stents (DES) as Compared to Bare Metal Stents (BMS) to EliminAte Restenosis |
Completed |
Coronary Artery Disease|Ischemic Heart Disease|Atherosclerosis |
NCT00369356 |
| Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes |
Unknown status |
Cardiotoxicity.|Anti Her2 Therapy.|Metastatic Breast Cancer |
NCT02101879 |
| FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma |
Suspended |
Metastatic Gastro-esophageal Adenocarcinoma |
NCT03528876 |
| An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies |
Completed |
Solid Tumors|Advanced Malignancies|Metastatic Cancer |
NCT02265510 |
| Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging |
Recruiting |
Peripheral Artery Disease|Vascular Disease|Critical Limb Ischemia |
NCT02807779 |
| Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy |
Terminated |
Carcinoma, Non-small-cell Lung |
NCT02004184 |
| NESC: Neoadjuvant Treatment Of Gastric Adenocarcinoma |
Unknown status |
Gastric Adenocarcinoma |
NCT01565109 |
| Ixabepilone to Treat Cervical Cancer |
Terminated |
Cervical Carcinoma|Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Carcinoma, Non-SquamousType |
NCT00924066 |
| Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) |
Terminated |
Neoplasms |
NCT00954512 |
| A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer |
Recruiting |
Non Small Cell Lung Cancer |
NCT03789604 |
| Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma |
Completed |
Ovarian Cancer|Adverse Effects |
NCT01824615 |
| To Study the Individual Variants of Chemotherapy-Induced Neurotoxicity |
Recruiting |
Neurotoxicity Syndromes |
NCT02481336 |
| Rotational Atherectomy for Calcified lEsion By Smart Angioplasty Research Team (SMART-RACE) |
Recruiting |
Coronary Artery Disease |
NCT02716363 |
| Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors |
Completed |
Mesenchymal Tumor|Carcinosarcoma|Leiomyosarcoma |
NCT00815945 |
| A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma |
Unknown status |
Recurrent Endometrial Cancer |
NCT01454479 |
| Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy |
Completed |
Ovarian Carcinoma|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma |
NCT01709487 |
| Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting |
Recruiting |
Breast Cancer |
NCT03831178 |
| Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding |
Completed |
Stomach Neoplasms |
NCT00539877 |
| Xience V at Wake Forest University Baptist Medical Center (WFUBMC) |
Completed |
Percutaneous Coronary Intervention|Stents |
NCT00937573 |
| Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen |
Unknown status |
Cancer|Lung Cancer |
NCT01850147 |
| The Clinical Research of Neoadjuvant Chemotherapy Combined Surgery for Locally Advanced Cervical Cancer |
Unknown status |
Cervical Cancer |
NCT02471027 |
| Pilot Study for Locally Advanced Head and Neck Cancer |
Withdrawn |
Head and Neck Neoplasms |
NCT01262859 |
| Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours |
Unknown status |
Focus of Study Instead |
NCT01728818 |
| Dexamethasone-Eluting Stent in Acute Coronary Syndrome to Prevent Restenosis |
Completed |
Vessel Restenosis |
NCT00190099 |
| Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer |
Recruiting |
Cervical Cancer |
NCT03029013 |
| DRUG ELUTING STENT FOR DIABETIC PATIENTS IN CORONARY ARTERY DISEASE TREATMENT |
Recruiting |
Coronary Artery Disease |
NCT03509532 |
| Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers |
Completed |
Locally Advanced Breast Cancer|Ductal Histologic Type|Without Her 2 Overexpression |
NCT01367288 |
| Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents |
Completed |
Coronary Artery Disease |
NCT00638794 |
| INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy |
Recruiting |
Head and Neck Squamous Cell Carcinoma |
NCT03953976 |
| Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC) |
Recruiting |
NSCLC |
NCT03986528 |
| Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer |
Unknown status |
Breast Cancer |
NCT01732939 |
| I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer |
Recruiting |
Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma |
NCT01042379 |
| Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian Cancer |
Recruiting |
Ovarian Cancer |
NCT03448354 |
| LEVANT 2 Safety Registry |
Active, not recruiting |
Peripheral Artery Disease |
NCT01790243 |
| Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT03983538 |
| LEVANT 2 Continued Access Registry |
Active, not recruiting |
Peripheral Artery Disease |
NCT01628159 |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer |
Active, not recruiting |
Metastatic Breast Cancer |
NCT02299999 |
| Auto Transplant for High Risk or Relapsed Solid or CNS Tumors |
Recruiting |
Ewing's Family Tumors|Renal Tumors|Hepatoblastoma|Rhabdomyosarcoma|Soft Tissue Sarcoma|Primary Malignant Brain Neoplasms|Retinoblastoma|Medulloblastoma|Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)|Atypical Teratoid/Rhabdoid Tumor (AT/RT)|CNS Tumors|Germ Cell Tumors |
NCT01505569 |
| Involvement of SK3 Calcium Channel in Taxane Neuropathy |
Recruiting |
Breast Cancer|Chemotherapy-induced Peripheral Neuropathy|Prostate Cancer |
NCT03816904 |
| Chemotherapy of NSCLC With or Without Icotinib |
Unknown status |
Carcinoma, Non-Small-Cell Lung |
NCT02430974 |
| Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) |
Recruiting |
Breast Cancer |
NCT03742986 |
| A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors |
Not yet recruiting |
Solid Tumors |
NCT03503604 |
| Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma |
Not yet recruiting |
Nasopharyngeal Carcinoma |
NCT04223024 |
| Atezolizumab Immunotherapy in Patients With Advanced NSCLC |
Active, not recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT03102242 |
| Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer |
Completed |
Non Small Cell Lung Cancer|Lung Cancer|Stage IIIA Non Small Cell Lung Cancer|Stage IIIB Non Small Cell Lung Cancer |
NCT00078390 |
| Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC |
Recruiting |
Esophageal Squamous Cell Carcinoma |
NCT03985046 |
| Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA) |
Recruiting |
Cervical Cancer|Cervical Cancer Metastatic|Cervical Cancer Recurrent |
NCT03912402 |
| A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer |
Completed |
Breast Neoplasms|Fever|Hematologic Diseases|Neutropenia|Sepsis |
NCT00001338 |
| Outcomes of Drug Coated Balloon Angioplasty, A UK Real Life Experience From 2009 to 2015 |
Active, not recruiting |
Ischaemic Heart Disease |
NCT03603210 |
| Researches of Retinal Artery Lesions and Acute Coronary Syndrome |
Unknown status |
Acute Coronary Syndrome |
NCT02415452 |
| Abscopal Effect for Metastatic Colorectal Cancer |
Withdrawn |
Colorectal Cancer|Metastatic Colorectal Cancer|Thymalfasin |
NCT02535988 |
| A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC |
Recruiting |
Non-Small Cell Lung Cancer |
NCT03215706 |
| Re-Establishing Flow Via Drug Coated Balloon for the Treatment of Urethral Stricture Disease - Registry Study |
Withdrawn |
Urethral Stricture|Urethral Stricture, Anterior|Lower Urinary Tract Symptoms|Anterior Urethral Stricture |
NCT03851952 |
| Comparison of Cypher Select and Taxus Express Coronary Stents |
Completed |
Coronary Artery Disease|Angina Pectoris |
NCT00388934 |
| Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer |
Terminated |
Non-small Cell Lung Cancer |
NCT02252796 |
| Re-establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease |
Active, not recruiting |
Urethral Stricture |
NCT03270384 |
| Oncoxin® and Quality of Life in Cancer Patients |
Completed |
Gastric Cancer Stage II|Non-small Cell Lung Cancer Stage II|Non-small Cell Lung Cancer Stage III|Gastric Cancer Stage III |
NCT03550482 |
| Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030) |
Terminated |
Nausea|Vomiting |
NCT01405924 |
| Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT01263886 |
| Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer |
Withdrawn |
Esophageal Cancer |
NCT03234842 |
| Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer|Metastatic Breast Cancer |
NCT01733628 |
| Neoadjuvant Goserelin for Triple Negative Breast Cancer |
Not yet recruiting |
Breast Cancer Triple Negative |
NCT03444025 |
| Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma |
Completed |
Esophageal Cancer |
NCT00230451 |
| A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors |
Completed |
Neoplasm Malignant |
NCT01455532 |
| Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer |
Recruiting |
Carcinoma|Ovarian Neoplasm|Endocrine Gland Neoplasm|Urogenital Neoplasms|Ovarian Diseases|Adnexal Diseases|Genital Diseases, Female|Female Urogenital Diseases|Female Urogenital Diseases and Pregnancy Complications|Endocrine System Diseases|Gonadal Disorders|Genital Neoplasm, Female|Neoplasms, Glandular and Epithelial |
NCT03562897 |
| Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer |
Completed |
Head and Neck Cancer |
NCT00014118 |
| RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) |
Recruiting |
Small Cell Carcinoma|Carcinoma, Non-Small-Cell Lung|Neuroendocrine Tumors|Ovarian Epithelial Cancer |
NCT02489903 |
| DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs |
Unknown status |
HER2-negative Metastatic Breast Cancer|HER2-positive Circulating Tumor Cells |
NCT01619111 |
| Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Patient With ESCC |
Recruiting |
Esophageal Squamous Cell Carcinoma (ESCC) |
NCT03957590 |
| A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China |
Completed |
Advanced Gastric Cancer |
NCT01472250 |
| BMS 247550 to Treat Kidney Cancer |
Completed |
Renal Cell Carcinoma |
NCT00030992 |
| AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer |
Active, not recruiting |
Advanced Solid Tumours |
NCT03421353 |
| Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00028938 |
| Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial) |
Recruiting |
Breast Cancer |
NCT02441933 |
| A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
Non-Small Cell Lung Cancer |
NCT02574078 |
| Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy |
Completed |
Head and Neck Cancer |
NCT00004865 |
| Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy |
Withdrawn |
Pancreatic Ductal Adenocarcinoma|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer |
NCT02414100 |
| Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients |
Recruiting |
Endometrial Cancer |
NCT04212377 |
| Drug Eluting Stents Versus Bare Metal Stents for Treatment of Symptomatic Extracranial Vertebral Artery Stenosis |
Completed |
Ischemic Stroke|Vertebral Artery Stenosis |
NCT03201432 |
| ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab |
Active, not recruiting |
Ovarian Cancer |
NCT02891824 |
| A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors |
Recruiting |
Colorectal Cancer|Pancreatic Cancer |
NCT03184870 |
| 99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer |
Terminated |
Breast Cancer|Doxorubicin Induced Cardiomyopathy |
NCT02677714 |
| A Study of Apatinib Treatment in for Advanced Ovarian Cancer |
Unknown status |
Ovarian Cancer|Chemotherapeutic Toxicity |
NCT03393507 |
| Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC |
Unknown status |
Non Small Cell Lung Cancer |
NCT02455843 |
| CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer |
Recruiting |
Breast Neoplasms |
NCT04059003 |
| Efficacy Study of Drug-eluting and Bare Metal Stents in Bypass Graft Lesions |
Completed |
Arteriosclerosis of Arterial Coronary Artery Bypass Graft |
NCT00611910 |
| Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer |
Recruiting |
Esophageal Carcinoma |
NCT01691625 |
| Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer |
Active, not recruiting |
Locally Advanced Pancreatic Adenocarcinoma |
NCT03536182 |
| Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries |
Active, not recruiting |
Femoral Artery Stenosis|Popliteal Artery Stenosis|Femoral Artery Occlusion|Popliteal Artery Occlusion |
NCT01412541 |
| Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT00216125 |
| Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Chemo Patients With Digestive Tract . |
Unknown status |
Digestive Tract |
NCT03455205 |
| Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer |
Recruiting |
Esophageal Cancer|Esophageal Adenocarcinoma|Esophageal Squamous Cell Carcinoma|Esophageal Neoplasms |
NCT03474341 |
| Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) |
Active, not recruiting |
Ovarian Cancer |
NCT03642132 |
| Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies |
Completed |
Advanced Cancer|Advanced Malignancies |
NCT02383212 |
| Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT03704467 |
| Drug-eluting Balloon in Acute Myocardial Infarction |
Completed |
Coronary Artery Disease|Atherosclerosis|Thrombosis|Acute Myocardial Infarction |
NCT00856765 |
| Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer |
Completed |
Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT01026467 |
| Combination of Pembrolizumab With Chemoradiation for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma |
Active, not recruiting |
Esophageal Squamous Cell Carcinoma |
NCT03792347 |
| Prospective HIV Chemotherapy Cohort Study |
Completed |
HIV|Cancer |
NCT01902693 |
| Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy |
Completed |
Lung Cancer|Non Small Cell Lung Carcinoma|Hypermethylation |
NCT01209520 |
| Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma |
Recruiting |
Locally Advanced Malignant Neoplasm |
NCT03815903 |
| Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis |
Completed |
Femoral Artery Stenosis|Femoral Artery Occlusion|Restenosis |
NCT02063672 |
| Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries |
Active, not recruiting |
Critical Limb Ischemia |
NCT01870401 |
| EUS-guided Ablation of Pancreatic Cyst Neoplasms |
Recruiting |
Pancreatic Cyst |
NCT02422147 |
| Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) |
Not yet recruiting |
Ovarian Cancer|Ovarian Neoplasms|Serous Adenocarcinoma|BRCA1 Mutation|BRCA2 Mutation|Chemotherapy |
NCT04055038 |
| A Study of the TAXUS Liberté Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels |
Completed |
Coronary Artery Disease |
NCT00371748 |
| Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer |
Terminated |
Neoplasms, Breast |
NCT01220128 |
| A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC |
Completed |
Esophageal Neoplasms |
NCT02721563 |
| A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric Junction |
Not yet recruiting |
Esophageal Cancer |
NCT04269083 |
| A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function |
Terminated |
Metastatic Cancer |
NCT01278758 |
| INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) |
Not yet recruiting |
Non-small Cell Lung Cancer |
NCT04203511 |
| Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma |
Recruiting |
Esophageal Squamous Cell Carcinoma |
NCT04275986 |
| Pre-Surgery If Needed for Oesophageal Cancer |
Recruiting |
Esophageal Cancer |
NCT03937362 |
| Acupuncture Treatment of Chemotherapy-Induced Peripheral Neuropathy in Women |
Recruiting |
Chemotherapy-induced Peripheral Neuropathy|Breast Cancer Female|Gynecologic Cancer |
NCT04067544 |
| A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer |
Active, not recruiting |
Lung Neoplasms |
NCT01770418 |
| Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma |
Completed |
Esophageal Carcinoma |
NCT00176800 |
| Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease Fatigue |
Terminated |
Metastatic Breast Cancer|Fatigue |
NCT02645175 |
| Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma |
Completed |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer |
NCT00157560 |
| A Nutritional Management Algorithm in Older Patients With Locally Advanced Esophageal Cancer |
Recruiting |
Localized Stage I-III Esophageal Cancer|Gastroesophageal Junction Cancer |
NCT02027948 |
| GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases |
Completed |
Breast Cancer|Brain Metastases |
NCT01480583 |
| A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC |
Not yet recruiting |
Breast Cancer |
NCT04215003 |
| 131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC) |
Terminated |
Non Small Cell Lung Cancer |
NCT01124812 |
| Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer |
Completed |
Breast Cancer |
NCT02468739 |
| Can Fasting Decrease the Side Effects of Chemotherapy? |
Enrolling by invitation |
Chemotherapy Effect|Chemotherapeutic Toxicity|Fasting |
NCT04027478 |
| Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer |
Completed |
Breast Cancer |
NCT00567554 |
| Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in N2 Positive IIIA Non Small Cell Lung Cancer (NSCLC) |
Unknown status |
Lung Cancer |
NCT00452803 |
| LegDeb2 Global Registry for Use of Legflow in Peripheral Arteries |
Not yet recruiting |
Peripheral Arterial Disease|Superficial Femoral Artery Stenosis|Iliac Artery Stenosis|Arterial Occlusive Diseases|Popliteal Artery Stenosis|Critical Limb Ischemia |
NCT04175197 |
| A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC |
Terminated |
Esophageal Neoplasms |
NCT02721550 |
| A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC |
Terminated |
Esophageal Neoplasms |
NCT02721576 |
| Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma |
Withdrawn |
Carcinoma, Squamous|Squamous Cell Carcinoma|Oropharyngeal Neoplasms|Oropharyngeal Cancer |
NCT02298595 |
| Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas |
Completed |
Refractory Aggressive Non-Hodgkin's Lymphoma|Relapsing Aggressive Non-Hodgkin's Lymphoma |
NCT01538641 |
| Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer |
Terminated |
Breast Neoplasms |
NCT01167192 |
| Shanghai Registry of Acute Coronary Events |
Terminated |
Coronary Artery Disease|Acute Coronary Syndrome |
NCT00713557 |
| De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study |
Active, not recruiting |
Carcinoma, Squamous Cell|Head and Neck Neoplasms|Oropharyngeal Neoplasms |
NCT02281955 |
| Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer |
Not yet recruiting |
Gastric Cancer|Peritoneal Carcinomatosis |
NCT03179579 |
| Bingo Drug-eluting Balloon in Bifurcation |
Completed |
Bifurcation Lesions|Drug Eluting Balloon |
NCT02325817 |
| Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy |
Recruiting |
Pancreatic Cancer|Liver Metastases|Surgery |
NCT03398291 |
| Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma |
Completed |
Cervical Cancer Recurrent or Persistent|Palliative Treatment|Monoclonal Antibody in Cervical Cancer Treatment |
NCT02083211 |
| Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma |
Terminated |
Melanoma|Metastatic Melanoma |
NCT01495988 |
| Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy |
Recruiting |
Breast Cancer|Triple Negative Breast Cancer |
NCT03750240 |
| Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Recruiting |
Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma |
NCT02502266 |
| Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer With Peritoneal Metastatis |
Recruiting |
Stage IV Gastric Cancer With Metastasis|Hyperthermic Intraperitoneal Chemotherapy|Exploratory Behavior |
NCT03604614 |
| Long-Term Safety of Drug Eluting Stents in the "Real World" (FReIburger STent Registry) |
Unknown status |
Stent Thrombosis |
NCT00905008 |
| A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer |
Unknown status |
Metastatic Breast Cancer |
NCT01784120 |
| A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC) |
Terminated |
Non-Small Cell Lung Cancer |
NCT00998166 |
| Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer |
Completed |
Breast Cancer |
NCT02483767 |
| Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients |
Completed |
Breast Cancer |
NCT03541863 |
| Individualized Precise Radiotherapy With the Guidance of Radiosensitivity of Locally Advanced Cervical Cancer |
Unknown status |
Cervical Cancer |
NCT03163979 |
| A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer |
Completed |
Breast Cancer |
NCT01156753 |
| Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy |
Terminated |
Esophageal Cancer|Esophageal Adenocarcinoma|Esophageal Squamous Cell Cancer|Esophageal Neoplasms|Squamous Cell Carcinoma |
NCT03223662 |
| A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC |
Recruiting |
Metastatic Non-Small Cell Lung Cancer (NSCLC) |
NCT03819465 |
| Breast Cancer Treatment Based on Organ-like Culture |
Enrolling by invitation |
Breast Cancer Organoids |
NCT03925233 |
| Everolimus- Versus Biolimus-Eluting Stents in All-Comers |
Completed |
Coronary Artery Disease |
NCT01472705 |
| Radical Colorectal Resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Colorectal Cancer |
Completed |
Malignant Neoplasm of Colorectum |
NCT02830139 |
| The Study of Active Transfer of Plaque Technique for Unprotected Distal Left Main Bifurcation Lesions |
Active, not recruiting |
Coronary Heart Disease |
NCT02127138 |
| Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer |
Completed |
Breast Neoplasms |
NCT00246571 |
| Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer |
Terminated |
Lung Cancer |
NCT03348904 |
| Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors |
Completed |
Small Cell Lung Carcinoma|Carcinoma, Squamous Cell of Head and Neck|Stomach Neoplasms|Triple Negative Breast Neoplasms|Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms|Esophagogastric Junction Neoplasms|Carcinoma, Pancreatic Ductal|Esophageal Squamous Cell Carcinoma |
NCT02658214 |
| Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients |
Completed |
Small-Cell Lung Cancer |
NCT00466466 |
| Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer |
Recruiting |
Breast Neoplasms|Cardiac Event|Chemotherapeutic Toxicity |
NCT03785704 |
| Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma |
Completed |
Urothelial Carcinoma|Bladder Cancer|Urinary Bladder Neoplasms |
NCT02788201 |
| ROBUST III- Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease |
Recruiting |
Urethral Stricture |
NCT03499964 |
| A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors ( PIVOT-02 ) |
Recruiting |
Melanoma|Renal Cell Carcinoma|Non Small Cell Lung Cancer|Urothelial Carcinoma|Metastatic Breast Cancer|Colorectal Cancer |
NCT02983045 |
| Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments |
Active, not recruiting |
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity |
NCT02282020 |
| Gated Intensity Modulated Radiation Therapy and Concurrent Chemotherapy for Inoperable NSCLC |
Terminated |
Non-small Cell Lung Cancer |
NCT00692380 |
| Drug Eluting Balloon Versus Drug Eluting Stent in PCI |
Completed |
Coronary Artery Disease |
NCT01760200 |
| Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract |
Completed |
Metastatic Transitional Cell Cancer of the Urothelial Tract |
NCT03159143 |
| DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01] |
Active, not recruiting |
Neoplasm, Gastrointestinal |
NCT03329690 |
| Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors |
Recruiting |
Carcinoma, Squamous Cell of Head and Neck|Carcinoma, Non-Small-Cell Lung|Small Cell Lung Carcinoma |
NCT03509012 |
| Drug Eluting Balloon for Treatment of Unstable Angina |
Unknown status |
Angina, Unstable |
NCT02760732 |
| Expanded Access to ANG1005 for Individual Patients |
No longer available |
Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Breast Cancer With Recurrent Brain Metastases|Leptomeningeal Carcinomatosis |
NCT02755987 |
| Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III) |
Recruiting |
Peripheral Arterial Disease |
NCT02923193 |
| Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma |
Recruiting |
Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma |
NCT03904927 |
| NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) |
Recruiting |
Adenocarcinoma of the Oesophagus|Adenocarcinoma of the Oesophago-gastric Junction|Oesophageal Tumours|Junctional Tumours|Oesophageal Cancer |
NCT01726452 |
| An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma |
Unknown status |
Mesothelioma |
NCT00685204 |
| A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases |
Completed |
Liver Cancer|Neoplasm Metastasis |
NCT00542048 |
| A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer |
Completed |
Advanced Solid Tumors With and Without Brain Metastases |
NCT00539383 |
| A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma |
Completed |
Recurrent or Progressive Malignant Glioma |
NCT00539344 |
| A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors |
Completed |
Hepatocellular Carcinoma |
NCT01733004 |
| Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC |
Recruiting |
Esophageal Squamous Cell Carcinoma Stage cT3-4aN0-1M0 |
NCT03001596 |
| Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB) |
Recruiting |
Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB |
NCT04293796 |
| Perioperative Chemotherapy Combined With HIPEC for High-risk Advanced Gastric Cancer |
Unknown status |
Survival |
NCT02960061 |
| Hypofractionated Radiotherapy (Stereotactic) Versus Conventional Radiotherapy for Inoperable Early Stage I Non-small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
Non Small Cell Lung Cancer |
NCT01014130 |
| Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA) |
Not yet recruiting |
Cervical Cancer |
NCT03912415 |
| Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer |
Completed |
Breast Cancer|Metastatic Breast Cancer |
NCT00148707 |
| Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer |
Unknown status |
Neoplasms, Breast |
NCT03273595 |
| Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer |
Active, not recruiting |
Esophageal Cancer |
NCT02735239 |
| Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors |
Completed |
Cancer |
NCT01188499 |
| The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial. |
Recruiting |
Non-small Cell Lung Cancer, NSCLC |
NCT03523702 |
| Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors |
Recruiting |
Childhood Germ Cell Tumor|Ovarian Cancer|Teratoma |
NCT00432094 |
| Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) |
Recruiting |
Neoplasms |
NCT02723955 |
| Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344 |
Recruiting |
Breast Cancer |
NCT00897026 |
| Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00075712 |
| Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC) |
Not yet recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT04255836 |
| A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2) |
Completed |
Metastatic Breast Cancer |
NCT00281697 |
| Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer |
Completed |
Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer |
NCT00146562 |
| Preoperative Stomach Cancer Induction Chemotherapy and Radiation Therapy |
Recruiting |
Locally Advanced Gastric Carcinoma |
NCT03223740 |
| Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung |
Completed |
Breast Cancer|Metastatic Cancer |
NCT00301730 |
| Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer |
Recruiting |
Breast Cancer |
NCT02810743 |
| Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer |
Recruiting |
Squamous Cell Carcinoma of Cervix |
NCT02879214 |
| A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer. |
Completed |
Non-Small Cell Lung Cancer |
NCT00531960 |
| BioFreedom FIM Clinical Trial. |
Completed |
Treatment Of Stenotic Lesions In Native Coronary Arteries. |
NCT01172119 |
| Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) |
Recruiting |
Lung Adenocarcinoma|Lung Large Cell Carcinoma|Resectable Lung Non-Small Cell Carcinoma|Stage IB Lung Non-Small Cell Carcinoma AJCC v7|Stage IB Lung Squamous Cell Carcinoma AJCC v7|Stage II Lung Non-Small Cell Cancer AJCC v7|Stage II Lung Squamous Cell Carcinoma AJCC v7|Stage IIA Lung Non-Small Cell Carcinoma AJCC v7|Stage IIA Lung Squamous Cell Carcinoma AJCC v7|Stage IIB Lung Non-Small Cell Carcinoma AJCC v7|Stage IIB Lung Squamous Cell Carcinoma AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Squamous Cell Carcinoma AJCC v7 |
NCT02194738 |
| Iowa |
Creston |
United States|Genesis Medical Center - East Campus |
Council Bluffs |
| New Jersey |
Flemington |
United States|The Cancer Institute of New Jersey Hamilton |
Camden |
| Washington |
Enumclaw |
United States|Providence Regional Cancer Partnership |
Edmonds |
| Drug Coated Balloons vs Plain Balloons for the Management of Dysfunctional Dialysis Fistula |
Terminated |
Dysfunctional Dialysis Arteriovenous Fistula |
NCT03189667 |
| Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer |
Terminated |
Muscle Invasive Bladder Cancer |
NCT02716896 |
| CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility |
Recruiting |
Lung Neoplasms|Lung Cancer|Neoplasm of Lung|Non Small Cell Lung Cancer |
NCT03986463 |
| GSK1120212 Rollover Study |
Terminated |
Cancer |
NCT01376310 |
| The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients |
Completed |
Distorted |
NCT02391818 |
| Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer |
Recruiting |
Gastric Cancer |
NCT01665274 |
| The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients |
Terminated |
Breast Cancer Stages I Through III |
NCT01996410 |
| Biomarker-based Study in R/M SCCHN |
Recruiting |
Carcinoma, Squamous Cell of Head and Neck |
NCT03088059 |
| P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck Cancer |
Unknown status |
Advanced Head and Neck Cancer |
NCT02429037 |
| Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents |
Completed |
Neoplasms, Breast |
NCT00790816 |
| Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents |
Completed |
Coronary Heart Disease|Coronary Restenosis |
NCT00552669 |
| Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery |
Completed |
Endometrial Cancer |
NCT00448643 |
| Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. |
Recruiting |
Breast Neoplasms |
NCT03283384 |
| Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic |
Completed |
Adenocarcinoma of Colon|Adenocarcinoma of Rectum|Metastatic Disease |
NCT01703910 |
| Genomic and Epigenomic Alterations After Cancer Treatment in Pregnancy |
Not yet recruiting |
Cancer|Pregnancy |
NCT04125446 |
| Trial Comparing ELUVIA Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery |
Recruiting |
Arterial Occlusive Diseases|Atherosclerosis|Vascular Diseases|Arteriosclerosis |
NCT02921230 |
| Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma |
Unknown status |
Carcinoma, Non-Small-Cell Lung|Synchronous Neoplasms |
NCT02805530 |
| ANG1005 in Patients With Recurrent High-Grade Glioma |
Completed |
Glioma|Glioblastoma|Brain Tumor, Recurrent |
NCT01967810 |
| Acoustic Cluster Therapy (ACT) With Chemotherapy in Metastatic Liver Metastases of Gastrointestinal Origin |
Recruiting |
Solid Tumor|Colorectal Cancer|Pancreatic Cancer |
NCT04021277 |
| PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation |
Completed |
Glioblastoma Multiforme |
NCT01402063 |
| A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC) |
Completed |
Cancer |
NCT02759250 |
| ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study |
N/A |
N/A |
NCT00490139 |
| West Reading |
United States|Novartis Investigative Site |
Pennsylvania |
United States|Novartis Investigative Site |
| Hamburg |
Hamburg |
Hamburg |
Germany|Novartis Investigative Site |
| CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer|Breast Cancer |
NCT00270907 |
| Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) |
Completed |
Non-Small Cell Lung Cancer (NSCLC) |
NCT00820755 |
| A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT) |
Completed |
Non-Small Cell Lung Cancer|Brain Neoplasms |
NCT00312728 |
| Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer |
Terminated |
Breast Cancer |
NCT01698281 |
| Nivolumab in Combination With Ipilimumab (Part 1) |
N/A |
N/A |
NCT02659059 |
| Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy |
Completed |
Cancer|Malignancy|Malignant Neoplasm|Neuropathy|Neuropathies Sensory|Chemotherapy-induced Peripheral Neuropathy |
NCT03909464 |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer |
Completed |
Head and Neck Cancer |
NCT00004089 |
| Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive |
Completed |
Breast Cancer |
NCT00372424 |
| Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma |
Terminated |
Cancer |
NCT00983541 |
| Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) |
Active, not recruiting |
Non Small Cell Lung Carcinoma NSCLC |
NCT03003962 |
| Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer |
Completed |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter |
NCT00028860 |
| Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE). |
Active, not recruiting |
Non Small Cell Lung Carcinoma NSCLC |
NCT02542293 |
| Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00003214 |
| Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer |
Recruiting |
Gastric Cancer|Gastro-oesophageal Junction Cancer |
NCT03957564 |
| A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1) |
Unknown status |
Metastatic Breast Cancer |
NCT00262067 |
| Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction |
Unknown status |
Breast Cancer |
NCT01917578 |
| Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. |
Recruiting |
Advanced Ovarian Cancer |
NCT03737643 |
| Pelvic RT Versus Prophylactic Extended-field RT in Patients With Cervical Cancer |
Recruiting |
Uterine Cervical Neoplasms |
NCT03955367 |
| Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy |
Not yet recruiting |
Radiation Oncology |
NCT03734952 |
| CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy |
Not yet recruiting |
Nasopharyngeal Carcinoma |
NCT03529279 |
| A Real World Evaluation of the ELUVIA Stent in Subjects With Lesions Located in the Femoropopliteal Arteries |
Recruiting |
Arterial Occlusive Diseases|Atherosclerosis|Vascular Diseases|Arteriosclerosis |
NCT03037411 |
| Breast Cancer Genome Guided Therapy Study (BEAUTY) |
Active, not recruiting |
Invasive Breast Cancer |
NCT02022202 |
| Orbital Vessel PreparaTIon to MaximIZe Dcb Efficacy in Calcified Below the Knee (BTK) Lesions - A Pilot Study |
Completed |
PAD|Vascular Calcification |
NCT02561299 |
| ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent |
Active, not recruiting |
Atherosclerosis of Native Arteries of the Extremities |
NCT02574481 |
| Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC |
Recruiting |
Lung |
NCT03141359 |
| A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer |
Recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT04025879 |
| Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer |
Recruiting |
Periampullary Adenocarcinoma|Periampullary Cancer|Pancreatic Cancer |
NCT03724994 |
| QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer |
Withdrawn |
Non Small Cell Lung Cancer |
NCT03574649 |
| Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies |
Terminated |
Solid Tumors |
NCT02711137 |
| Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer |
Recruiting |
Recurrent Ovarian Carcinoma |
NCT03690739 |
| Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). |
Active, not recruiting |
Non Small Cell Lung Cancer NSCLC |
NCT03164616 |
| An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease |
Not yet recruiting |
Non-Small Cell Lung Cancer|Non-Small-Cell Lung Carcinoma|Circulating Tumor DNA |
NCT03770299 |
| A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
Non Small Cell Lung Cancer |
NCT02998528 |
| An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) |
Recruiting |
Non-Small Cell Lung Cancer |
NCT02477826 |
| Serum Protein Research Substudy |
Unknown status |
Breast Cancer |
NCT02393833 |
| Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer |
Unknown status |
Breast Cancer |
NCT00533936 |
| Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00003877 |
| Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00003899 |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer |
Unknown status |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00003064 |
| A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors |
Terminated |
Neoplasms |
NCT00811993 |
| Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer |
Completed |
Gastric Cancer |
NCT00003862 |
| Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00003111 |
| Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer |
Unknown status |
Breast Cancer |
NCT00629278 |
| Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection |
Active, not recruiting |
Carcinoma, Pancreatic Ductal |
NCT02750657 |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer |
Completed |
Ovarian Cancer |
NCT00003413 |
| High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00003392 |
| Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00083083 |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer |
Terminated |
Ovarian Cancer |
NCT00005612 |
| Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery |
Completed |
Breast Cancer |
NCT00311636 |
| Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer |
Withdrawn |
Lung Cancer |
NCT00055887 |
| High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery |
Completed |
Ovarian Cancer |
NCT00004921 |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer |
Completed |
Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Ovarian Cancer|Teratoma|Testicular Germ Cell Tumor |
NCT00002931 |
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer |
Terminated |
Ovarian Cancer |
NCT00003386 |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma |
Completed |
Lymphoma |
NCT00003957 |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer |
Completed |
Breast Cancer |
NCT00003972 |
| Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma |
Completed |
Lymphoma |
NCT00003397 |
| Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer |
Completed |
Brain and Central Nervous System Tumors |
NCT00014573 |
| Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos |
Recruiting |
Liver Cancer|Pancreatic Cancer|Gastric Cancer|Esophageal Cancer|Colo-rectal Cancer|Gall Bladder Cancer|Biliary Tract Cancer |
NCT03668418 |
| Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer |
Unknown status |
Breast Cancer |
NCT00003086 |
| Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer |
Completed |
Breast Cancer |
NCT00052351 |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors |
Terminated |
Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor |
NCT00003852 |
| APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies |
Recruiting |
Advanced Solid Tumors or Hematologic Malignancies |
NCT03386526 |
| Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer |
Completed |
Prostate Cancer |
NCT00030654 |
| Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma |
Completed |
Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific |
NCT00027937 |
| Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00011921 |
| Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00003159 |
| Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT00003042 |
| P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC |
Recruiting |
Carcinoma, Squamous Cell|Head and Neck Neoplasms|Oropharyngeal Neoplasms |
NCT03077243 |
| Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). |
Active, not recruiting |
Non-Small-Cell Lung Carcinoma NSCLC |
NCT02453282 |
| Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) |
Recruiting |
Non-metastatic Muscle Invasive Bladder Cancer |
NCT03674424 |
| Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) |
Recruiting |
Non-small Cell Lung Cancer NSCLC |
NCT03775486 |
| Acupuncture Prevents Chemobrain in Breast Cancer Patients |
Completed |
Chemo-brain|Drug-Related Side Effects and Adverse Reactions|Mild Cognitive Impairment|Breast Cancer |
NCT02457039 |
| Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen |
Completed |
Neoplasm Malignant |
NCT01587040 |
| Bingo Drug-Coated Balloon in Real World |
Recruiting |
Coronary Stenosis|Drug-coated Balloon|De Novo Stenosis|Coronary Artery Disease in Transplanted Heart Accelerated |
NCT04234893 |
| Pilot Study of 18F Fluoropaclitaxel (FPAC) |
Completed |
Breast Cancer |
NCT00572598 |
| Ketogenic Diet With Chemoradiation for Lung Cancer (KETOLUNG) |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT01419587 |
| A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors |
Terminated |
Advanced Solid Tumors |
NCT01299701 |
| The Dual Antiplatelet Therapy Study (DAPT Study) |
Completed |
Coronary Artery Disease |
NCT00977938 |
| An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function |
Terminated |
Histologically-proven and Radiologically-confirmed Solid Tumors |
NCT01278849 |
| Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer |
Not yet recruiting |
Breast Cancer |
NCT04290793 |
| Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") |
Active, not recruiting |
Pancreatic Adenocarcinoma |
NCT01726582 |
| QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer |
Recruiting |
Pancreatic Adenocarcinoma Metastatic |
NCT03127124 |
| Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer |
Completed |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer |
NCT01248962 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients |
Completed |
Chemotherapy Patients |
NCT01238562 |
| EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment |
Recruiting |
Metastatic Pancreas Cancer|Locally Advanced Pancreatic Cancer|Pancreatic Adenocarcinoma |
NCT03126435 |
| Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs |
Unknown status |
Chemotherapy|Nerve Degeneration|Nerve Conduction |
NCT01208545 |
| A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL TUMOR RESONSE TO NEOADJUVANT CHEMORADIATION |
Recruiting |
Esophageal Cancer |
NCT03151642 |
| High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia |
Recruiting |
Acute Leukemia of Ambiguous Lineage|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia |
NCT02551718 |
| Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer |
Recruiting |
Pancreatic Cancer Non-resectable|Chemotherapy-induced Nausea and Vomiting|Pancreatic Cancer Metastatic |
NCT03984214 |
| Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC) |
Completed |
Non-Small Cell Lung Cancer |
NCT00240097 |
| Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT01498458 |
| Bioavailability Study of SPARC1210 and Reference1210 in Subjects With Metastatic Breast Cancer |
Terminated |
Breast Cancer |
NCT02136927 |
| Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer |
Recruiting |
Breast Cancer |
NCT03414684 |
| Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy |
N/A |
N/A |
NCT02456857 |
